Deciphering the role of the gut microbiome in autoimmune thyroid disease by Masetti, Giulia
 Deciphering The Role 
Of The Gut Microbiome  
In Autoimmune Thyroid Disease 
 
 
 
 
 
 
 
 
 
 
Thesis submitted in fulfillment of the requirements for the degree of 
Doctor of Philosophy (PhD), School of Medicine. 
 
Giulia Masetti 
 
 
2019 
  
  
 
 II 
  
  
 
 III 
Author’s Declarations 
Declaration 
I hereby declare that this work has not been submitted in substance for any other 
degree or award at this or any other University or place of learning, nor is being 
submitted in candidature for any other award. 
 
Signed…………………..(candidate) Date……………… 
 
Statement 1 
This thesis is being submitted in partial fulfilment of the requirements for the 
degree of Doctor of Philosophy (PhD). 
 
Signed…………………..(candidate) Date……………… 
 
Statement 2 
This thesis is the result of my own independent work/investigation, except where 
otherwise stated, and the thesis has not been edited by a third party beyond what 
is permitted by Cardiff University’s Policy on the Use of Third Party Editors by 
Research Degree Students. Other sources are acknowledged by explicit 
references. The views expressed are my own. 
 
Signed…………………..(candidate) Date……………… 
 
Statement 3 
I hereby give my consent for my thesis, if accepted, to be available for 
photocopying and for inter-library loans, and for the title and summary to be made 
available to outside organisations. 
 
Signed…………………..(candidate) Date……………… 
 
Statement 4: Previously approved Bar on Access 
I hereby give my consent for this thesis, if accepted, to be available for 
photocopying and inter-library loans after the expiration of a bar on access, 
previously approved by the Academic Standard & Quality Committee. 
 
Signed…………………..(candidate) Date……………… 
  
  
 
 IV 
  
  
 
 V 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ai miei genitori 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
 
 VI 
  
  
 
 VII 
Acknowledgments 
This work was supported by the Marie-Sklodowska Curie Industry-Academia Pathways 
and Partnerships (IAPP) action, GA number 612116 project INDIGO (Investigation of 
Novel biomarkers and Definition of the role of the microbiome In Graves Orbitopathy, 
http://www.indigo-iapp.eu/). My role in the project as an “early-stage” researcher was to 
perform the microbiome analyses on both patients and mouse model samples, which 
were recruited/generated in other work packages of this project.  
I thank my former PTP Science Director Dr. John Williams, for giving me the opportunity 
to participate in such a dynamic and interesting project. I wish to thank all the INDIGO 
colleagues for these four years of work together. The specific contribution of each 
colleague to the work I performed and presented in this thesis is acknowledge at the 
beginning of each chapter.  
I’m also thankful for patients and healthy controls all over Europe who voluntarily and 
kindly donated their time and their samples, without whom this work couldn’t have been 
performed.  
I couldn’t get very far without the amazing support provided by my supervisors. I wish to 
thank Prof. Marian Ludgate for always being supportive and for always providing the right 
direction, even when the statistics was getting “exotic”. She is truly an inspirational role 
model both as a researcher and as a woman, wife, mother and grandmother. Thank you 
to my second supervisor Prof. Julian Marchesi for his presence, his constant support and 
for believing in me and my skills. I also wish to thank Dr. Filippo Biscarini, my former PTP 
supervisor, for the outstanding mentorship and support he provided on statistics and 
bioinformatics and during the completion of this thesis.  
I wish to thank my former Science Director Dr. Alessandra Stella and my colleagues and 
friends at PTP Science Park (Lodi, Italy). Even if we are not working together anymore 
and we are spread all over the world, I really value the time we spent together. 
Moreover, this work couldn’t have been finished without the amazing support of Dr. Sue 
Plummer and my colleagues at Cultech Ltd (UK).  
During these four years I’ve met amazing friends (Evi, Andreas, Debbie, Ally and Duaa). 
Thank you for your presence and constant support. A special thanks to my friend and 
colleague Dr. Ilaria Muller for the huge support and the help both at work and outside.  
To my Italians lifelong friends: thank you for your amazing support even if I was not 
always physically present. I’m really lucky to have you in my life.  
  
 
 VIII 
At last but not least: thank you to my wonderful parents. All of this couldn’t have even 
existed without you. I like to think that this work reflects both of you: medics from mum 
and informatics from dad! A massive thanks to my “bear”-in-life and in-crime Fabrizio, I 
honestly don’t know what I would have done without you.  
 
Grazie di cuore, 
Thank you, 
Diolch i chi. 
 
 
  
  
 
 IX 
Summary 
The aetiology of hyperthyroid Graves’ disease (GD) is incompletely understood. I 
hypothesized that the gut microbiome affects tolerance to the thyrotropin receptor 
(TSHR) leading to GD and associated Graves’ orbitopathy (GO). My work comprises two 
observational studies and two interventional trials, applied to a GD/GO mouse model and 
GD/GO patients.  
I applied metataxonomics (16S rRNA gene sequencing) to samples from TSHR-
immunised mice from two independent laboratories and observed significant differences 
in alpha-diversity, beta-diversity and taxonomic profiles. I also compared TSHR-treated 
and control mice in one centre and identified disease-associated taxonomies (i.e. 
reduced Bacteroidetes and enriched Firmicutes), correlating with orbital-adipogenesis in 
diseased but not controls.  
Changes in gut microbiota taxonomy (e.g. reduced Bacteroides/increased Roseburia 
spp. and increased Firmicutes:Bacteroidetes ratio) were also observed in GD (n=59) and 
GO (n=46) patients compared with controls (n=41), and associated with hyperthyroidism 
or GO severity. Moreover, GD/GO patients-predicted metagenomic pathways included 
increased “Bacterial epithelial invasion” and “glycosaminoglycan synthesis”. 
The role of the gut-microbiota in TSHR-induced GD/GO was confirmed by manipulating 
it in early life using antibiotics which enriched Bacteroides spp. and reduced/ablated 
disease symptoms. The faecal material transplant from GO patients, despite showing 
similarities with the GO patients gut microbiota, did not exacerbate murine GO, which 
also remained unaffected by probiotics. In contrast, in a randomised trial, GD/GO 
patients receiving probiotics (in addition to anti-thyroid therapy) displayed a more stable 
gut microbiota composition and sustained improvement in thyroid hormone levels 
compared with placebo.   
My results illustrate significant perturbation in the gut microbiota in TSHR-induced murine 
GD/GO and patients with spontaneous disease. Furthermore, the similarities in 
differential abundance and disease-associated taxonomies noted in both species 
support their relevance to disease.  Future studies are needed to dissect the mechanistic 
role of the gut microbiome in activating the immune system and determining the onset of 
GD/GO.  
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1.1. AUTOIMMUNE THYROID DISEASES 
Mention of autoimmune diseases (AD) first appeared in the medical and scientific 
literature in 1950 [1], and initially constituted a puzzling medical problem, because the 
possibility that the immune system could react against self-molecules had not been 
previously recognised. Initially, the majority of the scientific literature and reviews 
considered autoimmunity as the result of the malfunctioning of the immune system, 
which fails to recognize self-antigens, but directing the immune-response against the 
host; and most of the theories related to the mechanisms underlying the outcome of an 
AD referred to this concept. However, later investigations recognised the importance of 
self-recognition in the correct functioning of the immune system. What is illustrated by 
the need for endogenous and exogenous antigens to be associated with self MHC-I and 
MHC-II molecules respectively to illicit an immune response.  More recently it has been 
suggested that the presence of self-reactive immune system cells (both T and B cells) 
might be physiological for the process of regeneration and clearance of the damaged-
self (e.g. damaged cells undergoing death and cellular debris after apoptosis) [2]. At the 
basis of an auto-immune response leading to an autoimmune disease there is 
overproduction of self-reactive T and B cells and auto-antibodies against self-antigens. 
Synergism between these, pro-inflammatory mediators (e.g. TNF-α, IL-1βb, IL-1) and 
other types of immune cells (e.g. Antigen-Presenting-Cells, APC, such as dendritic cells 
or macrophages), cause the damage, dysfunction or the over-stimulation of the one or 
more targeted tissue and organ leading to disease.  
When self-antigens are localized into a specific tissue, organ or region, we speak of 
organ-specific autoimmunity. Examples of organ-specific ADs include autoimmune 
thyroid diseases like Graves’ disease (GD) or Hashimoto’s thyroiditis, Crohn's disease 
(CD, chronic inflammation of the intestine) and type 1 diabetes (T1D). When, on the other 
hand, self-antigens are scattered throughout the body, they are described as systemic 
ADs, such as Systemic Lupus Erythematosus (SLE), in which the autoantigen is the DNA 
itself, more specifically the ribonucleoprotein complexes of the spliceosome [3].  
Until now, there are more than eighty recognized autoimmune conditions, twenty-four of 
them have been well characterized in epidemiological studies (data according to NIH 
statistics on autoimmunity1). Autoimmune diseases, both systemic and organ-specific, 
are therefore a growing public health concern, compounded by the discovery of 
                                               
1 NIH, National Institute of Environmental Health Sciences. “Autoimmune Diseases” available at 
https://www.niehs.nih.gov/health/materials/autoimmune_diseases_508.pdf 
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autoimmune features in pre-existing diseases (i.e. Parkinson’s disease [4]) and to the 
increasing number of affected patients [5]. 
1.1.1. The thyroid function in health  
The thyroid gland, with its prototypical “butterfly” shape is located close to the larynx, and 
is essential in regulating growth and the metabolic processes (e.g. brain and nerves 
development and function, intestinal and heart functions) through the production of two 
main thyroid hormones, triiodothyronine (T3) and thyroxine (T4), which are released into 
the circulation and transported to virtually all cells in the body. Synthesis of thyroid 
hormones from the thyroid follicular cells is regulated by the thyroid stimulating hormone 
(TSH) secreted by the pituitary gland when the levels of T3 and T4 are low, to increase 
their production. The TSH production in the pituitary gland is itself regulated by the 
hypothalamic-produced TSH releasing hormone (TRH); secretion of TRH is also 
regulated by T3 and T4 in a negative feedback loop (Figure 1.1).  
Thyroid hormones T3 and T4 are synthetized from iodide (I-) and the amino acid tyrosine 
by the thyroid peroxidase (TPO) enzyme, an integral membrane protein in the apical 
plasma membrane of the thyroid epithelial cells. Iodide, usually derived from food, is 
sequestered from the blood via the sodium iodide symporter (NIS) located on the outer 
plasma membrane of the thyroid epithelial cells and transported to the follicular lumen in 
conjunction with thyroglobulin (Tg), a large soluble glycoprotein (330 kDa) produced by 
the thyroid epithelial cells and secreted into the thyroid follicular lumen, which contains 
approx. 134 tyrosine residues undergoing iodination operated by TPO. Such a post-
translational modification is necessary for the production of thyroid hormones from two 
iodinated tyrosine. Thyroid hormones are stored in epithelial cells and released into the 
blood. TSH regulates the T3 and T4 release process: the higher the TSH levels, the 
faster the production and the rates of endocytosis and release into the circulation, and 
vice versa in the presence of low TSH amounts. The hypothalamus-pituitary-thyroid axis 
regulates also the gene expression and the production of NIS, TPO and Tg themselves 
via the binding of TSH to the TSH receptor (TSHR), as will be explained in further details 
later in this section.   
In humans, only 20% of the thyroid hormones are secreted in the active T3 form, while 
80% are released as T4 [6], termed a “prohormone”, since deiodination by deiodinase 
enzymes in the outer ring of the T4 can reverse the less-active T4 isoform to its more 
active counterpart T3. However, deiodination occurring in the inner ring leads to an 
inactive form of T3 called reverse T3 (rT3) [7]. Deiodinases enzymes have mainly three 
different isoforms (D1, D2 and D3) that reside in different tissues and while the D1 and 
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D3 are more likely to produce the inactive rT3, the D2 isoform (expressed in the brain, 
placenta and adipose tissue) is more involved in the outer ring T4 deiodination, as 
reviewed in [8]. Other modifications in the thyroid hormones structure may occur in the 
4’-OH of the phenolic group by either sulphation or glucuronidation, which result in the 
inactivation of the thyroid hormones. Phenol sulfotransferases promote the sulphation of 
both T3 and T4, which facilitate the D1 deiodination into the inactive form rT3S. UDP-
glucuronyl transferase (UGTs), instead, promote the attachment of glucuronic acid which 
may occur more frequently on T4. Both sulphation and glucuronidation increase the 
water-solubility of thyroid hormones facilitating their secretion through the serum, bile, 
urine and also in the intestine [9]. It is interesting to note that, as reviewed in [10], 
sulphatase and beta-glucuronidase enzymes from tissues, but also from the gut 
microbiota, may convert the inactive form of T3S or T4G into T3 and T4 respectively, 
acting as a reservoir for thyroid hormones.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1. Production of thyroid hormones in health.  
Thyroid-stimulating hormone (TSH) secreted by the pituitary activates the production of 
thyroid hormones (T3,  triiodothyronine and T4, thyroxine), in the thyroid follicular cells.  
T4 is produced from Iodide (I-) and the amino acid Tyrosine (Tyr) by the thyroid 
peroxidase enzyme (TPO). Iodide is obtained from food, captured from the blood by the 
sodium iodide symporter (NIS) and internalized in the thyroid follicles with thyroglobulin 
(Tg). The prohormone T4 undergoes deiodination to produce the active form T3. Once 
T4 and T3 are released in the bloodstream, they are transported to virtually all cells in 
the body. The production of TSH by the hypothalamic-produced TSH releasing hormone 
(TRH) is regulated through a negative feedback loop by high levels of T3/T4. (Modified 
from http://www.indigo-iapp.eu). Description of the pathological status in Figure 1.4.   
  
 
 
5  
To exert their physiological role in regulating neurodevelopment, growth and metabolic 
processes, thyroid hormones bind to the thyroid hormone receptors (TRs) to initiate the 
expression of target genes, inducing a conformational change of the receptor structure. 
TRs are part of the nuclear receptors family encoded by two genes Thra and Thrb, which 
express for TR-alpha and TR-beta, although four alternative splice variants are described 
according to tissue and developmental stages (e.g. TR-B1 mainly expressed in brain, 
heart, kidneys, liver and thyroid; TR-B2 exclusive in hypothalamus, anterior pituitary and 
developing ear and TR-beta generally over-expressed after birth) [11]. TRs themselves 
bind via zinc-fingers to short-repeated “AGGTCA” hexamers called T3 response 
elements (TREs), which can be arranged  in a direct, palindromic or inverted manner. 
Moreover, TRs can bind TREs as a monomer (either alpha or beta), homodimer (e.g. 
alpha/alpha, alpha/beta, beta/beta) or heterodimer in conjunction with the retinoid X 
receptor (alpha/RXR or beta/RXR), which also has the highest binding affinity. TR-TRE 
binding to DNA would occur independently of the T3-TR binding, which would then 
determine the activation or the repression of the gene expression. In a T3-free state, in 
fact, the TR bound to the chromatin forms a co-repressor complex with histone 
deacetylase (HDA), repressing the gene expression [12], while in presence of T3, a 
conformational change of the receptor activates the expression of target genes via 
histone transacetylase (HAT) [13], although a more dynamic mechanisms has been 
recently proposed [14].  
Healthy individuals with a normal thyroid function are considered as euthyroid, while 
disease conditions are usually diagnosed when TSH and “free” T4 levels are out of 
ranges. Hyperthyroidism is diagnosed in presence of a low or undetectable TSH and a 
high level of T3/T4, while the hypothyroidism is present with an above TSH and a below 
ranges free T4. Individuals with mutations in the TR-β gene, which is responsible for T3 
binding, may develop a syndrome of thyroid hormone resistance, characterized by signs 
of hypothyroidism. Also due to the role of thyroid hormones in neurological and brain 
development, imbalances in the maternal thyroid hormones levels or in the T3-TR-TRE 
might lead to developmental defects and neurocognitive disorders [15].  
1.1.2. Graves’ disease 
Graves’ disease (GD) is an organ-specific antibody-mediated autoimmune disease, 
characterized by the presence of thyroid-stimulating antibodies (TRAB) that mimic the 
TSH in activating the TSHR, which results in an overproduction of thyroid hormones 
(both T3 and T4), hyperthyroidism, goitre and thyrotoxicosis (i.e. elevated thyroid 
hormone levels); but also a range of extrathyroidal manifestations, of which Graves’ 
orbitopathy (GO) is the most common - as I will later describe. GD constitutes the majority 
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of cases of the thyrotoxicosis [16]  afflicting about 2% of the UK population, with a 8:2 
female predominance. Clinical symptoms are mostly related to hyperthyroidism 
including: loss of weight, tachycardia, heat intolerance and tremor, but also bowel 
discomfort, exophthalmos and pretibial myxedema (Figure 1.2). Diagnosis of GD is 
usually made on patients who already have some of the clinical symptoms described, 
with a biochemical signature of low or undetectable TSH, high T3 and free-T4 and 
presence of TRAB and other thyroid autoantigens such as TPO.  
 
 
 
Figure 1.2. Summary of Graves’ disease and Graves’ orbitopathy characteristics.  
Graves’ disease (GD; also called Basedow disease in Italy and France) is caused by the 
presence of antibodies (TRAB) directed against the thyroid-stimulating hormone receptor 
(TSHR), which activate the TSHR in over-producing T3 and T4 hormones, at the 
expenses of the TSH. Hyperthyroid is manifested through weight loss, tachycardia, 
tremors and some extra-extrathyroidal manifestations (i.e. pretibial myxedema). Also, 
bowel discomfort is usually reported with an increased intestinal mobility and diarrhoeal 
episodes. The concomitant presence of Coeliac Disease has been reported [17, 18]. 
Around 50% of GD patients may experience some sign of eye disease called Graves’ 
orbitopathy (GO), while 5% of them develop a severe form, which involves inflammation 
and remodelling of the orbital tissues leading to proptosis, corneal exposure, and 
diplopia. Symptoms are heterogenous ranging from eye irritation, watering, discomfort 
to dry eyes, grittiness and photophobia. Most severe cases GO may result in blindness. 
GO patients experience a reduction of their quality of life, and develop psychological 
distress due to the disfiguring phenotype of the disease (i.e. protrusion of the eyeball, 
eyelid retraction). 
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The main GD autoantigen is TSHR, whose gene is located on chr. 14q31 and is 
composed of ten exons [19]. It is expressed at high level on the plasma membrane of 
the follicular epithelial cells in the thyroid, but also in other sites such as adipose tissues, 
fibroblasts and - most important for further descriptions - the human retro-orbital tissue 
[20, 21]. The TSHR belongs to the G-protein-coupled receptor (GPCR) family, sharing 
structural similarities with the follicle-stimulating hormone receptor (FSHR) and the 
lutropin receptor (LHR), however retaining unique characteristics. The large extracellular 
domain (Subunit A) of the TSHR contains several leucine-rich repeats (LRRs), with a 
cysteine-rich N and C-terminus including some polypeptides that differentiate the TSHR 
amongst LHR, while the second domain (B subunit) is ‘rhodopsin-like’ having the seven 
transmembrane spanning helices characteristic of the GPCR (Figure 1.3). The TSHR 
structure at the thyrocyte surface is the result of several post-translational modifications 
including glycosylation, intracellular cleavage, and disulphide-bond formation. During the 
intracellular cleavage, probably operated by a metalloproteinase [22], a 50aa peptide (C 
peptide) originally located at the N-terminus of the B subunit (aa 317-366, Figure 1.3) is 
removed. The two subunits are linked together via a disulphide bridge. For some TSHRs, 
cell-surface enzymes could reduce the disulphide bond, releasing the A-subunit by so-
called “receptor shedding”. The TSHR is highly glycosylated, approximately 40% of the 
A-subunit [23], due to six N-linked glycosylation sites located on the ectodomain, at least 
four of which are necessary for the location of the TSHR at the cell surface.  
Physiological TSH binding occurs in multiple sites of the A-subunit of the TSHR, 
specifically between residue 280-400, potentially favoured by the concave shape of the 
A-subunit. The binding itself leads to a conformational change of the receptor which 
assumes an agonist state and activates the signal transduction via the cyclic AMP 
(cAMP), PI3K-Akt and PIP2/Ca2+/arachidonate signalling pathways, as extensively 
described in [24], resulting ultimately in the regulation of gene expression, regulation of 
the iodide efflux, Tg degradation, production of thyroid hormone and thyrocyte growth. 
Whilst these signalling pathways increase the gene expression of Tg, TPO and NIS,  
expression of the TSHR is down-regulated, as well as the expression of Human 
Leukocyte Antigen (HLA) -class I genes. 
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Figure 1.3. Molecular structure of the thyroid-stimulating hormone receptor. 
(A) The TSHR is a G-protein-coupled receptor constituted of a large extracellular domain 
(Subunit A) and of a B-subunit. The TSHR expressed at the thyrocyte surface is the 
result of several post-translational modifications such as glycosylation, intracellular 
cleavage, and disulphide-bond formation. The intracellular cleavage removes a peptide 
of 50aa (C-peptide). A-subunit and B-subunit are bond through a disulphide bridge, 
which, if reduced, it may result in a “receptor shedding”. (B) A-subunit of the TSHR 
contains several leucine-rich repeats (LRRs), with a cysteine-rich N and C-terminus, 
characterized. The B-subunit is constituted of a ‘rhodopsin-like’ seven transmembrane 
spanning helices, characteristic of the GPCR. Physiological TSH binding occurs in 
multiple sites of the A-subunit of the TSHR, specifically between residue 280-400, 
potentially favoured by the concave shape of the A-subunit. (Modified from [25]).  
 
In GD, TRABs compete with the TSH for binding the TSHR. Due to the high levels of T3 
and T4, the TSH expression is repressed and the TRAB signalling predominate, along 
with the overexpression of the genes and the overproduction of thyroid hormones (Figure 
1.4). As the result of the failure of immunological mechanisms that will be further 
described, self-specific B cells secrete auto-antibodies against the TSHR (TRABs), and 
the type of auto-antibodies binding to the TSHR would decide the fate of this activation. 
Besides the thyroid-stimulating antibodies (TSAb), in fact, TSHR blocking and neutral 
antibodies have been described. TSHR stimulating antibodies are a class of IgG1 
antibodies that, by mimicking the TSH, are able to bind the receptor when in a natural 
conformation, inducing the cAMP pathway and inhibiting any binding of naturally-
occurring TSH itself [24]. Blocking antibodies (TSBAb) also prevent TSH binding to the 
receptor, but also block any other thyroid functions, possibly resulting in hypothyroidism, 
although there is the report of signal cascade activation via preferred pathways in some 
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of the TSBAb [24], which would act like a weak agonist. The binding sites of both TSAb 
and TSBAb might be different from that of the natural TSH and from each other’s. In fact, 
the TSH requires the complete structure of the TSHR; while the TSAbs display high 
affinity for epitopes located along the ectodomain LRRs in its natural concave 
conformation [26] or the shed A-subunit itself [27, 28], the TSBAb are conformationally 
dependent [29]. Moreover, the glycosylation patterns of the TSHR are necessary for the 
binding of both TSAb and TSBAb [30]. Neutral antibodies do not activate or block the 
TSH and they do not induce the signalling through the cAMP; although two neutral TSHR 
antibodies, when tested on rat thyroid cell, were capable of suppressing the signalling 
activity or stimulating some signalling cascades independent from cAMP, respectively 
[31]. 
The TBII (thyrotropin-binding inhibitory immunoglobulin) and the TSAB or thyroid-
stimulating immunoglobulins (TSI) are methods used to measure levels of TRABs in the 
sera of patients. The TBII measures both stimulating and blocking antibodies since it 
quantifies the titre of Igs that inhibit the binding of the TSH to the TSHR. On the other 
hand, TSAB measure the levels of stimulating or blocking antibodies through the 
quantification of the cAMP production in a cell line (CHO) stably transfected to express 
the TSHR [32]. In recent years M22, a human monoclonal TSAB derived from a patient 
with severe hyperthyroidism [33], and whose structure has also been characterized in 
depth [26, 33-35] has been invaluable in providing insight into the TSAB/TSHR 
interaction.   
Most GD patients also produce autoantibodies against the other two autoantigens 
involved in the AITD: Tg and TPO, showing a possible overlap in the mechanisms of loss 
of immune-tolerance to one or more thyroid autoantigens [36].  
Treatment options for GD includes anti-thyroid drug administration, radioiodine and 
thyroid surgery, depending on the severity of the disease itself and the presence of co-
occurrent eye disease or other conditions. Hyperthyroid GD patients are usually treated 
with thionamide anti-thyroid drugs such as methimazole (30 mg/day) or carbimazole 
(CBZ, 40 mg/day), according to the country of residency (e.g. CBZ is used in UK, while 
methimazole is prescribed in Italy and the USA) for 4 to 8 weeks to achieve the euthyroid 
status [37]. Such a compound becomes preferentially iodinated by TPO, avoiding the 
iodotyrosine formation by Tg and gradual disruption of iodine storage in the thyroid, since 
the iodinated thionamide residues are metabolized peripherally [38]. Once the 
euthyroidism is reached, CBZ can be administered in a “dose titration” regimen starting 
at 20 mg/day dosage and gradually reduced to 5-10 mg/day, according to the thyroid 
functions (i.e. TSH and fT4 levels), which have to be tested every one or two months. 
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The lowest effective dosage is usually administered for 12-18 months, to ensure the 
optimal remission (i.e. recovery from the disease) of the disease, and stopped. In GD 
patients with already a concomitant eye disease (which will be extensively discussed in 
the following paragraph), a “block and replace” regimen is usually preferred (e.g. CBZ at 
a fixed dose of 40 mg/day plus levothyroxine 100 μg/day to maintain the euthyroid status) 
to quickly control the thyroid function and avoid the hyper-hypothyroid fluctuations, 
known to worsen the eye condition. In case of recurrent GD relapses after thionamides 
withdrawal, radioiodine (131I) or thyroidectomy followed by a lifelong replacement with 
levothyroxine might be considered. Relapsing GD patients with eye disease may also 
undergo thyroidectomy instead of radioiodine treatment. Since some GD patients may 
experience side effects with CBZ (e.g. erythema, agranulocytosis), the propylthiouracil 
(PTU) might be used instead, although it can have higher risk of developing neutropoenia 
(i.e. abnormally low concentration of neutrophils in the blood) and liver toxicity than CBZ. 
PTU is only preferred in the first trimester of pregnancy, since it has been shown to lower 
the incidence of foetus malformations compared to CBZ, which is then used from the 
second trimester onwards.   
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4. Activation of the TSHR in Graves’ disease.  
TSHR autoantibodies (TRABs) compete with the TSH for binding the TSHR. The high 
levels of T3 and T4, repress the TSH expression and the TRAB signalling predominate, 
along with the overexpression of the genes and the overproduction of thyroid hormones. 
(Modified from http://www.indigo-iapp.eu).  
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1.1.3. Graves’ orbitopathy 
About 30-50% of GD patients may experience some sign of eye disease called Graves’ 
orbitopathy (GO), while 5% of them develop a severe form, which involves inflammation 
and remodelling of the orbital tissues leading to proptosis, corneal exposure, and 
diplopia. Symptoms range from eye irritation, watering, discomfort to dry eyes, grittiness 
and photophobia; in severe cases GO (3-5% cases) may result in blindness (Figure 1.2). 
For these reasons, GO patients may experience a reduction of their quality of life, and 
develop psychological distress due to the disfiguring phenotype of the disease (i.e. 
protrusion of the eyeball, eyelid retraction). GO is still considered a rare disease, with 
10-16 per million per year incidence and 2-4/10,000 prevalence [39]. 
The excess of adipogenesis (i.e. differentiation of pre-adipocyte into mature adipose 
tissue) and the over-production of extracellular matrix (ECM) have been shown to drive 
the orbital tissue remodelling and the increase in volume of the adipose/connective 
tissues that lead to proptosis, as extensively reviewed in [40, 41]. The adipogenic 
cascade is responsible for the orbital fibroblast expansion (ranging from a 30μm diameter 
of a pre-adipocyte to 150μm in mature adipocyte) and involves the activation of different 
key transcription factors for adipocyte differentiation, namely the CAAT/enhancer-
binding proteins alpha (C/EBPa) and the peroxisome proliferator activated receptor-
gamma (PPAR-γ). Oedema and proptosis are instead consequences of the 
overproduction of ECM including glycosaminoglycans (GAGs) and collagens. The 
hyaluronate (HA) is the major representative amongst GAGs in the orbital tissues and is 
mainly produced by the HA synthetase 2 (HAS2) [42], followed by the chondroitin 
sulphate. The two mechanisms of adipogenesis and HA production in the orbit are not 
acting independently one to another; but perhaps they are linked to each other through 
the regulation of the HAS2 expression itself in a depot-specific manner [43]. 
Are TRABs and pathways involved in GD also responsible for GO pathogenesis? In the 
majority of the cases, GO arises after the first episode of hyperthyroidism, suggesting a 
temporal association between the two diseases and patients with higher titres of TSAB 
are more likely to develop signs of GO [44]. Moreover, the more relapsing episodes of 
GD (i.e. uncontrolled hyperthyroidism), the higher the risk of developing GO. We have 
recently confirmed a higher TRAB levels in a group of GO patients used to identify 
disease biomarkers using proteomics and genomics, when compared to the cohort of 
patients with GD but free of GO [45]. The second evidence is supported by the fact that 
the TSHR is expressed in the orbital fibroblasts. Zhang and collaborators reported the 
activation of the TSHR signalling via the cAMP pathway in human orbital fibroblast 
leading to the initiation of adipogenesis [46], and to the HA production in human pre-
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adipocytes/fibroblasts cell line [42]. The monoclonal antibody M22, instead, was able to 
induce the differentiation of the human orbital fibroblast into adipocytes through the PI3K 
pathway, at least in part [47]. It has been reported later that the mechanistic target of 
rapamycin complex 1 (mTORC1) is necessary for adipogenesis, while the PI3K 
signalling regulates the HA production via HAS2 in the orbit [48]. Such pathways have 
been further investigated to possibly develop non-immunosuppressive therapy for GO, 
such as inhibitors of the transcription factor Forkhead box O (FoxO) activated in the PI3K 
pathway [49]. It is interesting to note that in our recent study on proteins and miRNAs as 
circulating biomarkers for GD and GO, PI3K-Akt signalling and ECM-receptor interaction 
pathways but also mTOR, FoxO and PPAR were identified [45]. 
Also, orbital fibroblasts express the insulin like growth factor receptor-1 (IGF1R) [50], 
considered as a possible second autoantigen in GO. However, whether autoantibodies 
against the IGF1R are present in GO patients, remains controversial [51]. Studies from 
Zhang and collaborators demonstrated the involvement of the IGF1R signalling via PI3K-
mTORC in activating the production of HA in the orbit alone [43] or in combination with 
the TSHR, specifically triggering the HAS2 isoform [48]. The latest data sustained a 
previous hypothesis that both autoantigens (TSHR and IGF1R) are involved in GO 
pathogenesis [52].  
Pharmacological and surgical treatments for GO are usually based on the clinical activity 
score (CAS), which consists of ten items assigned on four signs of inflammation (e.g. 
pain, redness, swelling and impaired functions). CAS was initially developed to predict 
the efficacy of immunosuppressive treatments in GO [53] and still used nowadays [54]. 
Intravenous steroid bolus (as immunosuppressive regimen) and/or local radiotherapy are 
mostly performed in the active phase of disease (i.e. inflammation signs and CAS > 4), 
while during the inactive or fibrotic phase, in case of persistent exophthalmos or diplopia, 
a surgical orbital decompression might be recommended. Supplementation with 
selenium has also shown beneficial effects, since it improved the quality of life of GO 
patients accompanied by a slowed progression of the eye disease and less eye 
involvement compared to placebo in a 6-months trial [55], possibly due to its antioxidant 
function.  
1.1.4. Immunological basis of GD/GO  
The immune system plays a major role in GD and GO pathogenesis. On one hand, the 
autoimmune response to thyroid autoantigens requires a first break-down of the immune-
tolerance, resulting in the production of IgG1 subclass autoantibodies [56].  On the other 
hand, pro-inflammatory and innate immune system cells are usually present in high 
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number in both the thyroid and the orbital fibroblasts during GD/GO pathogenesis. GD 
patients serum was enriched by a number of circulating proinflammatory cytokines such 
as tumour necrosis factor-alpha (TNF-a), IL-2, IL-6, IL-8 and IL-17 [57-59], while IL-1 
and TNF-a were produced by intrathyroidal infiltrated lymphocytes [60]. Such an 
inflammatory status is also sustained by thyroid-cells-secreted proinflammatory 
cytokines such as TNF-a, interferon-gamma (IFN-g) and IL-1. Interestingly, increased 
serum and PBMCs levels of IL-37, known to suppress inflammatory response, were 
reported in a Chinese GD cohort compared to healthy control, possibly representing an 
attempt of the immune system to suppress the concomitant inflammation in GD [61].  
Antigen-specific T cells have been reported in the thyroid, in which the Th1 immune 
response may sustain a more destructive outcome in the thyroid cells via apoptosis, and 
the Th2-mediated response, in turn, may sustain the production of stimulating antibodies 
by B cells and enhance the autoimmune response [62]. RNA sequencing performed on 
thyroid tissue of GD patients revealed the high expression of immune system genes (in 
particular B cells genes in the top 100 genes), followed by signalling cascades and 
metabolic processing genes compared to normal thyroid tissues [63]. In particular, six 
human leukocyte antigen (HLA) genes were in the top-15 most upregulated genes, 
followed by four between chemokines and cytokines gene or regulators, plus growth and 
synthesis-related genes and one uncharacterized protein compared to that of healthy 
controls. HLAs, the human counterpart of the MHC genes, play a key role in the immune 
system through the presentation of the processed antigens to the T cells in a specialized 
manner. Class I HLA in fact, interacts with the CD8 lymphocytes activating a cytotoxic 
immune response, while Class II HLA presents the antigen to CD4 which are involved in 
the regulation of specific immune response. Antigen presentation pathways were the 
most abundant from those related to the immune system, followed by T-helper signalling 
and B cell development, suggesting considerable involvement of immune system 
activation in GD compared to normal thyroid, from both the innate and the adaptive sides.  
Within the orbit, infiltration of macrophages, B and T cells (Th1 and Th2) and natural 
killer (NK) cells have been reported. Cytokines such as IL-6 and RANTES participate in 
the recruitment of T cells in the orbital fibroblasts, while TGF-b, IFN-g and TNF-a possibly 
counteract the adipogenesis mechanism, as reported in [62]. 
Mechanisms preventing or driving the autoimmune response are described in the next 
paragraphs, more in general and with specific examples for GD/GO, since they tend to 
be quite common amongst autoimmune conditions. It is also possible that patients with 
a particular autoimmune disease would develop a second different autoimmune 
condition later. 
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1.2. MECHANISMS PREVENTING AUTOIMMUNITY 
A singular characteristic of adaptive immunity is the sufficiently large repertoire of 
receptors, expressed by both T cells (TCR) and B cells (BCR). The activation of these 
cells usually requires a two-signal process: the antigen-specific stimulatory signal and 
the non-antigen stimulatory signal (or co-stimulation) often provided by the interaction 
with other molecules produced by the innate immune response actors. Generally, the 
activation of a B cell requires a first signal of activation provided by the interaction 
between the B-Cell Receptor (BCR) and the antigenic epitope and the co-stimulation 
provided by T cells (T-helper cells). Once the appropriate lymphocyte recognizes and 
binds selectively to the antigen, the resulting activation is serially replicated and 
production of a clone of lymphocytes all expressing the same antigen-specific receptor. 
The efficacy of the adaptive immune system relies on the total range of receptors on the 
lymphocyte populations which are able to recognize virtually any foreign epitopes they 
would have previously encountered [64]. The immune tolerance to self-antigens, instead, 
is generally well preserved by both T cells and B cells in the central immune system and 
in peripheral tissues. 
1.2.1. Central immune tolerance 
During their development, lymphocytes undergo a mechanism of “clonal selection” 
through which the early exposure (i.e. during the generation of the lymphocyte) of the 
cognate antigen of a lymphocyte receptor leads to the death of that lymphocyte rather 
than its proliferation [65]. This should avoid the presence of circulating clones that react 
to self-antigens defined as auto-reactive cells. The selection process is different for T 
cells in the thymus and B cell clones in the bone marrow. T cells usually undergo a two-
step selection process. Their T-Cell Receptors (TCR) have a unique ability to transmit 
both weak and strong signals depending on the number and the specificity of the 
antigenic peptides bound, in other words, depending on their affinity and avidity for that 
antigen. In the “positive selection”, weak signals derived from the interaction between 
TCR and the antigen processed and presented by the major histocompatibility complex 
(MHC) generally allows the survival and the differentiation of a T cell clone, otherwise 
strong signals would eliminate that clone via apoptosis. On the other hand, during the 
“negative selection” process all clones that react with self-antigens would usually be 
removed from the thymus, promoting the immune tolerance at a central level [66]. The 
process of thymus education is sustained by the self-antigen presentation that arises in 
the thymic medulla. Central immune tolerance to thyroid antigens such as the TSHR is 
sustained by the intrathymic expression of the TSHR mRNA. One proposed 
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mechanisms, in fact, involved the exposure of thyroid antigens to T cells in the thymus, 
promoting a state of anergy (i.e. non-responsiveness to specific antigens) against them 
[67, 68]. A lower intrathymic expression of the TSHR mRNA either due to genetic 
variants, epigenetic, environmental contributions or a combination of those (which will be 
described later in in this chapter), might be responsible for the loss of immune-tolerance 
to this antigen leading to self-reactive T-cells survival, as also demonstrated in a recent 
study in an animal model of GD [69]. Also, evidence supporting this proposed 
mechanism come from the autoimmune polyendocrinopathy-candidiasis-ectodermal-
dystrophy (APECED) in mice [70] or the polyendocrine syndrome type 1 (APS-1) in 
humans [71], caused by defects in the autoimmune regulator (AIRE) protein leading to 
the production of autoantibodies to multiple organs. The AIRE gene, primarily expressed 
in the thymus, but also on peripheral tissues on dendritic cells, encodes for a transcription 
factor which regulates the expression of numerous self-proteins in the thymic medulla 
such as for example insulin [72]. Accordingly to its function, mutations in this gene 
impairs the presentation of the self-antigens and leads to autoimmune response.  
Positive and negative selection processes, however, are likely to be influenced by the 
absence of the secondary co-stimulation signal but also by the modality of antigen 
presentation itself [73]. Unlike T cells, B cells diversify their antigen receptors (BCR) 
binding specificity at two different stage of diversification. After the initial variable (V) 
region gene rearrangements, B cells undergo the negative selection in the bone marrow. 
The encounter of the B cell with an antigen in the absence of the non-antigenic specific 
signal may lead the cell to enter a state of anergy. However, this state of non-
responsiveness may be reversed if the secondary stimulatory signals are provided later 
in life from other sources as, for example, an infection. On the other hand, auto-reactive 
BCRs can avoid deletion undergoing a secondary receptor re-arrangement mechanism 
or receptor editing [74]: the rearranged Ig V-region gene with specificity for an auto-
antigen can be “edited” and replaced with different antibody gene arrangements. After 
receptor differentiation, the unique challenge to maintain the B-cell self-tolerance is the 
second run of BCR diversification in which B cells are recruited into the germinal centres 
(GCs) in a T-cell-dependent immune response fashion [75]. In GCs, somatic 
hypermutation (SHM, i.e. accumulation of mutations in the variable V-regions of the 
immunoglobulins) naturally occurs in order to generate high-affinity antigen binding sites 
[76]. However, the random nature of mutations in V-regions via SHM may lead to the 
generation of self-reactive B cells in the GCs that have the potential to trigger production 
of antibodies directed against self-antigens (auto-antibodies). 
According to the general view provided by the large amount of literature over the past 
sixty years, the elimination processes of self-reactive lymphocytes, both T cells and B 
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cells, are naturally imperfect and the survival of lymphocytes capable of auto-immune 
response is quite common [77], also for the clearance of self-damaged cells. The 
presence of autoantibodies specially, is remarkable since it was observed that much of 
the total immunoglobulin content of the human serum includes naturally-occurring 
autoantibodies [78], while cross-reactive autoantibodies have been characterized in a 
number of autoimmune diseases, often preceded by infections, such as rheumatic 
arthritis [79], Chagas disease, Guillain-Barrè syndrome [80] and, as already described, 
GD [56]. Moreover, the presence of SHM features on most pathogenic autoantibodies 
suggests a failure in self-tolerance mechanism in GCs [75]. Patterns of somatic 
hypermutation in both light and heavy chains were described in two mAbs derived from 
a mouse model of GD immunised with TSHR [81]. Whether the immune tolerance is 
broken at either T cell or B cell level is still debated.  
1.2.2. Peripheral tolerance 
The process of elimination of self-reactive B or T lymphocytes in the thymus might be 
incomplete, leading to the escape of self-reactive clones into the circulation. Since many 
antigens may not be presented at a sufficient level of expression in the thymus, antigen 
presentation is sustained also at the draining lymph nodes and/or in organs, such as the 
thyroid gland. Evidence suggested that the presentation of the thyroid autoantigens such 
as the thyroglobulin and the shed TSHR A-subunit, either in the thyroid gland or in the 
peripheral draining lymph nodes, is mediated by the mannose receptor (ManR) 
expressed at the cell surface of dendritic cells. Whether such an auto-antigen 
presentation leads to immune response or tolerance has to be further investigated as 
proposed in [82]. The immune tolerance is also promoted peripherally (peripheral 
immune tolerance) through a different mechanisms [83].   
Anergy of T lymphocytes prevents auto-immune response also in peripherally sites. As 
mentioned before, proliferation and differentiation of naïve T cells require i) the signal 
provided by the TCR and the processed peptide-MHC and ii) co-stimulation via APCs 
(CD80 and CD86). While CD28 constitutively expressed on T cells sustains their survival, 
CTLA-4 (CD152) promotes T lymphocytes anergy, along with the inhibition of IL-2 
expression. Moreover, CTLA-4 blocks the CD4+ lineage with higher influence compared 
to the CD8+.  
Apoptotic death of T cells leads to the removal of pro-inflammatory lymphocytes at the 
end of the immune response to foreign antigens, but also of T cells with high avidity for 
a self-antigen. Repeatedly antigen-stimulated lymphocytes are usually removed through 
the activation-induced cell death (AICD) pathway, which promotes apoptosis mediated 
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by Fas, Fas-ligand (Fas-l) and caspase 8. Inhibition of AICD is performed by both protein 
blocking the death receptor (e.g. FADD-like IL-1B converting enzyme protein) and IL-2. 
Mutations in the Fas gene in lpr mouse model inhibits the regulation of the peripheral 
tolerance and leads to lymphadenopathy (i.e. enlarged secondary lymphoid tissues) 
along with autoimmunity and production of auto-antibodies similarly to SLE [84]. 
Similarly, the autoimmune lymphoproliferative syndrome (ALPS) is caused by mutations 
in either Fas or Fas-l genes [85].  
A particular case of peripheral tolerance is represented by the self-antigen sequestration 
by barriers or its expression into a privilege site (e.g. brain, eye and testis), where the 
self-antigen is not physiologically and immunologically available to lymphocytes or 
processed via APCs. In privilege sites, in fact, self-antigens or pro-inflammatory antigens 
are removed via apoptosis or suppressed via cytokines (IL-10/ TGF-b) as a general 
suppressive mechanisms without any distinctions on the type of antigens.  
Tregs are T-helper lymphocytes characterized by the expression of CD4 (T helper), 
CD25 (IL-2 receptor a chain) and the transcription factor Foxp3, as extensively reviewed 
in [9, 36, 86] (Figure 1.5). Naturally-occurring Tregs (nTregs) are produced in the thymus 
during the normal T cells maturation process and enter the blood circulation to exert their 
function in protecting against self-reactive lymphocytes. While they already express 
Foxp3, IL-2 and TGF-b are essential for their generation, expansion and their survival 
outside the thymic environment, respectively [87]. Induced Tregs (iTregs), instead, are 
generated directly in the peripheral lymph nodes as the result of the antigen presentation 
to the naïve CD4+ T cells. Foxp3 expression driven by IL-2 and TGF-b is essential for 
their differentiation. By secreting TGF-b and anti-inflammatory IL-10, Tregs are involved 
in the clearance of self-reactive T cells in the periphery, usually operated by a subset of 
cells expressing the CD8+ and CD122+ (IL-2 receptor b-chain) [88]. Moreover, Tregs 
negatively regulates  the immune response against foreign antigens (e.g. through the 
expression of the CTLA-4), avoiding a prolonged inflammation which may turn into a 
chronic disease. The role of gut-mucosa associated Tregs is described in section 1.6 
below. 
An important concept in the outcome of autoimmune diseases is the disruption of the 
balance between Tregs and Th17 cells. Beside the Th1 and the Th2 immune response, 
driven respectively by IL-18/IL-12 and IL-2/IL-4, the Th17 immune response is 
characterized by the IL-17-secreting T-helper 17 (Th17) cells involved in the protection 
of mucosa such as skin, gut and lung against fungal (e.g. Candida albicans) or bacterial 
infections [86, 89]. Pathways and molecules differentiating naive T cells into Th17 cells 
are very similar to those differentiating into Tregs (Figure 1.5). TGF-b plays a critical role 
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in determining the activation of one immune response at the expenses of the other, since 
the expression of Foxp3 (Tregs) and RORgt (Th17) transcription factors is regulated by 
the same cytokines but in a mutually exclusive manner [90]. TGF-b alone provided to 
naïve T cells, without any other inflammatory stimulations, promoted the Tregs 
differentiation inducing the Foxp3 expression in vitro, which inhibited the RORgt 
expression [91]. However, the TGF-b induce the retinoid-related orphan receptor (RORgt 
in mice and ROR-c in humans) and the signal transducer and activator of transcription 3 
(STAT3) in differentiating into Th17 in presence of IL-6, IL-21 and IL-23 [9, 90, 91]. In 
murine Th17-cell differentiation, TGF-b and IL-6 cytokines are sufficient for inducing the 
IL-17 expression in naïve T cells through the expression of RORgt; while IL-21 and IL-23 
are necessary for their subsequent amplification, expansion and phenotype stabilization, 
respectively [86]. In humans, both TGF-b and IL-21 are able to induce the differentiation 
in Th17, while amplification of ROR-c-expressing cells is sustained by IL-1b and IL-6 and 
ultimately, IL-23 is responsible for their expansion and stabilisation. Interestingly, the IL-
23 receptor (IL-23R) expression is likely to be promoted by TGF-b/IL-6/IL-21 [92]. Once 
differentiated, Th17 cells secrete not only IL-17 but also IL-21 and IL-22 and their effects 
are reviewed in [89, 93], including the activation of proinflammatory chemokines and 
cytokines in non-hematopoietic and mesenchymal cells or in myeloid cells (IL-6 and G-
CSF). Interestingly, IL-17, as well as the NF-kB, may activate the CAAT/enhancer-
binding proteins (C/EBP) transcription factors [94], which I’ve previously described 
involved into the orbital adipogenesis cascade.  
The imbalance between Tregs and Th17 leading to autoimmune conditions can be 
promoted by the presence of elevated Th17 cell numbers or by self-reactive Th17 cells 
on one hand, and by the reduction in the number of the Tregs milieu or of a reduced 
efficacy on the other hand. Multiple sclerosis, psoriasis and IBD, amongst others, 
showed an impairment of the Tregs/Th17, as reviewed in [86, 89, 93]. In GD patients not 
treated with antithyroid medications, Mao and colleagues showed a reduced CD4+ 
CD25+ Foxp3+ natural Tregs milieu, possibly due to the polarization of the dendritic cells 
which induced their apoptosis. Moreover, hyperthyroidism worsened such condition [95].  
B-cell tolerance is also exerted peripherally, since B cells leaving the bone marrow can 
be considered relatively immature. B cells outer the T cell area are usually short-lived (1-
3 days) and only in the follicles can survive longer (1-4 weeks) re-circulating. In presence 
of self-reactive B cells, mechanisms of anergy, preventing migration into B cells follicles 
and cell death are promoted. Although self-reactive clones may be left circulating to 
enhance the immune response to a wider range of foreign antigens. In absence of 
infection and co-stimulation, B cells enter anergy and apoptotic pathways rapidly. Also 
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secondary B cells, thus generated from memory B cells, are highly susceptible to 
tolerance and would be eliminated as soon they acquire self-reactivity. Similarly to Tregs, 
B cells with suppressor functions (Bregs or B10) have been described, as extensively 
reviewed in [96]. Heterogeneous subsets of Bregs have been described and they are 
more likely to be derived from B cells to suppress local inflammation under certain stimuli, 
since there is no particular transcription factor at the moment capable of driving their 
differentiation as for the Tregs. By producing IL-10, TGF-b and IL-35, Bregs directly 
promote a T cells differentiation into Tregs both in humans and mice [97, 98]. Moreover, 
they indirectly suppress the Th1 and Th17 differentiating lymphocytes suppressing the 
driving pro-inflammatory cytokines production by DCs [99]. Zha et al. [100] isolated and 
stimulated ex vivo B10 cells from GD patients (without any antithyroid drug) and healthy 
controls PBMCs and quantified the amount of IL-10 produced. Newly diagnosed GD 
patients showed a lower proportion of B10 cells, which belonged to the 
CD19+CD24highCD27+ B-cell subset, compared to healthy controls. Interestingly, GD 
patients in disease remission shared similar frequency of B10 cells with that of healthy 
controls, but a lower proportion of them in the total PBMCs. Such a subset of Bregs was 
shown to negatively regulate CD4+ T cells proliferation through both IL-10-dependent 
and independent pathways, at least in vitro, and this function was impaired in GD 
patients. Patients with other autoimmune disorders such as rheumatoid arthritis, multiple 
sclerosis and SLE reported a higher B10 proportion compared to healthy controls [101]. 
1.2.3. Role of the innate immune system cells 
For years the innate immune response was not considered to be important in the 
outcome of ADs and most of the theories proposed, in fact, did not take into account the 
role played by innate immunity cells, receptors and pro-inflammatory molecules as 
possible inducers of an autoimmune response. As the first line of immune defense, the 
innate immune system acts to recognise conserved microbial features, known as 
pathogen-associated molecular patterns (PAMPs), through a group of germline-encoded 
pattern recognition receptor (PRRs). Toll-Like receptors (TLRs) are able to recognize 
PAMPs, such as bacterial lipopolysaccharide (LPS) and flagellin and initiate an effective 
immune response that may involve the activation of the adaptive immune system. As 
well as the adaptive immune response, several pathways of the innate immune response 
may lead to an autoimmune outcome, as reviewed in [102]. Variants in innate immunity-
related and autophagy genes that confer susceptibility to the host have been described 
[103]. In particular, single-nucleotide polymorphisms (SNP) in the TLR4 and TLR5 able 
to selectively recognize and bind the bacterial LPS and the bacterial flagellin, 
respectively, have been associated with different autoimmune conditions such as 
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rheumatoid arthritis, Crohn’s disease and SLE, as recently reviewed in [104, 105]. More 
recently, the polymorphism rs5744174 of the TLR5 gene was associated with GD in 
females but not in males in a Chinese cohort. In particular, the AC haplotype in TLR5 
(rs2072493–rs5744174) and the C of rs5744174 were associated with reduced 
susceptibility, while the TC and TC/CC genotypes were shown to be protective for the 
disease [106]. Instead, no significant association of TLR4 polymorphisms were found in 
the Chinese cohort [106] or in a Taiwan Chinese population [107]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5. Schematic representation of the CD4+ and CD8+ T-cell lineages and 
their differentiation into regulatory T cells.  
(next page). CD4+ , CD8+ T cells and CD4+ CD25+ Foxp3+ natural Tregs (nTrges) 
originate in the thymus and colonise secondary lymphoid tissues, after surviving clonal 
selection process. In periphery, Naïve T cells undergo Th1/Th2/Th17 differentiation 
according to the type of interleukins they are expose to, or become cytotoxic CD8+ T 
cells. Th17 cells differentiate under exposure of IL-6 and TGF-b (in humans under IL-21 
and TGF-b) and necessitate of IL-1b and IL-6 for amplification and IL-23 for clonal 
expansion and stabilisation. nTregs need IL-2 and TGF-b for expansion and stabilisation 
in the peripheral sites. Inducible Tregs (iTregs) originate instead from either CD4+ or 
CD8+ T cells after the antigen (or self-antigen) presentation via APCs. iTregs in presence 
of IL-2, TGF-b and retinoic acid (RA) differentiate into CD4+ CD25+ Foxp3+ iTregs, while 
in presence of IL-10 differentiate into Tr1 CD4+ CD25low Foxp3+ iTregs. Suppression of 
APCs activity is mediated by iTregs via the downregulation of co-stimulatory signals or 
upregulation of CTLA4 or by nTregs via DCs inhibition. Suppression of the Th1/Th2/Th17 
responses is mediated by both nTregs and CD4+ and CD8+ iTregs, through cell-to-cell 
contacts, the upregulation of CTLA4 and production of IL-10, TGF-b and possibly IL-35. 
(Modified from [108]). 
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1.3. MECHANISMS TRIGGERING THE AUTOIMMUNE OUTCOME 
“Even if some form of B cell and T cell natural autoimmunity is universal, autoimmune 
diseases are not a frequent event [64]”. So what may determine the breakout of an 
autoimmune condition seems to be a combination of the auto-immune stimulus, possibly 
given by the environment and the polygenetic predisposition of the host. Those factors 
have been investigated for years and molecular mechanisms whereby tolerance can be 
broken have been proposed. To better represent their contribution in the breakdown of 
immunological tolerance, they could be divided into two classes, the “intrinsic and 
extrinsic mechanisms”. 
1.3.1. “Intrinsic mechanisms” leading to autoimmune diseases 
“Intrinsic mechanisms” include molecular mechanisms distinct to the host by which 
immune tolerance can be broken down, such as the genetic background, mechanisms 
of antigen presentation, education processes of lymphocytes, B cells and T cells 
regulatory pathways, some of which have already been described in previous 
paragraphs. It is not fully understood how they start to get compromised. 
The genetic background of ADs was investigated both in humans and animal models (as 
reviewed in [36, 64, 109]) and the general assumption is that genes confer most 
susceptibility to the host, determining the risk of developing an autoimmune disorder, 
rather than directly causing the disease. There are very few autoimmune conditions that 
are connected to rare single-gene mutations, such as the mutations in the Autoimmune 
Regulator (AIRE) gene responsible for the development of APECED, previously 
mentioned. However it has been generally recognized that the most common 
autoimmune diseases are non-Mendelian polygenic diseases. The main source of 
genetic susceptibility is the Human Leukocyte antigen (HLA), also known as Major 
Histocompatibility Complex (MHC) in mice, whose contribution was discovered initially 
in experimental thyroiditis and then attributed to virtually any autoimmune diseases, both 
in murine models and humans [110, 111].  
In the past years, HLA loci were associated to either conferring susceptibility or 
protection from the development of GD to the host, as reviewed in [112]. In Class II HLA, 
the variant HLA-DRB1*03 with an Arginine in position 74 seemed to confer susceptibility 
to GD [113], although it was not always confirmed; while the HLA-DRB1*07 with Gln-74 
was associated with a decreased frequency among GD compared to controls. For Class 
I HLA, the HLA-C*07 was associated with GD, while C*03 and C*16 had a more 
protective effect [113]. However, even if common variants or genetic loci remain to be 
identified, HLA remain the strongest amongst the genetic factors for predisposition of 
  
 
 
23  
GD. Other genes found to confer susceptibility in most autoimmune conditions belong to 
the cluster of genes that usually regulates immune responses such as the cytotoxic T 
lymphocyte-associated protein 4 (CTLA4), CD40, protein tyrosine phosphatase-22 
(PTPN22), programmed death 1 (PD1) and IL-23 receptor (IL-23R), which are commonly 
shared amongst different autoimmune conditions. Of interest, two polymorphisms of IL-
23 (rs10889677 and rs2201841), despite conferring susceptibility for Crohn’s and 
rheumatoid arthritis, were associated to GO rather than to GD [114], suggesting a 
possible cross-talk of the Th17 immune response in the GO pathogenesis.  
Genetic susceptibility is also often attributed to gene variants expressed in the target 
organ such as the TSHR in GD, Tg in Hashimoto's thyroiditis and Insulin in T1D. Gene 
variants that occur at the promoter site of those genes, especially, seem to affect the 
expression of the autoantigens in the thymus: the lower the intrathymic expression of 
these genes, the higher the risk of developing autoimmunity. In individuals with particular 
genetic variant for the insulin gene, a decreased intrathymic expression of insulin was 
associated with a decreased central tolerance to insulin that can lead to an autoimmune 
response to insulin and to type 1 diabetes [115]. Similarly, several Single Nucleotide 
Polymorphisms (SNPs) have been described in the TSHR gene conferring genetic 
susceptibility to GD [116-118]. In particular, two of them mapping to the TSHR promoter 
region [112, 119], were recently associated with a decreased expression of the TSHR in 
the thymus and, in turn, a higher risk of developing autoimmunity to TSHR, as previously 
introduced [67, 68]. However, loci conferring genetic susceptibility to AD (and GD in 
particular) failed to be completely generalized since they reflected the genetic variability 
of the ethnic groups in which they have been investigated [112]. 
Another component of genetic susceptibility of interest is sex, especially for autoimmune 
thyroid diseases (AITDs) such as GD, where the female predominance is remarkable. 
Establishing the reasons why women are more likely to develop ADs is difficult. Female 
hormones seem to play an important role in the outcome of these pathologies, as shown 
by the influence of oestrogens in the B cell repertoire [120]. Hormone levels themselves 
might be regulated by the presence of certain types of gut bacteria, regulating the risk of 
developing an AD [121]. In AITD, the connection between sex differences and leptin has 
been proposed [122]. Also, the role of foetal microchimerism in pregnant women has 
been connected either to the initiation or the exacerbation of AITD and GD, but also to 
cancer development [123, 124]. The presence of foetal cells in the maternal body during 
pregnancy, in fact, may lead to the breakdown of immune tolerance, especially after the 
delivery when the mother’s immune suppression mechanisms are lost. However, these 
theories are not applicable for other autoimmune conditions such as rheumatoid arthritis 
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and multiple sclerosis that are quite balanced between sexes, or for myocarditis which 
occurs more in males. 
In parallel to the genetic variation of the host, an emerging compromising mechanism 
seems to involve epigenetics that, instead of genetics, refers to molecules and pathways 
that control expression of individual genes in a manner that goes beyond the sequence 
of DNA. The structural composition of the chromatin, in fact, influences whether a gene 
is expressed and at which level and, on the structural chromatin composition itself is 
regulated by epigenetic modifications. These include post-translational modification of a 
single residue, e.g. methylation of DNA cysteines, or important post-translational 
modification at a nucleosome level (e.g. ubiquitination, acetylation and methylation), but 
also chromatin remodeling or gene silencing by RNA interference (RNAi) and non-coding 
RNAs. All together, these modifications can either activate or inactivate gene expression, 
depending on their amount and localization [125]. Several lines of evidence connect 
epigenetics to autoimmune outcomes. The case of the AIRE gene, encoding for a 
transcription factor that regulates the expression of several important self-proteins in the 
thymus (e.g. insulin) [72], represents the contribution of the epigenetics in the APECED’s 
outcome. In GD, the reduction of the intratymic TSHR mRNA expression resulting in the 
loss of immune-tolerance might be triggered by epigenetics. As described in elegant 
work by Tomer and collaborators, thyroid cells exposed to INF-alpha (triggered for 
example by a viral infection) display an enriched methylation pattern in the intron 1 of the 
TSHR spanning two SNPs previously associated with GD. One of those, rs12101261, 
serves as a binding motif for the transcriptional repressor promyelocytic leukaemia zinc 
finger protein (PLZF). These results can also be transposed to the central immune 
system, since the intrathymic down-regulation of the TSHR mRNA was observed in 
patients homologous for the rs12101261 SNP which negatively correlated with levels of 
PLZF in the thymus [67].  
MicroRNA (miRNA) are small non-coding RNA sequences (about 22 nucleotides) that 
can regulate the expression of protein-coding genes even in trans since they can be 
found circulating in the blood. Their role in repressing gene expression was found in 
cancer and in autoimmune diseases [126], such as multiple sclerosis, type 1 diabetes 
and systemic lupus erythematosus. In GD, two (hsa-miR-30c-2* and hsa-let-7b*) out of 
16 miRNAs differentially expressed were upregulated in the peripheral blood 
mononuclear cells (PMBC, i.e. lymphocytes and monocytes) of patients compared to 
controls. Three miRNA were associated with the newly diagnosed patients, since they 
were normally regulated in remission [127]. Other upregulated miRNA (miR-636 and 
miR-30a-5p) suppressed genes involved in the retinoic acid pathway in the Tregs of GD 
patients [128]. Recently, we identified five novel circulating miRNA as biomarkers for 
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distinguishing GD or GO patients, such as Novel:19_15038 miRNA and Novel:hsa-miR-
182-5p both up-regulated in GO, from controls from a robust analysis combining both 
differential expression (DE) analysis and Lasso-penalized prediction models. miRNAs 
with a known functions were identified from the DE analysis only [45].  
Given that genetic/epigenetic susceptibility is necessary but not sufficient for the 
development of autoimmunity, immune tolerance is  at the very basis of an autoimmune 
outcome and environmental factors, in combination with the genetic predisposition, 
account for its breakdown. 
1.3.2. “Extrinsic mechanisms” underlying autoimmune diseases 
1.3.2.1. The hygiene hypothesis 
Epidemiological observations are reporting an increase in type I hypersensitivity (allergy) 
and autoimmune diseases incidence (such as IBD, ulcerative colitis, and MS…) in 
developed countries, as reviewed in [129, 130], whereas the exposure to potentially 
harmful microbes is reduced by a number of preventing measures such as vaccinations, 
personal hygiene, antibiotic usage and water treatments. Although allowing a higher 
survival rate and an improved quality of life, such measures may lead to a dysregulation 
of the immune system for not being exposed to a sufficiently wide repertoire of 
environmental and microbial epitopes. In the so-called “hygiene hypothesis” [131], a 
correct exposure to micro-organisms and parasites is of a particular importance in the 
early-stage of life, when the immune system is trained to discriminate between self and 
non-self. Children growing up in a farm environment seem to be more protected from 
asthma and allergies reactions than children in urban environment, possibly due to 
proper modulation of both innate and adaptive immune systems by microbial and 
environmental exposure before or soon after birth [132]. Also differences in farming 
practises may also have an impact. USA Amish children, exposed to a traditional farming 
environment shown a lower incidence of asthma and allergic reactions along with an 
increased levels of endotoxins compared to the USA Hutterite children, living in a more 
industrialized farming environment. The exposure to the dust extracts of the Amish, but 
not to the Hutterite’s homes, prevented the development of allergic features in an 
experimental allergic asthma mouse model [133]. Hygienic measures may also influence 
the composition of the gut microbiota, which in turn (as it will be later discussed) has an 
effect in training a proper immune response, possibly increasing the incidence of 
autoimmune responses. Vatanen and collaborators from the DIABIMMUNE project 
reported the higher presence of E. coli-derived lipopolysaccharide (LPS) in the gut 
microbiota of Russian children along with a decreased incidence of developing type 1 
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diabetes (TD1) compared to that of infants from Estonia and Finland, whose microbiota 
was increased in Bacteorides dorei LPS and with an higher incidence of TD1. Moreover, 
administration of B. dorei-LPS did not prevent the development of diabetes in non-obese 
diabetic (NOD) mice [134]. 
1.3.2.2. Mechanisms involving bacterial antigens   
Since the majority of lymphocyte receptors recognise non-self antigens from microbial 
and viral epitopes it is logical to consider infection as the activator of autoimmunity. This 
is reflected in the literature of the past 10 years, which highlights the role of infections in 
human autoimmune disease [135-140] and in induced animal models. Moreover, the role 
of the infectious agent in the induction of autoimmune disease in animal models has 
been established [141]. Theories such as hidden/cryptic antigens, epitope spreading, 
anti-idiotypes, molecular mimicry, antigenic complementarity and bystander effects have 
been largely proposed as mechanisms by which immune tolerance can be compromised, 
largely reviewed in [135]. 
The most popular theory is molecular mimicry, first proposed in 1964 by Damian [142] 
as a definition of the molecular mechanism by which microorganisms should become 
“invisible” to the host immune system, escaping the control of the immune response. The 
role of the molecular mimicry as a mechanism to drive autoimmunity  [142, 143]: a 
susceptible host acquires an infection with an agent that has antigens with immunological 
similarity to the host antigens but they differ sufficiently to induce an immune response 
when presented to T cells. As a result, the tolerance to auto-antigens breaks down, and 
the pathogen-specific immune response cross-reacts with the host structure to cause 
tissue auto-damage or auto-stimulation. The theory was further defined as molecular-
epitope mimicry [64] since T cells and B cells are tailored to recognize particular short 
amino acid sequences or peptides processed upon presentation by APCs. Several lines 
of evidence have connected the role of epitope mimicry to the induction of autoimmune 
conditions [144]. Auto-antibodies against the serum glycolipids constitute the hallmark 
feature of the Guillain-Barre syndrome (GBS), causing a paralysis of the peripheral 
nervous system by targeting neural tissues. They are potentially derived from a cross-
reaction with Campylobacter jejuni antigens, whose infection may occur days or weeks 
before the GBS onset [80]. Other examples include Streptococcus pyogenes in 
rheumatic fever and in rheumatic heart disease [145] and of Borrelia burgodoferi in Lyme 
disease [146].  
In GD, the molecular mimicry between Yersinia enterocolitica (YE) antigens and thyroid 
auto-antigens has been proposed [147] and recently extensively reviewed in [148], as it 
will be further discussed in Chapter 4. Ultimately, the contribution of viral infection was 
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described as well, indicating the Coxsakie B and the Hepatitis C viruses as an increased 
risk factor for the development of autoimmune thyroiditis [149, 150]. 
The second theory which has to be considered is the epitope spreading mechanism. This 
introduces the possibility that the resulting autoantigenic epitope may be different from 
the early stage of the disease pathogenesis [151], since the spreading of the epitope 
would be the result of the normal activation of the immune response. At the first 
encounter of the pathogen’s epitope, the immune system produces T cells and B cells 
with high affinity against it. At the second re-encounter of the same pathogen, the 
immune system would produce a response to a second epitope of the pathogen to assure 
the enhancement of the immune response in future events. In line with this theory, it 
seems that multiple infections result in multiple auto-autoantibodies, some of which are 
capable of driving an autoimmune disease, and temporally that the autoimmune disease 
must be preceded by infections and epitope spreading and not simultaneously [135].  
These two theories assume that the initiating event in the development of ADs is the 
infection driven by a single pathogen. Along with some of the theories mentioned above, 
two other theories have been recently proposed [152], namely molecular modification 
pathway and hyper immune-inflammatory response pathway also defined as “pathogen-
driven autoimmunity mimicry” (PDAIM). The first implies that the infecting mechanisms 
of the pathogen might enzymatically modify proteins or targets of the host, thus inducing 
the normal host’s immune response acting against that, causing an autoimmune-
disease-like condition. The second implies that an individual with one or more genetic 
disorders in the immune-inflammatory molecular signaling pathways is more likely to 
have a prolonged immune-inflammatory response against infection, which may lead to 
the development of an autoimmune condition. Although these two new mechanisms are 
not prone to compromise self-tolerance and the contextual auto-reactive cell reactivation, 
some evidence seems to support them for AD’s outcome, as reviewed in [152], moreover 
there are no described examples for the thyroid autoimmune diseases.  
In contrast to the theories above, another popular theory called the “adjuvant effect or 
bystander effect” is more referred to general infections rather than to a specific pathogen 
triggering the AD outcome. It is well known that infections stimulate the activation of the 
innate immune response leading to the release of cytokines and other pro-inflammatory 
molecules, preventing the outcome of infectious disease. On the other hand, these 
molecules might activate some auto-reactive T or B cells which escaped deletion 
processes, to drive or exacerbate autoimmunity [135]. As previously described, 
lymphocytes need two signals to initiate the immune response. In the context of the 
induction of AD, the second non-antigen-specific signals necessary to activate the 
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response could be given by the bystander or the adjuvant effect. The most striking 
examples of this theory and the role of microorganisms to induce the overcoming of self-
tolerance come from the induction of experimental autoimmune disease in animal 
models using complete or incomplete adjuvants that seem to mimic microbial infections, 
which are described in the next paragraph. In particular, adjuvants such as inorganic 
salts (e.g. alum and magnesium) but also bacterial or viral product, such as LPS or the 
complete Freund’s adjuvant (CFA, i.e. heat-killed Mycobacterium tuberculosis in 
emulsion oils) can act concentrating the antigen in a specific site where it would be 
exposed to the immune system (“depot effect”) or induce the cytokines production 
enhancing the immune response and the subsequent antibodies production. Different 
types of adjuvants may induce a different response: alum may cause the “depot effect” 
but also activate the inflammasome, as well as LPS via TLR4 signaling; while CFA 
triggers a Th17/Th1 immune response [153] and the incomplete Freund’s adjuvant, by 
lacking the Mycobacterium contribution, may enhance a Th2 response. Nevertheless, 
autoimmunity was induced without adjuvants when non-autologous antigens are used to 
immunize the animal model [154]. 
1.3.2.3. Other environmental factors 
Apart from the genetic and microbial contribution in predisposing an autoimmune 
response, other common environmental factors may play an additional role in 
predisposing GD and its progression to GO.  
Cigarette smoking has been directly associated to other conditions such as lung 
carcinoma and vascular diseases and may increase the susceptibility for an individual to 
develop an autoimmune disease [155]. In autoimmune thyroid diseases, smoking is 
considered a strong risk factor for GO development rather than GD, as reviewed in [155, 
156]. While there were no differences in the TRAB serum levels between smokers and 
non-smokers GD patients, smokers group experienced a slower reduction of TRAB 
levels during anti-thyroid drug treatments [156] and an increased risk of GO after 
radioiodine treatment [157]. Moreover, smoking increases the chances of relapsing GD 
[158], which is in turn a strong predisposing factor for GO (as previously described in 
par. 1.1.3). Currently smokers GD patients are more likely to develop signs of GO rather 
than non-smokers or ex-smokers [159] accompanied by a less effective GO treatments 
with steroids or irradiation [58], and to develop a more severe GO condition in a dose-
dependent manner [160]. Smoking induces pro-inflammatory cytokines expression, 
activating the both the innate and the adaptive immune systems. Human orbital 
fibroblasts when exposed to cigarette smoke extract in vitro showed an increase of 
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prototypical pathways described in GO in the previous par. 1.1.3, such as adipogenesis 
and hyaluronan overproduction [161].  
1.4. PRECLINICAL AND INDUCED GD/GO DISEASE MODELS 
Diagnosis of AD is usually made on patients who already present some or all the clinical 
symptoms. For this reason, mechanisms underlying the loss of immune-tolerance may 
have to be investigated in depth using pre-clinical models, which can resemble the 
characteristic of the disease in question. 
1.4.1. Animal models of GD/GO 
Spontaneous thyroiditis was reported in obese strain (OS) chickens, dogs, marmosets 
and in Bio-breeding rats, non-obese diabetic (NOD) mice and NOD.H2h4 mice, as 
reviewed in [36, 162]. Specifically the thyroid autoimmune response in chickens and rats 
is directed against Tg, while the NOD mice have an anti-TPO response. On the contrary, 
spontaneous form of GD and TSHR auto-antibodies production are rarely found in non-
human species, including great apes [163]. Few possible explanations of this lack of 
spontaneous GD/GO in animal models, according to [164], are that: i) the TSHR has the 
lowest expression amongst thyroid autoantigens, while Tg is the most expressed, and ii) 
the murine TSHR A-subunit lacks one N-glycan pattern compared to the human  and 
they only share less than 90% sequence identity. Therefore, models for the hyperthyroid 
GD and GO have to be induced and different methods were developed so far, leading to 
heterogeneous responses as reviewed in [36, 162, 165].  
One of the main limitation initially faced by researchers was the production of an 
adequate amount of TSHR from protein recombination techniques [166], with a correct 
and functional N-glycosylation patterns and folding [167]. The first successful method for 
inducing a GD model was reported in 1996 and consisted in the injection of a fibroblast 
cell line expressing the MHC-II and the full-length and functional human TSHR (hTSHR) 
[168]. The majority of female AKR/N mice injected with the murine RT4.I5HP fibroblasts 
- co-expressing the full-length hTSHR and MHC-II - shown the induction of TBII and 20% 
of them developed higher T4 and TSAb activity. Control mice injected with either MHC-
II or hTSHR alone fibroblast did not developed any sign of disease. The aberrant 
expression of MHC-II itself, and not the regulation via non-MHC genes, served for the 
presentation of the hTSHR to helper T cells in thyrocytes, acting as APCs, and leading 
to the induction of the auto-immune response and TSABs production [169]. When the 
same protocol was replicated providing alum as a Th2-adjuvant, an earlier onset of the 
disease with higher T4 levels and goitre were reported in some of the animals, while in 
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presence of complete Freund’s Th1-adjuvant, a slower onset of the disease was 
observed but high T4 levels were retained for a longer period of time (14 weeks) [170].  
The in vivo expression of the hTSHR cDNA in eukaryotic plasmids, or genetic 
immunization, initially led to TBII-TSBAb development and some signs of thyroiditis with 
only one inbred BALB/c mouse positive for TSAb [171] and inconsistency in model 
replication [172, 173]. However, when performed in outbred mice, hyperthyroidism was 
induced in some female mice and some signs of eye involvement were reported [171]. 
Increased incidence (i.e. hyperthyroidism in 50% of BALB/c immunised mice) and 
reproducibility of the model were obtained by employing adenoviral plasmids for in vivo 
hTSHR expression [174]. Moreover, the highest incidence of hyperthyroidism in 
immunised mice (60-80%) was achieved using the shed A-subunit of the hTSHR, 
indicating not only the auto-antigenic nature of the ectodomain but also its immunogenic 
role in inducing autoimmunity in murine models [175]. Even if the adenoviral delivery of 
hTSHR A-subunit became one of the most common method for inducing GD in murine 
models [175], the duration of the anti-TSHR response and the strength of the antigenic 
stimulus were not enough adequate to induce the eye disease [165].  
Different approaches were reported to induce changes in the orbital histology typical of 
GO. Based on their previous observation regarding the TSHR expression in orbital 
tissues [162, 176], Ludgate and colleagues specifically investigated orbital tissues from 
BALB/c and NOD female mice receiving either unfractionated or CD4+-enriched in vitro 
primed T cells generated from an in vivo primed mice with either GI or by recombinant 
hTSHR-ectodomain fusion protein [177]. While NOD group developed a disruptive 
thyroiditis but no changes in orbital tissues, BALB/c mice shown a more heterogenous 
response in terms of T4 levels between 4 and 18 weeks after transfer, and changes in 
orbital histology such as adipogenesis accumulation, oedema and immune-cells 
infiltration were reported in 17 out of 25 T-cells primed mice. Banga and colleagues, 
instead, optimized the electroporation procedure in the biceps femoris for the injection of 
hTSHR plasmid previously described [178] and reported signs of orbital fibrosis [179]. 
Interestingly, their work described an interaction between the anti-TSHR and anti-IGF1R 
immune responses possibly implicated in GO, which was also previously described in 
par. 1.1.3. Subsequently, the protocol was replicated including in vivo magnetic 
resonance imaging (MRI) for the evaluation of the orbital muscles and an in-depth 
analysis of the orbital pathology. Despite mice were mostly hypothyroid with TSBABs 
levels, retrobulbar inflammation, adipogenesis and chemosis (i.e. swelling of the 
conjunctiva) were reported [180].  
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The heterogeneous response to the induction of GD and GO in animal model somehow 
recapitulates the heterogeneous manifestation of the disease in humans, caused by a 
combination of genes and environmental factors. In fact, some MHC-mediated genetic 
background seemed resistant to GD development, such as the C57/BL6 strain [167, 
169]. Resistance in developing GD/GO is also imputable to the use of human TSHR 
(either full length or the A-subunit), whose induced TSAbs has to cross-react with the 
murine TSHR in order to breaks the immune tolerance in mice [36]. Strains such as the 
BALB/c and C3H/He, but not the C57/BL6 demonstrated cross-reactivity of TSAbs when 
measured in CHO cells expressing the murine TSHR [181]. Using the murine TSHR led 
to a variety of outcomes. BALB/c mice treated with baculovirus-expressed murine TSHR 
recombinant protein, in presence of alum and pertussis toxin as adjuvant, shown 
presence of TBII/TSBAb and reduced T3, with consequently increased TSH, but no signs 
of thyroiditis [182]. TSHR knockout (KO) conferred susceptibility to BALB/c female mice 
immunised with the mouse TSHR A-subunit in producing TSAb levels with activity 
against the murine TSHR, but poorly cross-reacting with the human TSHR. Instead, 
TSHR-KO mice immunised with hTSHR A-subunit adenovirus generated high levels of 
TSAb cross-reacting well with the murine TSHR in vitro. However, no thyroiditis was 
reported [183]. A transient hyperthyroidism (TSAb levels and low-incidence high T4) 
followed by a persistent hypothyroidism (TSBAb abd high TSH) were obtained when 
transferring splenocytes from TSH-KO mice immunised with mouse TSHR A-subunit into 
wild-type athymic nude BALB/c mice (i.e. lacking mature lymphocytes). Interestingly, 
only 2 out of 9 athymic mice Tregs-depleted after adoptive transfer shown signs of 
immune cells infiltration in the orbits [184]. Only recently, Banga and Eckstein group 
reported the induction of GO through the injection via electroporation of the mouse 
TSHR-A subunit in female BALB/c mice. TSAb levels shown activity against the mouse 
TSHR but low cross-reactivity with the human TSHR. Despite T4 and thyroiditis were not 
induced, immunised mice shown adipogenesis and increased inflammation 
accompanied by immune infiltrates in the orbit [185]. 
One can argue that only limited mechanisms of loss of immune tolerance can be drawn 
from these experiments on the moment that the majority of the studies used female mice, 
being a disease with a female prevalence. Only recently, GO was induced in both male 
and female BALB/c mice [185]. Also, studies present in literature so far involved mice 
being immunised when at no more than 8 weeks old; disease mechanisms in an older 
cohort might be different and it would be of interest to observe specially because the 
average age of disease onset in GD/GO patients is between 30 and 50 years old, even 
if it can arise at any age [186]. 
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Other environmental factors such as the use of adjuvants but also the housing of the 
mice (specific pathogens free, more sterile, vs. conventional caging) may interfere with 
the auto-immune response and determine slightly different disease phenotypes [187] or 
cause the failure when replicating the animal model [172, 188]. Also, the role of the 
microbial environment and the gut microbiota composition were suggested to be 
implicated in the heterogeneity of the disease outcomes [64, 187, 188]. 
1.4.2. Induced GD after Alemtuzumab treatment  
Immunosuppressive treatment with alemtuzumab (Campath-1H) is usually required in 
presence of relapsing-remitting multiple sclerosis (RR-MS), characterized by of new or 
increasing symptoms followed by disease remission episodes [189], but also in cases of 
rheumatoid arthritis and after some organ transplants. Alemtuzumab is a humanized 
mAb directed against CD52, expressed on the surface of lymphocytes, monocytes and 
some DCs. It causes the fast and long-lasting depletion of lymphocytes (both B and T 
cells), namely lymphocytopenia, followed by the so-called “immune reconstitution” phase 
which can last few months to years, as recently reviewed in [190]. B cells are the first to 
recover, usually after 3 months from depletion, and are generally characterized by 
mature naïve lymphocytes. T cell-reconstitution appear to be delayed, within 35 months 
for CD4+ and 20 months for CD8+-T cells, and usually derived from circulating memory 
T-cell clones [191]. In this context, during the period in-between B and T cells 
reconstitution, B cells are left without the proper co-stimulatory signals which may 
enhance auto-immune responses post-Alemtuzumab [192]. Also the T cells 
reconstitution itself may lead to autoimmunity, since the newly formed T cell-clones 
mostly derive from circulating memory T cells, more prone to react against self-antigens. 
Interestingly, no involvement of the innate immune system has been observed.  
About 40% RR-MS patients develop GD in five years-time after alemtuzumab 
administration (40.7% in a recent Belgium assessment [193]), with a higher risk of 
developing the disease in the first year up to three years after lymphocytes depletion, 
with a lower risk after four years. GD symptoms and disease progression seem to be 
more manageable with anti-thyroid drugs than normal GD [193], and shift from 
hyperthyroidism to hyperthyroidism spontaneously occurs [194], suggesting the 
involvement of both TSAb and TSBAb. Low incidence of GO was also reported, i.e. 1.7% 
in [194] and 7/62 with two severe GO cases reported in [195]. Interestingly, post-
alemtuzumab GD patients had a higher level of IL-21 compared to patients without 
autoimmunity after alemtuzumab [196]. IL-21, as already described in par. 1.2.2, is 
involved in IL-17 proliferation/Tregs suppression and a consequently antibodies 
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production, and therefore higher IL-21 levels before immune reconstitution may 
constitute a risk factor for developing GD after alemtuzumab.  
GD post Alemtuzumab-induced immune reconstitution can be considered as an induced 
human model of GD, which can help providing new insights on the loss of immune-
tolerance mechanisms, as recently proposed [197]. 
1.5. INTRODUCTION TO THE GUT MICROBIOME  
1.5.1. The gastrointestinal tract 
The digestive or gastrointestinal tract (GI) tract is formed by oral cavity, oesophagus, 
small and large intestines and the anus (Figure 1.6). Salivary glands, liver and pancreas 
constitute the associated glands of the GI. GI functions include: i) digestion of nutrients 
and macro-molecules, which are ingested and pre-processed via mastication, ii) 
absorption of water and electrolytes, iii) energy production, iv) synthesis of vitamins (e.g. 
Vitamin B12) , v) hormones release and vi) elimination of indigestible food source.   
The oral cavity, or mouth, is responsible for the pre-processing of food via the mechanical 
action of teeth and the enzymatic digestion of complex carbohydrates via ptyalin, mucin 
and amylase enzymes secreted in the saliva. The oesophagus, a 25-26 cm-long 
muscular tube, transports the food bolus after swallowing through involuntary peristalsis 
from the pharynx to the stomach, which is located in the abdominal cavity, under the 
diaphragm. The stomach content of an adult varies from 1L at pH 2 during fasting to 
doubled its volume at pH 3-4 after a meal intake, depending on the status of the ingested 
meal (solid vs. liquid; as reviewed in [198]). Besides the digestion of the complex 
carbohydrates already initiated by amylase, secreted gastric enzymes including lipases 
and pepsin initiate the digestion of triglycerides and proteins, respectively, in presence 
of a highly acidic environment sustained by the secretion of hydrochloric acid (HCl), 
which can last on average 3 hours (depending on the caloric values of the meal), 
accompanied by low peristaltic movement. The small intestine is about 5 meters-long 
and is divided into duodenum, jejunum and ileum. The leading function of the small 
intestine is the absorption of the nutrients, which is enhanced by its microscopic 
structure. The wall of the small intestine, in fact, presents circular creases (plicae 
circulares, especially situated in the jejunum) and its mucosa is characterized by finger-
like protrusions into the lumen, called villi, which contain lamina propria tissue connecting 
microcirculation and lymphatic system (lacteals). Villi are finely covered by columnar 
enterocytes and some goblet cells, and the apical section of each enterocyte is itself 
characterized by microvilli, increasing the absorption of degraded nutrients (Figure 1.6C). 
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While di- or mono-saccharides and amino acids are absorbed by enterocytes and 
released in the microcirculation, lipids and fats are further processed by the liver-
secreted bile and the pancreas-secreted pancreatin enzyme, in a basic environment (pH 
6.5-7.5). Glycerol, short and medium-chain fatty acids are introduced into the blood 
circulation, while triglycerides covered by lipoproteins (chylomicrons) enter the lacteal2 
(Figure 1.6). Transit time through the small intestine takes on average 3 hours. The large 
intestine is about 1.8 meters-long and is composed in cecum (with ileocecal vales and 
appendix), colon (ascending, transverse, descending and sigmoid, respectively) and 
rectum, comprising the distal end or the anal canal. Mucus layer is produced by goblet 
cells, especially in the colon and the rectum. Water and electrolytes absorption is 
mediated by an increased number of columnar colonocytes with irregular microvilli 
through the large intestine, which terminates at the distal end of the rectum, where non-
absorbed and indigested food (e.g. high-fibre vegetables) are stored before being 
expelled as faeces.  
Studies on the involvement of the gut in human diseases (as they will be further 
implemented in this work) often rely on the use of mouse models, also due to the 
similarity in terms of anatomical and physiological structures of the gut between the two 
mammalian species (Figure 1.6A and B). However, as a result of the adaptation to 
different diets, energy requirements and metabolisms, important differences can be 
identified; i.e. larger cecum, taller intestinal villi, smooth and single colon tract with a thin 
mucosa, amongst others, as reviewed in [199] and Figure 1.6. 
 
 
 
 
 
 
 
 
 
                                               
2 Digestive Tract. In: Mescher AL. eds. Junqueira's Basic Histology, 14e New York, NY: 
McGraw-Hill 
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Figure 1.6. Anatomy of the gastrointestinal tract. 
The gastrointestinal tract (GI) is constituted of stomach, small and large intestines, in 
both (A) mice and (B) humans, with some differences (e.g. larger cecum, taller intestinal 
villi, smooth, single colon tract with a thin mucosa, lack of taenia coli and haustra in the 
colon tract of mice). (Modified from [199]). (C) The leading function of the small intestine 
is the absorption of the nutrients, which is enhanced by its microscopic structure. The 
wall of the small intestine in humans, characterized by finger-like protrusions into the 
lumen, called villi, which contain lamina propria tissue connecting microcirculation and 
lymphatic system (lacteals). Villi are finely covered by columnar enterocytes (intestinal 
epithelial cells) and some goblet cells, and the apical section of each enterocyte is itself 
characterized by microvilli, increasing the absorption of degraded nutrients. (Modified 
from https://bio.libretexts.org).  
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1.5.2. The microbiota-microbiome concept 
A microbiota is a collection of microorganisms such as bacteria but also fungi, Archaea, 
viruses and protozoa residing in a specific ecological area, whose term was first 
introduced by Lederberg and McCray [200], referring to microorganisms associated with 
human health or to a disease status. As proposed by Marchesi and Ravel [201], such a 
terminology should be used to indicate the results of a microbial survey (identity and 
relative or absolute quantification) based on a genetic marker. Beside the standard 
microbiology methods, which can suffer of some limitations due to the stringent culture 
conditions required by most of anaerobic bacteria, molecular techniques were developed 
to study the microbiota in its overall composition based on the variable regions of the 
16S rRNA gene for bacteria or the 18S rRNA gene for fungi [202], or based on real-time 
quantitative PCR [203, 204], to overcome the impossibility of culturing most of the 
bacteria due to their unique growth conditions.   
Metataxonomics is a culture-independent approach based on the high-throughput 
sequencing of variable regions of the bacterial 16S rRNA gene to obtain information 
about the taxonomic diversity, such as the identity and the relative quantification usually 
involving complex microbiomes, such as the gut microbiome [205]. Polymerase Chain 
Reaction (PCR) primers used for the amplicon-sequencing are often based on the highly 
conserved regions of the 16S rRNA gene to target variable regions (e.g. V1-V2 or V3-
V4), which belong to a determined bacterial species and may act as a marker for 
phylogenetic analyses [206]. As the results of the high-throughput sequencing, e.g. 
Illumina platform (Illumina, San Diego, USA), reads are processed via bioinformatics 
pipelines (e.g. Mothur [207] or QIIME [208]) to filter poor quality bases and chimeric reads 
(i.e. generated when two markers are joint together during amplification, leading to an 
apparent novel taxon [205]) out and to align the passing-filter reads to one of the 16S 
gene reference databases now available (e.g. SILVA [209], the Ribosomal Database 
Project [210] or GreenGenes [211]), which were created from previous studies and 
collections of different ranges of cultured and environmental bacterial isolates. Aligned 
tags which cluster together at a certain cut-off (usually 97%) are considered as identical 
and referred to as Operational Taxonomic Unit (OTU), often representative of bacterial 
species. OTUs can be binned into phylogenetic levels from phylum to genus or species. 
A pivot table called OTU table with OTU or taxonomic abundances in rows and each 
sample in columns is used for subsequent analysis, which would be described 
extensively in the subsequent chapters. The term “microbiome”, instead, should be used 
when referring to the interplay between microorganisms, the surrounding environment 
and their genomes [209]. Since such a term includes also the functions of 
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microorganisms, a metagenomics or metatranscriptomics approach should be used. 
Metagenomics or whole-metagenome shotgun (WMS) involves the sequencing of the 
whole microbial genome (e.g. bacterial, but also Archaea and fungal).   
One of the advantages in using such methodologies relies on their high-throughput, 
enabling processing of several samples in a run and being suitable for large trials and 
longitudinal studies, benefitting also from the decreasing cost for sequencing and the 
increased speed in sequencing the DNA. Some major projects contributed to the 
establishment of the bacterial genomic reference catalogues used nowadays when 
processing and analysing microbiome data. The Human Microbiome Project (HMP) was 
a direct consequence of the Human Genome Project, aiming to characterise the 
microbiome and factors that influence the presence of such microorganisms, to better 
understand the variability in human genetic and physiology diversity [212]. Initially funded 
by the NIH and with the collaboration of other international consortia, the first phase of 
the project (2008-2012) obtained the genomes from 900 strains sequenced by the HMP 
Jumpstart Centres [213], 100 genomes from the E.U.-funded Metagenomics of Human 
Intestinal Tract (Meta-HIT) project from 124 healthy individuals [214], plus additional 
genomes sequenced by other international centres, along with the generation of 
technologies and bioinformatic tools for analysis and data repositories. The healthy 
microbiome of 18 body sites from 242 individuals has been extensively characterized in 
terms of taxonomy and functions [215], which was further extended to a second wave of 
analysis including 1,631 new metagenomes from different body sites and multiple 
timepoints from 263 individuals [216]. In the second phase of the project (2014-2017), in 
fact, the Integrative Human Microbiome Project (iHMP) aimed at the complete 
characterization of the human microbiome, in longitudinal studies with a focus on the 
relationship of the microbiota in healthy and specific-diseases cohorts, such as preterm 
babies, type 2 diabetes and inflammatory bowel diseases [217]. 
1.5.3. Colonisation and development of the human microbiota 
The human body is colonized by 3.8 x 1013 bacterial cells in males and 4.4 x 1013 in 
females [218]. Due to the differences in compositions and functions, microbiota can be 
distinguished in skin, ocular, oral cavity (including both the dental plaque and the oral 
mucosa), lungs and upper respiratory tract, gastro-intestinal (GI) and vaginal. Of those, 
the gut is the most colonized organ accounting for a 1011  bacterial cells/mL of the colon 
content as revised in [218].  
The metabolic functions of the GI tract are exerted in different GI-specialised areas. As 
they are characterized by a different gradient of pH (from acid to neutral from the stomach 
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to the colon), along with a different mucus production, digestive enzymes and acid or bile 
secretions, they are colonized in a specialised manner. Due to the variable peristalsis, 
high level of acids (e.g. HCl) and a consequently low pH (1-3), the stomach and the upper 
small intestine (duodenum) have a reduced bacterial composition, which is dominated 
by facultative anaerobes capable of growing through adhesion to the epithelial-mucus 
layer and in a transient manner. Bacterial genera such as Prevotella, Streptococcus, 
Veillonella, Rothia and Haemophilus sp. were described to reside in the gastric 
environment of healthy individuals, as reviewed in [219]. Long-term infection with the 
Gram-negative Helicobacter pylori has been shown to alter a normal gastric mucosal 
microbiota and promote the development of gastric cancer [218]. Members of the 
Lactobacillaceae family, in which the genus Lactobacillus is included, were identified in 
both murine and human small intestines. The ileum, characterized by a physiological pH 
(7-9), is more favourable for bacterial growth which is increased compared to that of the 
duodenum. The large intestine is highly colonized by strictly anaerobic bacteria capable 
of digesting complex carbohydrates through fermentations. Firmicutes and 
Bacteroidetes are the predominant phyla residing in the colon [220-222], and their ratio 
(Firmicutes:Bacteroidetes) has been associated to disease conditions such as obesity 
[223], although it has also shown variability amongst healthy individuals. Prevalence of 
genera Bacteroides, Prevotella and Ruminococcus were associated to a healthy gut 
microbiota [224], along with a reduced presence of Proteobacteria and other pathogenic 
species. When combined the NIH-HMP and E.U.-funded Meta-HIT dataset, Arumugam 
and collaborators described the presence of enterotypes of the gut microbiota, which 
were identifiable by the prevalence of one of these genera: Bacteroides (enterotype 1), 
Prevotella (enterotype 2) or Firmicutes-prevalence of Ruminococcus (enterotype 3) 
[225]. The presence of one of these led to a preferred microbial composition in the gut, 
which was not associated to age, gender, BMI or country of origin (Denmark, Spain and 
US). Most of the studies on the human gut microbiota is based on faecal samples, due 
to its non-invasive collection method; however differences between faecal and luminal 
or colonic mucosa gut composition were observed, e.g. higher Bacteroidetes counts in 
faecal/luminal contents compared to the mucosa samples, while Clostridium cluster XIVa 
higher in mucus layer compared to the lumen [226]. 
How is the human body colonized by bacterial species? It was believed for years that the 
foetal environment was mostly sterile until birth, however it has been recently shown the 
presence of bacterial DNA in the womb and a possible placenta colonisation with 
Proteobacterium spp. [227]. The delivery methods, whether natural or through C-section, 
determine a colonisation of the new-born through the maternal bacteria transmission. 
The gut microbiota of newborns in their first day after natural birth was more similar to 
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the maternal vaginal microbiota, while that of babies from a C-section delivery was more 
similar to the maternal skin microbiota [227, 228]. The breastfeeding or the administration 
of an artificial formula can shape the gut microbiota composition and the immune system 
of the newborn in the following months after birth. The human breast milk is highly 
populated by bacterial species which share similarity with other maternal microbiotas 
(e.g. gut, saliva and skin), but also being a result of the retrograde transmission from the 
baby, although precise mechanisms of transmission are not fully understood [229-231]. 
Faecal samples of breastfed babies showed a higher concentration of Actinobacteria 
phylum, in which the genus Bifidobacterium spp. is included, compared to samples from 
babies fed on formula milk [232]. 
From childhood and adolescence through adulthood, the composition of the gut 
microbiota is generally stable, unless perturbed by external factors (i.e. diet, surgery or 
medications) which will be described in the next paragraph. A change of the gut 
microbiota composition can be observed at the age 63/65. Elderly individuals (63-76 
years old) showed a more similar gut microbiota to that of younger individuals (aged 25-
40), rather than that of centenarians (99-104 years old) [233]. The latter showed, in fact, 
reduction of the Clostridium XIVa group. Interestingly, in an Italian cohort of semi-
supercentenarians (105-109 years old), the gut microbiota was enriched of genera 
previously associated to health status (i.e. Akkermansia and Bifidobacterium spp.) [234]. 
Older people may attend day hospital or residential care (either short or long-stay) and 
are also at risk of recurrent hospitalizations. Claesson and colleagues showed 
differences in the gut microbiota of elderly (mean age 78 years old) attending the long-
stay residential care compared to that of community-dwelling or younger subjects [235]. 
In particular, long-stay residents showed increased Bacteroidetes compared to an 
enriched Roseburia and Coprococcus spp. in community-dwelling individuals. Moreover, 
changes in the gut microbiota from community-dwellers to long-stay residents correlated 
with indices of frailty.  
1.5.4. External factors modulating the gut microbiota composition  
As mentioned before, from adolescence to senescence, the microbiota composition of a 
healthy individual is considered generally stable. Dethlefsen and Relman analysed the 
gut microbiota variations in people over 18 years old on a daily basis for ten months. In 
an unperturbed status, daily shifts of the gut microbiota composition were observed, but 
they were based on an average community structure which was stable for months [236]. 
Lloyd-Price and colleagues reported a higher similarity of the stool microbiota in the 
within-subjects compared to the between-subjects, although a slight reduction in the 
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similarity index was observed within-individuals across time [216]. However, 
environmental factors such as lifestyle and diet, medications intake, but also the genetic 
background and the immune system might trigger some modifications. 
1.5.4.1. The effect of the diet on the gut microbiota 
Bacteria residing in the gut, especially those in the colon, are capable of producing 
unique metabolites from host-undigested molecules, usually derived from food intake. 
The effects of those metabolites on the host is related to the type of substrate available 
to bacteria. In excess of carbohydrate, the saccharolytic fermentation process would 
preferably lead to health-related molecules, such as short-chain fatty acids (SCFAs), 
while carbohydrate-deprivation may cause the production of potential harmful products. 
SCFAs, including acetate, propionate and butyrate (Appendix 25), play an important role 
in the host homeostasis not only by providing energy sources to intestinal epithelial cells 
but also through the interaction with the immune cells, as reviewed in [237] and as 
discussed later in the present study. Other products of the gut microbiota metabolism 
include gas, proteins and vitamins (i.e. vitamin A, B12 and B6), as reviewed in [238] 
The diet has been considered one of the factors modulating the gut microbiota 
composition, since the early days of life. As previously described, in fact, breastfeeding 
or formula have the first impact on the colonisation of the gut microbiota of the newborn, 
possibly conferring a long-term health status and cognitive development3. Dietary habits 
can be very different in relationship to the country of residence and the lifestyle. A most 
striking example of this interplay is represented by the work of De Filippo and colleagues 
[239]. By comparing the gut microbiota of African children to that of children in Western 
countries, they reported different Firmicutes and Bacteroidetes phylum counts, 
accompanied by an increased production of SCFAs in the African children [239]. Children 
from a rural African village in Burkina Faso were on a prevalent rural vegetarian diet rich 
in fibres, plant polysaccharides and starch, which favours the fermentative activity (as 
previously described). Western diet, on the other hand, is high in processed food,  animal 
proteins, fat, sugars and starch (i.e. high fat and high sugars diet), but low in fibres.  
Another example on the relationship between the gut microbiota composition and the 
diet/lifestyle is represented by the study of the Hadza hunter-gatherers, a Tanzanian 
rural population whose diet is based on hunted and foraged products [240]. Their gut 
microbiome was characterised of an increased levels of Firmicutes, Bacteroidetes 
                                               
3 Horta BL and Victora CG, 2013. “Long-term effect of breastfeeding. A systematic review. WHO 
Library Cataloguing-in-Publication Data. ISBN 978 92 4 150530 7. 
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phyla, but also in Proteobacteria compared to that of the a Westernized population 
(i.e. Italian group). In terms of SCFAs production, the Hadza showed increased levels 
of propionate, while Italians were enriched in butyrate. The diet of the Hadza 
population is high in meat, tubers, honey and baobab, while Italians are on a 
Mediterranean diet which includes fruits and vegetables, dairy products, meat (i.e. 
poultry and read meat), processed foods and especially carbohydrates (i.e. pasta), 
which may have increased the amount of butyrate-producers bacteria in the gut 
microbiota. To this extent, the Hadza gut microbiota lacked of the Bifidobacterium 
spp., which might be due to the lack of any dairy products intake. Moreover, the 
availability of food from hunt and gather is influenced by seasons, also the gut 
microbiome of the Hadza population showed seasonal modifications, which was 
absent in industrialized population [241].  
One may argue that the lack of adaptability of the human gut microbiome upon diet, 
and a consequent loss of certain bacterial species, can thus be a contributing factor 
to the increased numbers of autoimmune and chronic diseases. The latter has been 
considered to be as a risk factor for developing Western-prevalent disorders, such as 
cardiovascular [242-244] and metabolic diseases, but also cancer [245]. High-fat diet 
(HFD) which is rich in fat but low in fibres and proteins (the prototypical fast-food diet), 
has been associated to obesity [246]. Changes in the gut microbiome following HFD 
included a reduced diversity of the bacterial community and an increased Firmicutes 
[247]. Interestingly, HFD can also be used to induce disease phenotype in animal 
models. HFD-induced obesity was shown to increase the neuronal cell death and 
cognitive impairment in the triple transgenic mouse model of Alzheimer’s disease (3xTg-
AD) [248]. On the other hand, a protective effect conferred by HFD was observed in the 
mouse model of the human’s chronic recurrent multifocal osteomyelitis (CRO), an 
inflammatory disease afflicting bones especially in children and adolescence [249]. The 
CRO mouse model, established through a mutation in the Pombe Cdc15 homology 
family protein PSTPIP2, showed a significant less severe induced phenotype, 
accompanied by a reduction of the genus Prevotellae and reduced production of pro-IL-
1β in neutrophils following HFD administration [250]. 
In contrast to the previous examples, a less extreme dietary intervention may lead to 
none or moderate changes in the gut microbiota or “may take several generations to 
evolve” [251]. As described in the work of Wu et al. [251], the composition of the gut 
microbiome following a vegan diet was less perturbed than expected. Moreover, the 
increased amount of fibres and substrates for saccharolytic fermentation did not increase 
the amount of faecal SCFAs compared to that produced in omnivores. The modification 
of long-stay residential care individuals occurred one year after the initiation of the 
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residential care diet [235], supporting the hypothesis of a more resilient microbiome upon 
moderate dietary changes.  
1.5.4.2. The effect of medications intake on the gut microbiota 
Medical therapies may also have considerable impact on the gut microbiota composition, 
since the majority of the active compounds would be processed and absorbed in the gut 
when orally administered, and in turn, the gut microbiota composition can alter their 
absorption, efficacy and toxicity [252].  
Antibiotics, first introduced in 1940s, are among the antimicrobial drugs able to block the 
growth of certain pathogenic bacterial species, through a different inhibition mechanisms 
provided by the type of each active compound. Considered broad-spectrum antibiotics 
(e.g. fluoroquinolones and β-lactams) are usually able to target both Gram-positive and 
Gram-negative bacteria, while other types of antibiotics might more specific for certain 
strains. β-lactams antibiotics, including penicillin and cephalosporin, block the synthesis 
of the bacterial cell wall of both Gram-positive and negative bacteria, through the 
interactions between their β-lactam ring and the transpeptidase enzyme involved in the 
construction of the bacterial cell wall. Although they are able to target both Gram-
negative and Gram-positive bacteria, their effects depend on the susceptibility of those 
bacteria to the antibiotic itself and they are widely used in medical practice [253]. 
Fluoroquinolones, in which ciprofloxacin and levofloxacin are included, inhibit the 
bacterial growth targeting the DNA-gyrase (Topoisomerase II) for Gram-negative and the 
Topoisomerase IV in Gram-positive bacteria [254, 255]. Although fluoroquinolones have 
been considered a broad-spectrum antibiotic, they were shown to be less effective on 
anaerobic bacteria, and mostly used against Haemophilus influenzae, Legionella 
pneumoniae and Mycoplasma pneumoniae. Also efficacy against GI pathogens such as 
Salmonella, Shigella, Yersinia enterocolitica and Campylobacter jejuni was observed 
[255]. Vancomycin, instead, is a non-absorbing glycopeptide able to block the second-
stage of the cell wall synthesis, more specific for both aerobic and anaerobic Gram-
positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA), 
clostridia and also Lactobacillus sp. [256]. Another class of antibiotics - macrolides - in 
which clarithromycin and azithromycin are included, are known to have a most broad-
spectrum bacteriostatic mechanisms since they inhibit the bacterial protein synthesis 
through the irreversible binding of the 50S ribosomal subunit. Such a class of antibiotic 
can also target fungi and may also have immunomodulatory effects in the host, as 
reviewed in [257].  
Apart from their efficacy against most pathogenic bacterial isolates, antibiotics show anti-
commensal effects, often resulting in a reduction of the richness and the diversity of the 
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bacterial communities in the gut microbiota. A 7-day intake of either the β-lactams 
amoxicillin-clavulanic acid or the fluoroquinolone levofloxacin decreased the diversity 
metrics of the microbiota composition, accompanied by an increase of the 
Bacteroidetes:Firmicutes ratio in hospitalized patients with non-digestive diseases [258]. 
The restoration of the gut microbiota composition after antibiotics exposure has been 
investigated and, in the majority of the cases, it resulted incomplete when compared to 
its pre-antibiotic status. In healthy individuals, ciprofloxacin intake resulted in a dramatic 
shift in the microbiota composition within 3-4 days from the first dose; the shift started to 
resolve and restore pre-antibiotic status soon after the antibiotic interruption. A second 
course with the same antibiotic after six months had a less dramatic effect on the gut 
microbiota compared to the first. However, at the end of the second antibiotic intake, the 
microbial composition in each subject differed from the pre-antibiotic composition, but of 
the newly acquired microbiota was stable for the following two months, with some inter-
individuals differences observed [259]. The long-term impact of a one-week 
clarithromycin intake was reported by Jakobsson and colleagues’ study [260], in which 
they observed a partial recovery of the gut microbiota after one and four years from the 
antibiotic intake, without any other antibiotic intake in the meantime.  
When describing the restorative process of the gut microbiota after an antibiotic 
exposure, several studies reported an important inter-individual variability component, 
which has been possible attributed to each individual composition of the gut microbiota 
before the antibiotic intake [259, 260]. Raymond and collaborators performed a 
metagenomic study (i.e. shotgun sequencing) on faecal samples of eighteen young, 
healthy and carefully selected volunteers before and after 7-days cefprozil 
(cephalosporin) intake. Despite such strict enrolment criteria, the gut microbiota 
displayed inter-individual differences at the beginning of the study, while the antibiotic 
intake produced a similar effect in  almost all the participants, with the decrease of 
several bacterial families and the increase of a number of specific genera. After 90 days, 
the gut microbiota of 16 out of 18 individuals was comparable to that of the controls [261].  
In many cases, an incomplete restorative process of the gut microbiome was 
accompanied by an increased abundances of certain bacterial species and, on the other 
hand, of antibiotic-resistance genes, as  was proposed and observed in the some of the 
previously cited works. The human microbiota can serve as a reservoir for antibiotic 
resistance genes (ARGs) [262] and an antibiotic intake, in fact, even for a short-time 
period, may select the resistance genes which are expressed at a low or undetectable 
levels before the treatments, such as the beta-lactamases [261].  
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Also, non-antibiotic drugs can have an impact on the gut bacterial communities. That 
might be the case of the proton pump inhibitors (PPIs) which act to increase the stomach 
pH via the inhibition of the hydrogen-potassium pumps releasing hydrochloric acid, 
usually prescribed to treat or prevent oesophagitis, gastric ulcers and reflux. Use of such 
medications lowered the diversity and the abundance of the gut microbial populations, 
with an increase of Streptococcaceae counts in PPI users. Increased abundance of 
bacteria were also likely to be from the pharyngeal microbiota, due to a change of pH 
between the upper GI and lower gut [263]. 
Maier and colleagues recently tested in-vitro the Prestwick Chemical Library, a collection 
of 1,079 FDA-approved drug compounds, against 40 bacterial isolates from healthy 
human gut microbiota [264]. Apart from the proven anti-commensal activity of most 
antibiotics (sulfonamides and aminoglycosides were the exception), 27% of non-
antibiotics drugs showed activity on at least one isolate tested, including anti-fungal and 
antivirals, while 24% were anti-human drugs including hormones, immunosuppressive 
azathioprine, antidepressant and anti-inflammatory agents, also confirming previous 
reports [265, 266]. Authors also reported a positive correlation between the anti-
commensal activity and the abundance of the bacterial species: those with higher relative 
abundance were, in fact, significantly more susceptible to anti-human drugs. 
Interestingly, anti-thyroid drugs (i.e. those described in the paragraph 1.1.12 as a 
treatment for GD/GO) are included in the Prestwick Chemical Library. They were tested 
at a final concentration of 20µM on the gut microbiota in vitro: carbimazole had no anti-
commensal effect, methimazole seemed to have an effect against Bacteroides caccae, 
although not reaching the significance threshold after multiple corrections. Similarly, 
propylthiouracil (PTU) significantly interfered with Ruminococcus bromii growth although 
only before correction. Levothyroxine, instead, exhibited anti-commensal effects on three 
bacterial species also after adjustment for multiple corrections such as: Clostridium 
saccharolytimun, Eubacterium eligens and Lactobacillus paracasei. 
1.6. INTERPLAY BETWEEN GUT MICROBIOME AND IMMUNE SYSTEM  
Relationships between the microbiota and the host varies from mutualistic (i.e. both 
members benefit from the symbiosis) to commensal (i.e. beneficial association of 
bacteria, with unknown effects on the host), to ammenalistic (i.e. when one species is 
negatively affected by an event but the other stays unaffected), to pathogen. 
Pathogenicity potential of the gut bacteria is considered highly contextual, since the 
same bacteria can shift from being commensal to parasitic according to their localization, 
possible co-infections and/or the activation of host immune response. In a steady-state, 
  
 
 
45  
commensals can control the growth of pathobionts (i.e. potential pathogen bacteria within 
the microbiota) with the “colonization resistance“ [267, 268] through 
nutrients/metabolites competitions [269], downregulation of virulence factors, and 
antimicrobial peptides production [270]. However, on the other hand, they can also 
promote pro-inflammation and autoimmune responses.  
In the past years, a great effort has been made in unravelling the complex relationship 
between the gut microbiome and the immune system, as showed by an increasing 
number of studies and reviews on this topic [267, 271-274]. Here are summarized the 
most important concepts on how the gut microbiota is tolerated by the immune system 
and, in turn, how it shapes the immune system. Association of the gut microbiota and 
autoimmune diseases, both in humans and mouse models, will be addressed in the 
course of the following chapters.  
1.6.1. Gut-associated lymphoid tissues (GALT) 
The GI tract is exposed daily to millions of foreign antigens derived from food intake 
(dietary proteins or haptens), but also to the dense population of residing microbes, 
possibly explaining the high amount of immune resident cells. Nevertheless, an 
immunological irresponsiveness or anergy has to be maintained because of the 
beneficial effects they exert within the host; however, the translocations of pathogenic 
bacteria through the mucosal barrier, which could result in systemic infections, has to be 
avoided. Intestinal epithelial cells (IECs) express a range of pattern recognition receptors 
(PRRs), such as Toll-like receptors (TLRs), capable of selectively recognizing and 
binding bacterial endotoxins such as lipopolysaccharide (LPS), peptidoglycans, flagellin 
and CpG DNA motifs. As a result, the innate immune response is activated with the 
production of proinflammatory molecules, such as chemokines (e.g. IL-8) and 
antimicrobial peptides via the NF-kB and MAPK pathways. 
Both innate and adaptive immune systems of the GI tract reside in both lamina propria 
(LP) and epithelium (called the “effector sites” as reviewed in [275]), which are enriched 
in lymphocytes (both CD4+ and CD8+ T cells and antibody-secreting plasma cells), 
dendritic cells (DCs) and macrophages, and in gut-associated lymphoid tissue (GALT), 
rather considered the “inductive sites” [275]. GALT can be sparsely isolated or 
aggregated in Peyer’s patches (PP), especially situated in the small intestine and 
characterized by B and T cells follicles, and in gut-draining mesenteric lymph nodes 
(MLNs). Microfold (M) cells are situated in the epithelium above the PP/isolated follicles 
and mediate both the uptake and the transport of antigens (even from the microbiota) 
from the gut lumen to the GALT lymphoid area [276]. Dendritic cells (DCs) are situated 
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at the basolateral side of the M cells, while recruitment of more DCs can be performed 
through the secretion of CCL20, to collect the M-cells-internalized antigens [277]. Other 
soluble or exosome-containing antigens (i.e. those derived from class II MHC 
enterocytes) can be directly sequestered in the gut lumen by DCs [275]. At the “effector 
sites”, LP-residing CD103+ DCs can sequestrate soluble antigens passing through the 
tight-junction of villi or throughout other transcellular routes (i.e. transcytosis at the apical 
sites of enterocytes). Also, LP-residing CX3CR1high macrophages can sequestrate 
antigens in the epithelium, which are further presented to CD103+ DCs [275].  
1.6.2. Immunological tolerance (ignorance) to commensal bacteria 
How the intestinal immune system discriminate between pathogenic and non-harmful 
antigens; in other words, how it does not activate against dietary antigens or the 
commensal microbiota? Dietary or orally-administered soluble antigens are tolerated 
through the so-called “oral tolerance” mechanism [278]. GALT and effector sites-
associated DCs are actively involved in promoting the oral tolerance to dietary antigens 
by up-regulating the production of nTregs and iTregs, under an IL-10-rich environment, 
TGF-b and retinoic acid [279, 280]. Such anergy can last several months after only a 
single encounter with the antigen, although maintenance mechanisms are necessary, as 
reviewed in [278]. Oral tolerance is characterized by a systemic effect, since food-related 
antigens can be detected into the blood, possibly enhanced also by tolerance 
mechanisms mediated in the liver. Food-sensitive enteropathies, such as the coeliac 
disease, are a result of the breakdown of the oral tolerance to dietary antigens [281].  
Tolerance to the gut microbiota is better addressed to as “mucosally-induced tolerance” 
[278] or “immune ignorance” [271], since it implies the physical separation of the 
commensal bacteria in the gut lumen from the mucosa. The mucus layer (i.e. mucin 
glycoproteins) produced by goblet cells prevents the bacterial adhesion to the mucosa; 
moreover, goblet cells produce a range of antimicrobial peptides such as a-defensins, 
lipocalin 1 and the C-type lectin RegIII-g, that kill bacteria by targeting the bacterial cell 
wall, amongst other mechanisms. Intestinal alkaline phosphatase (IAP) is a brush-border 
enzyme secreted by enterocytes, and mainly present at high concentrations in luminal 
vesicles, released in both the circulatory and luminal sides of the gut epithelium. IAP has 
several identified functions within the gut environment [282]; its role in protecting the gut 
barrier is achieved through the ability of detoxifying endotoxins and limiting bacterial 
translocations through the mucosal barrier into the lymph nodes [283]. Bacterial LPS is 
dephosphorylated by the cleavage of acyl-chains from the lipid A moiety, which is 
responsible for the endotoxic activity [284]. Bacterial adhesion to the epithelium is further 
prevented by Immunoglobin A (IgA), which can be commensal bacteria-specific [285]. 
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“Mucosally-induced tolerance” to microbiota antigens has no systemic effects, compared 
to the oral tolerance, but it can be extended to virtually all the gut mucosa via circulation 
of B and T cells through lymphatics and microvasculature [278]. The continuous 
sampling of the microbial lumen content via DCs is necessary to maintain the adequate 
tolerance at the mucosa.  
In the event of a commensal bacterial translocation through the mucosa, the MLNs act 
as a “mucosal firewall”, as defined in the review [273] (Figure 1.7). The first response 
mechanism to bacterial translocation involves the rapid clearance or sequestration of the 
bacterial antigen: macrophages, in fact, rapidly clear through phagocytosis translocating 
bacteria/antigens and DCs prevent further penetration beyond the LP by sequestering 
the antigen in MLNs. T cells-residing in the intestinal mucosa play a double role in 
promoting the tolerance through natural and induced Tregs with the production of anti-
inflammatory cytokines (TGF-b and IL-10) on one hand, and the maintenance of the 
adequate firewall against bacterial translocation, on the other hand. A proportion of 
iTregs in colon showed antigen-specificity against commensal bacteria [286]. A 
constitutive activation of the Th17/Th1 responses is therefore needed for the intestinal 
barrier integrity maintenance, other than for the pro-inflammatory response itself, since 
it sustains the production of mucus and antimicrobial peptides via IL-17 and IL-22 
secretion [287] and the activation of macrophages via INFg.  
Breakdown of the mucosal tolerance to commensal microbiota causes autoimmune 
diseases, such as Crohn’s disease (CD), which will be further described later in this work, 
and the necrotizing enterocolitis (NEC) in premature babies [288]. 
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Figure 1.7. The “mucosa firewall”.  
(1) The first line of defense from 
translocating bacteria is the mucus 
layer produced by goblet cells to 
prevent the bacterial adhesion to the 
mucosa. (2) Goblet cells produce a 
range of antimicrobial peptides such 
as a-defensins, lipocalin 1 and the 
C-type lectin RegIII-g, that kill 
bacteria by targeting the bacterial 
cell wall, amongst other 
mechanisms. Intestinal alkaline 
phosphatase (IAP) detoxifies 
endotoxins and limits the bacterial 
translocation. (3) Bacterial antigens 
translocated through the mucosa are 
rapidly sequestered and cleared by 
macrophages through phagocytosis, 
while dendritic cells  prevent further 
penetration beyond the lamina 
propria by sequestering the antigen 
in MLNs (4). T cells-residing in the 
intestinal mucosa play a double role in promoting the tolerance through natural and 
induced Tregs with the production of anti-inflammatory cytokines (TGF-b and IL-10) on 
one hand, and the maintenance of the adequate firewall against bacterial translocation, 
on the other hand. (Modified from [273]).  
 
1.6.3. Gut microbiota and immune homeostasis 
Germ free (GF) animals show reduced expression of innate immunity molecules such as 
TLR and MHC II [289, 290], smaller PPs and lowered number of CD4+ T cells and IgA-
secretory plasma cells in the LP [291-293]. Besides, GF mice are more susceptible to 
infections, for the concept of colonisation resistance previously introduced. Therefore, 
the gut microbiota is needed for defining the correct development of secondary lymphoid 
tissues and promoting the tolerance, which, in turn, has no reasons for being induced in 
their absence. At birth, the absence of a mature immune system, whereas regulatory 
response is preferred, prevents any inflammatory activation against colonising bacteria. 
Bacterial translocation from mother to foetus during pregnancy and components of the 
breast milk (oligosaccharides, IgAs, DCs and bacteria) may promote the colonisation of 
defined beneficial bacteria, such as the Bifidobacterium genus. Lactic acid-producing 
bacteria (LAB), such as Lactobacillus and Bifidobacterium genera, inhibited the adhesion 
and the growth of intestinal pathogens by either lowering the lumen pH or producing 
antimicrobial peptides (e.g. bacteriocins), as reviewed in [294]. Bifidobacterium infantis 
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[295], as well as Faecalibacterium prausnitzii [296], induced the production of Foxp3+ 
CD4+ Tregs and iTregs in the intestinal mucosa. The role and mechanisms of action of 
probiotic bacteria will be describe more in details in Chapter 5.  
In fact, the gut microbiota can directly produce immune-modulation effects on the host. 
The polysaccharide A (PSA), uniquely produced by Bacteroides fragilis, protected the 
development of an intestinal inflammation in the induced colitis mouse model, possibly 
mediated by IL-10 from a subset of Tregs [297] (Figure 1.8). On the other hand, the 
segmented filamentous bacteria (SFB) were associated with increased Th17 response 
[298] (Figure 1.8). One of the most striking example is the experimental autoimmune 
encephalitis (EAE) mouse model of multiple sclerosis, whose disease phenotype was 
exacerbated by the presence of SFB in the small intestine in a Th17-mediated manner 
[299]. To note, SFB were only described in mice, rats and chickens, while their human 
counterpart seems to cluster within a Clostridiaceae clade [300]. Interestingly, 
Clostridium species from the cluster IV and XIVa, normally present within the gut 
microbiota, increased the number of Foxp3+ Tregs, under TGF-b environment in the 
murine colonic mucosa [301]. Early-life inoculation of those clostridia in conventional 
mice prevented the induced colitis and the immune-modulatory effects were also 
extended to the adult life. Seventeen clostridial strains belonging to the IV, XIVa and 
XVIII clusters were isolated from human healthy microbiota based on the capacity of 
expansion and differentiation of Tregs under TGF-b production. When transferred into 
adult mouse models of allergic diarrhoea, the colitis symptoms were attenuated [302].  
Tolerogenic immune-modulation can also be exerted by commensal-derived metabolites 
and peptides, rather than from a determined species or bacterial cluster. Butyrate, 
acetate and propionate SCFA (Appendix 25), synthesized by commensals bacteria 
through fermentation, induced a potent stimulation of Tregs specifically in the colon [303]. 
As elegantly presented in the review [304], SCFAs, in particular butyrate, exert immune-
regulation by i) enhancing the generation of Tregs, including those pre-existing, via 
epigenetic mechanisms [303]; ii) inducing the differentiation of naïve CD4+ T cells into 
Tregs via the epigenetic-mediated upregulation of Foxp3 [305, 306] and iii) inducing the 
differentiation of Tregs via DCs stimulation under genetic and epigenetic mechanisms 
[307]. Butyrate, in fact, acts as histone deacetylase (HDA) inhibitor, thus leading to 
acetylation of histone-H3 and allowing gene expression [308]. Specifically, butyrate 
inhibits class-II HDAs, which naturally suppress Tregs expansions [309], allowing the 
transcription of Tregs-induction genes via histone acetylation [306]. 
As previously introduced, the unbalance between regulatory (Tregs) and inflammatory 
(Th17) responses may lead to inflammation and autoimmune responses. Similarly for 
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commensal-specific Tregs, also intestinal Th17 cells with commensal-antigens 
specificity were described [89], which may trigger autoimmunity. Promoting and/or 
restoring tolerogenic response in the gut may assume a therapeutic importance. In vitro 
supplementation of six butyrate-producing bacteria, plus Faecalibacterium prausnitzii or 
Butyricicoccus pullicaecorum, to Crohn’s disease-derived samples increased the 
butyrate production and improved the intestinal barrier integrity [310]. Probiotics bacteria, 
including lactic-acid-producing bacteria (LAB) such as Lactobacillus and Bifidobacterium 
spp., deliver – by definition4 - beneficial effects to the host health. One of them consists 
in the induction of Tregs in the gut, through different mechanisms (not necessarily 
mediated by butyrate, i.e. immunomodulins secreted by Lactobacillus plantarum [311]). 
The role of probiotics in autoimmune diseases will be further discussed in the next 
chapters. 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.8. Immunomodulatory effects of the gut microbiota.  
(A) Segmented filamentous bacteria (SFB) induced a Th17 immune response in the 
small intestine, which exacerbated the experimental autoimmune encephalitis (EAE) 
mouse model of multiple sclerosis [299]. (B) Polysaccharide A (PSA), specifically 
produced by Bacteroides fragilis, induced the expansion of IL-10-producing-Tregs and 
protected the development of an intestinal inflammation in the induced colitis mouse 
model mediated [297]. (C) Bacterial translocation rapidly activates macrophages and 
                                               
4 FAO/WHO. Probiotics in food: health and nutritional properties and guidelines for evaluation: 
report of a Joint FAO/WHO Expert Consultation on Evaluation of Health and Nutritional Properties 
of Probiotics in Food, including powder milk with live lactic acid bacteria: Cordoba, Argentina, 1–
4 October 2001: report of a Joint FAO/WHO Working Group on Drafting Guidelines for the 
Evaluation of Probiotics in Food (Food and Agriculture Organization of the United Nations, 2006). 
  
 
 
51  
pro-inflammatory Th1 response for the clearance of translocated antigens. (Modified 
from http://www.indigo-iapp.eu). 
 
1.7. HYPOTHESIS AND AIMS OF THE PRESENT THESIS 
Given the emerging role of the gut microbiota as a triggering factor in various diseases 
and the possible role of bacterial antigens in the breakdown of the immune-tolerance in 
autoimmune diseases, I hypothesized that the gut microbiota composition and functions 
can be considered as an environmental risk factor for the outcome and/or the 
progression of GD and GO. Therefore, I aimed at describing:  
i) the composition of the gut microbiota during the induction of GO in a mouse 
model, its correlation with disease features and how it influences the 
replicability of animal models in different laboratories; 
ii) the adjuvant role of the gut microbiota in inducing GO through the 
manipulation of its composition in early-stage of life; 
iii) the gut microbiota composition of GD and GO patients in a multi-centre 
observational study compared to matching healthy controls, and its 
correlation with immunological (TRAB) and endocrinological (TSH, T4) 
features;  
iv) the gut microbiota of GD/GO patients administered either a consortium of 
probiotics or placebo, along with the anti-thyroid drugs, in a pilot double-blind 
randomized trial, to possibly observe beneficial effects of a probiotics intake 
in the disease progression.  
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2. Chapter 2 
 
 
Gut microbiota composition in an experimental murine 
model of Graves’ orbitopathy, established in different 
environments, may modulate clinical presentation of 
disease. 
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2.1. INTRODUCTION 
The poor reproducibility of murine models of human diseases has become a puzzling 
phenomenon in recent decades. Apart from the genetic background of the strains used, 
the type of animal housing, diet and even the vendor can influence disease phenotype 
[312, 313]. 
Several mouse models have been developed using different immunization protocols, 
however with no signs of concomitant eye disease, as previously discussed in Chapter 
1 par. 1.4.1. Ludgate and colleagues established a TSHR-induced GO model by genetic 
immunization; i.e. injecting an expression plasmid carrying the human TSHR full-length 
cDNA [177]. Female BALB/c mice developed thyroiditis plus some aspects of GO and 
the disease could be transferred to naïve recipients using the TSHR-primed T cells from 
the genetically immunised mice. However, the model could not be reproduced in a 
different animal unit (neither was specific-pathogen free (SPF)) and the TSHR-induced 
disease was quite distinct from that previously described, which the authors postulated 
might be due to microorganisms [188]. It has also been reported that TSHR-immunised 
mice from a conventional environment had higher and more persistent TSAb levels than 
mice in SPF units (Bhattacharyya et al., Poster presentation 20053). 
Recently, Berchner-Pfannschmidt and colleagues reported the induction of GO-like 
disease in two independent SPF units [187]. The immunization protocol utilized the 
genetic delivery of human TSHR A-subunit plasmid by close field electroporation, which 
leads to features of GD accompanied by symptoms of eye disease, such as 
adipogenesis and inflammatory infiltrates in the orbit [165, 180]. Controls received a 
plasmid encoding the β-galactosidase (βgal) gene delivered by the same procedure. 
Most aspects of the model were reproduced successfully, however, there was 
heterogeneity in induced disease and differences in thyroid function in the animals 
undergoing experimental GO in the two locations [187]. 
Over the years, the gut microbiota not only has been associated with several diseases, 
as it will be extensively discussed in Chapter 4, but its confounding role in establishing 
or reproducing disease phenotype in murine models has also been proposed [314].  
The murine model of multiple sclerosis, experimental autoimmune encephalomyelitis 
(EAE), proved to be highly influenced by the gut microbiota. Oral antibiotic immunization 
and consequent depletion of the gut bacteria, before disease induction, resulted in 
                                               
3 Poster presentation: Bhattacharyya KK, Coenen MJ, Bahn RS. Effect of environmental 
pathogens on the TSHR-directed immune response in an animal model of Graves’ disease. 
Thyroid 2005; 15:422-426. 
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protection from disease development, along with reduction in pro-inflammatory 
mediators such as IL-17 and an increased Th2-immune response [315]. On the contrary, 
the intestinal monocolonization of germ free mice (sterile) with segmented filamentous 
bacteria (SFB) restored the disease phenotype, along with an increased number of Th17 
cells in the central nervous system (CNS), suggesting a direct interplay of the gut 
microbiota and the immune response in EAE development [316].  
2.2. AIMS OF THE CHAPTER 
Based on these observations, I hypothesized that the gut microbiota itself might play a 
major role not only in the establishment, but also in the reproducibility of the GO animal 
model described above. The aim of the present chapter is therefore the characterization 
of the gut microbiota of the GD/GO models, recently replicated in two different centres 
[187], using the 16S rRNA gene sequencing (metataxonomics).  
For this study the gut microbiota of TSHR immunised mice from the two centres was 
compared, to understand whether variation in gut microbiota composition could explain 
differences in the disease induced. Within one centre, the gut microbiota between 
different immunizations (TSHR and βgal) was characterized and compared with 
untreated mice, to determine whether the gut microbiota can influence the outcome and 
correlate with disease features. 
2.3. MATERIALS AND METHODS 
2.3.1. GO preclinical mouse model samples 
Mouse samples used in the present work were collected by UBP and SM in a recent 
work [187], conducted in parallel in two independent animal housing units, under 
comparable SPF conditions. The study was approved by the North Rhine Westphalian 
State Agency for Nature, Environment and Consumer Protection, Germany and by the 
Ethics Committee of King’s College London, United Kingdom (UK). 
Samples from the animal unit of King’s College London (UK) will be referred to as the 
“Centre 1” and included a total of 5 TSHR-immunised mice (TSHR). Samples from the 
University of Duisburg-Essen (Germany) will be referred to as the “Centre 2”, including 
10 TSHR-immunised (TSHR), 8 βgal plasmid controls (βgal) and 6 untreated mice 
(included as a background control), as shown in Table 2.1. 
The GO immunization protocol has been previously described [180]. Briefly, 6-8 weeks 
old BALB/cOlaHsd female mice were immunised via intramuscular injection into each 
biceps femoris muscle [179] and electroporation of either the eukaryotic expression 
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plasmid carrying the human TSHR-A subunit gene (pTriEx1.1Neo-hTSHR or 
hTSHR289) (TSHR group) or the control plasmid pTriEx1.1Neo-β-gal (plasmid-control, 
βgal group). All animals, whether TSHR or βgal controls, received a total of four plasmid 
injections at three week-intervals of the experiment (0, 3, 6, 9 weeks). Mice in Centre 1 
were maintained conventionally in open cages in one room and co-housed at a maximum 
of 3 animals per cage. In Centre 2, the mice were co-housed according to their 
immunizations, 2-4 animals per individually ventilated cage in one room. All mice were 
provided by different outlets of the same supplier (Harlan Ltd. or Harlan laboratories BV). 
All immunised and control mice in both locations were sacrificed nine weeks after the 
last immunization (18 weeks) to permit the development of the chronic phase of the 
disease in the TSHR group (Figure 2.1). 
After sacrifice, murine intestines were snap-frozen, stored in sterile containers at −80°C 
and shipped in dry ice to Cultech Ltd. (UK). The microbial content of each animal was 
immediately obtained by HLK and DC via the scraping of the large intestine from oral to 
aboral end and prepared for subsequent analysis. Within the Centre 2 only, faecal pellets 
of βgal and TSHR immunised mice were also collected in sterile tubes before each 
injection (week 0, 3, 6, 9), immediately stored at -80°C and shipped to Cultech Ltd. in dry 
ice. Total DNA was extracted from faecal pellets as described below. 
Clinical and histological assessment was conducted by UBP, SM, AE and PB and 
already described in Berchner-Pfannschmidt et al. Supplementary Methods [187]. 
Briefly, i) thyroid hormone thyroxine blood levels (fT4) and TRAB (both stimulating TSAb 
and blocking TSBAb) antibodies were quantified in a single experiment in Centre 2. 
Serum thyroid hormone T4 was determined by RIA (RD Ratio Diagnostics, Germany). 
The TSH binding inhibitory immunoglobulin activity (TBII) measured using human TRAK 
assay kit, following manufacturer instructions (ThermoFisher, BRAHMS, Germany), 
while the TSAb and TSBAb subtypes were determined using an hTSHR stably 
transfected CHO cells, as described in Zhao et al. [179]; ii) the measurement of the 
expansion of fat cells (adipogenesis) was assessed in orbital sections of extraorbital 
nasal and inferior muscle with ImageJ, as described previously [180], with a 
normalization of the adipose tissue area to the area of the optic nerve, and iii) muscular 
atrophy in the orbit has been quantified by diameter (<50μm) and round shape of muscle 
fibers. A full description of the mice involved, and samples collected in the present study 
is represented in Table 2.1.  
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Figure 2.1. Schematic representation of the GO immunization protocol and sample 
collection.  
Female BALB/cOlaHsd, 6-8 weeks old mice were immunised via the intramuscular 
injection and electroporation of either the eukaryotic expression plasmid pTriEx1.1Neo-
hTSHR (hTSHR289) to develop signs of GO (TSHR A-subunit) or the control plasmid 
pTriEx1.1Neo-β-gal, as a plasmid-control group (βgal). Each animal received a total of 
four plasmid injections at three week-intervals. All immunised and control mice were 
sacrificed 9 weeks after the last immunization to permit the development of the chronic 
phase of the disease in the TSHR immunised group. Faecal pellets have been collected 
during the time course of the immunization trial from the baseline (T0) and before any 
other injection until the end of the procedure (T4). After euthanasia, the microbial content 
residing on the colonic mucosa has been collected through scraping.  
 
 
Table 2.1. Description of the mouse groups involved in this study 
 
No. of animals Immunization Centre a Source b Timepoint 
5 TSHR 1 Intestinal scraping T4 
10 TSHR 2 I.S./Faces T0-T4§ 
8 βgal 2 I.S./Faces T0-T4§ 
6 Untreated 2 I.S./Faces T4° 
 
A total of 23 female BALB/cOlaHsd, 6-8 weeks old mice were challenged either with the 
pTriEx1.1Neo-hTSHR to induce disease (TSHR group) or with pTriEx1.1Neo-β-gal as a 
plasmid control group (βgal group). An untreated group of 6 mice has been included as a 
background control. a Independent SPF animal units were based in London (Centre 1) and 
Essen (Centre 2).  b Samples collection comprised of intestine scraping (I.S.) from Centre 1 
and both faecal pellets and I.S. within the Centre 2. §Faecal pellets of βgal and TSHR 
immunised mice have been collected before any immunization (T0) and during the time 
course of the immunization protocol until the sacrifice (T4), as represented in Figure 2.1. 
°Untreated mice were sampled at T4 before (faecal) and after the sacrifice (intestinal 
scraping).  
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2.3.2. Extraction of total DNA from gut contents and faeces and 16S rRNA 
gene sequencing 
The extraction of total DNA was performed by HLK and DC. A total of 29 scraped 
intestinal samples and 95 faecal pellets were individually placed in 2mL microcentrifuge 
tubes prefilled with 0.1 mm silica and zirconia bead mix (Benchmark Scientific, Edison, 
USA), dissolved in 1 mL InhibitEX buffer (Qiagen Ltd, West Sussex, UK) and vortexed 
until homogenized. A bead-beating step (Beadbug microcentrifuge homogenizer, 
Benchmark Scientific, USA) was applied for 3 x 60 sec at 5 m/s with 5 min rest in-
between. The DNA extraction has been performed with QiAmp Fast DNA Stool Mini kit 
(Qiagen Ltd, UK), following the manufacturer’s instruction. Total genomic DNA was 
eluted in sterile microcentrifuge tubes and quantified by Qubit Fluorimetric Quantitation 
(ThermoFisher Scientific Ltd, UK), following manufacturer's instructions. DNA aliquots 
were kept at -20°C until used. Sequencing of the variable regions of the 16S rRNA gene 
was performed at Research and Testing Laboratory LLC. (Lubbock, Texas, USA). 
Primers such as the 28F and 388R were used to amplify the V1-V2 regions of 16S rRNA 
gene (Table 2.2), while 28F-combo and 388R primers were used to amplify the V1-V2 
regions including the bifidobacteria-specific regions. Sequencing was performed using 
an Illumina Miseq (Illumina, San Diego, USA), with 10K paired-end sequencing protocol.  
2.3.3. Quantification of the total bacterial load via 16S rRNA quantitative 
real-time PCR  
E. coli Nissle 1917 (from Marchesi lab collection) was grown in Nutrient Broth (Sigma 
Aldrich, Germany, Appendix 1) at 37°C and viable cells (expressed as Colony Forming 
Unit, cfu) were counted through serial dilutions on Nutrient Agar (Sigma Aldrich, 
Germany, Appendix 1), incubated for 48 hours at 37°C. Half of a confluent plate 
(7.75x108 CFU/mL) was harvested, resuspended in 1mL broth and centrifuged for 10 min 
at 5,000 x g. Supernatant was discarded and pellet was resuspended in 1mL InhibitEX 
buffer (Qiagen Ltd., UK) for DNA extraction, following the procedure described in the 
previous paragraph, including the bead-beating step. Genomic DNA was quantified with 
Qubit© (ThermoFisher Scientific Ltd., UK), following manufacturer's instructions. The 
effective E. coli 16S rRNA gene copy number was calculated from the gDNA 
concentration and a standard curve was run in every experiment using 8.9x107 to 8.9x101 
E. coli 16S gene copy number. 
The total bacterial load or 16S rRNA copy number of faecal and gut gDNA was tested 
according to the BactQuant protocol [203], with some modifications. Briefly, 2.5μl of 
template DNA were added to 5μl of Platinum® Quantitative Polymerase Chain Reaction 
(PCR) SuperMix-UDG with ROX (Invitrogen), in presence of 1.8 μM of each BactQuant 
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forward and reverse primer (Invitrogen), 225 nM of the TaqMan® probe (Applied 
Biosystem, Warrington, UK) and molecular-grade water to reach 10 μl final volume.  
Probe and primers sequences are listed in Table 2.2 below. Real-time PCR cycles and 
fluorescence signal acquisition were performed on Chromo4TM Real-Time PCR 
Detection (Bio-Rad, USA), with the following thermal cycles: 50°C for 3 mins, 95°C for 
10 mins, 95°C for 15 sec and 60°C for 1 min repeated 40 cycles. Each sample’s reaction, 
including the standard curve, was tested in duplicates. Data were analysed with Opticon 
Monitor software (Bio-Rad, USA) with a manual Cycle Threshold value (Ct) of 0.05 and 
blank-reduction was applied. Copy numbers were log-transformed for statistical analysis. 
 
Table 2.2. Primers set used to detect the V1-V2 regions of the 16S rRNA gene, including 
bifidobacteria-specific regions (28F-combo) and for quantitative 16S rRNA gene load 
qPCR.  
 
Primer ID Sequence (5’ to 3’) 
28Fw GAGTTTGATCNTGGCTCAG 
28F-YMa GAGTTTGATYMTGGCTCAG 
28F-Borreliaa GAGTTTGATCCTGGCTTAG 
28F-Chloroflexa GAATTTGATCTTGGTTCAG 
28F-Bifidoa GGGTTCGATTCTGGCTCAG 
388Rv TGCTGCCTCCCGTAGGAGT 
BactQuant Fwb CCTACGGGDGGCWGCA 
BactQuant Rvb GGACTACHVGGGTMTCTAATC 
BactQuant probeb 6FAM-CAGCAGCCGCGGTA-MGBNFQ 
 
a These primers are mixed at a 4:1:1:1 ratio (28F-YM is at 4 parts) and referred to as a 28-
combo. b From the BactQuant protocol [203]. 
 
2.3.4. Processing of metataxonomic sequences 
Processing of the sequences was performed using Mothur v1.36, to reduce possible 
PCR effects and to cluster sequences into Operational Taxonomic Units (OTUs) at the 
97% identity cut-off and provide the taxonomic annotations [207] (see Appendix 2 for 
detailed explanation of the pipeline). Paired-end reads (R1 and R2) were joined for each 
sample using the Mothur function “make.contigs” and trimmed at the 2.5%-tile and 
97.5%-tile on the distribution lengths of the amplicons. Sequences with any ambiguities 
(i.e. Ns) were removed by setting parameter N=0. Filtered sequences were aligned 
against the SILVA 16S rRNA gene reference database (http://www.arb-silva.de) [209]. 
Removal of chimera sequences was done with the Uchime tool [317]; singleton and non-
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bacterial sequences (e.g. Archaea, Eukaryotic, Chloroplast and Mitochondria) have been 
removed from the analysis. The taxonomic assignment from phylum to genus level of the 
processed sequences was done using the Ribosomal Database Project (RDP) Naïve 
Bayesian Classifier, using Trainset 14 with a cut-off of 80% [210]. FastTree (version 
2.1.7) has been used to build a phylogenetic tree, using an approximated maximum 
likelihood solved by Jukes-Cantor evolutionary model [318]. To reduce the effect of 
possible different sampling methods and to obtain comparable sequencing libraries, 
each sample library has been subsampled based on the smallest library size. OTUs with 
less than 10 counts have been excluded from the dataset and grouped as “OTU_low”, 
and the analysis has been performed collapsing OTUs at the phylum-genus levels.  
2.3.5. Statistical methods for analysis of metataxonomic data 
Statistical analysis was performed in R version 3.2.2  and STAMP tool for metataxonomic 
data analysis [319]. Statistical tests with P≤0.05 were considered as significant. 
2.3.5.1. Diversity indices 
Rarefaction curves were calculated to check whether sequencing depth and sample size 
were adequate to characterize the composition of the gut and faecal microbiota. The 
sequence-based rarefaction curves were calculated in Mothur through the function 
“rarefaction.single“.  
Alpha diversity indices, whose mathematical formula are included in Appendix 3, were 
calculated from Mothur function “summary.single“ and tested for association with 
covariates (e.g. locations or immunizations) using a linear model, followed by Tukey’s 
Honest Significant Difference (HSD) post-hoc analysis.  
Beta-diversity was calculated according to the weighted UniFrac [320] (Appendix 3) and 
the between-samples distances were represented in a Non-Metric Dimensional Scaling 
(NMDS) plot. The non-parametric permutational multivariate analysis of variance 
(PERMANOVA) was calculated through the Adonis function [200] in R Vegan package 
(using 999 permutations) and was used to test the association between the microbiota 
composition and the covariates (e.g. location of the laboratories or immunizations).  
2.3.5.2. Testing differential abundant taxonomy  
The hierarchical clustering of genera was performed using the Spearman distance and 
the Ward agglomeration method. Annotated heatmap of the top-30 most abundant 
genera amongst samples was created using the heatmap function of the NMF R package 
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with scaled genus abundances to column Z-scores after clustering (e.g. center and 
standardize each column separately to column Z-scores).  
Differences in the taxonomic abundances (e.g. phylum to genus level) between locations 
were assessed using the analysis of variance (ANOVA) with Tukey’s HSD post-hoc 
analysis and 95% confidence interval (c.i.). Differences between immunizations groups 
were assessed using a Welch’s T-test assuming unequal variance with Welch’s inverted 
95% c.i. as implemented in STAMP.   
2.3.5.3. Longitudinal analysis of faecal microbiota 
Over multiple timepoints, the effects of time, immunizations and their interactions, have 
been estimated on the faecal microbiota composition, all by means of the following linear 
model (Equation 1): 𝑦"#$ = 𝜇 + 𝑇𝑖𝑚𝑒" +	𝐼𝑚𝑚𝑢𝑛𝑖𝑧𝑎𝑡𝑖𝑜𝑛# + (𝑇𝑖𝑚𝑒	 ∗ 	𝐼𝑚𝑚𝑢𝑛𝑖𝑧𝑎𝑡𝑖𝑜𝑛)"# + 𝑒"#$  
where 𝑦"#$ is the vector of either the log-transformed 16S rRNA gene copy number, 
alpha-diversity Chao or Shannon indices, or of the Firmicutes/Bacteroidetes ratio 
calculated from the relative abundances in each sample at each timepoint; 𝜇 is the 
overall mean; time is the effect of timepoint in classes (T0, T1…T4); immunization is the 
type of immunization (either the TSHR or βgal). The factorial interaction between 
immunization and time has also been included in the model; 𝑒"#$ is the vector of residual 
effects. Comparison between βgal and TSHR immunizations at each timepoint was 
made using the pairwise t-test in R.  
To test differences in genera counts between immunizations over timepoints, the design 
model represented in Equation 1 was used to calculate the dispersion and fitting the 
negative binomial (NB) generalized linear model (GLM) with the glmFit function in EdgeR 
package [321]. The output of such function was passed to the EdgeR glmLRT function 
to compute contrasts between coefficients from the design model (i.e. immunisation over 
timepoints) through the likelihood ratio test. The baseline timepoint (T0) was used as a 
reference. Pairwise comparisons of genera counts between immunizations in each 
timepoint, including the T0, have been assessed with Fisher’s Exact Test in EdgeR 
package with the dispersion calculated from the same design model of Equation 1. 
2.3.5.4. Stability of the faecal microbiota over time 
The function Adonis [200] implemented in the Vegan package was used to test the 
variations between-samples of the microbial communities (calculated using the weighted 
Unifrac distance) over timepoints and among cages, via a permutational analysis of 
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variance or non-parametric MANOVA. The linear predictors and response matrix were 
as described in Equation 2: 𝑦"#$7 = 𝜇 + 𝑇" +	𝐼# + (𝑇 ∗ 𝐼)"# + 𝐶$ 	+ (𝐶 ∗ 𝑇)$" 	+ 	(𝐶 ∗ 𝐼)$# 	+ 	𝑒"#$7  
whereas: 𝑦"#$ is the weighted Unifrac matrix for treatment i, time j and cage k, µ is the 
overall mean; 𝑇" is the effect of the ith time which was set as a class (T0, T1…T4); 𝐼# is 
the type of jth immunization which is represented by either TSHR or βgal; 𝐶$ is the effect 
of kth cage which is expressed as a class (C1, C2…C5); (𝑇𝐼)"#, (𝐶𝑇)$" and (𝐶𝐼)$# 
represent factorial interactions between time, immunizations and cage; 	𝑒"#$7 is the vector 
of the residual effects. A pairwise interaction within immunizations, cages and timepoints 
has been assessed using a built-in pairwise PERMANOVA script in R.  
2.3.5.5. Correlations between gut microbiota and disease features  
Correlations of either the taxonomy counts (phylum and genus relative abundances) and 
disease features, such as anti-TSHR antibodies and thyroid hormone thyroxine levels 
(fT4), orbital adipogenesis or muscular atrophy values, were estimated using the 
Spearman correlation coefficient (Rho) and represented in a correlation plot, using the R 
Corrplot package. 
2.4. RESULTS 
2.4.1. Summary of the GO clinical outcomes 
Clinical differences of GO models replicated in the two centres were already described 
by UB-P, SM1 and colleagues [187]. From the original set of experiments, I was able to 
obtain the gut of 5 (out of 11) TSHR-immunised mice from Centre 1 and 10 out of 10 
TSHR-immunised from Centre 2. We assume that the mice from Centre 1 were randomly 
selected and therefore there was no selection bias. A summary of the disease 
characteristics of this reduced cohort of mice collected by UBP, SM and colleagues is 
shown in Table 2.3 below. TRAB were induced successfully in all mice being immunised 
with TSHR-plasmid in both laboratories, while levels of TSAb were detected in 40% of 
the animals analyzed in both locations. Mice in Centre 2 showed a higher level of TSBAb 
(90% animals) and were more euthyroid compared to those of the Centre 1.  
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Table 2.3. Summary of disease characteristics induced in mice in Centre 1 and Centre 
2 using the TSHR expression plasmid illustrating the heterogeneity of response.  
 
Disease Feature Centre 1 (n=5) Centre 2 (n=10) 
TRAB (%) 5/5 positive 10/10 positive 
TSAb (pmol/mL) 2/5 positive 4/10 positive 
TSBAb (%) 3/5 positive 9/10 positive 
Thyroxine fT4 (mg/dL) 2/5 hyperthyroid 10/10 euthyroid 
Orbital adipogenesis N.A.° 4/8 increased 
Orbital muscle atrophy N.A.° 3/8 significantly increased 
Thyroid Histology 2/5 thyroid focal infiltration 10/10 normal histology 
° N.A. not available. 
2.4.2. Total bacterial load and metataxonomics metrics 
The total bacterial load of each sample was obtained from the real-time qPCR Ct value 
by interpolating the E. coli 16S rRNA gene copy number standard curve. Data were 
generated from reactions presenting a standard curve with a slope near -0.3 and R-
squared (R2) near 0.99 with an efficiency of 90-100%, otherwise the experiment was 
repeated. An average of 9.74e+06 copy number, ranging from 2.29e+05 min to 4.40e+07 
max, were observed in total. A difference in the copy number was observed between the 
total of gut (mean 3.77e+06 copy number) and faecal samples (mean 1.57e+07 copy 
number) used in this chapter (P<0.001).  
From the 16S rRNA gene sequencing (V1-V2 regions), a total of 5,333,798 reads were 
obtained which reduced to 4,047,186 reads after a first quality filtering. Following 
alignment on SILVA reference database, an average of 20,534 reads was obtained per 
sample, ranging from 3,502 to 134,901. The complete summary of the number of reads 
and 16S rRNA gene copy number in each category is described in Table 2.4. 
Subsampling per library size resulted in a 96% average coverage per OTU definition at 
3,052 reads per sample. The averaged coverage and subsampling was sufficient to 
describe gut bacterial communities according to sequence-based rarefaction curves 
(Figure 2.2).  
A total of 4,281 OTUs were identified: 1,037 OTUs had more than 10 counts across 
samples and were grouped in taxonomic levels, which resulted in a total of 7 phyla, 16 
classes, 27 orders, 49 families and 129 genera identified amongst samples.  
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Figure 2.2. Murine microbiota rarefaction curves.  
Sequence-based rarefaction are represented to as the number of detected OTUs in 
function of the reads sequenced. Library sub-sample was performed according to the 
smallest library size (i.e. 3,502 reads/sample). Each curve, in a different colour, 
represents a unique sample. Curves tended towards a plateau: increasing the 
sequencing depth would therefore not increase the number of OTUs described.  
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Table 2.4. Summary of the sequencing metrics (mean number of reads before 
subsampling) and the 16S gene copy number (bacterial load) according to different 
metadata categories. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
aFaecal and gut samples are comprising of all the timepoints, immunizations and locations. 
bDifferences in locations for TSHR-immunised mice gut samples. cDifferences in 
immunizations comprising only Centre 2 gut samples. dTimepoint from faecal samples 
collected in Centre 2, including both TSHR and βgal immunizations. #Statistical test 
computed on log-transformed data. §Number of sample failed on 16S qPCR. 
 
2.4.3. Comparative analysis of the gut microbiota of GO preclinical mouse 
models in different centres  
To assess whether the microbiota has an impact on the GO mouse model in different 
laboratories, I compared the gut microbial contents of 5 TSHR mice from Centre 1 and 
10 TSHR immunised BALB/c female mice from Centre 2, after sacrifice (T4).  
The bacterial load (16S copy number) was very similar in both centres (Table 2.4). 
Comparison of the alpha diversity indices shown a significant reduction in the richness 
(P=0.01), but not in the diversity of the Centre 2 microbial community (P>0.05, Figure 
2.3A). The gut microbiota composition from the two centres showed a good separation 
according to the Spearman distance and Ward hierarchical clustering (Figure 2.3B), and 
 Mean number of 
reads 
Mean 16S copy  
Number# 
Microbiota sourcea   
Faecal samples (n=95)  22,071.21 1.57e+07§ 
Gut samples (n=29) 17,943.14 3.77e+06§§ 
P value  <0.001 
Locationsb   
Centre 1 (n=5) 13,910.4 3.55e+06 
Centre 2 (n=10) 21,140.3 3.61e+06§ 
P value  0.96 
Immunizationsc   
TSHR (n=10) 21,140.3 3.61e+06§ 
βgal (n=8) 12,512 3.24e+06§ 
Untreated (n=6) 23,216.66 4.82e+06 
P value  0.04 
Timepointd   
T0 (n=18) 23,314.5 2.23e+07 
T1 (n=17) 17,128.58 1.77e+07 
T2 (n=18) 25,207.22 1.14e+07 
T3 (n=18) 21,464.38 1.04e+07 
T4 (n=24) 22,742.87 1.62e+07 
P value  0.009 
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a PERMANOVA test on the weighted UniFrac distances revealed a spatial difference 
between bacterial communities (P=0.005 with 999 permutations, data not shown). 
At a phylum level, Bacteroidetes and Firmicutes were the most represented of the 7 phyla 
identified, with no differences between them in the two centres (P=0.99). 
Lactobacillaceae, Ruminococcaceae and Porphyromonadaceae families were more 
abundant in Centre 2 than in Centre 1 TSHR mice (P<0.01, Figure 2.3C). Significant 
differences were observed in the abundance of eighteen genera between the two 
centres, as detailed in Table 2.5. 
The results obtained using metataxonomics largely confirmed results obtained via the 
traditional microbial culture approach performed by HLK and DC at Cultech Ltd. [322]. 
However, a few differences have been highlighted. Microbial cultures revealed 
significantly higher yeast counts (P=0.0318) in Centre 2 TSHR-immunised mice - which 
obviously could not be seen via the bacterial metataxonomics - and a nearly significant 
difference in the Actinobacteria genus Bifidobacterium (P=0.057), which was not 
detected in our metataxonomics data. Primers based on the V1-V2 regions of the 16S 
rRNA gene did not detect Bifidobacterium OTUs. Consequently, a new set of primers 
(28F-combo) capable of targeting the V1-V2 with bifidobacteria-specific regions (Table 
2.2) was selected, with which a significant enrichment of bifidobacteria counts was 
reported in the Centre 1 (Table 2.5 and Appendix 4), in agreement with the microbial 
culture results.  
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Table 2.5. Genera differentially abundant between Centre 1 (n=5) and Centre 2 (n=10) 
TSHR-immunised mice intestinal scraped samples from the analysis of variance with 
Tukey’s HSD post-hoc analysis (95% confidence interval), generated with STAMP.  
 
a Genera were entered in alphabetical order. b Mean freq: mean frequency (%) normalized 
through a cumulative sum-scaling (CSS) implemented in STAMP. c std. dev: standard 
deviation. °Generated from 28-combo primers detecting V1-V2 regions and bifidobacteria 
sequences.  
 
2.4.4. Gut microbiota differences in immunised and control mice within the 
Centre 2 
To observe the possible contribution of the gut microbiota in the disease, I compared the 
gut microbiota composition between immunization groups in mice within the Centre 2. 
No significant differences were observed in alpha diversity indices among 
immunizations, apart from the Abundance-based Coverage Estimator (ACE) index 
between untreated and TSHR groups (Figure 2.4A, P=0.01), which relies on the 
presence of rare OTUs5. A higher bacterial load was also observed in the untreated 
group compared to the plasmid-immunised mice (P=0.04, Table 2.4). The βgal group 
                                               
5 Chao A. 2005. Species estimation and applications. In Encyclopedia of Statistical Sciences, ed. 
N Balakrishnan, CB Read, B Vidakovic, 12:7907–16. New York: Wiley.  
Generaa  
Centre 1:  
mean freq. 
(%)b 
Centre 1:  
std. dev  
(%) c 
Centre 2:  
mean freq. 
(%)b 
Centre 1:  
std. dev 
(%) c 
P values  
Allobaculum 1.001 1.306 0.003 0.009 0.042 
Alloprevotella 6.135 4.462 0.432 0.717 0.003 
Bacteroides 9.370 8.401 1.525 0.855 0.017 
Bifidobacterium° 0.668 0.505 0.006 0.012 0.003 
Clostridium XI 0.840 0.733 0.000 0.000 0.005 
Coprobacter 1.835 0.976 4.226 1.973 0.033 
Fusicatenibacter 0.989 0.429 3.295 1.983 0.032 
Guggenheimella 0.006 0.011 0.169 0.114 0.011 
Helicobacter 0.200 0.231 0.000 0.000 0.024 
Intestinimonas 0.097 0.034 0.861 0.339 0.000 
Lactobacillus 2.304 1.436 18.632 13.893 0.030 
Lactonifactor 0.023 0.021 0.401 0.309 0.025 
Meniscus 1.149 0.671 0.000 0.000 0.000 
Oscillibacter 0.640 0.501 1.748 0.698 0.011 
Parabacteroides 0.292 0.265 0.031 0.045 0.015 
Pseudoflavonifractor 0.154 0.106 0.466 0.252 0.028 
Rikenella 3.921 1.693 1.216 1.097 0.004 
Turicibacter 3.629 2.673 0.000 0.000 0.002 
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showed a slightly skewed distribution of the Shannon index when compared to the 
others; however, the post-hoc comparison was not significant. 
The non-metric dimensional scaling (NMDS) of the weighted UniFrac distances matrix 
showed a separation of the three immunization groups, confirmed by a significant 
permutation test (P<0.01, 999 permutations; Figure 2.4B). βgal bacterial communities 
were closer to those of the untreated mice, while a spatial shift of the TSHR immunised 
bacterial communities was observed. 
OTUs from Bacteroidetes and Firmicutes phyla were the most abundant among the phyla 
identified (Figure 2.4C) and showed a different distribution pattern among immunised 
groups. In particular, Firmicutes counts were higher in TSHR immunised mice (P=0.05) 
and Bacteroidetes were found to be higher in the untreated group (P=0.012). Differential 
taxonomic abundances analysis was performed pairwise between groups and described 
in the Table 2.6. At the genus level, eight genera were differentially abundant between 
TSHR and βgal groups; three genera between TSHR and the untreated group and four 
genera between βgal and the untreated group. I reported an enrichment of OTUs in the  
Acetitomaculum genus in the βgal group compared to both TSHR (P=0.004) and the 
untreated group (P=0.003); an enrichment of Lactobacillus OTUs in the TSHR compared 
to the untreated group (P=0.018) and a reduction of Bacteroides OTUs in TSHR when 
compared to the βgal group (P=0.047).  
In the scraped intestinal samples, no cage effect on the composition of the large intestine 
microbiota was observed (PERMANOVA P>0.05; Figure 2.4D).  
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Figure 2.3. Comparative analysis of the gut microbiota in independent animal 
units.  
(A) Box and whisker plot of the alpha diversity indices for richness (Chao1 and observed 
OTUs indices) and evenness (Shannon index) of the bacterial communities in TSHR 
immunised mice housed in Centre 1 (blue) and Centre 2 (red), respectively. Tukey’s HSD 
post-hoc: Chao1, P=0.01; Observed OTUs, P<0.001; Shannon, P=0.08. (B) Annotated 
heatmap based on Spearman distance and Ward hierarchical clustering of the top-30 
genera shows how well the two locations cluster together. Taxonomy explanation 
includes genera, family and phylum, which are entered in order of abundance. Genus 
abundances were centered and standardized according to each column Z-scores and 
described by the change in the intensity of the grey colour, as annotated. (C) Differentially 
abundant family from a pairwise comparison with Welch’s t-test with 95% confidence 
intervals (STAMP).  
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Figure 2.4. Gut microbiota composition in TSHR immunised mice and control mice 
in Centre 2 at final timepoint.  
(A) Box and whisker plot describing the measurement of alpha diversity (Chao, ACE and 
Shannon indices). Tukey’s HSD post-hoc analysis Chao and Shannon P>0.05, ACE 
index between TSHR and untreated groups, P=0.01. (B) Non-metric dimensional scaling 
(NMDS) plot of weighted Unifrac distances showed a spatial separation of microbial 
communities according to the immunizations. PERMANOVA based on 999 permutations 
P=0.001. Pairwise PERMANOVA TSHR-βgal P=0.024; TSHR-untreated P=0.026; βgal-
untreated=0.024. (C) Boxplot of the phylum counts according to immunizations. ANOVA 
on phylum counts P<0.0001 and pairwise T-test between Bacteroidetes-Firmicutes 
counts adjusted P=0.0003. Pairwise t-test comparing Bacteroides-Firmicutes counts in 
immunizations: TSHR P=0.05, βgal P=0.2 and untreated P=0.012. (D) Non-Metric 
Dimensional Scaling (NMDS) plot based on weighted Unifrac distances shows spatial 
separation of the microbial community according to the immunization groups within the 
Centre 2 (black ellipses). PERMANOVA based on 999 permutation P=0.0005. Pairwise 
PERMANOVA Benjamini-Hochberg (BH) adjustment TSHR-βgal P=0.024, TSHR-
untreated P=0.026, βgal-untreated P=0.024. Superimposed lines with different colours 
represent distances of the bacterial community according to the cages as described in 
the legend. Mice were co-housed according to their immunization at a maximum of 4 
animals. No significant difference in cage effect is observed. PERMANOVA based on 
cage effect (999 permutations) for all comparisons P=0.12. 
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Table 2.6. Differential abundant taxonomic analysis between TSHR (n=10), βgal (n=8) 
and untreated (n=6), within Centre 2. Welch’s T-test with 95% confidence interval using 
STAMP.  
aMean frequency, normalized through a cumulative sum-scaling (CSS) method, as 
implemented in STAMP. bStandard deviation, std. dev.  
 
2.4.5. Dynamics and stability of faecal microbiota during the immunization 
protocol 
To assess whether the immunization plasmids and the duration of the protocol could 
have influenced the gut microbiota composition, I calculated the total bacterial load and 
sequenced the bacterial 16S rRNA gene from the faecal pellets of the βgal and TSHR 
group from the baseline (T0) for 18 weeks afterwards, until the end of the experiment 
(T4).  
From Equation 2, I observed a significant association of the 16S copy number with time 
(P=0.016, Table 2.7); however, no significant differences between immunisations were 
observed in each timepoint, a part in the latest timepoint. 
A significant increase of the richness (Chao index, figure 2.5A; P=0.02) and the diversity 
(Shannon index, figure 2.5B) were observed over time, which were less apparent in the 
TSHR immunised group. Significant differences regarding richness between TSHR and 
βgal have been observed at T4 (P=0.027, Table 2.7). The Shannon index of diversity 
was significantly different between TSHR and βgal immunization at T1 (P=0.023, Table 
2.7).  
Comparison Genus 
mean 
freq. 
(%)a 
std. 
dev. 
(%)b 
mean 
freq. 
(%) 
std. 
dev. 
(%) 
difference 
between 
means 
P 
value 
TSHR 
vs. 
βgal 
Acetitomaculum 0.086 0.068 0.285 0.129 -0.200 0.004 
Bacteroides 1.520 0.853 3.430 2.055 -1.909 0.047 
Fusibacter 0.040 0.039 0.007 0.012 0.033 0.035 
Genus_low 1.075 0.249 1.372 0.263 -0.297 0.037 
Lachnobacterium 0.317 0.238 0.620 0.304 -0.304 0.049 
Parabacteroides 0.031 0.045 0.078 0.034 -0.047 0.030 
Parasporobacterium 0.331 0.158 0.139 0.138 0.192 0.020 
Peptococcus 0.086 0.075 0.367 0.301 -0.282 0.043 
TSHR 
vs. 
untreated 
Flavonifractor 0.128 0.067 0.043 0.048 0.086 0.016 
Lactobacillus 18.591 13.883 5.048 3.732 13.543 0.019 
Thiofaba 0.034 0.033 0.005 0.011 0.029 0.031 
βgal 
vs. 
untreated 
Acetitomaculum 0.285 0.129 0.071 0.056 0.214 0.003 
Alloprevotella 0.157 0.288 1.344 0.873 -1.187 0.027 
Caminicella 0.053 0.052 0.000 0.000 0.053 0.030 
Flavonifractor 0.160 0.082 0.043 0.048 0.118 0.009 
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The murine faecal microbiota comprised Bacteroidetes and Firmicutes phyla 
predominantly (Figure 2.5C); followed by Tenericutes, Proteobacteria, Deferribacteres 
and Candidatus Saccharibacteria phyla. The Firmicutes/Bacteroidetes ratio has been 
used to describe the shift in the gut microbiota associated with ageing [323] and also in 
disease conditions such as obesity [223]. The ratio showed differences amongst the 
timepoints of the experimental procedure (P<0.01) and between TSHR and the βgal 
group after three weeks from the first injection (T1, P=0.011; Figure 2.5C).  
 
Table 2.7. Summary of the statistical test (P values) from the time-course analysis of the 
faecal microbiota during the immunization protocol (T0-T4) and between immunizations 
(βgal and TSHR).  
 
Index 
Linear regression modela TSHR vs. βgal groupb 
Immunization Time Time x Immun T0 T1 T2 T3 T4 
16S# 0.129 0.016 0.81 0.74 0.49 0.56 0.56 0.08 
Chao  0.006 0.02 0.8 0.75 0.066 0.28 0.33 0.03 
Shannon 0.054 0.28 0.47 0.44 0.023 0.35 0.35 0.29 
F:B° 0.406 0.0003 0.16 0.39 0.028 0.46 0.2 0.26 
 
#Log-transformed 16S gene copy number. °F:B, Firmicutes/Bacteroidetes ratio. aANOVA 
model as described in equation 1. bPairwise comparison between βgal and TSHR in each 
time point.  
 
I fitted a generalized linear model (GLM) to compare the taxonomic counts at different 
timepoints within each group independently (either TSHR or βgal). Thirty-four genera 
have been identified as differentially abundant amongst all timepoints in reference to the 
baseline (T0) in the TSHR immunised group (Appendix 5), while 25 were found in the 
βgal group (Appendix 6). Differences in the taxonomic profile between TSHR and βgal 
groups were observed at each timepoint using an exact test (EdgeR). Once again T1 
was identified as the timepoint with the highest number of genera differentially abundant, 
as illustrated by the diversity indices. Such genera were more abundant in the TSHR 
group, in particular, the genus Prevotella was nearly 9-fold more abundant in TSHR than 
in the βgal group (P=0.0163) (Table 2.8).  
In contrast to data obtained from the gut microbiota (Figure 2.3D), a cage effect was 
observed in the faecal microbiota, in particular, in interaction with time (P=0.001) and 
immunization (P=0.002; Figure 2.6). The latter is probably due to the mice being caged 
according to the type of plasmid injection they received, but I also observed a significant 
difference within the same immunization group (e.g. TSHR in cage 4 and cage 5, 
P=0.01).   
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Figure 2.5. Time-course analysis of GO preclinical faecal microbiota during the 
immunization protocol.  
Box and whisker plot of alpha diversity such as Chao, (A), and Shannon, (B), indices 
showed differences over time. Differences in richness (Chao) over time (ANOVA, 
P=0.02) in particular between the baseline and the last timepoint (post-hoc test, P=0.04) 
and between immunizations (P=0.006). A slightly significant difference in the Shannon 
diversity index was observed between immunizations (P=0.054). (C) Phylum dynamics 
over time and between immunizations. Firmicutes and Bacteroidetes were the most 
abundant phyla, showing differences with time and immunizations. Significant 
differences among timepoints have been observed at the Firmicutes/Bacteroidetes ratio 
(P<0.001), in particular between the baseline T0 and the last timepoint T4 (post-hoc, 
P=0.0013), but not related to immunization. A significant difference in the ratio was 
observed after three weeks from the first injection (T1) between βgal and TSHR (pairwise 
T-test, P=0.011).  
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Figure 2.6. Temporal stability of faecal microbiota and cage effect of the 
immunizations.  
(Next page) Weighted Unifrac distances of mice faecal microbial communities 
represented over the time course of the experiment according to the immunization (A) or 
the cage (B). PERMANOVA of weighted Unifrac distances according to timepoint, 
immunizations, caging and their interactions (time x cage; time x immunization; 
immunization x cage) as described in Equation 2. The time had a significant effect on the 
stability of the faecal microbiota (P=0.001), in particular between the baseline (T0) and 
the latest timepoint (T4, P=0.003); and between the T1 and T4 (P=0.009). The interaction 
between time and immunization was significant (P=0.007). Cage was also significant, in 
particular the interaction cage x timepoint (P=0.001) and cage x immunization (P=0.002). 
Significant differences within the same immunization group cage has been observed 
(TSHR group in C4 and C5, P=0.01).  
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Table 2.8. Pairwise comparison of TSHR and βgal mice using Fisher’s Exact Test in 
EdgeR at each timepoint (T0 to T4).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
§ LogFC, Log2 fold change of βgal compared to TSHR at each timepoint.  
 
 
 
 
Timepoint Genera logFC
§ 
(βgal vs. TSHR) P value 
T0 
Guggenheimella -1.5934 0.0030 
Peptococcus -2.6142 0.0195 
Lactobacillus 1.3432 0.0246 
T1 
Robinsoniella -3.0655 0.0012 
Clostridium_IV -2.7232 0.0036 
Butyrivibrio -2.2934 0.0066 
Mucispirillum -2.7743 0.0134 
Prevotella -8.9035 0.0163 
Acetitomaculum -2.1154 0.0179 
Anaerovorax -1.7909 0.0179 
Lachnospiracea incertae sedis -1.5169 0.0236 
Faecalibacterium -3.0879 0.0265 
Intestinimonas -1.2177 0.0403 
Lachnobacterium -1.3480 0.0449 
T2 
Parasporobacterium 2.6409 0.0075 
Parabacteroides -1.4670 0.0156 
Lactobacillus 1.2957 0.0292 
Galenea -3.5744 0.0459 
Barnesiella -0.9705 0.0492 
T3 
Papillibacter -2.4871 0.0006 
Butyrivibrio 2.6026 0.0029 
Marvinbryantia 1.8713 0.0049 
Butyricimonas -1.4919 0.0226 
Ruminococcus -2.2425 0.0307 
T4 
Lachnobacterium -1.7259 0.0067 
Acetitomaculum -1.8684 0.0202 
Parasporobacterium 2.2330 0.0221 
Coprobacter 0.7723 0.0224 
Clostridium IV -1.5336 0.0327 
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2.4.6. Correlating the gut microbiota composition with clinical features and 
differences in GO development  
I then investigated possible correlations between disease features, such as anti-TSHR 
antibodies, thyroxine levels (fT4), orbital adipogenesis and muscular atrophy, and the 
gut microbiota composition to determine whether it contributes to the heterogeneity of 
induced responses, previously summarized in Table 2.3.  
Within the Centre 1 TSHR-immunised group, OTUs from Firmicutes and Bacteroidetes 
negatively correlated to each other (Rho=-1, P<0.0001). Moreover, a positive correlation 
between levels of TSAb and Deferribacteres phylum, which include one-genus 
Mucispirillum, was found (Rho=0.92, P=0.028; Figure 2.7A).  
From those genera differentially abundant between TSHR-immunised mice from Centre 
1 and Centre 2 (Table 2.5), identified via metataxonomics, a strong negative correlation 
of the Firmicutes genus Intestinimonas spp. and the levels of TSBAb was observed in 
the Centre 1 (Rho=-0.89, P<0.05), but not in the Centre 2 counterpart (Figure 2.7B). No 
significant correlation was observed between OTUs from the genus Intestinimonas spp. 
and levels of TSAb or levels of free thyroxine hormone (fT4; data not shown). 
 
Figure 2.7. Correlating the gut microbiota and disease features in Centre 2 TSHR 
group. 
(A) Spearman correlation coefficient strength (Rho) of phylum counts from TSHR mice 
in Centre 2. Firmicutes and Bacteroidetes showed a strong negative correlation between 
each other. A positive correlation between the one-genus phylum Deferribacteres and 
the level of thyroid-stimulating antibodies (TSAb) has been observed. Correlations with 
P<0.05 are shown and strength of the Rho coefficient is represented by the change in 
the colour intensity. fT4, free thyroid hormone thyroxine levels; TSAb, thyroid stimulating 
antibodies; TSBAb, thyroid-stimulating blocking antibodies (as a percentage values). (B) 
Enriched Firmicutes genus Intestinimonas between Centre 1 (blue) and Centre 2 (red) 
showed a strong negative correlation with the percentage of thyroid-stimulating blocking 
antibodies (TSBAbs) at 95% confidence interval in Centre 1 (Rho=-0.8, P=0.04), but not 
in Centre 2. 
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Within the Centre 2, Bacteroidetes and Firmicutes negatively correlated to each other 
(Rho=-0.99, P<0.0001). I also found a significant positive correlation (Rho=0.6, P=0.009) 
between the OTUs from the Firmicutes and the orbital adipogenesis value and a negative 
correlation of this value with the phylum Bacteroidetes (Rho= -0.57, P=0.014; Figure 
2.8A). These correlations were specific to the TSHR immunised mice, moreover, the 
correlation pattern previously reported (Firmicutes positively correlated, Bacteroidetes 
negatively correlated) was also recapitulated at the genus level. Among the genera of 
the Firmicutes, three, within the Clostridia family (Butyricicoccus, Parvimonas and 
Fusibacter) and the genus Lactobacillus were correlated positively with adipogenesis; 
while three Bacteroidetes genera (Anaerophaga, Paraprevotella and Tannerella) 
correlated negatively with the orbital adipogenesis values (Figure 2.8B). 
 
 
Figure 2.8. Correlation of the gut microbiota composition with clinical features and 
differences in Centre 2 mice.  
(A) Positive strong correlation of the Firmicutes/Bacteroidetes ratio with the adipogenesis 
value (calculated in the orbit) resulted significant in TSHR immunised group (Rho=0.8, 
P=0.013) but not in the βgal group (Rho=0.08, P=0.98). (B) Spearman correlation 
coefficient (Rho) of genera among phyla Bacteroidetes and Firmicutes and the orbital 
adipogenesis values. The strength of the correlation coefficient is represented on x-axis: 
bars on the left represent a negative correlation coefficient, while bars on the right 
represent a positive correlation coefficient. Correlations with P<0.05 are shown; order of 
entrance depends on their P values: * P<0.05; ** P<0.01; *** P<0.005.  
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2.5. DISCUSSION   
Animal models have been invaluable in dissecting the mechanisms causing loss of 
immune tolerance leading to autoimmune conditions such as GD. Thus, the hypothesis 
to be tested was “that the gut microbiota may affect both outcome and reproducibility of 
induced autoimmune disease”, such as reported in the recent research article of UB-P 
and co-workers [187]. 
2.5.1.  Animal conditions and effect of the conventionalized housing   
Animals were maintained in similar conditions. We are confident that there were no 
infections ongoing at the moment of sampling, since animals in both centres were 
routinely tested for the presence of viruses, mycoplasma and parasites; moreover, 
housing facilities had comparable SPF conditions. Animals were from the same supplier 
but in different countries (Harlan Ltd. for Centre 1 and Harlan Lab. BV for Centre 2) and 
had been fed similar commercial diets, with the exception that food pellets provided in 
Centre 2 contained twice the amount of iodide compared to Centre 1 food. Although 
iodide excess can be associated with abnormal thyroid function, this dietary variation is 
not enough to explain the results (i.e. elevated thyroxine levels were apparent in the 
Centre 1, but not Centre 2 mice).  
The importance of SPF conditions is indicated by a previous study which failed to 
reproduce a GO animal model, despite using mice from the same supplier and identical 
bedding, water and chow [188]. However even SPF may be inadequate since differences 
were found in the gut microbiota of C57BL/6 colonies bred in two different rooms of the 
same SPF facility [324], fortunately mice in our study were all housed in the same room. 
Cage effects were apparent in the faecal microbiota results, which highlight the 
importance of studying the gut microbiota instead when comparing autoantigen (TSHR)-
immunised and control mice, which is in the close proximity of the intestinal mucosa and 
the immune system, enabling us to explore its relationship with disease features. The 
total bacterial load was significantly different between the gut and the faecal microbiota. 
Also, faeces and intestinal scrapings of the same animals before and after euthanasia 
showed a heterogeneous composition of the microbiota in terms of richness and diversity 
of the bacterial communities and spatial organization of the beta-diversity (Appendix 7). 
Moreover, paired faecal and intestinal samples showed a highly variable strength of 
correlations (Spearman coefficient) ranging from weak (Rho = 0.50) to strong (Rho > 
0.80) correlation depending on the sample, which is possibly attributed to the collection 
method of the faecal materials from the cage or the coprophagy habits of the mice.  
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2.5.2. Correlations between gut microbiota and disease features  
Several disease-associated taxonomies were described; the abundance of the newly 
described butyrate-producing genus Intestinimonas [325] was reduced in the Centre 1 
group compared to Centre 2 and correlated negatively with TSBAb. The Intestinimonas 
species butyroproducens has a unique ability to produce butyrate from lysine and is 
involved in the detoxification of Advanced Glycosylation End (AGE) products such as 
fructoselysin, which have been linked to type-1 diabetes [326]. Administration of short-
chain fatty acids (SCFA), including the butyrate, ameliorated the severity of the EAE 
model by increasing the Tregs, but increased the severity of the antibody-induced 
arthritis model [327]. At the present, we are unaware of any link between butyrate-
producing bacteria and thyroid autoimmunity.  
The TSHR-immunised group developed some signs of GO and their gut microbiota had 
increased OTUs of the phylum Firmicutes but decreased Bacteroidetes compared with 
controls. This difference mirrors preliminary data in human disease, where we observed 
a dramatic reduction in the Bacteroides genus in GD patients when they develop GO, 
which will be further described in Chapter 4 of this thesis. 
A positive correlation between several Firmicutes counts, such as clostridia and bacilli, 
with orbital adipogenesis in TSHR-immunised mice was also reported. Million and co-
workers have previously reported a positive correlation between OTUs from the 
Firmicutes and weight-gain/obesity in both animal models and humans [328]. 
Interestingly, the role of the genus Lactobacillus and its products in either triggering or 
protecting from adipogenesis has been debated and seems to be species-specific. In the 
present work, we could exclude a possible gain-of-weight relationship with the 
adipogenesis value calculated in the orbit since no changes in mouse weights have been 
observed during the development of the chronic phase of the disease (data not shown). 
Furthermore, molecular mechanisms driving obesity and orbital adipogenesis may well 
be different, since the latter is derived from the neural crest and the gut microbiota may 
have varying effects on different fat depots [329]. 
2.5.3. Longitudinal analysis for faecal microbiota dynamics and stability  
Time series or longitudinal analysis of the microbial communities can be useful to 
investigate the dynamics and the stability of those microbiota over time in the presence 
or absence of certain stimuli. Different methodologies are now available to be applied to 
ecological data as reviewed by Faust et al. [330]. The approach adopted in this chapter 
was to consider the time as a factor and test its interaction with other covariates in a 
model, using alpha, beta diversity indices or genus profiles as response variables.  
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Amongst observed covariates, our longitudinal analysis revealed that time had a 
dramatic role in shaping the faecal microbiota of the female mice which were 6-8 weeks-
old at the outset and 24-26 weeks at the end of the experiment, confirming previously 
published works [331, 332]. The richness and diversity of βgal control mice increased 
with age, but this was less apparent in the TSHR immunised animals. Significant 
differences in microbiota composition between control and TSHR immunizations were 
most apparent three weeks after the first immunization, at the initiation of the induced 
immune response. 
2.5.4.  Use of the βgal expression plasmid as plasmid-control animals   
The control group comprised mice immunised with the βgal expression plasmid in which 
I observed a reduced bacterial load and a slight skew in the microbiota richness and 
diversity which may be caused by the systemic overexpression of the β-galactosidase 
enzyme, whose natural role is in glycan metabolism, e.g. the hydrolysis of the lactose to 
galactose and glucose [333]. Kaneda and collaborators reported a βgal overexpression 
peak in the muscle fibres following electroporation from five days to 2 weeks after the 
injection [178]. This effect merits further investigation, but we are confident that the βgal 
vector plasmid provides the optimum control group since its microbial communities were 
more closely related to that of the naïve non-immunised group than to TSHR immunised 
mice. 
2.6. CHAPTER CONCLUSIONS 
In conclusion, results presented in this chapter indicate a role for the gut microbiota in 
modulating the heterogeneity apparent in the TSHR-induced model of GD and GO. 
Whether the correlations observed also correspond to causation has to be further 
proved. For example, the transfer of the gut microbiota of TSHR-immunised mice from 
one location to those in the other would determine whether the gut microbiota 
composition is directly responsible for the differences in the clinical outcomes observed 
in the two centres. Similarly, the faecal material from severe GO patients can be 
transplanted into murine recipients to observe the potential of the gut microbiota in 
transferring signs of GO. 
In the next chapter the presence, absence or amounts of certain bacteria and their ability 
to directly influence the outcome of the GO model will be investigated, via the 
manipulation of the gut microbiota with the administration of either antibiotics, probiotics 
or the faecal material transplant from GO patients. 
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3. Chapter 3 
 
 
 
 
Functional role of the gut microbiome in GO mouse 
models undergoing manipulations of the gut bacterial 
composition 
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3.1. INTRODUCTION 
In the previous chapter, a possible role for the gut microbiota was observed in the 
establishment of the mouse model of Graves’ orbitopathy (GO) and its replication in a 
different laboratory. Moreover, some of the taxonomies differentially present in the 
disease model compared to controls showed a positive correlation with disease features, 
such as the orbital adipogenesis in the hTSHR-immunised mice. Such an association or 
correlation itself, however, is not sufficient to explain the causative role of these bacteria 
in triggering the disease status. For that reason, experimental manipulations of the gut 
microbiota would be necessary to allow functional and mechanistic description of the 
host-microbe interactions, and possibly assess a direct causality in disease-associated 
alterations in gut microbiota composition [199]. 
The type of diet, age, hormones and medications may naturally modulate the gut 
microbiota composition in humans and mouse models, as previously described in the 
general introduction. However, several and more specific gut microbiota manipulation 
strategies are now available and have been used in the past years to study the interplay 
between the immune response and the gut microbiota in autoimmune disease mouse 
models. 
As previously described (chapter 1, par.. 1.5.5), apart from pathogenic bacteria, the gut 
microbiota composition can be affected by the use of antibiotics, showing a reduction of 
the richness and diversity of bacterial communities and, on the other hand, the growth of 
certain resilient or resistant bacterial species, depending on the type of antibiotic, dose 
and the duration of the treatment. When studying the functional role of the gut microbiota 
in a disease model, it might be of interest to observe changes in the disease phenotype 
due to the absence of certain or all bacterial species [334], which can be obtained using 
antibiotics or germ-free (GF, sterile) mice. Systemic lupus erythematosus (SLE), a 
systemic autoimmune conditions characterized by the presence of anti-nuclear 
antibodies (ANA), can be reproduced spontaneously in the MLR/lpr mice (i.e. 
homozygous for the lymphoproliferation spontaneous mutation Faslpr) [335]. The 
administration of either vancomycin alone or a mixture of broad-spectrum antibiotics to 
female SLE-prone MLR/lpr mice after the onset of the disease, attenuates the symptoms, 
with decreased serum levels of pro-inflammatory IL-6 and increased IL-10 levels – a 
known protective cytokine for SLE. The gut microbiota composition of these mice is 
significantly enriched in Lactobacillus spp. [336]. A delayed and less severe disease was 
also observed in the spontaneous model of autoimmune uveitis in R161H mice 
(transgenic for the expression of the TCR against the retinal protein IRBP) after treatment 
with a broad-spectrum antibiotics or in GF conditions [337]. While the absence of the gut 
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bacteria seemed to be protective for the development of some autoimmune conditions, 
in non-obese diabetic (NOD) mice – which spontaneously developed type-1 diabetes 
(T1D) with similar features as humans - treated with broad-spectrum antibiotics from 
conception to the end of the experimental procedure, showed a significantly increased 
incidence of type-1 diabetes (T1D), along with an accelerated onset compared to 
controls [338]. A similar situation was observed in GF MyD88-deficient NOD mice (i.e. 
lacking the innate immunity signal adaptor for bacterial stimuli) [339].  
Another method of microbiota manipulation includes the transfer or the transplant of 
faecal material (FMT), which can be performed between murine strains (faecal material 
transfer) or from human to mice (humanized mice), depending on the purpose of the 
experiment. Such a transfer is usually performed through a gavage using either freshly-
passed or frozen faecal samples, usually preceded by an antibiotic treatment or using 
GF animals, to reconstitute the entire microbiota. Faecal transfer from different murine 
strains might confer resistance or susceptibility to a certain disease from the donor to 
recipients; in fact, the microbiota from the diabetes-resistant MyD88-deficient NOD mice 
significantly delayed the onset of the disease when transferred into the diabetes-prone 
NOD mice [340]. In the case of humanized mice, the FMT is performed from humans to 
murine models usually to recapitulate the human microbiota possibly associated to a 
disease status [341]. In recent developments, faecal microbiota transplantation from a 
healthy donor, has been used as an efficient treatment to clear infections with the 
antibiotic-resistant Clostridium difficile in humans, which may arise after hospitalization 
and recurrent usage of antibiotics and might have a fatal outcome. Several strategies 
have been implemented to avoid the use of conventional faecal slurry transfer through 
colonoscopy in humans [342], aiming to retain the efficacy of the transplant such as the 
production of freeze-dried faecal microbial products [343] or the transfer of faecal filtrate 
[344]. 
Ultimately, modification of the intestinal bacterial composition can be also be driven by 
the administration of probiotics or “live organisms which when administered in adequate 
amounts confer a health benefit on the host”, according to FAO and WHO guidelines and 
the probiotic consensus statement [345]. Probiotics, as a dietary supplementation, can 
be administered as a single-strain or in consortium, most of them include the lactic-acid 
producing bacteria (LAB) Lactobacillus and Bifidobacterium spp. As will be further 
discussed in Chapter 5, one of the beneficial effects of probiotic intake is related to their 
ability to induce an anti-inflammatory immune response. A prevention of the TD1 onset 
was observed in NOD mice receiving multiple strains of Lactobacillus and 
Bifidobacterium spp. and of Streptococcus salivarius subsp. thermophilus which was 
associated with an increased production of IL-10 [346]. 
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As a summary of the various manipulation strategies available, the experimental 
autoimmune encephalomyelitis (EAE) mouse model for multiple sclerosis has been 
extensively characterized in the past years, employing several of the manipulation 
methods described above, to dissect the functional role of the gut microbiota in the 
disease phenotype. The administration of antibiotics seemed to prevent the onset of the 
disease, due to a reduction of IL-17 levels and the increase of the Th2 immune response 
[315]. On the other hand, the mono-colonization with the segmented filamentous bacteria 
(SFB) of GF EAE mice increased the disease phenotype, associated to an increase of 
the IL-17 levels and a Th17 cells in the central nervous system [316]. The administration 
of a single-strain Lactobacillus paracasei or in combination of a three-strains probiotic 
reduced the pro-inflammatory response and reversed the induced phenotype with the 
up-regulation of Tregs via the production of IL-10 [347]. Similarly, oral administration of 
the LAB Pediococcus acidilactici R037 before the immunisation until the end of the study 
ameliorates the EAE onset in both C57BL/6 and SJL/L mice and contributed to a milder 
disease phenotype perpetuated as a therapeutic effect [348]. Recently, the transfer of 
faecal material derived from MS patients increased the frequency of a spontaneous 
development of relapsing-remitting EAE SJL/J mice (i.e. transgenic for the TCR-specific 
against the myelin oligodendrocyte glycoprotein [349]), along with the reduction of IL-10 
and the decreased abundance of the genus Sutterella compared to mice receiving 
samples from healthy donors [350].  
3.2. AIMS OF THE CHAPTER 
The aim of the present chapter was to understand the complex host-microbiome interplay 
that underpins the TSHR-induced GD/GO model via the modification of the gut 
microbiota at the early-stage of life with either antibiotics, probiotics or FMT from sight-
threatening GO patients compared to controls (water), along with the hTSHR-A subunit 
immunisation protocol described in the previous chapter. Specific goals from the 
microbiome analysis would cover: i) differences in the gut microbiota during the course 
and at the end of the study amongst treatments and immunisations groups and their 
correlations with the disease features, ii) the accuracy in the prediction for treatments 
and immunisations based on the gut microbiota composition through a Random Forest 
classification algorithm, iii) quantification of the extent of the hFMT from donors to 
recipients (engraftment) expressed as a percentage of similarity and calculated through 
an iterative Bayesian model (SourceTracker), iv) the prediction of the metagenomic 
functional profile and their differential variances amongst treatments and immunisations. 
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3.3. MATERIALS AND METHODS  
3.3.1. Patient recruitment  
Six Graves’ orbitopathy (GO) patients with sight-threatening disease were recruited at 
the Ophthalmic Clinic of the University Hospital of Duisburg-Essen (Germany) by AE in 
the framework of the E.U.-FP7 Indigo project (http://www.indigo-iapp.eu/). The study was 
approved by the local research ethical commission (Ethik-Kommission reference 14-
5965-BO) and written informed consent was obtained from each patient at the time of 
the enrollment. Eye disease activity and severity were assessed based on the EUGOGO 
guidelines [351]. All six patients were treated with steroid bolus and selenium before 
orbital decompression surgery (performed between 2014-2015). One patient (4011) had 
the decompression of both eyes, and two patients (4011 and 4015) continued steroid 
treatment after surgery. Faecal samples were collected at the time of the enrolment, 
when all patients were euthyroid, following procedures further described in Chapter 4 
par. 4.3.1, stored at -80°C and shipped frozen to Cultech Ltd. (Port Talbot, UK). Samples 
were processed to generate the product to be used in faecal material transplant (hFMT) 
and DNA was extracted for metataxonomics by HLK, DC and GM. Thyroid function tests 
(TSH and FT4) and levels of the thyroid stimulating antibodies (TRAB) were measured 
according to the University Hospital of Duisburg-Essen local bioassays. A complete 
description of the patient characteristics used for hFMT production is described in Table 
3.1. 
Table 3.1. Characteristic of patients with sight-threatening GO recruited at the University 
Hospital Duisburg-Essen providing samples for hFMT production. 
 
 1TSH is expressed as mU/L; 2FT4 is expressed as pmol/L and 3TRAB is expressed as UI/L.  
n.a. not available. 
3.3.2. Production of freeze-dried faecal material for transplant (hFMT) 
Faecal samples from sight-threatening GO patients were processed by HLK at Cultech 
Ltd. (Port Talbot, Wales, UK) for the production of a freeze-dried faecal material to be 
administered to mice (hFMT). Faeces were pooled together and prepared for a 
sequential culture method in maximum recovery diluent broth (MRD). Initially, 0.1g of the 
pooled sample was added to 50 mL pre-reduced MRD broth and incubated overnight at 
Patient ID Age Gender Smoking TSH1 FT42 TRAB3 
4008 43 female current 2.72 13.2 1.45 
4009 59 male never 0.01 10.7 3.89 
4010 60 female current 5.76 14.2 14.75 
4011 50 male current 0.02 25.1 n.a. 
4015 74 female current 1.52 20.6 16.83 
4020 51 female current 5.2 16.1 n.a. 
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37°C under aerobic or anaerobic conditions. The mixture was further inoculated into 
500mL pre-reduced MRD, followed by an overnight incubation at 37°C under aerobic or 
anaerobic conditions. As a control, pooled faecal samples from each inoculum were 
plated on non-selective agars (horse blood agar and anaerobic blood agar) and 
incubated overnight at 37°C under aerobic or anaerobic conditions in order to count 
viable cells. After a centrifugation step at 3,000 x g for 30 min, the resulting supernatant 
was discarded and the pellet was weighed and transferred into petri dishes, where they 
were supplemented with 10% w/v skimmed milk powder as a cryoprotectant agent, and 
placed at -80°C until completely frozen. The freeze-dried process was performed in a 
freeze-dryer machine from overnight to several days. 50µl from a stock of 0.5g powder 
in 4.5 mL MRD were used to count viable cells on non-selective agars (as previously 
described), MRS agar for lactobacilli and MRSx agar for bifidobacteria and incubated 
overnight at 37°C under aerobic or anaerobic conditions. The resulting powder was 
aliquoted into small vials to 0.125g final content and shipped to SM at the University 
Hospital of Duisburg-Essen (Germany) to be provided via a gavage to mice. 
3.3.3. GO animal model and treatments 
Female BALB/c mice used in this study were bred at the University Hospital of Duisburg-
Essen (Germany) facility, in order to administer the treatments from an early-stage of 
life, and manipulation studies were performed by SM, UB-P and colleagues. The study 
was approved by the North Rhine Westphalian State Agency for Nature, Environment 
and Consumer Protection, Germany. 
The antibiotic vancomycin was provided in the drinking water at a starting dose of 0.2 
g/L to both dams first and pups later from their first day of life for the entire course of the 
experiment. 
The probiotic Lab4® (Cultech Ltd., Port Talbot, UK) is a consortium of lactic acid-
producing bacteria (LAB) comprising two strains of Lactobacillus acidophilus CUL60 
(NCIMB 30157) and CUL21 (NCIMB 30156), Bifidobacterium lactis CUL34 (NCIMB 
30172) and Bifidobacterium bifidum CUL20 (NCIMB 30153) and was administered at a 
total of 1x1010 CFU/50μl autoclaved water in each gavage. The hFMT powder was 
dissolved in sterile water and provided at a final concentration of 1x1010 CFU/gavage. A 
group of mice receiving autoclaved water was included as a control. Administration of 
both interventions and control was performed through a gavage (50μl) on pups for a total 
of four times from the first day after birth, at weaning, before and in the middle of the 
immunisation procedure, as described in figure 3.1. After receiving three gavages, at 6-
7 weeks old, mice from each treatment or control group were divided in two more groups 
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for being immunised with either the immunisation with the human TSHR-A subunit 
(TSHR) or the β-galactosidase (βgal) control for immunisation, following the same 
protocol previously described in chapter 2 par. 2.3.1. 
Faecal pellets were collected from mouse cages after three treatment-gavages, but 
before any immunizations with hTSHR or βgal (baseline), and after four gavages, but 
before the 3rd immunization (mid timepoint). At the end of the experimental procedure 
(6 weeks after the last immunization and almost 9 weeks after the last gavage), after the 
sacrifice of the mice, the contents of small, colon or entire intestines were collected for 
analysis by metataxonomics (endpoint), as described in Table 3.2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1. Experimental design of the gut microbiota manipulation.  
Female BALB/c mice were immunised either with TSHR or the βgal expression plasmids 
alone (control) or in combination with a consortium of probiotics (Lab4) or faecal material 
transplant from severe GO patients (hFMT), or long-term treatment with vancomycin. 
Vancomycin was provided in the drinking water to dams before and pups from birth for 
the entire duration of the study; other treatments (hFMT and Lab4) and water (control) 
were provided through a gavage after birth, at weaning, before the first immunisation and 
before the third immunisation. Immunisation protocol (in blue) was the same as 
described in Chapter 2. Samples for microbiome analysis (red dots) were collected after 
three gavages but before the first immunisation (baseline), after four gavages but before 
the third immunisation (mid) and at the end of the experiment, after the sacrifice of the 
mice (end). 
3.3.4. DNA extraction and 16S rRNA gene sequencing  
A total of 297 mouse samples from either faecal pellets or intestinal contents (small, 
colon or entire sections) were extracted using the QiAmp Fast DNA Stool Mini kit 
(Qiagen, Germany), as previously described in Chapter 2 par. 2.3.2, by SM, UB-P and 
colleagues at the University Hospital Duisburg-Essen. Faecal samples from six GO 
donors for hFMT were processed for DNA extraction before the freeze-drying at Cultech 
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Ltd. (UK) using the same protocol as above. Metataxonomic sequencing (16S rRNA 
gene sequencing) was performed at Research & Testing RTL Genomics (Lubbock, 
Texas, USA), using primers detecting the V1-V2 regions of the 16S rRNA gene plus 
bifidobacteria regions (28F-combo, Chapter 2 Table 2.2) to generate 10,000 paired-ends 
reads on a Illumina MiSeq (Illumina, San Diego, USA).  
3.3.5. Processing of metataxonomic reads  
A first quality check on raw demultiplexed paired-end sequences (R1 and R2) was done 
using FastQC. All of the below steps were performed with the QIIME 1.9 open-source 
bioinformatics pipeline for microbiome analysis [208], which were configured and run 
using PipEngine (https://github.com/fstrozzi/bioruby-pipengine), as represented in 
Appendix 8. The complete QIIME command-line is available in Appendix X. Joining of 
paired-end sequences was done using the function “multiple_join_paired_end.py”, using 
the SeqPrep method (https://github.com/jstjohn/SeqPrep), which were quality-filtered 
according to the Phred quality score (Q), or the probability of a base-calling error (P), 
which is defined by the following equation: Q = -log10 P. In particular, the following filtering 
parameters have been selected, as we have previously described [352]: i) maximum of 
three consecutive low-quality base calls (Phred < 19) allowed; ii) fraction of consecutive 
high-quality base calls (Phred > 19) in a read over total read length >= 0.75; iii) no “N”-
labeled bases (missing/uncalled) allowed. A Phred > 19 would allow 1 error in 100 base-
calling, resulting in 99% accuracy (to note that the default QIIME parameter is Phred = 
3). Reads not matching all the above criteria were filtered out. Passing-filter reads were 
combined into a single FASTA file and were aligned against the SILVA 123 reference 
database using the “pick_closed_reference_otus.py” approach. A pre-defined taxonomy 
file of reference sequences to taxonomies is used for taxonomic assignment with a 97% 
cluster identity [353]. The OTU-table was created by counting the abundance of each 
OTU in each sample, and OTUs with total counts lower than 15 in fewer than 2 samples 
were filtered out. To correct potential biases in library size due to sampling procedures 
or sequencing depth, OTUs were normalized in each library through the cumulative sum 
scaling (CSS), where OTU counts were divided by the cumulative sum of counts up to a 
percentile determined using a data-driven approach [354] implemented in the 
“normalized_table.py” function. Filtered and normalized OTUs were collapsed into each 
phylogenetic level (from phylum to genus) using the function “taxa_summary.py”.  
3.3.6. Statistical analysis 
Statistical analysis, figures and tables were produced within the R environment (v3.4.1), 
unless specifically stated. In particular, the R packages ggplot2 and ggpubr were used. 
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The annotated heatmap including taxonomic data was produced with the NMF R 
package, scaling the values to each library size.  
3.3.6.1. Alpha and beta diversity indices  
To check whether sequencing depth was adequate, sequence-based rarefaction curves 
were generated from the unfiltered OTU table using the “alpha_rarefaction.py” function 
in QIIME 1.9, using the median sequence counts per sample as a “max_rare_depth” 
parameter. Within-sample alpha diversity indices of richness and diversity (Appendix 2) 
were estimated from the filtered OTU-table using the QIIME function “alpha_diversity.py”. 
Association of indices with variables (e.g. immunisations, treatments or microbiota 
sources) was done using the non-parametric Kruskall-Wallis analysis of variance, 
followed by a non-parametric pairwise Wilcox-test with Benjamini-Hochberg (BH) 
adjustment for multiple corrections [355]. Between-sample beta diversity matrix was 
calculated with the Qiime function “beta_diversity.py” with 
“SILVA123_QIIME/trees/97/97_otus.tre” as the phylogenetic tree. In particular, the Bray-
Curtis matrix [356] was calculated from the filtered and normalized OTU table, according 
to the equation listed in Appendix 2. Dissimilarities amongst and pairwise variables were 
evaluated non-parametrically using the permutational analysis of variance approach 
(PERMANOVA) with 999 permutations [200], as implemented in the R Vegan package. 
When necessary, a stratification of the permutations was applied to correct for the 
different microbiota sources sampled (e.g. small, entire and colon samples).  
3.3.6.2. Analysis of differential abundant taxonomies  
Within each immunisation group (TSHR or βgal), differences in the microbial counts 
amongst treatments were tested using a linear regression model, correcting for the 
source of the anatomical site sampled (e.g. colon and entire). Pairwise differences 
between treatments were tested using a pairwise t-test with Benjamini-Hochberg (BH) 
adjustment for multiple corrections. Within each treatment (either control, Lab4, hFMT or 
vancomycin), differences between the two immunisations were assessed using a 
Welch’s t-test for unequal variance, with BH adjustment.   
3.3.6.3. Random Forest 
Random Forest (RF) is a statistical learning method [357, 358], based on the 
construction of a forest of “decision trees” for classification and regression purposes. A 
single decision tree is composed of i) internal nodes or splits, ii) branches that connect 
nodes and iii) terminal nodes or leaves carrying the label/value of prediction. RF usually 
grows a very large number of trees and each tree provides the classification/value of the 
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input vector. The RF training set is selected from a bootstrapped sample of N records 
(with the same size, but different composition due to sampling with replacement) and a 
subset of M variables (e.g. sqrt(M)). Every decision tree is different from any other, since 
they originate from randomly bootstrapped copies of the original dataset (bagging) and 
randomly sampled subsets of the variables [359]. Usually, 1/3 of N records are left out 
of the training set and can be used to test the model and they are called “out-of-bag 
examples” (Tn). When the input values pass through each tree, they return an output 
(one per tree) and the final prediction is given by the majority of the vote (classification), 
or the average (regression). The out-of-bag (OOB) classifier would count the vote 
specifically over Tn. In such a way, OOB is estimating the general classification error 
based on the OOB error rate of the training set, which has been proved to be unbiased, 
since both bagging and RF mainly reduce the variance component of the error (i.e. 
variance of the prediction) [359]. Variables that played the major role in the prediction 
accuracy can be derived [357] e.g. based on the mean decrease Gini Index for “node 
impurity” (classification) or on the mean squared error (MSE). A high decrease in the 
Gini index, for instance, defines important prediction variables that most likely played the 
major role in the classification algorithm. In this chapter, RF was employed to classify 
samples either amongst treatments (control, hFMT, Lab4 or vancomycin) or between 
immunizations (bgal or TSHR) based on their microbiota composition (classification), and 
to identify genera driving the classification (variable importance). Relative abundance 
counts with non-zero values in at least 20% samples were retained, scaled and centred. 
To estimate the accuracy of prediction, a repeated cross-validation (repeatedcv) method 
with number=10 and repeats=3 was used. The tuning hyperparameter mtry, calculated 
around the square root of the number of variables of the dataset, was tuned testing from 
10 to 50 and 5,000 or 10,000 number of trees (ntree) using the R package Caret. RF 
was next run using the identified parameter values providing the highest prediction 
accuracy during the cross-validation step using the R package RandomForest. The 
mean decrease Gini was used for the variable importance selection.   
3.3.6.4. Correlation analysis between gut microbiota and disease features 
Disease features were grouped into specific categories such as: Lymph node T cells 
(CD25+, CD4+ and memory/effector T cells), orbital pathology (muscular atrophy, brown 
fat and total fat), thyroid function and auto-antibodies (fT4, TRAK and mTSAB) and 
orbital T cells (CD4+ and CD8+, but only available for some mice). Finite values (missing 
data were excluded) were correlated to the abundance of microbial biomarkers from the 
large intestine (obtained from the RF analysis) in each treatment and per immunisation 
through the Spearman correlation coefficient (Rho), using the Corrplot R package.  
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3.3.6.5. Prediction of metagenomic functions (Tax4Fun)  
The functional profile of the metagenome can be imputed or predicted from the 
taxonomic composition obtained in a 16S rRNA gene sequencing in a cost-effective 
manner, using a database of pre-computed reference genomic profiles, as we previously 
employed [352]. However, the main limitation of this approach derives from the prediction 
of a whole set of metagenomic functions from the variable regions of the 16S rRNA gene 
and thus should need the validation through a whole-genome sequencing 
(metagenomic) approach. The Tax4Fun R package [360] employs the nearest neighbor 
identification with a minimum sequence similarity to link the representative 16S rRNA 
gene sequences to functional annotations of prokaryotic genomes [361], with the 
SILVA123 release reference sequence collection. Gene ontologies and associated 
metabolic pathways of the predicted metagenomes were obtained from the Kyoto 
Encyclopedia of Genes and Genomes (KEGG) reference database of genome 
annotations [362].  
3.3.6.6. Longitudinal analysis   
The combined effects of treatment, immunisation and time in shaping the gut microbiota 
of the GO model were estimated and considered to as fixed effects in the following linear 
model (Equation 3): 𝑦"#$7 = 𝜇 + 𝑇𝑟𝑒𝑎𝑡" +	𝐼𝑚𝑚𝑢𝑛# +	𝑇𝑖𝑚𝑒$ + (𝑇𝑟𝑒𝑎𝑡	 ∗ 	𝐼𝑚𝑚𝑢𝑛)"#	+ 	(𝑇𝑟𝑒𝑎𝑡	 ∗ 	𝑇𝑖𝑚𝑒)"$	 + 	(𝐼𝑚𝑚𝑢𝑛	 ∗ 	𝑇𝑖𝑚𝑒)#$		 + 𝑒"#$7 
where 𝑦"#$7 is one of the alpha-diversity indices, Bray-Curtis matrix (assessed using the 
Adonis function in the Vegan package) or the Firmicutes/Bacteroidetes ratio calculated 
from the Firmicutes and Bacteroidetes normalized relative abundances in each sample; 
μ is the overall mean; Treat is the type of manipulation treatment (i.e. control, hFMT, 
Lab4 or vancomycin administration), Time is the effect of timepoint (either baseline or 
mid); Immun, is the type of immunisation (either the TSHR or βgal). The factorial 
interactions between immunisation and time, immunisation and treatment and time per 
treatment were also included in the model; 𝑒"#$7 is the vector of residual effects. 
Comparison between βgal and TSHR immunizations at each timepoint was made using 
the pairwise t-test with BH correction. 
3.3.6.7. SourceTracker Bayesian model  
The SourceTracker R package [363] was used to determine the possible transfer of 
taxonomies from donors to recipients – or engraftment [342] - as a result of the hFMT in 
mice. Originally created to test the contamination level of a microbiota sample, the 
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software implements an iterative Bayesian model which calculates the probability that 
recipient microbiota samples (sink) come from one donor sample (source), through the 
calculation of the posterior probability via Gibbs sampling in the donor samples.  
An extensive description of the methodology is presented in the original paper [363]. 
Given each sink sample (x) a set of n taxonomic sequences, each of those can be 
assigned to any of the source environments 	𝑣	 ∈ 1…𝑉}, including also unknown 
sources. Implementing the collapsed Gibbs sampling for topic model, each sink-taxon is 
assigned to a random source environment, termed “hidden variable” 𝒛"BC…D 	∈ 1…𝑉}. 
Assuming that these assignments are correct - although random – the proportions of 
source environments in the sink samples are tallied. Subsequently, one taxon is removed 
from the tallies, and the assignment of the source environment is repeated. Thus, the 
probability of selecting each source environment is proportional to the probability of 
observing that sink-taxon in that source, times to the probability of observing the source 
in the sink sample. Once re-assigned, the tally is updated for the selected taxon and the 
operation is repeated on another randomly chosen taxon. At the end of all the possible 
assignment iteratively performed, each obtained set is the representative distribution of 
the possible taxon/sources assignment. Repeating such operation n times, it provides 
the estimation of the conditional distribution. The original equation is as follow (Equation 
4): 𝑃F𝑧" = 𝑣G𝒛¬", 𝑥J ∝ 𝑃(𝒙"|𝑣) 	× 	𝑃F𝑣G𝒙¬"J 	= 	 O PQRST	UPVST	UPVSW 	× 	O DS¬RT	XDYCT	XZW  
Whereas: 𝑚[\ is the number of training sequences from taxon t in environment v; 𝑛\ is 
the number of sink sequences assigned to environment v, while ¬𝑖 represents the 
exclusion of the 𝑖[] sequence. The first fraction is the posterior distribution calculated on 
sink taxa in the source environment, while the second provides the posterior distribution 
calculated over source environments in the sink sample. Such Bayesian model uses 
Dirichlet continuous distribution: a and b are the Dirichlet parameters to smooth the 
distribution for low-coverage source and sink samples. Moreover, they allow the 
assignment to the unknown source, when the sink sample is not like to any sources.  
The GO patients and the control mice microbiota were used as “source” while the hFMT 
microbiota was used as “sink” (later defined as a test). To test the specificity of the hFMT 
engraftment, I used the hFMT and human microbiota communities as “source” and the 
murine control microbiota as “sink” (later defined as a control). The SourceTracker was 
run on the filtered OTU table, using either OTU, genus or family taxonomic levels (as 
integers) and default parameters (10 restart Gibbs sampling, 100 burn-in iterations for 
Gibbs sampling and 1,000 rarefaction depth). Counts that could not be assigned to a 
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source at a certain significant threshold (a=0.001) were defined as “unknown”. The 
command-line for the SourceTracker activation and run is listed in Appendix 8. 
SourceTracker returns a list of possible “invaders”. I selected the most abundant 
taxonomies and the extent of the invasion for each taxa specifically occurring in the 
hFMT-receiving mice (sink) was quantified. For each taxa, in fact, I subtracted the mean 
value of the control group (murine source) from that of the hFMT group (Equation 5): 𝑑𝐹𝑀𝑇a = 	𝜇𝑥]bcd − 	𝜇𝑥fgD[hg7 
Where 𝑥 is the each taxonomy and 𝜇 is the mean of that taxonomy in the group, either 
hFMT or controls. For each taxonomy, I next calculated the mean percentage change of 
the dFMT from the GO patients (human source) as in Equation 6: 𝑑𝑑𝐹𝑀𝑇a = 	𝜇𝑥ibcd − 	𝜇𝑥jk𝜇𝑥jk 	× 	100 
Where 𝑥 is the each taxonomy and 𝜇 is the mean of that taxonomy in the group, either 
the dFMT previously calculated or GO patients.  
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Table 3.2. Summary of the total murine sample processed according to timepoint and 
variables such as treatments, immunisations and microbiota samples.  
 
 Baseline Mid Final 
Treatment & Immunisation°    
Control 16 (6/10) 20 (9/11) 33 (14/19) 
hFMT 15 (6/9) 24 (9/15) 39 (16/23) 
Lab4 14 (5/9) 22 (11/11) 20 (10/10) 
Vancomycin 20 (8/12) 28 (14/14) 37 (18/19) 
Immunisation#    
βgal 25 43 58 
TSHR 40 51 71 
Microbiota Sources^    
Faecal samples 65 (16/15/14/20) 94 (20/24/22/28) none 
Small none none 51 (13/20/0/18) 
Colon none none 48 (10/19/0/19) 
Entire none none 30 (10/0/20/0) 
 
° total amount of samples and per immunisation (βgal/TSHR); # total amount of samples; ^total 
amount of samples and per treatment: control/hFMT/Lab4/vancomycin. At the baseline and mid 
timepoints faecal samples were collected from each cage while at the end of the 
experimental procedure, after the euthanasia, microbiota samples were collected from 
the small intestine, the colon or from the entire intestine. °paired samples of small 
intestine and colon were obtained from the same mouse, but some paired samples (3/51) 
were lost during sequencing, although a few samples failed during sequencing; *entire 
intestines were collected from Lab4 treated and a small group of the control mice 
3.4.  RESULTS 
3.4.1. Clinical outcomes of the GO model 
Disease assessment was performed by SM, UB-P and AE. Briefly, antibodies against 
the human TSHR, measured by TSH binding-inhibition (TRAK assay) or their ability to 
alter thyroid function by stimulating cAMP production (TSAB), were induced in all TSHR-
immunised mice, but not in the equivalent βgal controls (in all cases results between 
TSHR and βgal immunised mice were compared within the 4 treatment groups). An 
exception to this was observed in the vancomycin-treated mice in which no pathological 
TSAbs were detected. Hyperthyroidism, quantified as thyroxine levels (fT4), was 
significantly induced only in the Lab4 probiotics-treated TSHR-immunised mice. Orbital 
examination was assessed by quantifying adipose tissue volume, proportion of ‘brown’ 
adipose tissue (‘BAT’) and atrophy of the extra-ocular muscles (EOM). These 
evaluations revealed significantly more ‘BAT’ in TSHR-immunised compared to βgal, 
only in control and probiotic-treated mice. Significant expansion of orbital adipose tissue 
was not observed in any of the TSHR immunised mice although significant atrophy of 
the EOM was detected, but only in control TSHR immunised mice. In draining lymph 
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nodes, numbers of CD25+ (Tregs) cells were significantly lowered in vancomycin-treated 
mice, while increased in the βgal-immune probiotic-treated mice.  
3.4.2. Summary of the sequencing outcomes 
 Sequencing of the V1-V2 plus bifidobacteria regions of the 16S rRNA gene produced a 
total of 13,782,107 sequencing reads after the “join paired-end.py” function in QIIME 1.9, 
with an average of 2,297,017.83 (± 1,820,298.366). Filtering of reads with a Phred > 19, 
allowing about 1 error in 100 bases, retained a total of 12,884,785 sequences with an 
average of 2,147,464,17 (± 1,726,134.85), which resulted in  6.5% of sequences being 
removed. A summary of the per-group sequences is represented in Table 3.3. While the 
control, hFMT and the Lab4 treatment groups showed very similar numbers of reads, the 
vancomycin treatment group showed double the amount of reads. A smaller number of 
reads were obtained from the six GO patients (plus some replications) providing the 
samples for the hFMT production. A total of 3,623 OTUs were obtained from the 
“closed_OTUpicking.py” function, after filtering for less than 15 counts in at least two 
samples.  
 Imputation of metagenomic functions with Tax4Fun produced a total of 266 KEGG 
pathways, which were reduced to 38 when accounting for more than 0.001 of their 
relative abundances. 
 
Table 3.3. Summary of the sequencing metrics before and after quality filtering. 
 
 °unknown samples were mislabeled samples which were sequenced but not included in  
further analysis; ^ standard deviation. 
 
3.4.3. Anatomical differences of the gut microbiome in GO mouse model 
In the previous chapter, differences between the gut microbiota in controls (βgal) and 
TSHR immunised mice (not receiving any treatments) at the end of the experimental 
procedures were reported [322]. Here we replicated the same experiment, looking at 
 Input Output 
Group 
number of 
Seq 
average std^ 
number of 
Seq 
average std^ 
control 2,593,620.00 18,794.35 21,365.58 2,418,786.00 17,527.43 22,024.42 
hFMT 2,972,296.00 19,053.18 22,141.82 2,757,051.00 17,673.40 22,825.32 
Lab4 2,102,509.00 18,772.40 20,909.85 1,945,969.00 17,374.72 21,642.50 
vancomycin 5,280,854.00 31,063.85 35,929.00 5,003,546.00 29,432.62 36,836.65 
GO patients 483,510.00 24,175.50 17,947.64 428,852.00 21,442.60 20,137.71 
unknown° 349,318.00 21,832.38 26,630.17 330,581.00 20,661.31 27,272.35 
total 13,782,107.00 2,297,017.83 1,820,298.36 12,884,785.00 2,147,464.1 1,726,134.85 
  
 
 
98  
different anatomical sections of the intestine (i.e. small intestines and colon vs. entire), 
compared to the whole intestinal scraping as previously employed, of gavage-control 
mice either immunised with TSHR or βgal (immunisation control). As previously observed 
[364], the small intestine showed a reduced richness and diversity compared to large 
intestines (P<0.05, BH corrected, Figure 3.2A). There were no significant differences 
between the entire and the colon samples (as for Chao1 and observed-OTUs) after 
correction; while the diversity (Shannon) and the evenness indices were not significantly 
different also before corrections. Therefore, the combination the two intestinal sections 
will be referred to as “large intestine”, where not specified which section was used. 
As far as immunisations are concerned, TSHR-immune mice showed a reduced richness 
compared to βgal control in colonic samples, while entire intestines displayed a slight but 
not significant increase in richness. However, in the small intestine, immunisation with 
the TSHR-A plasmid seemed to increase the richness (although not significantly), the 
diversity (P=0.05) and the evenness (P=0.03) of the bacterial communities compared to 
the βgal (Figure 3.2B). A separation of the immunisations was also observed between-
samples (beta-diversity) using the Bray-Curtis matrix in both large (P=0.036) and small 
intestines (P=0.002, using 999 permutations, figure 3.2C). Differential abundant 
taxonomies between immune groups were identified in each intestinal sites. At the 
phylum level, Tenericutes counts were reduced/absent in the colon samples in TSHR 
compared to βgal (P=0.012). A significant reduction in genera belonging to phylum 
Bacteroidetes were observed in TSHR-immunised colon and entire samples, while a 
prevalence of genera from Firmicutes were enriched in TSHR-immunised small 
intestines and entire samples, as summarized in Table 3.4. Also, an uncultured genus 
from Bacteroidales was decreased in TSHR immune mice compared to βgal in entire-
gut samples.  
Metagenomic functions were predicted from the filtered OTU table using the Tax4Fun 
tool [360] from the three anatomical sections of TSHR-immune and bgal mice. Metabolic 
pathways for nitrogen, starch and sucrose and methane metabolism, but also glycolysis 
and gluconeogenesis were prevalently described in the small intestine (Figure 3.3A), 
while those for the amino-sugar and nucleotide-sugar, fructose and mannose, galactose, 
glycine, serine and threonine, porphyrin and chlorophyll metabolism were present in 
colon and entire samples (Figure 3.3C and E), in line with the specialized functions of 
the gut microbiota. Moreover, RNA degradation was predicted in colon and entire 
samples, but not in the small intestinal microbiota. While most of the top-variant 
pathways were shared between colon and entire samples, the latter showed the unique 
presence of the oxidative phosphorylation pathway. Pathways such as the degradation 
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of other glycans, bacterial ATP-binding cassette (ABC) transporters and the two-
component system, despite being in the top-10 most variant, were shared amongst 
intestinal sections. Differences between immunisations were observed in each intestinal 
section (Figure 3.3B, D and F). Although differences were not enormous, nitrogen 
metabolism and other glycan degradation had higher variance in the TSHR group 
compared to βgal in small intestine (Figure 3.3.B). In the colon samples, ABC 
transporters, the two-component system and the porphyrin and chlorophyll metabolisms 
were reduced in TSHR compared to βgal, while the other pathways were increased in 
TSHR (Figure 3.3.D). Amongst them, the fructose/mannose, galactose, 
glycine/serine/threonine metabolism and the degradation of other glycan were the most 
different. Interestingly, differences between the two immunisations in the entire samples 
seemed to be opposite to that in the colon samples, e.g. other glycans degradation 
reduced in TSHR (Figure 3.3F). 
 
Figure 3.2. Microbiota composition of small intestine, entire intestine and colon in 
TSHR and bgal-immunised mice in control mice groups.  
(A) Box-and-whiskers plot of alpha-diversity indices of richness (Chao1 and observed-
OTUs), diversity (Shannon) and equitability (evenness) according to the source of the 
microbiota sampled (colon and small). (B) Alpha-diversity indices of richness, diversity 
and equitability between immunisations according to the source of the microbiota 
sampled (colon, entire and small). (C) Non-metric dimensional scaling (NMDS) based on 
Bray-Curtis distances according to immunisations and microbiota sources.  
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Table 3.4.  Differentially abundant taxa between TSHR and βgal immunisation in 
different intestinal sections. 
 
Differentially abundant taxonomy 
(phylum; genus) Section 
Diff. meana 
(βgal -
TSHR) 
βgal 
(mean) 
TSHR 
(mean) 
P 
value§ 
Actinobacteria;Enterorhabdus colon 19.110 32.898 13.789 0.036 
Bacteroidetes;Parabacteroides colon 6.930 12.705 5.776 0.032 
Bacteroidetes;Paraprevotella colon 3.142 4.355 1.212 0.005 
Firmicutes;[Eubacterium] hallii group colon 4.097 4.995 0.898 0.020 
Firmicutes;[Eubacterium] nodatum 
group colon 2.964 10.821 7.857 0.037 
Firmicutes;[Eubacterium] 
oxidoreducens group colon 6.990 10.638 3.647 0.015 
Firmicutes;Anaerotruncus colon 27.183 43.423 16.241 0.003 
Firmicutes;Erysipelatoclostridium colon 2.109 6.994 4.885 0.023 
Firmicutes;Incertae Sedis colon 18.706 23.135 4.429 0.034 
Firmicutes;Intestinimonas colon 4.625 11.013 6.388 0.015 
Firmicutes;Lachnospiraceae 
FCS020 group colon 3.670 5.788 2.117 0.006 
Firmicutes;Peptococcus colon 2.392 4.308 1.916 0.032 
Firmicutes;Ruminiclostridium 5 colon 13.087 21.738 8.651 0.005 
Firmicutes;Ruminiclostridium 9 colon 18.509 43.987 25.478 0.006 
Firmicutes;Ruminococcaceae UCG-
003 colon 4.985 8.098 3.112 0.005 
Firmicutes;Ruminococcus 1 colon 17.752 26.337 8.585 0.000 
Firmicutes;Ruminococcus 2 colon 1.379 1.701 0.323 0.039 
Tenericutes;Anaeroplasma colon 3.871 4.085 0.214 0.009 
Tenericutes;Other colon 5.422 5.422 0.000 0.019 
Tenericutes colon 9.293 9.507 0.214 0.012 
Bacteroidetes;Prevotellaceae UCG-
001 entire 1.850 17.892 16.042 0.029 
Bacteroidetes;uncultured 
Bacteroidales bacterium entire 5.227 13.309 8.081 0.001 
Firmicutes;Blautia entire -8.571 10.914 19.486 0.024 
Firmicutes;Family XIII AD3011 group entire -1.755 0.000 1.755 0.015 
Firmicutes;Intestinimonas entire -5.168 8.249 13.417 0.019 
Firmicutes;Lachnospiraceae 
FCS020 group entire -4.557 6.003 10.560 0.033 
Firmicutes;unidentified entire -4.930 8.876 13.806 0.020 
Proteobacteria;Bilophila entire -1.207 3.385 4.592 0.017 
Proteobacteria;Escherichia-Shigella entire -2.754 2.054 4.808 0.044 
Bacteroidetes;Alloprevotella small -1.826 0.358 2.185 0.046 
Firmicutes;Allobaculum small 7.000 14.626 7.626 0.036 
Firmicutes;Blautia small -10.981 5.998 16.979 0.011 
Firmicutes;Lachnospiraceae 
ND3007 group small -2.695 0.000 2.695 0.040 
Firmicutes;Lachnospiraceae UCG-
004 small -16.709 3.927 20.636 0.000 
Firmicutes;Ruminococcus 2 small -2.335 0.287 2.621 0.030 
a difference in means (βgal – TSHR); § only taxa with P value < 0.05 are shown. 
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Figure 3.3. Metagenomic functions predicted in the control group between 
immunisation along the intestinal tract.  
Top-10 and least-10 variant KEGG pathways according to anatomical sections of the 
gut: small (A), colon (C) and entire (E) and differences in the top-10 variant pathways 
between immunisations (TSHR or βgal) in each gut section (B, D and F). varCount, 
across-group coefficient of variation (standard deviation/mean pathway relative 
abundance) in percentage (%).  
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3.4.4. Treatment effect on endpoint βgal-microbiota composition  
Differences amongst manipulation treatments in the βgal -control group were analysed. 
At the alpha diversity level, the entire and colon samples were analysed together as large 
intestine, since there was no differences between the two in terms of diversity and 
evenness (Figure 3.2A). The long-term vancomycin treatment depleted the microbiota 
composition in terms of richness and diversity (P<0.0002), while there were no significant 
differences between the other treatments and the control group (Figure 3.4A). On the 
contrary, the small intestines showed a less severe effect of the vancomycin treatment, 
with no significant reduction of the richness indices (Chao and observed OTUs). The 
hFMT treatment, on the other hand, increased the Shannon diversity (P=0.02) and the 
equitability indices (P=0.045) compared to vancomycin and to the controls, however, not 
reaching significance (Figure 3.4B). Between-group differences were observed using the 
Bray-Curtis matrix amongst treatments (P=0.001, 999 permutations), taking into 
consideration the different microbiota sources used. Pairwise differences were observed 
between all the treatments (P<0.05, with 999 permutations and BH adjustment), apart 
from the hFMT-control (P=0.42), whose centroids laid more closely to each other (Figure 
3.4C).  
Differential abundance analysis investigated the differences in taxonomic composition 
amongst treatment and in-pairwise. In large intestines, the abundance of eighty-three 
taxonomies (including phylum and genus levels) were significantly altered between 
treatments in the bgal group from a linear model (Appendix 9), correcting for different 
microbiota sections (e.g. colon and entire intestine). At the phylum level (Figure 3.5), 
Actinobacteria were enriched in the control group (37.39 ± 12) and drastically decreased 
in the vancomycin group (0.36 ± 1); Bacteroidetes were enriched in the Lab4 group 
(837.97 ± 131) and decreased in the vancomycin group (233.60 ± 42.59). Firmicutes was 
the most abundant phylum amongst all, whose counts were highest in the control group 
(1650.51 ± 374.94) and lowest in the vancomycin group (218.09 ± 65.59). The long-term 
vancomycin treatment increased the number of Proteobacteria (312.20 ± 129.71) and 
Verrucomicrobia (16.56 ± 1.6) compared to all the other treatments, while completely 
depleted the number of Tenericutes. At the genus level, while the majority of the genera 
were decreased or completely removed in the vancomycin treated mice (e.g. 
Faecalibacterium), the Clostridium sensu-stricto 1 was specifically enriched in the 
vancomycin group (1.98 ± 1.8 vs. 0 in other treatments), as well as the Escherichia-
Shigella counts (84.27 ± 45.54 vs. average of 2 in other treatments), followed by 
Enterobacter, Salmonella and Pseudomonas sp.  
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Figure 3.4. Alpha and beta diversity in βgal mice amongst treatments.  
Box-and-whiskers plot of alpha diversity amongst treatment in (A) colon and entire, and 
(B) small intestines of βgal mice. Beta-diversity NMDS (C) based on Bray-Curtis amongst 
treatments (colors) and microbiota sources (shapes).  
 
 
Figure 3.5. Heatmap of the phylum distribution in βgal-immunised mice amongst 
treatments.  
(A) Large and (B) small intestines. Annotated heatmap based on Spearman distance 
and Ward hierarchical clustering. Phyla abundances were centered and standardized 
according to each column Z-scores and described by the change in the intensity of the 
blue colour, as annotated. 
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Differential abundance of genera was tested pairwise between treatments, taking into 
account the different intestinal sections (e.g. control and Lab4 only entire samples): the 
abundance of 72 genera were significantly different in the vancomycin group compared 
to controls (data not showed), while 71 genera between vancomycin and hFMT samples 
(data not showed). Twenty-four genera were differentially abundant between hFMT and 
controls samples, while 12 genera were differentially abundant between controls and 
Lab4 (using the entire samples only), as summarized in Table 3.5. 
Similarly, what was observed in the large intestine was also found in the small intestines, 
for example, Proteobacteria enrichment and a decreased abundance of Actinobacteria, 
Bacteroidetes and Firmicutes in the vancomycin-treated mice (Figure 3.5B). On the 
contrary, a significantly different abundance of the genus Bacteroides was observed 
amongst groups, along with an increased count in the vancomycin treated mice (44.6 ± 
12), and an increase of the genus Lactobacillus counts in both hFMT (433.66 ± 132.59) 
and vancomycin (441 ± 92.44) treated mice compared to controls (Appendix 10). Also, 
fewer Ruminococcaceae genera were differentially abundant in the small intestine 
compared to the large intestines. In the pairwise comparison, 28 genera were 
differentially abundant between mice in the vancomycin and the control groups (data not 
showed), 40 genera between vancomycin and hFMT (data not showed) and 7 genera 
between hFMT and controls (Table 3.5), all of them more prevalent in the hFMT such as 
the genus Lactobacillus (P=0.015).  
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Table 3.5. Pairwise differential abundant taxonomies between treatments in the βgal 
group.  
 
Section Differentially abundant genera P value 
hFMT vs. controls 
small 
Bacteroidetes;Alloprevotella 0.0126 
Bacteroidetes;Odoribacter 0.0315 
Bacteroidetes;Rikenella 0.0165 
Firmicutes;Blautia 0.0012 
Firmicutes;Faecalibacterium 0.0260 
Firmicutes;Lachnospiraceae UCG-004 0.0009 
Firmicutes;Lactobacillus 0.0152 
colon 
Actinobacteria;Enterorhabdus 0.0020 
Bacteroidetes;Alistipes 0.0393 
Bacteroidetes;Other 0.0216 
Bacteroidetes;Paraprevotella 0.0323 
Bacteroidetes;Prevotellaceae UCG-001 0.0265 
Bacteroidetes;Rikenella 0.0122 
Firmicutes;[Eubacterium] brachy group 0.0009 
Firmicutes;[Eubacterium] nodatum group 0.0157 
Firmicutes;[Eubacterium] oxidoreducens group 0.0201 
Firmicutes;Coprococcus 1 0.0092 
Firmicutes;Erysipelatoclostridium 0.0481 
Firmicutes;Faecalibacterium 0.0016 
Firmicutes;Lachnospiraceae UCG-004 0.0443 
Firmicutes;Lachnospiraceae UCG-008 0.0002 
Firmicutes;Marvinbryantia 0.0259 
Firmicutes;Peptococcus 0.0305 
Firmicutes;Pseudobutyrivibrio 0.0060 
Firmicutes;Roseburia 0.0050 
Firmicutes;Ruminiclostridium 5 0.0000 
Firmicutes;Ruminococcaceae UCG-005 0.0001 
Firmicutes;Ruminococcus 1 0.0103 
Firmicutes;Turicibacter 0.0224 
Proteobacteria;Desulfovibrio 0.0098 
Tenericutes;Other 0.0000 
Lab4 vs. controls 
entire 
Actinobacteria;Coriobacteriaceae UCG-002 0.0349 
Bacteroidetes;Odoribacter 0.0286 
Bacteroidetes;Parabacteroides 0.0428 
Bacteroidetes;uncultured Bacteroidales 
bacterium 0.0036 
Firmicutes;Candidatus Arthromitus 0.0239 
Firmicutes;Coprococcus 1 0.0045 
Firmicutes;Lachnospiraceae NK4A136 group 0.0373 
Firmicutes;Oscillibacter 0.0464 
Firmicutes;Oscillospira 0.0268 
Firmicutes;Turicibacter 0.0136 
Firmicutes;Tyzzerella 3 0.0178 
Verrucomicrobia;Akkermansia 0.0153 
Pairwise differences assessed using the Welch’s t-test for unequal variance in control-Lab4 
entire intestine; only tests with P<0.05, BH corrected are shown.  
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3.4.5. Treatment effect on endpoint TSHR-immunised microbiota 
composition 
Similar to what was previously described for the βgal group, the vancomycin treatment 
determined the majority of the differences at the alpha diversity indices in the TSHR-
immunised group large intestines as well (P<0.001, Figure 3.6A). Moreover, differences 
between the other manipulation treatments and controls were observed. The diversity of 
the hFMT (Shannon index) was reduced in comparison to the control group (P=0.019) 
and the equitability was lowered in the Lab4 compared to the controls (P=0.045). In the 
small intestines, the vancomycin treatment led to a significant reduction in richness 
(Chao1), diversity (Shannon) and equitability compared to both controls and hFMT 
(P<0.05), while it was significantly reduced compared to the hFMT only in terms of 
number of observed OTUs (P=0.0004). Vancomycin treatment also led to a unique 
spatial organisation of the between-group diversity (Beta-diversity) (P=0.001, 999 
permutations and intestinal section as a stratification, Figure 3.6C). 
Figure 3.6. Alpha and beta diversity in TSHR-immunised mice amongst treatments.  
Box-and-whiskers plot of alpha diversity amongst treatment in colon and entire (A) and 
small (B) intestines of TSHR mice. Beta-diversity NMDS (C) based on Bray-Curtis 
amongst treatments (colors) and microbiota sources (shapes).  
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Significant differences in the taxonomic composition amongst treatment groups were 
reported, using a linear model adjusting for the different microbiota section (as for colon 
and entire samples, Appendix 11), followed by a pairwise comparison between groups. 
In the large intestines (colon and entire samples, Figure 3.7A), the phylum 
Actinobacteria, comprising  the genus Bifidobacterium, showed higher counts in the Lab4 
treated mice (32.77 ± 11.6) and was depleted by the vancomycin treatment (0.68 ± 1.45). 
A similar trend was shown by the phylum Bacteroidetes, increased in the Lab4 (815.75 
± 206.35) and decreased in the vancomycin group (220.90 ± 35.87), while the control 
and the hFMT showed a very similar abundance (685.39 ± 184.17 and 683.36 ± 219.56, 
respectively). Of interest, the genus Bacteroides was enriched in the vancomycin-treated 
mice (62.96 ± 12.87) compared to controls (54.77 ± 22.87), Lab4 (46.22 ± 37.51) and 
hFMT (23.28 ± 22.08), which showed the lowest counts (P=0.003). Firmicutes was the 
most abundant phylum amongst all and showed an enrichment in the Lab4 treatment 
(1550.55 ± 546.25), followed by controls and hFMT, while it was reduced by the 
vancomycin treatment (320.90 ± 113.11). Such a long-term antibiotic treatment had the 
most dramatic effects at the genus level, where it depleted a clade of the Eubacterium 
sp. (mean count 0), Faecalibacterium and clades of Ruminiclostridium and 
Ruminoccocaceae sp., while it specifically selected the growth of Proteobacteria genera 
Citrobacter and Cronobacter (9.95 ± 4.26 and 8.68 ± 2.57, respectively, vs. 0 in the other 
groups) and promoted an increased number of Enterobacter, Escherichia-Shigella, 
Salmonella and Pseudomonas species. Interestingly, a slight, but significant increase of 
the Acetitomaculum sp. (0.86 ± 1.48 vs. 0 in the other groups) was observed in the hFMT 
group and also a decrease of the Faecalibacterium counts compared to the controls and 
Lab4.  
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Figure 3.7. Heatmap of the phylum distribution in TSHR-immunised mice amongst 
treatments.  
(A) Large and (B) small intestines. Annotated heatmap based on Spearman distance 
and Ward hierarchical clustering. Phyla abundances were centered and standardized 
according to each column Z-scores and described by the change in the intensity of the 
blue colour, as annotated. 
 
 
From the pairwise comparisons, the abundance of 59, 66 and 15 genera were 
significantly different when comparing vancomycin with controls, hFMT with vancomycin 
(Data not showed), and hFMT with control, respectively (Table 3.6). In the entire 
samples, 12 genera were differentially abundant between Lab4 and control (Table 3.6).  
In the small intestines (Figure 3.7B), the hFMT group had a higher amount of 
Actinobacteria (43.17 ± 26.89) and Bacteroidetes (400 ± 149.28) counts compared to 
controls and vancomycin groups, while the genus Bacteroides was enriched in the 
vancomycin-treated mice (49.97 ± 12.5). A higher abundance of Firmicutes was 
observed in the control mice (1077.7 ± 554.81), while higher prevalence of 
Proteobacteria was triggered in the vancomycin group, with a total of 53 phyla and 
genera differentially abundant amongst treatments (Appendix 12). Pairwise, 44 taxa 
(between phyla and genera) were differentially abundant between vancomycin and the 
controls, 45 between vancomycin and hFMT and 7 between hFMT and control, including 
also Deferribacteres and Verrucomicrobia phyla enriched in the control small intestines 
(Table 3.6).  
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Table 3.6. Pairwise differential abundant taxonomies between treatments in the TSHR 
group.  
 
Pairwise differences assessed using the Welch’s t-test for unequal variance in control-Lab4 
entire intestine; only tests with P<0.05, BH corrected are shown.  
  
Section Differentially abundant genera P value 
hFMT vs. control 
small 
Deferribacteres;Mucispirillum 0.0288 
Firmicutes;Ruminiclostridium 6 0.0090 
Firmicutes;Tyzzerella 0.0105 
Firmicutes;Tyzzerella 3 0.0137 
Verrucomicrobia;Akkermansia 0.0230 
colon 
Actinobacteria;Enterorhabdus 0.0064 
Actinobacteria;Parvibacter 0.0049 
Actinobacteria;Slackia 0.0220 
Bacteroidetes;Alistipes 0.0384 
Bacteroidetes;Alloprevotella 0.0040 
Bacteroidetes;Odoribacter 0.0001 
Bacteroidetes;Paraprevotella 0.0336 
Bacteroidetes;Prevotellaceae UCG-001 0.0201 
Bacteroidetes;uncultured Bacteroidales bacterium 0.0173 
Firmicutes;[Eubacterium] ventriosum group 0.0311 
Firmicutes;Incertae Sedis 0.0212 
Firmicutes;Ruminiclostridium 6 0.0159 
Firmicutes;Tyzzerella 3 0.0001 
Tenericutes;Anaeroplasma 0.0096 
Tenericutes;Other 0.0002 
Lab4 vs. control 
entire 
Bacteroidetes;Other 0.0467 
Firmicutes;Acetatifactor 0.0112 
Firmicutes;Intestinimonas 0.0127 
Firmicutes;Lachnoclostridium 0.0397 
Firmicutes;Ruminiclostridium 0.0241 
Firmicutes;Ruminiclostridium 6 0.0306 
Firmicutes;Ruminococcaceae UCG-011 0.0082 
Firmicutes;Tyzzerella 0.0100 
Firmicutes;unidentified 0.0101 
Proteobacteria;Methylobacterium 0.0141 
Tenericutes;Anaeroplasma 0.0210 
Tenericutes;Other 0.0241 
  
 
 
110  
3.4.6. Microbial biomarkers for manipulation treatments and 
immunizations classification 
Random Forest (RF) analysis was used to classify the samples into treatments (control, 
Lab4, hFMT and vancomycin) or into immunisations (βgal or TSHR) based on their 
genus-level microbiota composition, using 10,000 decision trees. Three different models 
were tested for the treatment classification (for both small or large intestines samples), 
while two models were used for immunisation classifications (for either small or large 
intestines samples), and the best model fit was decided based on the smallest out-of-
bag (OOB) error rate, as described in Table 3.7. 
 
Table 3.7. Summary of the models used to run the RandomForest (RF) classification 
algorithm using either small or large intestine microbiota. 
 
Source Classification predictive variables CV mtry§ 
OOB error-
rate (%) 
Small 
Treatments 
treatment 43 66.67 
treatment + immunisation 34 64.71° 
Immunisations 
immunisation 27 54.9 
immunisation + treatment 36 49.02° 
Large 
(colon + 
entire) 
Treatments 
treatment 45 41.03 
treatment + source 23 26.92° 
treatment + source + 
immunisation 24 29.49 
Immunisations 
immunisation 48 32.05 
immunisation + source 49 32.05 
immunisation + source + 
treatment 41 29.49° 
 
§ derived from the repeated-cross validation (CV) step performed to tune the 
hyperparameters with the Caret R package; ° models used to obtain per-class OOB and 
variable importance. 
 
Treatment classification using the large intestinal samples (including both TSHR and 
βgal immunisations) showed an initial OOB error-rate of 41.03%, which decreased to 
26.92% when including the microbiota sources effect in the model and to 29.24% when 
including both immunisations and microbiota sources (Table 3.7). The OOB error rate 
was also obtained per-class, to observe a possible class-driving effect in the overall 
classification accuracy. In the “treatment+source” model, long-term vancomycin 
treatment showed a 0% per-class OOB error (19/19 correctly classified), having selected 
a unique microbiota. The Lab4 and hFMT treatments showed 30% and 26% class error 
with 14/20 and 14/19 samples correctly predicted in each group, respectively. The control 
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group, instead, showed a more overlapping composition of the gut microbiota with the 
other two treatments, with a per-class OOB of 50% with 10/20 samples correctly 
classified (Figure 3.8A). By growing decision trees, RF operates a variable importance 
selection, based on the Mean Decrease Gini index or the mean decrease in node 
impurity (not related to a mean decrease in accuracy). In the case of the treatment 
classification, the microbiota source was the most important effect, followed by the 9 
most important genera (Figure 3.8B). In the small intestine, model for treatment 
classification originally showed an OOB error of 66.67%, meaning that the genus-level 
composition was highly shared amongst treatments, even when including the 
immunisation effect in the model (64.71% OOB). Differently to what was observed in the 
large intestine samples, the vancomycin treatment class error was 47%, while the hFMT 
and control class error rate resulted of 70% and 77%, respectively (Figure 3.9A). 
For the immunisation classification, all the treatments were taken into account. The 
classification using the large intestine samples showed an initial OOB error-rate of 
32.05% which was identical when including the source effect in the model. The OOB 
error-rate decreased to 29.49% when including both source and treatment effects. The 
βgal group showed a 37% per-class error rate (22/35 samples correctly classified), while 
23% for the TSHR (33/43), as in figure 3.7C. The small intestine showed an overall 
54.9% OOB error-rate, which decreased to 49.02% when including the treatment effect 
in the model. While the βgal showed a 65% per-class error (8/23 samples), the TSHR 
showed almost 36% per-class error with 18/28 samples correctly classified (Figure 3.8C). 
Variable importance was derived with the top-10 prediction variables in either the large 
intestine samples (Figure 3.8D) or in the small intestines (Figure 3.9D). 
Genera with the highest mean decrease in Gini, from the prediction of treatments (Figure 
3.8B) and immunisation (Figure 3.8D) in large intestines, were tested for differential 
abundance, in order to report robust bacterial biomarkers for either monitoring the 
success of the manipulation or differences between the two immunisations. Differentially 
abundant genera amongst treatments were mostly dominated by taxa depleted or 
enriched in the vancomycin group, apart from the Lachnospiraceae NK4A136 also 
differentially abundant in the hFMT compared to control (P=0.038, Table 3.8). 
Differences between the two immunisations in each treatment were identified (Table 3.9), 
with the genus Bacteorides reduced in TSHR compared to βgal in the hFMT group 
(P<0.001), resembling previous observations (Chapter 2, Table 2.6.).  
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Figure 3.8. RF classification accuracy and variable importance amongst 
treatments and between immunisations in the large intestines (entire and colon 
samples).  
(A) Confusion matrix with the per-class OOB and classification for treatments. Each box 
represents the true treatment while the bar-chart represents the number of samples 
being assigned to a treatment according to the model used. Vancomycin had the 100% 
accuracy in classification, followed by hFMT and Lab4, while the control group shared 
the microbiota composition with the other two treatments, excluding vancomycin. (B) 
Top-10 variable importance for treatment classification according to the Mean Decrease 
Gini. The model included the microbiota source as an effect which was identified as the 
most important variable. (C) Confusion matrix with the per-class OOB and classification 
for immunisations. Each box represents the true immunisation while the bar chart 
represents the number of samples being assigned to an immunisation according to the 
model used. The TSHR immunisation showed a higher accuracy in classification. (D) 
Top-10 variable importance for immunisation classification according to the Mean 
Decrease Gini. 
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Figure 3.9. RF classification accuracy and variable importance amongst 
treatments and between immunisations in the small intestines.  
Accuracy in prediction is lower than the one showed in the large intestines. (A) Confusion 
matrix with the per-class OOB and classification for treatments. Each box represents the 
true treatment while the bar-chart represents the number of samples being assigned to 
a treatment according to the model used. The majority of the hFMT and almost all of the 
vancomycin samples were predicted correctly. (B) Top-10 variable importance for 
treatment classification according to the Mean Decrease Gini. (C) Confusion matrix with 
the per-class OOB and classification for immunisations. (D) Top-10 variable importance 
for immunisation classification according to the Mean Decrease Gini. 
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Table 3.8. Differential abundance of genera derived from RF treatment model in large 
intestines. 
Genus differentially abundant group1 group2 P value° 
Alistipes vanco control 3.10E-12 
Alistipes vanco hFMT 6.46E-10 
Alistipes vanco Lab4 1.79E-12 
Lachnospiraceae NK4A136 group hFMT control 0.0388366 
Lachnospiraceae NK4A136 group vanco control 6.20E-17 
Lachnospiraceae NK4A136 group vanco hFMT 5.66E-13 
Lachnospiraceae NK4A136 group vanco Lab4 1.03E-13 
Oscillibacter vanco control 3.84E-13 
Oscillibacter vanco hFMT 3.54E-11 
Oscillibacter vanco Lab4 5.93E-10 
Pantoea vanco control 9.46E-37 
Pantoea vanco hFMT 1.92E-36 
Pantoea vanco Lab4 9.46E-37 
Parabacteroides vanco control 4.06E-33 
Parabacteroides vanco hFMT 9.54E-33 
Parabacteroides vanco Lab4 4.06E-33 
uncultured vanco control 8.23E-06 
uncultured vanco hFMT 6.74E-05 
uncultured vanco Lab4 6.74E-05 
 
° Welch t-test, BH corrected only P<0.05 are reported. Vanco, vancomycin. hFMT, 
humanized-faecal microbiota transplant. Lab4, probiotics. 
 
Table 3.9. Differential abundance of genera derived from RF immunisation model in 
large intestines. 
 
 
 
 
 
 
° Welch t-test, BH corrected only P<0.05 are reported. Vanco, vancomycin. hFMT, 
humanized-faecal microbiota transplant. Lab4, probiotics. 
 
3.4.7. Correlation of the gut microbiota and the disease features amongst 
treatments and between immunisations 
Disease features were correlated with the microbial biomarkers identified by the two RF 
models through the Spearman correlation coefficient. Irrespective of treatment, TRAK 
were induced in all TSHR-immune mice. A positive correlation was observed in the 
vancomycin-TSHR mice between the TRAK levels (calculated against the hTSHR, 
potentially including both stimulating and blocking antibodies) and counts of unidentified 
and uncultured genus of the phylum Firmicutes, respectively, and a negative correlation 
with the genus Lactobacillus (Figure 3.10C). A weak negative correlation (Rho< -0.5) 
Genus treatment βgal (mean) TSHR (mean) P value° 
Akkermansia Lab4 6.744 8.583 0.04062332 
Akkermansia vanco 16.558 12.994 0.01134477 
Bacteroides hFMT 76.846 23.278 5.93E-05 
unidentified hFMT 12.183 7.685 0.02631315 
unidentified vanco 4.595 11.639 0.00134518 
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was observed in the hFMT-TSHR mice between TRAK levels and Parabacteroides 
genus counts (Figure 3.10G). Stimulating antibodies (TSAB) were induced in all TSHR-
immune mice except for the vancomycin group. A negative correlation with TSAB was 
observed in the control-TSHR and the genus Lactobacillus (in colon samples, Figure 
3.10A) and with two uncultured/unidentified Firmicutes genera and Lachnoclostridium 
counts in the hFMT-TSHR mice (Figure 3.10E). Thyroxine levels were not increased in 
the vancomycin treatment, and seemed to be increased in the TSHR mice of the control 
and the hFMT groups, although not reaching significance. A significant increase was 
however observed in the Lab4-TSHR group compared to βgal. A negative correlation 
was observed in the Lab4-TSHR mice between the fT4 and the genus Ruminiclostridium 
(Figure 3.10E), while a positive correlation was reported in the vancomycin-TSHR mice 
with Lachnoclostridium counts (Figure 3.10C). Serum thyroid functions (i.e. 
autoantibodies and thyroxine levels) did not correlate with any microbial biomarkers in 
the βgal-immune mice, apart from the positive correlation between an uncultured 
Firmicutes and fT4 levels in the entire control samples (Figure 3.10B).  
The eye disease was calculated in the orbits in terms of total adipose tissue, muscular 
atrophy and the percentage of the brown fat out of the total adipose tissue. No significant 
differences were observed in the total adipose tissues between immunisations in each 
treatment, while the percentage of brown fat - out of the total adipose tissue – was 
increased in the TSHR-immunised control and Lab4 groups compared to βgal. Also, a 
significantly increased muscular atrophy was reported in the control-TSHR immune 
group compared to βgal. No significant correlations were reported in the control-TSHR 
mice and orbital pathogenesis. In the vancomycin-TSHR group, a strong negative 
correlation was observed between the total adipose value and the brown fat and the 
Akkermansia genus and the Bacteroides genus with the total adipose tissue, while a 
positive correlation was observed between Lachnoclostridium counts and the brown fat 
values (Figure 3.10C). The vancomycin- βgal group showed a negative correlation of the 
genera Bacteroides and Parabacteroides and the brown fat percentage, while two 
uncultured Firmicutes genera correlated negatively with the muscular atrophy. In Lab4-
TSHR, atrophy correlated negatively with Lachnoclostridium and uncultured 
Bacteroidetes, while Akkermansia counts correlated negatively with the total adipose 
tissue (Figure 3.10E). In hFMT-TSHR, orbital muscular atrophy positively correlated with 
genus Lactobacillus counts, while uncultured Firmicutes positively correlated with brown 
fat (Figure 3.10G). The immune response at the draining lymph node was calculated in 
terms of CD4+, CD25 positive fraction of the CD4+ (CD4+CD25+) and the memory/effector 
T cells, while the response in the orbit was calculated in terms of CD4+ and CD8+ T cells. 
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Figure 3.10. Correlations between microbial biomarkers and disease features in 
each treatment and per immunisation.  
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Correlations were calculated in colon and entire samples separately. TSHR-control mice 
in (A) colon and (B) entire samples, while control-βgal mice did not show any significant 
correlations. Vancomycin-TSHR mice (C) and βgal (D) using colon samples; Lab4-TSHR 
(E) and βgal (F) entire samples and hFMT-TSHR (G) and βgal mice (H) using colon 
samples. Only correlations with P<0.05 are shown and the strength of the Spearman 
correlation coefficient (Rho) is represented by the change in color from blue (negative) 
to red (positive correlation). Thyroid function calculated in the serum: %TRAK, fT4 
(mg/dL). Lymph nodes: %CD4, %CD25 pos. of CD4 and %memory/effector T cells. 
Orbital T cells: %CD4 and %CD8.  
 
No significant difference was observed in the percentage lymphocytes between 
immunisations. A positive correlation between CD4+ and the genus Oscillibacter was 
observed in the control-TSHR colon samples, while the memory/effector T cells 
negatively correlated with Pantoea and weakly positively with Bacteroides. Orbital CD4+ 
T cells negatively correlated with genus Akkermansia and CD8+ T cells positively 
correlated with Lactobacillus counts and negatively with uncultured Bacteoridetes and 
Alistipes (Figure 3.10A). Bacteroides was positively correlated to CD4+CD25+ in the 
entire control-TSHR (Figure 3.10B). In the vancomycin-TSHR immune group, 
Akkermansia was positively correlated with both CD4+CD25+ and memory/effector T 
cells, while an uncultured Bacteroidetes was positively correlated with CD4+ T cells 
(Figure 3.10C). Genus Akkermansia was also negatively correlated with both orbital 
CD4+ and CD8+ T cells, while genus Lachnoclostridium positively correlated to orbital 
CD4+. On the contrary in the Lab4-TSHR, genus Akkermansia was negatively correlated 
to CD4+CD25+ (Figure 3.10E). In the same group, an uncultured Bacteroidetes correlated 
positively with CD25+ and memory/effector T cells, and negatively correlated to CD4+; 
genus Alistipes negatively correlated to both CD4+CD25+ and memory/effector T cells, 
while genus Bacteroides positively correlated to memory/effector T cells and negatively 
correlated to CD4+. Uncultured Actinobacteria a weak negative correlation to CD4+, 
while unidentified Firmicutes negatively correlated to memory/effector T cells. In hFMT-
TSHR, genera Bacteorides and Alistipes negatively correlated to CD4+ and genus 
Akkermansia positively correlated to memory/effector T cells (Figure 3.10G). In the 
hFMT-Βgal counterpart, uncultured Bacteroidetes genus, Bacteroides and in a weak 
manner also Alistipes, negatively correlated to CD4+ and memory/effector, while Pantoea 
counts negatively correlated to CD4+CD25+ T cells (Figure 3.10H). In the same group, 
orbital CD8+ correlated negatively with uncultured Bacteroidetes, Alistipes and 
unidentified Firmicutes genera, which also strong negatively correlated (Rho> -0.5) with 
orbit CD4+ (Figure 3.10H).  
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3.4.8. Imputed metagenomic functions across manipulation treatments and 
between immunisations  
As previously described in different gut anatomical sections of the control GO mouse 
model, metagenomic functions were also predicted in the large intestine samples of GO 
mice, whose gut was manipulated either via hFMT, vancomycin or Lab4 administrations.  
Across immunisations, high-variant metabolic pathways previously described in the 
control large intestines were also found in the hFMT microbiome, e.g. starch/sucrose, 
amino sugar/nucleotide sugar, glycine/serine/threonine and fructose/mannose 
metabolism, with the exception of the nitrogen metabolism, previously described in the 
control small intestine (Figure 3.11A). Also, the glycerophospholipid metabolism was 
described for the first time, possibly as a result of the hFMT itself. Of those top-10 most 
variant pathways, metabolic pathways including the nitrogen metabolism were increased 
in βgal, while the glycerophospholipid metabolism, ABC transporters and the 
glycolysis/gluconeogenesis were increased in the TSHR-immune mice (Figure 3.11B).  
Across immunisations, long-term vancomycin treatment selected bacteria mostly 
involved in the ABC transporters (having the highest variance), bacterial secretion 
system, RNA degradation and nucleotide excision repair. Also, oxidative 
phosphorylation, two-component system and phenylalanine/tyrosine/tryptophan 
biosynthesis were described. Interestingly, metabolic pathways previously described 
being in the top-10 most variant pathways in the control group, such as the 
amino/nucleotide-sugar and starch/sucrose metabolisms, were now included in the 
least-10 variant group (Figure 3.11C). Between immunisations, ABC transporter, two-
component system and the glycolysis/gluconeogenesis were increased in TSHR, while 
degradation of other glycans, RNA degradation, nucleotide excision repair and the 
bacterial secretion system were increased in βgal mice(Figure 3.11D).  
Highest-variance pathways induced by Lab4 probiotic mostly included metabolic 
pathways, such as starch/sucrose, fructose/mannose, galactose, amino/nucleotide-
sugar, glycine/serine/threonine and porphyrin/chlorophyll metabolisms, similarly to the 
control large intestine, and the nitrogen metabolism similar to the hFMT group. Also, 
bacterial secretion system, ABC transporter and other glycan metabolism pathways were 
described (Figure 3.11E). Interestingly, no major differences were found in the relative 
abundance of the top-10 most variant pathways between immunisations, with the 
degradation of other glycans increased in βgal and ABC transporter and 
porphyrin/chlorophyll metabolism slightly increased in the TSHR (Figure 3.11F).  
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Figure 3.11. Metagenomic functions predicted in the control group between 
immunisation along the intestinal tract.  
Top-10 and least-10 variant KEGG pathways according to anatomical sections of the 
gut: small (A), colon (C) and entire (E) and differences in the top-10 variant pathways 
between immunisations (TSHR or βgal) in each gut section (B, D and F). varCount, 
across-group coefficient of variation (standard deviation/mean pathway relative 
abundance) in percentage (%). 
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3.4.9. Combined effect of treatments, immunisations and time on the distal 
(faecal) microbiota composition of the GO mouse model 
In the previous chapter, I demonstrated that time had a major effect in shaping the 
richness and the organization of the faecal microbiota in GO mouse model. To assess 
how the different gut-manipulation treatments interacted with immunisations over time, 
we collected and analysed the faecal microbiota after two gavages, but before any 
immunisations (baseline) and after four gavages and before the third immunisation (mid 
timepoint) and compared to that of respective controls. At baseline, differences in alpha 
diversity indices were uniquely associated to treatments (P<0.001). A slight increase in 
the richness (Chao1 and observed OTUs) appeared in the Lab4 treatment compared to 
that of the control, while the hFMT seemed to reduce the diversity (Shannon) and the 
evenness (equitability index) of the bacterial communities compared to controls, 
however, these did not reach significance. Significant differences were dominated by the 
antibiotic treatment (P<0.001), which drastically reduced the bacterial richness and 
diversity (Table 3.10). At this timepoint, prior to receive any immunisation, the two groups 
showed a similar composition of the gut microbiota, calculated through alpha diversity 
indices (Table 3.10). 
At the mid timepoint, after two immunisations and four gavages, differences in the 
Shannon and in the equitability indices appeared significant between immune hFMT and 
controls (P=0.002), and in the richness between βgal-Lab4 and βgal-control (P=0.021, 
Table 3.11). 
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Table 3.10. Summary of the alpha diversity indices (mean values) and test statistics 
amongst treatments and between hTSHR and βgal immunisations within each treatment 
at baseline timepoint. 
 
a Mean values of each index per immunisation and treatment; ° Analysis of variance based 
on linear model; §Pairwise comparison between immunizations in each treatment.  
 
 
Table 3.11. Summary of the alpha diversity indices (mean values) and test statistics 
amongst treatments and between hTSHR and βgal immunisations within each treatment 
at mid timepoint. 
a Mean values of each index per immunisation and treatment; ° Analysis of variance based 
on linear model; §Pairwise comparison between immunizations in each treatment. * P<0.05. 
 
 
Index immunization controla hFMTa Lab4a vancomycin P value° 
Chao1 
βgal 785.64 868.81 1042.99 183.61 1.04E-07 
TSHR 876.29 781.37 816.43 179.69 3.51E-11 
P value§ 0.361 0.464 0.108 0.8767   
Observed  
OTUs 
βgal 575.33 661.33 774.00 120.88 9.02E-07 
TSHR 617.80 558.00 592.89 108.00 1.00E-09 
P value§ 0.612 0.337 0.126 0.410   
Shannon 
βgal 5.95 6.29 6.64 3.09 1.00E-10 
TSHR 6.59 5.95 6.24 2.93 6.27E-18 
P value§ 0.095 0.267 0.307 0.129   
Equitability 
βgal 0.65 0.68 0.70 0.45 8.00E-08 
TSHR 0.71 0.66 0.69 0.44 4.88E-12 
P value§ 0.069 0.654 0.855 0.648   
Index Immunization controla hFMTa Lab4a vancomycin P value° 
Chao1 
βgal 1095.04 930.77 915.15 176.12 1.04E-07 
TSHR 1054.38 968.09 893.78 216.71 3.51E-11 
P value§ 0.723 0.622 0.833 0.097   
Observed  
OTUs 
βgal 842.78 666.11 647.82 108.64 9.02E-07 
TSHR 812.18 731.53 638.91 128.21 1.00E-09 
P value§ 0.763 0.312 0.919 0.140   
Shannon 
βgal 6.69 6.66 6.46 2.77 1.00E-10 
TSHR 6.75 5.67 6.13 2.74 6.27E-18 
P value§ 0.773 0.015* 0.056 0.801   
Equitability 
βgal 0.69 0.71 0.70 0.41 8.00E-08 
TSHR 0.71 0.60 0.67 0.40 4.88E-12 
P value§ 0.453 0.004* 0.072 0.447   
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As previously observed, time had a major effect in the richness (P=0.002 and P=0.003) 
and in the evenness (equitability, P=0.033), but not in the diversity of the bacterial 
communities. Factorial interactions of time with treatments and immunisations are 
represented in Table 3.12. A significant increase of the richness indices over time was 
observed in the hFMT-treated group (Chao1, P=0.0038) and in controls (Chao1 P=0.035; 
observed OTUs P=0.001), as represented in Appendix 13. In particular, the post-hoc 
analysis confirmed previous observations in the control groups (i.e. richness increase 
less apparent in the TSHR group) and showed a significant increase of the richness 
indices over time (Chao1, P=0.023; observed OTUs, P=0.019) in the TSHR-immune 
hFMT treated group (Table 3.13). 
 
 
Table 3.12. Summary of the statistics from Equation 3 testing for treatments, 
immunisations, time and their factorial interactions in alpha, beta-diversity and in the 
Firmicutes:Bacteroidetes ratio. 
 
§Firmicutes:Bacteroidetes ratio 
  
Index 
ANOVA model 
Treatment Immunisation Timepoint 
Treat x  
Immun 
Treat x  
Time 
Immun x  
Time 
Chao1 <0.001 0.547 0.002 0.571 0.022 0.343 
Observed OTUs <0.001 0.501 0.003 0.77 0.004 0.174 
Shannon <0.001 0.012 0.709 0.001 0.064 0.205 
Equitability  <0.001 0.056 0.033 0.001 0.226 0.036 
Bray-Curtis  0.001 0.01 0.009 0.001 0.007 0.329 
Firm:Bact§ 0.0015 0.0001 0.718 0.003 0.117 0.290 
  
 
 
123  
Table 3.13. Summary of the alpha diversity indices (mean values) and test statistics 
between baseline and mid timepoint, for each treatment and for each immunisation. 
 
Index Treatment Immunization Baseline (mean) Mid (mean) P value 
Chao1 
control 
βgal 785.644 1095.039 0.017* 
TSHR 876.288 1054.383 0.096° 
hFMT 
βgal 868.806 930.774 0.592 
TSHR 781.373 968.093 0.023* 
Lab4 
βgal 1042.988 915.151 0.229 
TSHR 816.426 893.776 0.524 
vancomycin 
βgal 183.606 176.124 0.743 
TSHR 179.686 216.707 0.165 
observed   
otus 
control 
βgal 575.333 842.778 0.021* 
TSHR 617.800 812.182 0.038* 
hFMT 
βgal 661.333 666.111 0.961 
TSHR 558.000 731.533 0.019* 
Lab4 
βgal 774.000 647.818 0.193 
TSHR 592.889 638.909 0.650 
vancomycin 
βgal 120.875 108.643 0.337 
TSHR 108.000 128.214 0.188 
Shannon 
control 
βgal 5.955 6.689 0.069 
TSHR 6.591 6.753 0.452 
hFMT 
βgal 6.289 6.658 0.077° 
TSHR 5.948 5.671 0.494 
Lab4 
βgal 6.645 6.465 0.149 
TSHR 6.244 6.131 0.705 
vancomycin 
βgal 3.090 2.765 0.002* 
TSHR 2.932 2.740 0.088° 
equitability 
control 
βgal 0.653 0.691 0.258 
TSHR 0.714 0.707 0.742 
hFMT 
βgal 0.677 0.715 0.116 
TSHR 0.662 0.596 0.108 
Lab4 
βgal 0.695 0.697 0.921 
TSHR 0.688 0.666 0.465 
vancomycin 
βgal 0.452 0.411 0.025* 
TSHR 0.441 0.398 0.058° 
Welch’s t-test BH corrected between baseline and mid timepoint: * P <0.05, ° P<0.1 
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The between-sample bacterial community relationships were assessed using the Bray-
Curtis dissimilarity matrix. At baseline, antibiotic, hFMT and Lab4-treated mice differed 
to each other (P<0.05), apart from hFMT and Lab4 mice, which became significant in the 
mid timepoint (P=0.0015). No significant differences were observed between 
immunisations at baseline, however, differences between the TSHR and the βgal 
immunisations were observed in the hFMT-treated mice (P=0.008) and retained at the 
mid timepoint (P=0.016, Figure 3.12B). Such a difference might be attributed to either 
the engraftment outcome itself or to a possible cage effect, which I showed to appear in 
the murine faecal microbiota in Chapter 2. Overall, the time had a significant effect on 
the stability of the faecal microbiota (P=0.001) between the two timepoints sampled, as 
it was its interaction with treatments (P=0.007), but not the interaction with 
immunisations, taking all the treatments together (Figure 3.12A). Differences in 
immunisations within each treatment were observed (Figure 3.12B), and centroids 
(sampling distribution of the mean) of each immunisation were close to each other 
similarly to what observed at T2 (9 weeks after second plasmid injection) in the previous 
chapter (Chapter 2, figure 2.6). 
At the phylum level, the Firmicutes:Bacteroidetes ratio was significantly associated with 
treatments (P=0.0015) and immunisations (P=0.0001), overall, while the time seemed 
not to have any significant effect (Table 3.12). The factorial interaction between 
treatments and immunisations was significant (P=0.003), while there was no significant 
interaction between treatment and timepoint and immunisation and timepoint. In 
particular, a significant difference was observed between TSHR and βgal immunisation 
in the hFMT-receiving mice (P=0.0006). Although not significant, only the control group 
showed an increase in the Firmicutes:Bacteroidetes with time (Figure 3.12C).  
The microbiota composition at baseline is the result of the various treatments without 
any influence from immunisations or aging. The vancomycin-receiving mice showed, as 
expected, a unique bacterial composition with increased Proteobacteria genera, 
Akkermansia and Lactobacillus spp. (Figure 3.12D and Appendix 15). hFMT and Lab4 
groups showed quite a similar composition of the gut microbiota, with a reduced 
Bacteroides spp. compared to controls and vancomycin treatment. However, 
Bacteroides spp. counts significantly increased with time in Lab4 mice, in both 
immunisations (Appendix 14).   
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Figure 3.12. Stability and diversity of the gut microbiota between timepoints.  
(A) Differences amongst treatments between baseline and mid timepoint, (B) differences 
between immunisations in each timepoint and per treatment. 
(C) Firmicutes/Bacteroidetes ratio between immunisations in each timepoint (either 
baseline or mid). (D) Distribution of the top-20 most abundant genera across treatments 
in each timepoint.  
 
3.4.10. hFMT engraftment into GO mouse model gut microbiome 
To test whether the resistance or the susceptibility to a certain disease is conferred by 
the composition of the gut microbiome, faecal material from human patients can be 
administered to murine models (either pretreated with antibiotics or GF), usually via 
gavage, leading to a humanized mouse model. The hFMT was performed three times 
before the start of the immunisation procedures (i.e. at birth, weaning and before the first 
immunisation) and once before the third immunisation, with 6-week interval from the third 
gavage. The NMDS based on Bray-Curtis matrix showed a clear separation between the 
human GO donors and the murine samples, both hFMT or control mice (PERMANOVA 
P<0.001, using 999 permutations). Within murine samples, a less clear separation 
between the hFMT-receiving and control mice was observed (Figure 3.13A) 
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Figure 3.13. Between-sample relationship (beta-diversity) of the human donors, 
control and hFMT mice in the three timepoint and per intestinal sections.  
NMDS based on the Bray-Curtis dissimilarity matrix showed a clear separation between 
human donors and murine samples, whether control or hFMT mice (A). Differences in 
the spatial organization between control and hFMT mice and (B) according to timepoint 
and anatomical section/sample used.  
 
At baseline, there was a more pronounced spatial separation of some hFMT-receiving 
mice compared to controls, which became less evident in the mid-timepoint (Figure 
3.13B). There were no differences between hFMT and control mice at the end of the 
experiment in the small intestine, whose groups were both spread along the two NMDS 
axis, while relying more closely in the colon samples. 
Similarity of the gut microbiota composition at the family taxonomic level, between hFMT-
receiving mice with that of the GO human donors, was calculated through the 
SourceTracker, with the rationale described in Figure 3.14A. At baseline (after three 
gavages), 4 out of 15 hFMT-receiving mice faecal samples (test) showed a >10% 
similarity with human source while none out of 16 control mice (control) shared any 
similarity with the human samples (Fisher’s exact test with Yates’ continuity correction, 
P<0.001, Figure 3.14B). At mid-timepoint (four gavages in total, after 6-week circa 
washout period between the third and the fourth gavage), half of the control mice (10/20) 
showed >10% similarity, while none of the hFMT-receiving mice (0/24) showed any 
similarity with the human donors (P<0.001, Figure 3.14C). Interestingly, at the end of the 
experiment (after 9 weeks after the fourth and last gavage), the same similarity to human 
donors samples was observed in both murine controls (26%) and hFMT-receiving colon 
samples (26%, P=1), while no similarity to human donors was observed in the small 
intestines (Figure 3.14D). Interestingly, when considering a >40% similarity with the 
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human donors, only the hFMT-receiving mice at baseline showed a significant 
observation (mean similarity 53% hFMT vs. 20% control). In particular, only the group 
that would have received the hTSHR immunisation showed a high similarity with the 
human donor pool, possibly due to a caging effect (P=0.001; Figure 3.15A and B). At 
mid timepoint (Figure 3.15C), the similarity to human donors was shared between both 
TSHR and βgal immune mice, while at the endpoint, the hFMT-receiving βgal-immune 
mice showed a higher similarity to human donors compared to the TSHR in the colon 
samples (P=0.001; Figure 3.15D). The engraftment however, was subjected to possible 
caging effect and individual variability.  
The extent of the engraftment was also calculated at the taxonomic level. SourceTracker 
returned a list of possible bacterial invaders possibly derived from the human samples, 
and the top-14 most abundant invaders were analysed according to Equation 5 and 
Equation 6 (Appendix 16). At baseline and at the endpoint, Peptococcaceae abundance 
increased in the hFMT-receiving mice of nearly 623% and 30.5% compared to GO 
patients, respectively. Instead, Lactobacillaceae increased 30.5% at the mid timepoint in 
the hFMT-receiving mice compared to donor samples.  
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Figure 3.14. Engraftment analysis calculated using the SourceTracker.  
(A) Rationale of the analysis: in the test analysis, both human donors and murine controls 
were used as sources to predict the similarity of the hFMT-receiving mice (sink). The 
control analysis used the human donors and the hFMT-mice as sources instead, to 
calculate the similarity of the control mice. Similarity was expressed as % probability 
using the control and the test analysis at baseline (B), mid timepoint faecal samples (C) 
and at the end of the experiment (D) in either small or colon samples. Unknown: 
observations not assigned to a specific source at the significant threshold (P=0.001). 
Fisher’s exact test with Yates continuity correction: *** P<0.001; ns non-significant P 
value. The test statistic was calculated considering only the number of observations 
>10% similarity to human source between analysis (test and control) in each timepoint. 
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Figure 3.15. Engraftment differences between immunisations.  
(A) NMDS based on the Bray-Curtis matrix for between-sample relationship in 
immunisations, according to timepoint and sources. (B) SourceTracker analysis for 
similarity to human or murine sources at baseline, (C) mid-timepoint faecal samples and 
(D) endpoint small and colon samples, based on immunisations. Fisher’s exact test with 
Yates continuity correction: *** P<0.001; ns non-significant P value. The test statistic was 
calculated considering only the number of observations >10% similarity to human source 
between immunisations (TSHR and βgal) in each timepoint.  
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3.5. DISCUSSION 
The aim of the present chapter was to investigate whether altered or absent composition 
of the gut microbiota through manipulation strategies in the early-stage of life may impact 
the outcome of the GO mouse model. In other words, whether the gut microbiota plays 
an important role in training the immune response, and whether certain bacterial species 
may have a protective/inducing role in the auto-immune response to TSHR in mouse 
model.   
The GO mouse model developed by Banga and his group first [180], replicated at 
Eckstein laboratory later [187] and used in this thesis does not involve the use of 
conventional adjuvants to promote the breaking of the immune-tolerance against the 
human TSHR. As previously described (Chapter 1 par.. 1.3.2.2), adjuvants (e.g. 
complete or incomplete Freund’s adjuvant, alum and pertussis extract…) can have a 
direct or an indirect effect on the immune system, creating a proper pro-inflammatory 
environment for the induction of the auto-immune response. Due to its close interplay 
with the immune system, the gut microbiota can itself act as a natural adjuvant, promoting 
(or not) the second immune stimulus needed for the activation of the (auto)immune 
response, as shown by [365]. We therefore manipulated the composition of the gut 
microbiota in the early-stage of life of mice (i.e. from birth) to expose their immune system 
to different environments before the immunisation procedures using either antibiotics, 
probiotics or faecal material transplant from GO patients. 
3.5.1. Vancomycin treatment  
The effects of a long-term vancomycin treatment on the large intestines were dramatic 
and resembled previous studies investigating chronic administration of antibiotics on the 
gut microbiota population [298]: the depletion of the richness and diversity indices was 
accompanied by a reduction of Gram positive bacteria (mainly represented by the 
Firmicutes phylum, e.g. Faecalibacterium, Eubacterium and Ruminococcaceae) and an 
increase in Proteobacteria species, including Salmonella, Pseudomonas and E.coli. 
Interestingly, the effects of the vancomycin were less evident in the small microbiota, at 
least in the βgal mice, remarking the concept that the gut microbiota has a different 
susceptibility to antibiotics depending on the gut anatomical site, as reviewed in [334].  
The lack of induced disease in the vancomycin-treated TSHR-immune mice strongly 
suggests the need of the gut microbiota for the GO to be successfully induced, potentially 
training the immune system in the early-stage of life, although the precise mechanisms 
remain to be understood. We recently reported the induction of TSAb but a lack of 
hyperthyroidism and orbital pathology in C57BL/6 female mice undergoing the same 
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immunisation procedure, however no similarity with the gut microbiota of the 
vancomycin-treated mice was observed, suggesting that the lack of hyperthyroidism in 
C57BL/6 is more related to a genetic background-specific microbiota [366]. Ivanov and 
collaborators reported a decreased Th17-produced pro-inflammatory cytokines milieu in 
the small intestines of the EAE newborn pups treated with vancomycin, which may have 
contributed in the protection from the disease development [299]. Removal of the 
majority of Gram positive/Firmicutes bacteria have led to a general unbalance amongst 
bacterial species (also known as dysbiosis) rather than the removal of a particular 
species; thus, further investigations using a more targeted antibiotic may have to be 
performed as also suggested by [334]. Moreover, since also dams were treated during 
pregnancy, the maternal transmission of the microbiota has been compromised. 
Such a long-term administration procedure, ideally to recapitulate the germ free (GF) 
status [367], have also led to the growth of resistant and compensating species, as also 
reported by [368], which may have been implicated in the disease outcome. Vancomycin 
treatment retained the highest counts of the Bacteroidetes genus Bacteroides (shown to 
be reduced in the TSHR-immune mice, Chapter 2) amongst other treatments in TSHR 
mice, which showed a negative correlation with the total fat in the orbit: the more the 
Bacteroides counts in the large intestine, the less the orbital fat. To a similar extent, the 
Verrucomicrobia genus Akkermansia was highly increased by vancomycin treatment in 
βgal compared to TSHR immunisations, and showed a significant negative correlation 
with both brown and total fat, CD4+ and CD8+ in the orbit and a positive correlation with 
the CD25+ (Tregs) and memory/effector cells in TSHR-immune mice, although there 
were no differences with those in the βgal. Akkermansia muciniphila constitutes a single-
species of the genus Akkermansia [369], which is involved in the mucin degradation 
[370]. Interestingly, the postnatal vancomycin treatment of NOD mice reduced the  
incidence of T1D along with an increased proportion of Akkermansia muciniphila [371], 
despite the majority of the studies reporting exacerbation of T1D after antibiotics 
administration [338, 372]. According to the authors [371], a possible degradation of the 
mucus layer by Akkermansia muciniphila may have increased the accessibility of the 
remaining bacteria (e.g. Gram negative/Proteobacteria) to the gut immune cells and their 
receptors such as the TLR4, whose activation was previously shown to reduce diabetes 
incidence [373], even if debated [374]. However, the underlined mechanism has not yet 
been proved and there are no data available of the role of TLR4 in protecting from GO; 
on the contrary a more active TRL4 was associated to GD [375].   
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3.5.2. Humanized (GO) faecal microbial transplant  
The faecal material transplant of sight-threatening GO patients’ samples in female 
BALB/c mice aimed at creating a humanized mouse model which recapitulates the GO 
gut environment in the early-stage of life of the mice. To perform such engraftment, three 
gavages were performed prior the immunisation procedure (i.e. at the day after birth, at 
weaning and before the first immunisation) and before the third immunisation, with a 
washout period in-between. The resulting TSHR-humanized GO mice, at the end of the 
procedure, showed a significantly higher TRAB and TSAb titres compared to βgal; 
hyperthyroidism (T4 levels) and brown fat in the orbit were induced in some TSHR-
immune mice, although not reaching the significance threshold. The gut microbiota of 
hFMT mice showed an increased richness between the baseline and the mid timepoint 
only in TSHR-immune mice. At the end of the experiment, the hFMT small intestines 
showed an increased diversity and evenness compared to the vancomycin-treated βgal-
immune mice; while the TSHR-immune mice showed a reduced diversity compared to 
that of the control mice in large intestine samples. Such a reduction in bacterial diversity 
accompanied by an altered gut microbiota was often associated to Crohn’s disease (CD) 
and IBD/colitis in both animal models and in humans [376]. Fourteen out of 19 mice were 
correctly predicted to the hFMT group based on their large intestine bacterial composition 
(74% class accuracy). In particular, Bacteroides spp. showed the lowest abundance 
amongst other treatments and it was significantly reduced compared to hFMT- βgal mice, 
possibly explaining the reduced microbiota diversity when compared to controls. Also, a 
negative correlation between Bacteroides spp. and CD4+ lymphocytes at the draining 
lymph nodes was observed in TSHR-immune mice.  
Given that the manipulation via FMT had some effect on the gut microbiota of the GO 
mouse model, I investigated the extent of the engraftment from the human donors to the 
murine recipients using the SourceTracker [363]. Such algorithms have been previously 
used to monitor the engraftment of faecal material transplant in the context of recurrent 
Clostridium difficile infections [342, 377] and in humanized mouse models [341, 378]. 
About 27% of hFMT-receiving mice showed more than 40% similarity (min 46%, max 
72%) with the human donors’ microbiota after three gavages but before any 
immunisations; thus, I can possibly speculate that at the start of the immunisation 
procedure at least some mice had a GO-like environment in their gut. At the mid timepoint 
(after 6 weeks washout), however, no similarity between hFMT and GO donors was 
observed, while at the end of the experiment, the large intestines of both controls and 
hFMT mice shared the same similarity with human samples. Such results may need 
some considerations: i) the SourceTracker was run using the OTU table at the family 
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level as in [341], because no similarity between murine (both hFMT and controls) and 
human samples (with a concomitant increased of unknown source assignment) was 
observed when using the genus and the OTU levels. Family level may be a less specific 
taxonomic description, since only OTUs/species and genera can discriminate between 
human and murine microbiota [199]. However, ii) we used a pooled, in-vitro cultured, 
freeze-dried faecal samples, which have been selected for certain viable anaerobic 
bacteria, possibly explaining the need of upper taxonomic description (e.g. family to 
phylum levels). Either freeze-dried or incapsulated freeze-dried faecal material 
transplants proved to be a safe and efficient treatment of diarrheal episodes in recurrent 
C. difficile infections, often accompanied by an increased/restoration microbiota diversity 
and a successful engraftment [379-381]. While there were no differences in the 
production of a humanized mouse model using either freeze-dried or freeze-dried plus 
in-vitro cultured samples [382]. The same group also tested various FMT strategies, from 
a single gavage only to repeated gavages (2 times a week for 4 weeks) after bowel 
cleansing. The engraftment of a single FMT lasted up to 4 weeks reaching a steady-state 
composition, while the repeated FMTs impacted negatively the stability of the gut 
microbiota, still showing individual or cage-related variability [382]. iii) Our strategy 
implied the manipulation at the very early-days of life, with three FMTs performed more 
closely to each other in a 6-8 week period of time, while the fourth gavage was performed 
after 6 weeks from the third. Such a washout period may have reduced the amount of 
transferred bacteria and also a possible cage effect might have been responsible for the 
heterogeneous engraftment, at least at baseline. Moreover, iv) the hFMT in GO mouse 
model was performed without any prior preparatory treatment (such as the bowel 
cleansing) or any antibiotic treatment to dams, thus the newborn mice, although being 
gavaged from the first day after birth, retained the maternal transmission of the gut 
microbiota, which can induce a colonization-resistance as discussed in [334].  
3.5.3. Lab4 probiotic 
Probiotics are considered to deliver beneficial effects to the host health, also involving 
the immune-modulation of the host [294]. Such an immune-modulation outcome was 
observed in our mice challenged with Lab4 probiotics prior to the immunisation 
procedure. In particular, CD4+CD25+ regulatory T cells were induced in the βgal but not 
in the TSHR-immune group, possibly suggesting a relevant connection with the disease 
mechanism. However, the gut microbiota of the TSHR-immune mice showed strong 
correlations with lymphocytes in the draining lymph nodes, e.g. Bacteroidetes uncultured 
genera, Bacteroides and Alistipes negatively correlated with CD4+ and simultaneously 
positively with CD4+CD25+ and memory/effector T cells. We can possibly speculate that 
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the Lab4 administration promoted an anti-inflammatory response, increasing the 
CD4+CD25+ T cells in the βgal control mice, which was however prevented by the TSHR 
immunisation, despite gut microbiota-correlating features. Moreover, Lab4-treated 
TSHR-immune mice showed a significantly higher T4 levels and orbital brown fat 
compared to βgal. Varian and collaborators provided Lactobacillus reuteri daily in 
drinking water to one-year old (aging) outbred mice and reported an increased serum T4 
levels, accompanied by a weight loss and increased activity levels in mice, compared to 
untreated group. Authors also observed an enlarged thyroid gland and induced activity 
dependent upon CD4+CD25+ Tregs [383]. Administration of L. acidophilus increased 
TSH and T3 levels but not T4 in weaning rats (30 days of life) for 32 days-treatment 
[384]. While providing a “healthful aging” in one-year old mice [383], it is possible that 
LAB supplementation worsens hyperthyroidism following TSHR immunisation. On the 
contrary, supplementation of Bifidobacterium lactis and Lactobacillus rhamnosus 
mitigated the outcome of the experimental autoimmune thyroiditis (EAT, i.e. similar to 
the Hashimoto’s thyroiditis) [385].  
Relationship between Lactobacillus and adipose tissue has been long debated, with 
evidence supporting the positive effect of the probiotics intake in ameliorating obesity 
[386, 387]. In the previous chapter, I identified a positive correlation between the genus 
Lactobacillus and the orbital adipogenesis in TSHR-immune mice. In the present work, 
no adipogenesis (in terms of total fat) and no correlation with the genus Lactobacillus 
was observed. Moreover, no correlation with brown adipose tissue (BAT) was reported. 
Since BAT was also induced in the control-TSHR mice, Lab4 did not prevent the BAT 
formation, which, however, has a different etiopathology compared to the white adipose 
tissue. Upon Lab4 treatment, TSHR-immunised mice showed an increase of 
Akkermansia spp. to the controls. Studies reported the increase of Akkermansia spp. 
upon probiotics intake [388] and potentially associated to a reduction in adipose tissue 
[389]. Interestingly, it correlated negatively with the total adipose tissue in Lab4-TSHR 
mice, although not significantly occurred as discussed previously.  
3.5.4. Gut anatomical differences in GO model  
TRAK and TSAb auto-antibodies titres were induced in the TSHR-immune control mice, 
however they were not hyperthyroid (T4 levels). This observation was consistent with the 
disease status observed in the centre 2 (Essen laboratory) in the previous chapter. Also 
orbital atrophy and BAT were induced; however, no adipogenesis (calculated as total fat) 
was here reported, which was instead induced in the TSHR group in the previous 
chapter. Interestingly, the genus Lactobacillus which correlated positively with orbital 
adipogenesis in chapter 2 (par.. 2.4.6), here, showed a positive correlation with orbital 
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CD8+, One can argue that the apparent BAT production is a prelude to adipogenesis; 
thus a longer experiment might have resulted in increased orbital fat volume, as in mice 
reported in chapter 2.  
The previous chapter analysed the gut microbiota from the scraping of the large 
intestines; however, no information are available on other anatomical sites of the gut in 
GO model, whose composition may be also involved in the pathogenesis. Notably, the 
Th17 lymphocytes involved in the pathogenesis of EAE mouse model specifically resided 
in the small intestine [299]. Compared to βgal, the TSHR-immune group showed a 
significantly increased Shannon diversity and evenness of the small intestines, despite 
the small intestine having a lowered richness and diversity compared to large/entire 
samples per se. Also, when predicting the immunisation groups with RandomForest, the 
TSHR-immune mice had a higher number of correct predictions. Correlations between 
small intestine microbiota and disease features are described in Appendix 17. 
Interestingly, significant positive correlation between the genus Streptococcus with both 
TSAb and atrophy were observed, which were both induced in TSHR-immune mice; 
while a negative correlation of Streptococcus and brown fat was observed in the βgal 
group. However, other manipulation treatments seemed to have minor impact on the 
composition of the small intestine.  
For reasons that would be discussed in Chapter 6, a direct comparison of the results 
obtained in this chapter with those presented in Chapter 2 was not possible. Differences 
in the gut microbiota composition observed here may also be related to gavage-related 
stress, despite using sterile water, as proposed in [390].   
3.5.5. Imputed metagenomic functions  
The vancomycin-treated microbiome had an increased variation in ATP-binding 
components (ABC) transporters and bacterial secretion system pathways (reviewed in 
[391]), possibly related to the efflux systems for antibiotic resistance; while RNA 
degradation, nucleotide excision repair and oxidative phosphorylation are more likely to 
be related to apoptosis/bacterial death. However, for the concept of redundant 
metagenomics functions and/or the establishment of a compensating gut microbiota, 
functions described in more “physiological” conditions were as well retained, e.g. 
glycolysis and gluconeogenesis, porphyrin and chlorophyll metabolism and other glycan 
degradation, whose functions may act as a rescue mechanisms for homeostasis 
maintenance.  
The hFMT predicted metagenome showed a proportion of metabolic pathways including 
those for glycine/serine/threonine, starch/sucrose, fructose/mannose, nitrogen and 
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glycerophospholipid metabolism, but also ABC transporters, other glycan degradation 
and the oxidative phosphorylation. While the oxidative phosphorylation was reported also 
in the vancomycin-treated metagenome, the glycerophospholipid metabolism has been 
uniquely predicted from the hFMT metagenome, and the combination of both pathways 
may suggest an increased oxidative stress in the large intestines. In particular, the 
glycerophospholipid metabolism has been previously related to intestinal mucosa 
inflammation in IBD [392] and a decreased Bacteroides vulgatus and Bacteroides 
caccae, along with an increase in glycerophospholipid metabolism was reported in 
Chron’s disease [393]. Since no major differences between βgal and TSHR were 
described for those two pathways, it might be a more general effect of the engraftment 
per se rather than the interaction with the immunisation procedure. Interestingly, the 
glycerophospholipid metabolism was the least abundant by all means of pathways 
predicted from the donor GO patients, whose microbiome showed higher ABC 
transporters and two-component system, followed by metabolic and biosynthetic 
pathways (data not showed).  
Lab4 probiotic treatment induced a range of metabolic pathways including the nitrogen 
metabolism. The bacterial secretion system pathway (which was also described in 
vancomycin metagenome) was reported as one of the top 10-most variant pathways. 
Interactions between probiotic bacteria and host mucosa may be promoted trough the 
secretion of extracellular proteins, as reviewed in [394]. 
Two predicted pathways may have biological relevance in the GD/GO pathogenesis: the 
other glycan degradation (K00511), involved in the N-glycan and ganglioside 
biosynthesis, and the phenylalanine, tyrosine and tryptophan biosynthesis (K00400). In 
particular, the first pathway was decreased in hFMT, vancomycin and Lab4-TSHR mice, 
while it was increased in small and large intestines in control-TSHR mice and it might be 
somehow related to the hTSHR A-subunit, used as immunisation antigen, which is highly 
glycosylated through N-glyc patterns. The second complex pathway involves tyrosine 
biosynthesis, which is a precursor of thyroid hormones T3 and T4, together with iodide 
(chapter 1, par. 1.1.1). A proportion of circulating thyroid hormones, specifically the T3, 
are secreted in the gut [395] or are stored in the gut as a reservoir [396]. The biosynthetic 
pathway was predicted from the gut microbiota of controls, whereas it was more 
abundant in TSHR small and large samples, and in vancomycin-treated mice, decreased 
in TSHR-immunisation. 
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3.6. CHAPTER CONCLUSIONS  
The manipulation strategies adopted in the present chapter successfully modified the gut 
microbiota in the early-stage of life, with an impact on the induced GO phenotype. As 
potentially expected, the vancomycin treatment prevented the disease, while the hFMT 
from sight-threatening GO patients transferred, at least in part, some of the human 
disease characteristics. Unexpectedly, the Lab4, despite its immune-modulation effects 
on regulatory T cells, induced hyperthyroidism and did not protect from disease 
development. As previously mentioned and more extensively addressed in Chapter 6, 
future investigations would better dissect the mechanistic role of the gut microbiota in 
GO disease (i.e. treatment with different classes of antibiotics, use of GF mice and hFMT 
using different stage of human disease).  
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4. Chapter 4 
 
 
 
 
Gut microbiome in European GD and GO patients at 
the time of recruitment: a multi-centre cross-sectional 
observational study 
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4.1. INTRODUCTION 
As previously introduced, autoimmune diseases are caused by a combination of both 
genetic predisposition and environmental factors. Amongst the latter, viral, fungal or 
bacterial infections preceding the onset of autoimmunity may predispose, to some extent, 
the loss of the immune-tolerance to autoantigens via the molecular mimicry or the 
antigen-spreading mechanisms, as already described (Chapter 1 par.. 1.3.2.2). 
Evidence for the involvement of a molecular mimicry of Y. enterocolitica (YE) antigens in 
GD were based on: i) the relatively high prevalence of antibodies to YE in GD patients 
[397, 398], ii) the presence of binding sites for TSH on YE envelope [399, 400], and iii) 
that antibodies against thyroid membranes have been shown to bind YE [397]. Recent 
results from proteomics have identified cross-reactivity between TSAbs and the outer 
membrane protein F (OmpF) epitope of YE [401]. Additionally, a bioinformatic study of 
YE outer membrane proteins suggested that it contained epitopes which could stimulate 
an antibody response that cross-reacts with T cell epitopes [402]. However, it is likely 
that the cross-reactivity of YE proteins only explains the aetiology of GD in some patients. 
The contribution of other microorganisms in the pathogenesis of GD was investigated 
and homologies between the TSHR and the spirochete Borrelia burgdorferi was found 
[403, 404]; although such analysis was only performed in silico. However, the incidence 
of GD cases cannot only be explained by infections, including YE (whose mean annual 
incidence in Germany was 7.2/100,000 people between 2002-2008 [405]). On the other 
hand, a less specific but, still effective pro-inflammatory environment underlying the 
autoimmune response can be provided via “bystander activation”.  
The gut microbiota plays an important role in the immune homeostasis of the host: 
bacterially-produced SCFAs exert beneficial effects by increasing a milieu favourable to 
regulatory T cells in the gut mucosa. Conversely, Gram’s negative LPS, and Gram’s 
positive-produced LTA and flagellin (i.e. those produced by a range of foodborne bacteria 
such as Campylobacter jejuni), but also commensal-derived metabolites themselves, 
can induce a Th1/Th17 pro-inflammatory response. We now know that such immune-
modulation can be related to an imbalance amongst commensal bacteria, either due to 
the overgrowth or the under-representation of certain taxonomies (known until recently 
as “dysbiosis” [406]), rather than to a single-species pathogen. Given this fine 
relationship in health status, in the past ten years, the gut microbiome has been 
investigated in disease conditions and its association with inflammatory bowel diseases 
(IBD) was described. In Crohn’s disease (CD) and ulcerative colitis (UC), the auto-
immune response is directly located in the gut. More specifically, CD is characterized by 
an abnormal presence of (auto)antibodies against intestinal microbiota antigens such as 
  
 
 
141  
the Saccharomyces cerevisiae oligomannan (ASCA), outer membrane porin (OmpC) 
and also against the bacterial flagellin (CBir1) [407]. Such auto-immune response is also 
sustained by predisposing polymorphisms in the host NOD2/CARD15 gene [408], coding 
for a protein expressed on macrophages and monocytes for LPS binding, which were 
associated to the auto-antibody reactivity, at least for CBir1 levels [409]. CD-associated 
gut microbiota showed an overall decreased diversity compared to that of healthy 
controls [410], along with increased abundance of E.coli, reduced counts of Bacteroides 
spp.  [411, 412] and Faecalibacterium prausnitzii [296], a butyrate-producing Clostridium 
known to increase IL-10-mediated anti-inflammatory immune response. 
The gut microbiome has also been associated with both systemic and organ-specific 
autoimmunity, not directly involving the gut. Rheumatoid arthritis (RA) is a chronic 
inflammation afflicting the joints and is characterized by a variety of auto-antibodies such 
as the rheumatoid factor, as reviewed in [413]. An increased amount of Prevotella copri, 
often accompanied by reduced Bacteroides genus, was associated with the new-onset 
untreated RA patients in the US [414] and in some Japanese patients [415]. A similar 
association was recapitulated in the RA animal model, in which P. copri induced a Th-17 
response. However, geographical variability in the RA-associated taxonomies was 
observed (i.e. increased Clostridium asparagiforme and Lactobacillus salivarius instead 
of Prevotella in a Chinese RA cohort), as reviewed in [415]. To note, also the involvement 
of the oral microbiome in RA has been described [416], further sustained by a higher 
incidence of periodontal infections with Porphyromonas gingivalis in RA patients, which 
was associated with higher levels of anti-citrullinated auto-antibodies [417]. Insights on 
the role of the gut microbiota in inducing, as well as protecting from, the multiple sclerosis 
(MS)-like disease were obtained from the EAE mouse model, whose mechanistic 
contribution was extensively studied also through manipulation strategies, as described 
in the previous chapter. As well as the EAE induced in mice, MS in humans has long 
been considered a T cell-derived autoimmune disease afflicting the central nervous 
system (CNS); however there is a major involvement of B-cells, as reviewed in [418]. 
The relapsing-remitting MS patients gut microbiota showed a decrease in bacterial 
species belonging to the Clostridia clusters XIVa and IV, Faecalibacterium, Prevotella 
and Alistipes genera [419]. Another study reported increased abundance of 
Methanobrevibacter and Akkermansia spp., and a reduction in Butyricimonas spp. in a 
MS cohort, including both treated and untreated patients, which correlated with a set of 
immune-related differentially-expressed genes in patients’ circulating mononuclear cells 
[420]. Interestingly, an increase in methane production quantified from breath was 
observed in MS patients, consistent with the increased Methanobrevibacter spp. 
abundance.  
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Type 1 diabetes (T1D) is an organ-specific autoimmune disease in which autoreactive T 
cells and inflammation are responsible for the destruction of the pancreatic insulin-
producing b-cells. It has an incidence of 5-10% diabetes cases worldwide, with an onset 
in childhood and adolescence. In contrast, Type 2 diabetes (T2D) arises more often in 
adulthood and is characterised by insulin resistance and/or a failure in compensatory 
mechanisms for insulin secretion [421]. Although T1D is strongly sustained by 
predisposing genes, environmental factors, including infections, may still have a role in 
its onset, as shown by studies in monozygotic twins, in which only 40% concordance rate 
of the disease were reported [422]. The role of the gut microbiota in T1D was proposed 
[423] and disease-associated taxonomies and metagenomic functions were obtained 
from the NOD and the Biobreeding Diabetes-Prone mouse models for T1D [339, 340, 
424, 425]. Children with T1D showed an increased Bacteroides, Clostridium and 
Veilonella genera, accompanied by a decrease in Bifidobacterium, Lactobacillus and 
Prevotella spp. in their faecal microbiome compared to healthy controls, suggesting a 
disruption of the intestinal barrier integrity. Such disease-associated taxa showed 
correlations with plasma glucose levels in T1D group [426]. A differential abundance of 
Lactobacillus, Prevotella, Bacteroides and Staphylococcus genera were associated to 
T1D susceptibility in children, i.e. autoantibodies-positive, seronegative first-degree 
relatives (FDRs) and new-onset T1D patients. Moreover, the gut microbiota of 
seropositive and seronegative FDRs, and that of new-onset patients and unrelated 
healthy controls, tended to cluster together but separately to each-other [427]. Increased 
Bacteroides, Veilonella and Alistipes spp. were reported in the faecal samples of a 
Finnish children T1D cohort, whose metagenomic functions were also described [428]. 
Interestingly, Bacteroides dorei-derived LPS, more prevalent in countries with high 
susceptibility to autoimmunity (i.e. Finland and Estonia in this study), may contribute to 
increased susceptibility to T1D in Finnish infants, via the inhibition of the immune-
stimulation against endotoxins. On the other hand, Russian infants showed a higher 
prevalence of E. coli-LPS, which induced the immune response and was subsequently 
shown to confer resistance to T1D in NOD mice [134]. A possible but different role of the 
gut microbiota in T2D was also considered [429].  
Gut microbiota metabolites not only cross-talk with the immune system, but also with a 
range of processes involved in the growth, reproduction, development and behaviour; 
and vice versa since its composition can be actively regulated by host-released 
hormones and metabolites. The gut microbiota itself, in fact, has been considered as the 
“neglected endocrine organ” [430], capable of synthetizing hormone-like molecules and 
to influence the endocrine system itself. Close interaction between bacterially-produced 
SCFAs and the neuro-endocrine system, more specifically the hypothalamic-pituitary-
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adrenal (HPA) axis, has been described [431]. Also the interplay between sex-hormones 
and the gut microbiota was observed [432]. The gut microbiota itself can also be 
responsible for gender-prevalent autoimmune diseases: female NOD mice showed a 
decreased T1D incidence after receiving a microbiota transfer from male mice, possibly 
related to the high testosterone-levels [433]. A second study reported higher testosterone 
levels, along with higher counts of Enterobacteriaceae and SFB in GF, SPF and mono-
colonized NOD male mice which protected them from developing T1D [434]. TD1 in 
humans has less gender prevalence; however, similar evidence of an interplay amongst 
hormones, gut microbiota and the immune system was also reported in the mouse model 
of SLE [304], which has a strong female bias in humans. Both steroid sex hormones (e.g. 
oestradiol, progesterone and testosterone) and thyroid hormones (thyroxine and T3) are 
metabolized in the liver and released with the bile. Gut-residing bacteria may play a direct 
role in metabolizing steroid hormones, as reviewed in [432]. Iodination, sulphation and 
glucuronidation of thyroid hormones, which are necessary for releasing the more active 
T3 hormone from reservoir, in certain conditions, may be performed by intestinal bacteria 
[435, 436] and SCFAs may promote such enzymatic reactions as reviewed in [432]. 
Moreover, SCFAs may also promote intestinal epithelial homeostasis by inducing a T3-
mediated activation of the intestinal alkaline phosphatase (IAP) [437]. 
Bowel discomfort is often reported in thyroid autoimmune disease (AITD), varying from 
constipation in Hashimoto’s thyroiditis (HT) (i.e. hypothyroidism) to diarrhoea in GD  
(reviewed in [16]). A recent study reported altered composition of the gut microbiota in 
HT patients compared to matched healthy controls: seven genera including Blautia, 
Roseburia, Dorea and Fusicatenibacter were increased in HT, while Fecalibacterium, 
Bacteroides, Prevotella and Lachnoclostridium were instead decreased in HT and such 
taxonomies correlated with disease features [438].  
4.2. AIMS OF THE CHAPTER 
At present, few studies described a possible role of the human gut microbiome in GD 
and it progression to GO [439, Shi, 2019 #2473]. The present chapter therefore aims to:- 
i) describe the gut microbiota composition of GD and GO (mild and moderate-severe) 
patients compared to that of healthy controls in a multi-centre observational study;  
ii) analyse the gut microbiota in hyperthyroid and euthyroid patients compared to 
euthyroid healthy controls irrespective of the diagnosis (whether GD or GO);  
iii) predict the diagnosis (GD or GO compared to healthy controls) based on the gut 
microbiota composition using a classification algorithm;  
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iv) describe possible interactions between the gut microbiota and gender and smoking 
habits in GD/GO patients, since they are already implicated in the disease and not 
only as confounding variables; v) correlate the taxonomic differences between 
disease types to endocrine (TSH and T4 levels) and immunological (TRAB) 
observations and  
vi) compare the imputed gut metagenomic functions between GD/GO and healthy 
controls and using the imputed KEGG orthologs to predict the patients’ diagnosis.  
4.3. MATERIALS AND METHODS 
4.3.1. Patients recruitment and sample collection 
Samples used in this chapter were collected between October 2014 and June 2016 
within the framework of the E.U.-FP7 INDIGO project (http://www.indigo-iapp.eu/) from 
four European countries, in a total of eight centres: United Kingdom (University Hospital 
of Wales Cardiff, Merthyr, Newcastle and Moorfields), Italy (Policlinico ca’ Granda 
Milano, Pisa), Belgium (Brussels) and Germany (University Hospital of Duisburg-Essen). 
An appropriate local research ethical approval was obtained from all recruitment centres 
(Essen: Ethik-Kommission reference 14-5965-BO; Cardiff: Wales Research Ethics 
reference 12/WA/0285; Milan: Comitato Etico Milano Area B, approval obtained on 
11/11/2014; Brussels: 2015/05JAN/002 approval obtained by Comitè d’Ethique 
Hospitalo-Facultaire Saint-Luc-UCL). Written informed consent was obtained from each 
participant at the moment of the enrolment in the study. According to the INDIGO study, 
criteria for patient enrolment were: i) GD patients untreated or at maximum of six weeks 
from commencing the anti-thyroid treatment from a new diagnosis or disease relapse, ii) 
euthyroid GO patients, iii) newly diagnosed GD patients with overt GO, as previously 
described [440]. Moreover, patients must have not taken any antibiotics in the three 
months prior to enrolment in the study. According to the observational multi-centres 
study, samples (including blood and faeces) were obtained at enrolment (baseline, BL), 
when euthyroid (euthyroid, EU) and after 6 months from anti-thyroid treatment withdrawal 
or relapse (end of follow up, EFU) as represented in Figure 4.1. 
Diagnosis was made by consultants in each recruiting centre. Patients were subdivided 
into GD patients with no sign of eye disease and GO with either mild, moderate-severe 
or sight-threatening signs of eye disease, based on the assessment of the EUGOGO 
guidelines [54]. Healthy donors from each recruitment centre, matched by age and 
gender, were all free of thyroid disease, with no signs of eye disease, euthyroid and 
negative for TRAB. Hyperthyroid patients were defined based on their suppressed or 
undetectable TSH, high T4 levels and positive TRAB titres. Euthyroid patients were 
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defined by the T4 thyroid hormone levels being in the normal range. Range values in 
each recruiting centre are represented in Table 4.1. Thyroid function tests and TRAB 
levels were measured in blood just before the enrolment in each recruiting centre. TRAB 
measurement in serum was also repeated by UB-P using the Immulite XPI (Siemens) 
for TSI (IU/L; positive result cut-off >0.1IU/L), the Cobas Roche for TRAK quantification 
(IU/L; cut-off >0.3IU/L) and an in-house bioassay for measuring the stimulating activity 
through cAMP production (pmol/mL; cut-off >1.67pmol/L), to obtain a more comparable 
results across recruiting centres. 
  
Table 4.1. Reference values for the biochemical thyroid function tests in each recruiting 
centre.  
 
Recruiting centre TSH (mU/L) fT4 (pmol/L) TRAB (IU/L) 
Brussels 0.3-4.2 12-22 >2.5 or >1.8° 
Essen 0.3-3.0 11.5-22.7 >1.75 
Cardiff 0.3-4.4 9-19.1 >1.6 
Newcastle 0.3-4.7 9.5-21.5 >1.8 
Milan 0.27-4.2 12-22 >2.5 
° changes in the TRAB references after 2016.  
 
A total of 211 patients and 46 healthy controls were initially enrolled in the INDIGO study; 
171 patients and 42 controls provided at least one faecal sample, further reduced to 105 
patients and 41 controls after removal of: i) patients with unclear diagnosis, ii) 
concomitant autoimmune conditions/with GD after immune reconstitution (i.e. MS 
patients treated with alemtuzumab) and iii) sight-threatening GO patients. The removal 
of those patients was dictated by the need of a more homogenous study cohort. At the 
time of the enrolment (baseline), characteristics per recruitment centre are summarized 
in Table 4.2 and Table 4.3. To facilitate the collection of the faecal sample at home, 
patients were provided with a packaged kit including the correct instructions for sampling, 
a sterile collection tube and a transport tube to be returned frozen to the clinic, where 
they were kept frozen at -20°C until shipped in dry ice to Cardiff University (UK) for 
processing.  
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Table 4.2. Characteristics of the patients enrolled in the INDIGO study at baseline (146 
participants in total; 105 patients and 41 controls). 
 
 Belgium Germany Italy UK Total 
Age (mean) 44.15/54 44.46/48.6 45.4/31.2 48.1/47.9 46.4/46.3 
Gender      
F 10/1 16/14 23/6 43/12 92/33 
M 0/0 0/3 7/1 7/4 14/8 
Ethnicity      
African 1/0 0/0 2/0 4/0 7/0 
Asian 0/0 0/0 0/0 3/0 3/0 
Caucasian 6/1 16/17 28/7 39/16 89/41 
Other 3/0 0/0 0/0 4/0 7/0 
Smoking      
current 3/1 6/3 5/2 11/1 25/7 
ex 1/0 3/1 1/0 15/1 20/2 
never 6/0 7/13 24/3 23/12 60/28 
not stated 0/0 0/0 0/2 0/2 0/4 
Values are expressed as case/control.  
 
Table 4.3. Clinical characteristics of eligible patients providing samples at baseline and 
included in the microbiome analysis at recruitment. 
 
Nation Type no. Thyroid status1 Orbitopathy2 TSH3 fT44 TRAB5 
Belgium control 1 1/0/0  0.86 19.10 0.20 
 GD 6 1/5/0  0.09 17.72 16.67 
 GO 4 0/4/0 4/0 0.01 41.10 20.10 
Germany control 17 17/0/0  1.59 12.86 0.02 
 GD 6 0/6/0  0.01 31.88 10.84 
 GO 10 1/9/0 7/3 0.04 24.17 16.44 
Italy control 7 7/0/0  NA NA NA 
 GD 11 0/11/0  0.01 17.71 15.81 
 GO 19 7/11/0 12/7 1.46 15.25 12.66 
UK control 16 17/0/0  1.22 13.39 0.30 
 GD 35 2/32/1  0.56 34.55 9.92 
 GO 14 3/11/0 13/1 0.68 22.71 11.46 
Total control 41 41/0/0  1.44 13.26 0.11 
 GD 59 3/55/1  0.34 28.95 12.44 
 GO 46 11/35/0 36/11 0.77 21.80 13.69 
1Thyroid status expressed as eu/hyper/hypo (few patients were not assessed); 2orbitopathy 
present only in GO patients and expressed to as mild/moderate-severe cases. 3mean TSH values 
(mU/L); 4mean free-T4 levels (pmol/L) and 5mean TRAB levels (IU/L), obtained from each 
Hospital.   
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4.3.2. DNA extraction and 16S rRNA gene sequencing  
DNA extraction was performed initially by HLV and DC (2014-2015) and by myself later. 
Faecal samples were kept frozen at -20°C for a maximum of two months prior to 
processing. Up to 180-220 mg of slowly-thawed faeces at room temperature were 
individually placed in 2mL FastPrep tubes prefilled with 0.1mm silica spheres (FastPrep 
lysing matrix B, MP Biomedicals, UK) and dissolved in 1 mL InhibitEX buffer (Qiagen 
Ltd, West Sussex, UK). Nucleic acid extraction procedure followed that described in 
Chapter 2, par. 2.2.2., including the bead-beating step. Aliquots of the extracted DNA 
were sent to Research and Testing RTL Genomics (Lubbock, Texas, USA) for 16S rRNA 
gene sequencing, using primers for V1-V2 regions of the 16S rRNA gene plus 
bifidobacteria regions (28F-combo, Table 2.2. Chapter 2) to generate 10,000 paired-
ends reads per sample on an Illumina MiSeq (Illumina, San Diego, USA), for a total of 
two sequencing runs (obtained in October 2016 and September 2017). Processing of the 
metataxonomics reads was conducted following the procedure described in Chapter 3 
par. 3.3.5 (Appendix 8) and in [352]. 
4.3.3. Software 
Reads from 16S rRNA gene sequencing were processed with the QIIME pipeline [208], 
used also to estimate diversity indices (alpha and beta). The sample-base rarefaction 
was estimated using the in-house developed R 
(https://github.com/filippob/sampleBasedRarefaction) script. Assignment of the 
enterotypes of the gut microbiota in each sample was performed using the classification 
algorithm available at http://enterotypes.org, according to [225], which is based on the 
HMP and MetaHIT training datasets. The prediction of the functional profile of the gut 
microbiota from 16S rRNA sequences was carried out using the Tax4Fun R package 
[360]. Plots were generated using the ggplot2 and ggpubr R packages. Additional data 
handling was performed with the R environment for statistical computing (R Core Team, 
2017). 
4.3.4. Statistical analysis 
4.3.4.1. Alpha and beta diversity indices  
To calculate the differences in each alpha diversity index (i.e. observed OTUs, Chao1, 
Shannon and equitability) across nations of recruitment, a linear model with nation as a 
categorical fixed effect was used. When testing differences in alpha diversity indices 
amongst disease diagnosis (GD, GO and healthy controls), thyroid status (hyperthyroid, 
euthyroid and hypo) and the stratification of the eye-disease (no sign, GO mild and 
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moderate-severe), the linear model considered those as fixed effects (one per each 
model) and was designed to correct for nation, age, gender and smoking habits. Beta-
diversity was calculated from the Bray-Curtis dissimilarity matrix and was represented 
using the non-metric dimensional scaling (NMDS) with the Vegan R package. 
Differences at the beta-diversity amongst and pairwise comparisons of the above fixed 
effects were assessed using the permutational analysis of variance (PERMANOVA) 
implemented in the Adonis function [200] with 999 permutations and the nation of 
provenance as a strata to block the permutations. 
4.3.4.2. Differential abundance analysis  
Similarly to the alpha diversity, differences in the taxonomic counts at phylum and genus 
levels were estimated using dedicated linear regression models. The disease diagnosis 
(GD, GO and healthy controls) or the severity of the eye-disease (no sign, GO mild and 
moderate-severe) were considered as fixed effects and were corrected for the thyroid 
status (hyperthyroid, euthyroid, euthyroid-control), nation of recruitment, age, gender 
and smoking habits. Post-hoc test was performed with the Bonferroni correction. When 
looking at the thyroid status as a fixed effect, correction was performed on the basis of 
nation of recruitment, age, gender and smoking habits. The hypothyroid patients were 
not included in the post-hoc analysis due the low number of samples. 
4.3.4.3. RandomForest prediction analysis  
A Random Forest (RF) model was trained to predict to which disease types (control, GD 
or GO) or GO status (no sign, GO mild, GO moderate-severe) each sample belonged, 
based on the microbiota composition at genus level. CSS-normalized and filtered CSS-
normalised abundances with non-zero values in at least 20% samples were retained , 
scaled and centred. As described in Chapter 3 par. 3.3.6.3, the accuracy of the prediction 
was estimated through a repeated cross-validation (repeatedcv) method with tenfold and 
3 repeats. The tuning hyperparameter mtry, approximated as the square root of the 
number of columns of the dataset, was tuned from 10 to 50 and 5,000 or 10,000 number 
of trees (ntree), with the R package Caret. RF was next run using the identified 
parameters providing the highest prediction accuracy during the cross-validation step 
using the R package RandomForest. The mean decrease accuracy was used for the 
variable importance selection (i.e. predictors driving the classification).   
4.3.4.4. Correlation with disease features  
Correlations between the gut microbiota biomarkers identified from the RandomForest 
variable importance and the diagnostic biochemical parameters (TSH and fT4 levels) 
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and the auto-antibodies titres (TRAB, TRAK, TSI), plus the cAMP levels, were assessed 
through the Pearson’s product-moment correlation coefficient (r) in R, using the Corrplot 
and ggpubr packages. The Pearson’s product-moment correlation calculates the best-
fitting line between two variables, while the correlation coefficient describes how far the 
value relies from the calculated line. Compared to Spearman’s rank correlation 
coefficient, Pearson’s deals better with interval values. 
4.3.4.5. Imputed metagenomic pathways and genes with Tax4Fun 
Metagenomic functions such as orthologs and pathways were imputed against the 
KEGG database starting from the filtered and normalized OTU table with Tax4Fun R 
package [360] (see Chapter 3, par. 3.3.6.5). Similarly to the differential abundance 
analysis, a linear regression model was used to calculate differences in metagenomic 
functions amongst disease diagnosis (GD, GO and healthy controls) or the stratified eye-
disease using either pathways or orthologs as dependent variables, and correcting for 
thyroid status (hyper, euthyroid), nation of recruitment, age, gender, smoking habits. 
Mean abundances of significant differentially abundant pathways in each group (whether 
GD,GO and controls or stratified by GO status) were represented in a heatmap using the 
“heatmap” function implemented in the gplot R package, with relative abundances scaled 
to row Z-score and the Euclidean function to compute dissimilarities between both rows 
and columns. Orthologs’ relative abundances were auto-scaled and represented in a 
principal components analysis (PCA), using the PCA function of the FactoMineR 
package. Biplots were produced from the FactoMineR ‘PCA’ object and both variables 
and individuals were plotted using the FactoExtra R package. The top-10 variables with 
the highest Cos2 (i.e. value indicating the quality of the individuals on the map) were 
displayed.  
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Figure 4.1. Design of the INDIGO study and patients/controls enrolled in the study.  
(A) GD patients (newly diagnosed/relapse untreated or within 6-weeks treatments with 
anti-thyroid drugs (ATD)) and GO patients (also euthyroid) enrolled in the study should 
have provided biological samples (blood, tears, nasal swab and faeces) at the time of 
recruitment (baseline), when being euthyroid (after ATD) and after 6 months of ATD 
withdrawal/relapse of the disease, ideally in 18-months’ time. Exclusion criteria included 
ATD for more than 6 weeks and antibiotics intake in the past 3 months, at least. (B) 
Number of patients/controls initially enrolled in the study and those providing at least one 
faecal sample. Samples considered suitable for the microbiome analysis were those 
available at the baseline and from patients with clear diagnosis, non-sight threatening 
GO patients and without other concomitant autoimmune diseases (e.g. MS).  
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4.4. RESULTS 
4.4.1. Sequencing metrics and replicability controls 
Sequencing the V1-V2 regions plus bifidobacteria-specific primer of the bacterial 16S 
rRNA gene produced a total of 13,056,151 reads (after joined R1-R2 paired-end reads). 
After quality filtering, 23,436 sequences were removed, leaving 13,032,715 sequences 
for subsequent analyses (99.8% average retention rate: maximum 99.9%, minimum 
95%). A complete summary is shown in Table 4.4. The closed-reference OTU picking 
step, which retains only those sequences that align to the reference database, almost 
halved the number of sequences, by removing chimeric, short and misaligned 
sequences, thus eliminating most spurious OTUs. 
The initial number of OTUs identified was 10,426; after removing OTUs with less than 
10 counts in at least 2 samples, 5,649 distinct OTUs were left. To check whether 
sequencing depth and sample size were adequate to characterize the composition of the 
gut microbiota, sequence-based and sample-based rarefaction curves were generated 
from the OTU table before pruning (10,426 OTUs). Sequence-based rarefaction curves 
were obtained from the QIIME pipeline [208]; the sample-based rarefaction curve was 
produced with ad hoc R functions (see: 
https://github.com/filippob/sampleBasedRarefaction). The observed number of OTUs 
detected was plotted as a function of the number of sequences (up to 25,000) in each 
sample (Figure 4.2A), and of the number of samples (Figure 4.2B). Both curves tend to 
plateau asymptotically towards a maximum, indicating that sequencing depth and the 
number of samples were adequate to characterize the gut microbiota in the present 
study. Deeper sequencing or the addition of any other samples would likely not increase 
significantly the number of new OTUs potentially discovered. 
Between 2014 and 2017, two MiSeq full runs were performed in order to sequence all 
the samples obtained. Due to possible differences between sequencing batches, some 
samples were replicated to calculate the inter and intra-batch variability. No significant 
differences were observed amongst groups (Figure 4.2C) and between replicated 
samples (Figure 4.2D), suggesting a good replicability of the obtained results.   
For the observational analysis of the microbiome at the time of recruitment, only samples 
matching the above-stated criteria were used (Table 4.4). A good sequencing depth was 
retained (data not shown), as well as the number of sample was sufficient to describe 
the microbiota composition.  
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Figure 4.2. 16S rRNA sequencing depth and intra/inter batches replicability.  
OTU-based (A) and sample-based (B) rarefaction curves tended asymptotically to a 
plateau, meaning that the sequencing depth and the number of samples were sufficient 
to describe all the possible microbial species: increasing the sequencing depth or the 
number of sample would not increase the numbers of newly-discovered OTUs. NMDS 
representing the spatial organisation of (C) intra/inter batches variability (triangle and 
circle shapes) based on Bray-Curtis dissimilarity matrix and (D) between sample pairs 
(colours; both PERMANOVA P>0.05, 999 permutations).  
 
 
 
Table 4.4. Quality filtering of reads through the main steps of the QIIME bioinformatics 
processing in terms of total number of sequence, percent reduction from the previous 
step and average number of reads per sample. 
 
 
 
 
 
 
 
 
QIIME step Total n. reads Reduction N.reads/sample 
multiple_extract_barcodes 26,112,576 - 83,161 
multiple_join_paired_ends 13,056,151 50.00% 41,580 
multiple_split_library 13,032,715 0.18% 41,505 
closed_otupicking 7,953,949 61.03% 25,331 
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4.4.2. Disease prevalence and gut microbiota differences across recruiting 
centres 
GD and GO patients were enrolled in the INDIGO study from eight recruiting centres in 
four European countries (Germany, UK, Italy, Belgium). Median TSH values tended to 
zero in all centres in agreement with the GD diagnosis; in Italy and the UK, some outliers 
presented higher TSH levels, possibly due to the anti-thyroid drug intake. Thyroxine level 
(fT4) was all above the hyperthyroidism threshold, as per GD diagnosis, i.e. >19-22, 
according to each centre reference values. The Italian cohort was less hyperthyroid 
compared to the others. TRAB levels showed a more heterogenous distribution amongst 
centres, with a slightly higher level in Belgium, where the majority of patients were 
untreated and newly-diagnosed GD and a lower values in the UK cohort (Figure 4.3A). 
 
Figure 4.3. Geographical differences in thyroid functions and gut microbiota 
composition.  
(A) Distributions of the thyroid function values in GD and GO patients across centres of 
recruitment. (B) Alpha diversity indices of richness (Chao1 and observed OTUs), 
diversity (Shannon) and equitability of both patients and controls gut microbiota across 
centres. (C) Non-metric dimensional scaling (NMDS) based on the Bray-Curtis 
dissimilarity matrix showed no spatial differences amongst nations. PERMANOVA 
P>0.05 with 999 permutations (D) Phylum distribution across nations of recruitment. 
Differences were observed in terms of Firmicutes and Proteobacteria counts.  
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Geographical variations of the gut microbiota were already reported, mostly associated 
to the type of diet and lifestyle (Chapter 1 par. 1.5.4.1). The analysis of alpha (Figure 
4.3B) and beta diversity (Figure 4.3C) revealed no major differences in terms of overall 
gut microbiota composition (including both patients and healthy controls) across 
geographic origin, apart from differences in the Shannon diversity (P=0.007) and 
equitability (P=0.006) indices between Germany and the UK. At the phylum level (Figure 
4.3D), significant differences amongst nations of provenance were reported in Firmicutes 
(P=0.045), Proteobacteria (P=0.031) and in the SHA-109 (P=0.01). More specifically, 
Firmicutes were enriched in the Belgium cohort compared to both Italy (P=0.024) and 
the UK samples (P=0.038). Proteobacteria, instead, were enriched in UK samples 
compared to Germany (P=0.03). The SHA-109 phylum was not significant after 
Bonferroni correction. At the deepest taxonomic level, 30 genera were differentially 
abundant amongst nations of provenience. Summary of the linear regression model and 
the post-hoc test statistic on genus level is presented in Table 4.5.  
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Table 4.5. Genera differentially abundant amongst nations of recruitment centres.  
 
Genera differentially present Belgium (n=11) 
Germany 
(n=33) 
Italy 
(n=37) 
UK 
(n=65) 
P 
value1 BH
2 
[Eubacterium]_nodatum_group 2.62E-04 8.29E-04 7.23E-04 3.51E-04 0.030 ns 
Acidaminococcus 0.00E+00 2.44E-04 5.74E-04 1.87E-04 0.042 A 
Christensenellaceae_R-7_group 1.67E-02 1.67E-02 1.51E-02 2.14E-02 0.024 B 
Clostridium_sensu_stricto_1 8.77E-03 4.71E-03 5.75E-03 9.94E-03 0.001 B,C 
Coprococcus_2 5.55E-03 2.66E-03 3.33E-03 4.62E-03 0.048 ns 
Corynebacterium_1 1.53E-04 1.66E-05 0.00E+00 1.96E-05 0.010 ns 
Cronobacter 2.99E-05 0.00E+00 1.20E-04 1.79E-05 0.010 ns 
Enterobacter 1.61E-03 1.29E-03 3.44E-03 5.08E-03 0.020 C,D 
Faecalibacterium 9.13E-02 1.04E-01 1.05E-01 7.95E-02 0.002 B,C 
Family_XIII_AD3011_group 3.03E-03 2.20E-03 1.54E-03 2.60E-03 0.047 ns 
Hafnia 1.49E-04 0.00E+00 4.00E-05 1.01E-05 0.015 ns 
Intestinibacter 6.47E-03 3.03E-03 4.23E-03 5.31E-03 0.001 C,E 
Klebsiella 0.00E+00 0.00E+00 3.11E-04 1.34E-04 0.028 ns 
Lachnospiraceae_NC2004_group 1.15E-02 1.17E-02 1.21E-02 9.59E-03 0.007 B 
Lachnospiraceae_NK4A136_group 7.51E-03 1.14E-02 7.13E-03 7.38E-03 0.000 C,D,F 
Lactococcus 1.11E-03 1.14E-03 3.84E-04 5.03E-04 0.010 ns 
Leuconostoc 5.84E-04 1.30E-05 7.01E-05 4.03E-05 0.000 ns 
Pantoea 7.19E-04 5.10E-04 1.08E-03 1.47E-03 0.045 C 
Paraprevotella 0.00E+00 6.98E-05 2.53E-04 3.68E-05 0.026 ns 
Peptoclostridium 1.95E-02 9.65E-03 1.11E-02 2.06E-02 0.001 B,C 
Peptococcus 4.70E-05 2.82E-04 4.19E-04 4.04E-05 0.043 ns 
Romboutsia 2.60E-04 1.01E-04 4.21E-05 3.20E-04 0.010 B 
Roseburia 3.53E-02 3.43E-02 3.60E-02 3.01E-02 0.034 ns 
Ruminiclostridium 4.99E-03 4.56E-03 5.42E-03 3.96E-03 0.047 ns 
Ruminiclostridium_5 9.27E-03 1.31E-02 1.04E-02 1.02E-02 0.003 C,E,F 
Ruminococcaceae_V9D2013_group 3.74E-05 1.03E-04 1.19E-05 2.86E-05 0.044 ns 
Saccharofermentans 8.52E-04 2.08E-04 8.91E-05 3.20E-04 0.001 ns 
Sedimentibacter 6.66E-04 2.46E-04 2.66E-04 7.19E-04 0.019 B,C 
Succiniclasticum 5.86E-04 0.00E+00 1.64E-04 0.00E+00 0.003 ns 
Syntrophomonas 3.69E-04 1.07E-04 1.03E-04 4.21E-04 0.005 B,C 
 
Mean values per nation of recruitment. Standard deviations are included in Appendix 18. 1 
regression model; only P<0.05 are shown. 2 Post-hoc with Bonferroni correction. ns, not 
significant after correction; A: Italy vs Belgium; B: Italy vs UK; C: UK vs Germany; D: UK vs 
Belgium; E: Germany vs Belgium and F: Germany vs Italy.  
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4.4.3. Composition of the gut microbiota in GD/GO patients compared to 
healthy controls  
A comparison amongst disease diagnosis (GD, GO) and GO status (no signs, mild and 
moderate-severe) compared to healthy controls was performed. The overall composition 
of the gut microbiota, in terms of richness, diversity and evenness (alpha diversity) of the 
microbial community was quite similar across disease types (Figure 4.4A) and GO 
groups (Figure 4.4B). None of the comparisons yielded a statistically significant 
difference. Between-sample distances measured as Bray-Curtis dissimilarities based on 
the gut microbiota composition (normalized abundances), did not show any clear 
clustering of the three groups, since controls, GD and GO patients overlapped 
substantially (Figure 4.4C), as it did for GO classes (Figure 4.4D). Beta-diversity 
organisation amongst disease types and eye-disease in each recruiting centre was also 
investigated, showing no significant clustering (Appendix 19). 
Figure 4.4. Diversity indices associated to disease types and severity of the eye 
disease.  
Box-and-whiskers plots of the alpha diversity of richness, diversity and equitability 
amongst disease types (GD, GO) compared to healthy controls (A) and amongst GO 
groups (no sign, mild and moderate to severe GO) compared to controls (B). NMDS 
based on Bray-Curtis dissimilarity matrix amongst disease types (C) and GO groups (D). 
No significant associations were observed in either alpha or beta-diversity in both 
analysis. 
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Thirteen phyla were identified and quantified across samples, in which Firmicutes phylum 
dominated in terms of abundance followed by Bacteroidetes and Actinobacteria. 
Amongst disease types, phyla Actinobacteria, Bacteroidetes and Proteobacteria 
displayed significant differential abundance, with the increase in abundance of 
Actinobacteria in GD (P=0.0017) and GO (P=0.0001) compared to controls, a decrease 
in the abundance of Bacteroidetes in GD (P=0.019) and GO (P=0.019) compared to 
controls (Figure 4.5A). Counts of Actinobacteria phylum was significantly increased in 
GD patients (P=0.004) and GO with mild disease (P=0.0001) compared to controls; while 
Bacteroidetes reduced in GD (P=0.025) and mild GO (P=0.025) compared to controls. 
Interestingly, the Firmicutes:Bacteroidetes (F:B) ratio was significantly increased in 
cases vs. controls (Figure 4.5B), in particular in GD vs. controls (Figure 4.5C). At a 
deeper taxonomic level, 22 genera resulted differentially abundant displayed significant 
differential abundance amongst disease types, resembling what was previously 
observed at the phylum level. Amongst others, Bacteroides genus was significantly 
decreased in GD (P=0.018) and GO (P=0.009) compared to controls, while 
Fusicatenibacter counts were enriched in GD compared to controls (P=0.013), as well 
as in GO compared to controls (P=0.002, Table 4.6). As far as the eye disease is 
concerned, reduction of Bacteroides (P=0.014) and increased Bifidobacterium (P=0.001) 
and Fusicatenibacter counts (P=0.008) were significantly associated to mild-GO, but not 
to moderate-severe GO (Table 4.7). Bifidobacterium spp. moreover decreased in the 
moderate-severe GO compared to the mild-GO (P=0.032). On the other hand, Roseburia 
spp. counts were enriched in moderate-severe GO compared to both controls (P=0.018) 
and GD (P=0.033). Luteimonas was specifically enriched in moderate-severe GO 
compared to all the others, even if not significant, due to a very low abundance (Table 
4.7).  
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Figure 4.5. Phylum distribution and F:B ratio amongst types of disease.  
Differences amongst disease types (A). Only Actinobacteria and Bacteroidetes showed 
significant differences amongst groups, pairwise differences are explained in Table 4.6. 
Bootstrapped distribution of the F:B ratio over 500 datasets resampled according to 
disease type (B), cases vs. controls (C) or by thyroid status (D), as hyper vs. euthyroid.  
 
Figure 4.6. Differentially abundant genera in GD/GO compared to healthy controls.  
Only P<0.05 from the ANOVA model were shown. Pairwise differences are explained in 
Table 4.6. 
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Table 4.6. Pairwise differences between GD (n=59), GO (n=46) and healthy controls 
(n=41). 
 
Differentially abundant taxa group1 group2 P value 
Actinobacteria (phylum) GD control 0.002 
Actinobacteria (phylum) GO control 0.000 
Bacteroidetes (phylum) GD control 0.019 
Bacteroidetes (phylum) GO control 0.019 
[Eubacterium]_nodatum_group GD control 0.033 
[Eubacterium]_nodatum_group GO control 0.018 
[Eubacterium]_oxidoreducens_group GD control 0.032 
[Eubacterium]_oxidoreducens_group GO control 0.029 
Alistipes GD control 0.038 
Alistipes GO control 0.015 
Bacteroides° GD control 0.018 
Bacteroides° GO control 0.009 
Bilophila GO control 0.032 
Collinsella GD control 0.004 
Collinsella GO control 0.004 
Fusicatenibacter° GD control 0.013 
Fusicatenibacter° GO control 0.002 
Lachnospiraceae_FCS020_group GD control 0.049 
Lachnospiraceae_FCS020_group GO control 0.020 
Lachnospiraceae_UCG-004° GO control 0.018 
Lactococcus GO control 0.022 
Oscillospira GD control 0.009 
Oscillospira GO control 0.019 
Ruminococcaceae_NK4A214_group° GO control 0.036 
Ruminococcaceae_UCG-011 GO control 0.023 
 
Pairwise t-test Bonferroni-corrected of ANOVA differentially abundant taxonomies in Figure 
4.6, only P<0.05 are shown. °Bacterial biomarkers confirmed in the RandomForest prediction 
analysis below. 
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Table 4.7. Genus average abundance and test statistics (both ANOVA model and 
pairwise) amongst eye-disease status (no sign, GO mild and GO moderate-severe) 
compared to healthy controls. 
 
Differentially abundant genera 
control GD   GO   GO 
P 
value1 PW
2 no sign 
(n=41)  
no sign 
(n=58)  
mild 
(n=36) 
mod-sev 
(n=11)  
[Eubacterium] nodatum group 0.0009 0.0004 0.0004 0.0003 0.0211 ns 
[Eubacterium] oxidoreducens 
group 0.0072 0.0055 0.0055 0.0046 0.0483 ns 
Alistipes 0.0158 0.0115 0.0104 0.0130 0.0314 B 
Anaeroplasma 0.0002 0.0001 0.0000 0.0005 0.0110 ns 
Bacteroides° 0.0781 0.0562 0.0529 0.0626 0.0151 A,B 
Bifidobacterium° 0.0088 0.0117 0.0135 0.0088 0.0193 B 
Clostridium sensu stricto 1 0.0062 0.0092 0.0080 0.0030 0.0231 C,D,E 
Collinsella 0.0079 0.0127 0.0122 0.0100 0.0204 A,B 
Fusicatenibacter° 0.0168 0.0214 0.0234 0.0213 0.0096 B 
Intestinibacter° 0.0036 0.0050 0.0056 0.0030 0.0115 B 
Lachnospiraceae FCS020 group 0.0021 0.0030 0.0035 0.0025 0.0353 B 
Lactococcus° 0.0011 0.0005 0.0004 0.0004 0.0092 ns 
Luteimonas 0.0000 0.0000 0.0000 0.0003 0.0092 ns 
Oscillospira 0.0008 0.0003 0.0004 0.0004 0.0031 A 
Peptoclostridium 0.0130 0.0177 0.0182 0.0062 0.0451 D,E,F 
Rikenellaceae RC9 gut group° 0.0005 0.0005 0.0022 0.0001 0.0156 D 
Roseburia 0.0310 0.0320 0.0339 0.0418 0.0228 C,E 
Ruminococcaceae NK4A214 
group 0.0061 0.0048 0.0042 0.0022 0.0247 C,E 
Ruminococcaceae UCG-011 0.0009 0.0008 0.0005 0.0000 0.0158 C,D,E 
 
In bold, genera with the highest average abundance across groups. Standard deviations are 
included in Appendix 20. 1P values derived from the ANOVA model, only differentially 
abundant genera P<0.05 are shown. 2Pairwise differences from the pairwise T-test 
Bonferroni-corrected: ns, not significant after correction; A, GD vs. controls; B, GO mild vs. 
controls; C, moderate-severe GO vs. GD; D, moderate-severe vs. GO mild; E, moderate-
severe vs. controls and F, GO mild vs. GD. °Bacterial biomarkers confirmed in the 
RandomForest prediction analysis below. 
 
4.4.4. Prediction of diagnosis based on gut microbiota composition  
Random Forests (RF) classification analysis was used to predict the type of disease 
(whether GD, GO or healthy controls) and the stratification in eye disease (no sign, mild 
and moderate-severe GO compared to healthy controls), based on the gut microbiota 
composition at genus level, using 10,000 trees. Both models took into account the thyroid 
status, nations of provenance, age, gender and smoking habits within the predicting 
variables. Samples with missing values for one of the above variables were excluded 
from the analysis. Prediction of the diagnosis (or disease types) returned an overall out-
of-bag (OOB) error rate of 40.14%, which accounted for 59.86% accuracy of the trained 
model. Within the healthy controls class, all but one sample (36/37) were correctly 
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predicted as controls (2.7% per-class OOB error rate); 42 out of 59 samples were 
correctly predicted as GD patients with 17 remaining GD samples predicted to as GO 
(28% per-class OOB error rate), and the majority of GO samples were erroneously 
predicted as GD (39/46) with only 7 samples correctly assigned to GO (84% per-class 
OOB, Figure 4.7A). When separating the GO class into mild and moderate-severe GO 
diagnosis, the accuracy of the model increased to 61.97% (overall OOB 38.03%). Forty-
nine out of 58 samples were predicted as GD, with one sample as healthy control and 8 
as GO mild (15.5% per-class OOB); 33/36 GO mild patients were predicted to as GD 
and just 3 to as GO mild (91.6% per-class OOB) and finally all of the eleven moderate-
severe patients were predicted as GD with no signs of eye disease (100% per-class 
error-rate; Figure 4.7D). Variable importance features were obtained from the top-
predicting variables, based on mean decrease accuracy parameter (Figure 4.7B and D). 
To note, Bacteroides spp. is present in both classification models and constitutes the first 
top-bacterial biomarker when predicting diagnosis with the eye disease stratification 
(Figure 4.7D). Bonferroni-corrected, pairwise differences amongst disease types and 
eye disease involvement are reported in Table 4.6 and 4.7. 
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Figure 4.7. Random Forests classification accuracy and variable importance in 
predicting the disease diagnosis based on the gut microbiota composition at 
genus level.  
(A) Confusion matrix with the per-class classification for disease type (GD, GO and 
healthy controls). Each box represents the true treatment while the bar chart represents 
the number of samples being assigned to a treatment according to the model used. (B) 
Top-10 variable importance for disease type classification according to the Mean 
Decrease Accuracy. The model included the thyroid status, nation of provenance, age, 
gender and smoking habits as predicting variables, of which thyroid status and nation of 
provenance were identified in the top-10 most important variables. (C) Confusion matrix 
with the per-class classification of the eye disease (no signs, mild, moderate-severe 
compared to healthy controls) and (D) Top-10 variable importance for eye-disease 
classification according to the Mean Decrease Accuracy. 
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4.4.5. Association of the gut microbiota with thyroid status 
The RF model revealed a strong effect of the thyroid status (i.e. being hyperthyroid or 
euthyroid/control euthyroid) in predicting the disease types or the stratification of the eye 
disease based on the genus-level gut microbiota composition. Here I investigated the 
gut microbiota composition between the thyroid status, regardless of the initial diagnosis 
(GD or GO), and compared with that of the euthyroid controls. Only one patients was 
hypothyroid due to the ATD therapy and was excluded from the statistical analysis. 
Similarly for the disease type and GO severity, no significant differences were observed 
in the alpha diversity indices. The NMDS based on Bray-Curtis dissimilarity matrix 
showed a significant separation amongst groups overall (P=0.02, based on 999 
permutations; Figure 4.8A), but not pairwise, even if a more clear separation was 
observed between hyperthyroid and euthyroid patients (Figure 4.8B), rather than 
euthyroid patients compared to euthyroid healthy controls (Figure 4.8C).  
 
Figure 4.8. NMDS based on thyroid status.  
(A) overall amongst thyroid status groups and (B and C) pairwise. P=0.02 overall, 
PERMANOVA based on 999 permutations. No significant differences were observed in 
pairwise comparisons after BH corrections, even if more separated groups were 
observed in (B) between hyper and euthyroid patients.  
 
Firmicutes:Bacteroidetes ratio was higher in hyperthyroid compared to euthyroid patients 
(Figure 4.5E). At the genus level, 27 taxa were significantly different among groups (i.e. 
euthyroid-control, euthyroid and hyperthyroid). Bacteroides counts were significantly 
reduced in hyperthyroid patients compared to euthyroid controls (P=0.0003), while there 
were no significant differences between the two euthyroid groups, although the euthyroid 
patients showed a lower Bacteroides counts. On the other hand, Fusicatenibacter genus 
was significantly increased in hyperthyroid patients compared to euthyroid-controls 
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(P=0.0002), while higher counts were found in euthyroid patients compared to controls, 
although not significant (Table 4.8).  
 
Table 4.8. Genus mean abundance and test statistics (both ANOVA model and pairwise) 
amongst thyroid status (hyperthyroid, euthyroid, hypothyroid) compared to euthyroid-
healthy controls, regardless of the type of disease. 
 
Differentially abundant genera EU-HC  (n=41) 
Hyper 
(n=90) 
EU 
(n=14) 
Hypo 
(n=1) 
P 
value1 PW
2 
[Eubacterium] hallii group 0.0336 0.0346 0.0224 0.0183 0.0333 A,B 
[Eubacterium] nodatum group 0.0009 0.0004 0.0002 0.0000 0.0121 A,B,C 
[Eubacterium]oxidoreducens group 0.0072 0.0056 0.0042 0.0032 0.0199 A,C 
Alistipes 0.0158 0.0111 0.0116 0.0231 0.0169 C 
Allisonella 0.0001 0.0000 0.0001 0.0000 0.0206 ns 
Ambiguous taxa 0.0003 0.0002 0.0004 0.0009 0.0273 ns 
Anaerostipes 0.0257 0.0285 0.0189 0.0091 0.0404 B 
Bacteroides 0.0781 0.0538 0.0624 0.1382 0.0014 C 
Bilophila 0.0010 0.0006 0.0006 0.0015 0.0356 C 
Blautia 0.0846 0.0998 0.0895 0.0358 0.0208 C 
Collinsella 0.0079 0.0127 0.0098 0.0026 0.0056 C 
Comamonas 0.0000 0.0000 0.0003 0.0000 0.0225 ns 
Filifactor 0.0000 0.0000 0.0000 0.0006 0.0000 ns 
Fusicatenibacter 0.0168 0.0225 0.0196 0.0136 0.0062 C 
Gordonibacter 0.0003 0.0005 0.0001 0.0006 0.0472 B,C 
Lachnospira 0.0019 0.0016 0.0017 0.0069 0.0352 ns 
Lachnospiraceae_FCS020_group 0.0021 0.0031 0.0033 0.0006 0.0497 ns 
Lachnospiraceae_UCG-004 0.0236 0.0169 0.0195 0.0400 0.0102 C 
Lachnospiraceae_UCG-006 0.0004 0.0003 0.0007 0.0000 0.0316 ns 
Lactococcus 0.0011 0.0005 0.0005 0.0000 0.0103 C 
Luteimonas 0.0000 0.0000 0.0002 0.0000 0.0336 ns 
Oscillospira 0.0008 0.0003 0.0006 0.0000 0.0015 C 
Prevotella_6 0.0000 0.0000 0.0000 0.0006 0.0000 ns 
Ruminiclostridium_5 0.0123 0.0103 0.0101 0.0056 0.0333 ns 
Ruminococcaceae_UCG-003 0.0032 0.0023 0.0037 0.0076 0.0080 ns 
Sutterella 0.0029 0.0021 0.0031 0.0165 0.0000 ns 
Thalassospira 0.0005 0.0002 0.0002 0.0029 0.0000 ns 
 
In bold, most abundant average across groups. Standard deviations are included in Appendix 
21. EU-HC, euthyroid-healthy controls; EU, euthyroid 1P values derived from the linear 
regression model, only differentially abundant genera P<0.05 are shown. 2Post hoc test 
Bonferroni-corrected, not taking into account the hypo status due to just one sample: ns, not 
significant after correction; A, EU-HC vs. EU; B, hyper vs. EU; C, hyper vs. EU-HC.  
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4.4.6. Correlation of the gut microbiota with thyroid function  
Correlation between the gut microbiota features identified from the variable importance 
analysis represented in Fig. 4.7B and the levels of TSH and free-T4 (fT4) quantified in 
the blood was assessed using the Pearson’s product-moment correlation coefficient (r). 
Out of the 10 genera selected, only counts of the genus Bacteroides showed a significant 
correlation with both TSH and fT4 levels in the GD group. Particularly, a positive 
correlation was reported with TSH, although the majority of the GD patients – as for 
definition of GD - had a low or undetectable TSH levels (r=0.51, P=0.0037; Figure 4.9A). 
On the other hand, Bacteroides spp. showed a weak negative correlation with fT4 levels 
(r= -0.37, P=0.046; Figure 4.9B). No significant correlation was observed in the GO 
patients group. In euthyroid patients, Bacteroides counts correlated negatively with TSH 
levels, although not significant (Figure 4.9C). Consistently, Bacteroides spp. showed a 
weak negative correlation with fT4 in hyperthyroid patients (r= -0.36, P=0.012), while 
showed a positive correlation in euthyroid patients, although not reaching the significant 
threshold (Figure 4.9D).  
Figure 4.9. Pearson’s correlation between Bacteroides counts and thyroid 
functions in GD patients hyperthyroid/euthyroid.  
Weak-positive correlation between Bacteroides counts and (A) TSH, Thyroid-Stimulating 
Hormone (U/mL) and weak-negative correlation between Bacteroides counts and (B) 
free Thyroxine levels, FT4 (pmol/L) in GD patients. No significant correlations were 
observed in GO patients. Bacteroides correlation in hyperthyroid and euthyroid patients 
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(with GD and GO together) with TSH (C) and FT4 (D) levels. r, Pearson’s product-
moment correlation coefficient. Hyper, hyperthyroid patients. Eu, euthyroid patients. 
 
4.4.7. Correlation of the gut microbiota with auto-antibodies titres  
Correlation with the auto-antibodies titres (TRAB) and the GD/GO gut microbiota 
biomarkers was also assessed (Figure 4.10). In the GD cohort, counts of the Firmicutes 
genus Turicibacter showed a weak negative correlation with both TRAK/TRAB and 
cAMP levels, while two genera of the Ruminococcaceae (UCG-001 and NK4A214, 
respectively) showed a weak negative correlation with TRAK levels. GO patients showed 
the majority of positive correlations, potentially sustained by the fact that GO patients 
tend to have a higher TRAB titres. Turicibacter and Ruminococcaceae UCG-001 genera 
positively correlated with TRAK and TRAK and cAMP, respectively. Genera 
Rikenellaceae RC9 gut group and Eubacterium coprostanoligenes were both positively 
correlated with TRAB levels while Bacteroides spp. showed a weak negative correlation 
with the TRAB levels.  
Figure 4.10. Correlation with auto-antibodies features quantified in GD and GO 
patients.  
TSI, thyroid-stimulating immunoglobulin (IU/L). TRAK, thyrotropin receptor antibodies 
using the TRAK-assay (IU/L). TRAB, thyrotropin receptor antibodies (IU/L) measured in 
and cAMP (pmol/mL). Only correlation with P<0.05 are shown and the strength of the 
Pearson’s correlation coefficient (r) is represented by the change of colour from red 
(positive) to blue (negative correlation).  
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4.4.8. Enterotypes of the gut microbiota and their association to GD/GO 
As previously introduced, Arumugam and colleagues identified three enterotypes, or 
preferred composition of the gut microbiota, such as those dominated by Bacteroides 
(enterotype 1), Prevotella (enterotype 2) or Firmicutes-prevalent (enterotype 3) [225]. 
The classification algorithm based on HMP and MetaHIT training datasets assigned 
11/157 samples to enterotype 1 (7%), 28/157 samples to enterotype 2 (17.83%) and the 
majority of samples (118/157; 75.15%) to enterotype 3. There was a significant 
separation of the three enterotypes overall (Figure 4.11A), which was consistent also 
across nations, apart from Belgium which had the lowest number of recruited patients 
(Figure 4.11B).  
Redundancy analysis (RDA) showed an association of GD and hyperthyroid patients to 
the enterotype 3 (Firmicutes-prevalent), while GO lay in-between the enterotype 2 
(Prevotella-prevalent) and enterotype 3 (Figure 4.11C). Mild-GO was associated in-
between the enterotype 2, while the moderate-severe GO pointed towards a mixed group 
between enterotype 3 and enterotype 1 (Bacteroides-based) (Figure 4.11D). 
4.4.9. Gender-differences of the gut microbiota in GD/GO patients 
The model used in the previous analyses corrected for gender biases, since sex-related 
hormones may modulate the gut microbiota composition [432]. However, GD is more 
prevalent in females (92:14 in our cohort) and for that reason, differences in the gut 
microbiota between gender were also investigated in GD and GO groups, respectively. 
Twenty-two genera were differentially abundant between females and males in the GD 
group, while seventeen were differentially abundant in the GO group (Table 4.9). In GD, 
males’ microbiota was significantly enriched in Alloprevotella, Butyrivibrio, Clostridium 
sensu-stricto 1, Enterococcus and Prevotella 2, amongst other genera, while females 
were enriched in Eggerthella spp. counts (P=0.036). GO microbiota in male patients, on 
the other hand, showed enrichment of Acinetobacter, Comamonas spp. and a clade of 
Prevotellae (1,2,6 and 9), while females GO patients showed increased 
Lachnospiraceae UCG-008 counts. Interestingly, none of these differentially abundant 
genera showed an association with either disease type or GO status, a part from 
Rikenellaceae RC9 gut-group, which was identified in the RF variable importance (Figure 
4.7B), but not from the differential abundance linear regression model.  
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Figure 4.11. Enterotypes of the gut microbiota associated to disease, thyroid 
status and eye disease.  
(A) NMDS based on the Bray-Curtis distribution of the three identified enterotypes: 
ET_B, enterotype 1 (Bacteroides-prevalent); ET_P, enterotype 2 (Prevotella- prevalent) 
and ET_F, enterotype 3 (Firmicutes-prevalent). (B) Redundancy analysis (RDA) was 
based on Bray-Curtis distances of the three enterotypes and superimposed arrows 
representing (C) both disease types (GD,GO and healthy controls) and thyroid status 
(hyper, eu, eu-control) or (D) signs of eye disease (GD no sign, GO mild and GO 
moderate-severe). 
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Table 4.9. Gender-related gut microbiota differences in GD (52 females and 7 males) 
and GO (40 females and 6 males) patients. 
  
1 Post-hoc using Bonferroni corrected, only P<0.05 are shown 
Genera differentially 
present in GD 
Female  
(mean) 
Female 
(st dev) 
Male  
(mean) 
Male 
(st dev) 
P 
value1 
Alloprevotella 1.48E-05 0.0001 0.0033469 0.0059 0.000 
Butyrivibrio 0.00066173 0.0008 0.00184197 0.0018 0.006 
Clostridium sensu 
stricto1 0.00833238 0.0078 0.01481178 0.0116 0.049 
Desulfobulbus 2.28E-05 0.0002 0.00022419 0.0004 0.014 
Eggerthella 0.00071418 0.0009 0 0.0051 0.036 
Enterococcus 0.00043935 0.0001 0.00271936 0.0002 0.003 
Fastidiosipila 1.71E-05 0.0003 0.00013241 0.0006 0.013 
Halocella 8.16E-05 0.0003 0.0003992 0.0012 0.011 
Lysinibacillus 5.08E-05 0.0142 0.00046353 0.0286 0.038 
Peptoclostridium 0.01523107 0.0001 0.03427896 0.0020 0.002 
Planomicrobium 2.18E-05 0.0011 0.0007482 0.0153 0.008 
Prevotella_2 0.00064905 0.0006 0.00959271 0.0062 0.000 
Rikenellaceae RC9 gut 
group 0.00026849 0.0004 0.00249368 0.0008 0.014 
Romboutsia 0.00019373 0.0010 0.00073504 0.0025 0.004 
Rummeliibacillus 3.33E-05 0.0009 0.00026846 0.0016 0.037 
Sarcina 0.00110107 0.0000 0.00231618 0.0009 0.020 
Sedimentibacter 0.0005297 0.0005 0.00144825 0.0009 0.018 
Sporosarcina 0 0.0002 0.00045386 0.0004 0.000 
Syntrophomonas 0.00029529 0.0011 0.0009008 0.0008 0.010 
Terrisporobacter 4.32E-05 0.0000 0.0002342 0.0003 0.023 
Victivallis 0 0.0001 0.00010796 0.0013 0.007 
Weissella 8.09E-06 0.0001 0.00050067 0.0059 0.007 
Genera differentially 
present in GO 
Female  
(mean) 
Female 
(st dev) 
Male  
(mean) 
Male 
(st dev) 
P 
value1 
[Eubacterium] 
ventriosum group 0.00364713 0.0029 0.00122805 0.0025 0.013 
Acinetobacter 0.00019003 0.0001 0.00080923 0.0059 0.047 
Alloprevotella 0.00021787 0.0002 0.00236527 0.0003 0.000 
Anaerofilum 1.16E-05 0.0000 0.0002121 0.0000 0.002 
Comamonas 0 0.0060 0.00066443 0.0066 0.010 
Lachnospiraceae UCG-
008 0.02705175 0.0019 0.02106659 0.0000 0.032 
Megamonas 0.0003968 0.0007 0.00169057 0.0000 0.027 
Oribacterium 8.84E-05 0.0006 0.00088919 0.0000 0.013 
Pectobacterium 6.43E-05 0.0011 0.00067172 0.0153 0.048 
Prevotella_1 0.00013616 0.0001 0.00070239 0.0000 0.010 
Prevotella_2 0.00078099 0.0191 0.00842799 0.0176 0.000 
Prevotella_6 0 0.0009 6.46E-05 0.0016 0.009 
Prevotella_9 0.0104742 0.0035 0.03525487 0.0024 0.010 
Ruminiclostridium_1 4.39E-05 0.0005 0.00020848 0.0009 0.034 
Sedimentibacter 0.00033413 0.0000 0.00118022 0.0000 0.012 
Syntrophomonas 0.00014302 0.0029 0.00068441 0.0025 0.006 
vadinBC27_wastewater-
sludge_group 0 0.0001 0.00023663 0.0059 0.009 
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4.4.10. Association of the smoking habits with the gut microbiota in 
GD/GO patients compared to healthy controls  
Smoking can alter the composition of the gut microbiota [441], therefore the previous 
model corrected for the smoking habits of both patients and healthy controls. However, 
cigarette smoking has long been considered a strong risk factor for GO, whose 
implications in the disease were explained in the introduction chapter (Chapter 1, par. 
1.3.2.3). Therefore, association between smoking habits and gut microbiota composition 
was investigated in GD, GO and healthy controls individually. Amongst current, ex and 
non-smokers, 17 genera were differentially abundant in the healthy control group, 7 in 
GD and 21 in GO (Figure 4.12). None of the smoking-associated genera in GD patients 
showed similarities with those GD-associated genera, previously identified (Table 4.6). 
Adlercreutzia, Faecalitealea, Gordonibacter and Prevotella 7 genera showed an 
increased abundance in the ex-smoker group, with only the Gordonibacter spp. 
significantly different between ex and never smokers after correction (P=0.017). In 
contrast, in GO patients smoking habit associated genera Bacteroides and 
Intestinibacter were previously associated to GO status. Bacteroides spp., whose counts 
significantly decreased in GD and mild-GO compared to healthy controls (Table 4.7), 
showed a significant decrease in current smokers (mean 0.045) and ex-smokers (mean 
0.042), compared to never smokers (mean 0.067) in GO patients (P=0.024), although 
not significant after correction. Amongst other differentially abundant genera not 
previously associated to GO status, Clostriudium sensu stricto 1 spp. was increased in 
GO ex-smokers compared to GO never smokers (P=0.035), while Faecalibacterium spp. 
was decreased in ex-smokers compared to the never smokers (P=0.043) and 
Peptoclostridium spp. was increased in GO ex-smokers compared to both current 
(P=0.023) and never GO-smokers (P=0.014). None of the differentially abundant genera 
amongst smoking habits in GD and GO showed similarity with those reported in the 
control groups.  
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Figure 4.12 Smoking-habits-associated taxonomies in GD, GO or healthy controls.  
Only significant (P<0.05) genera were represented and the genus mean abundance in 
each group (current/ex/never smokers) was scaled according to the row Z-score in (A) 
healthy controls (7/2/28), (B) GD (10/9/40) and (C) GO patients (15/11/20). Blue to red 
colours indicate whether the genus is more or less abundant.   
 
4.4.11. Anti-thyroid drug treatment effects on the gut microbiota  
Medications have been shown to impact the gut microbiota composition [264]. Not only 
antibiotics, whose effects are directly targeted against bacteria, but also anti-human 
treatments, including the anti-thyroid drugs (ATD; i.e. carbimazole (CBZ), methimazole 
(MTZ), propylthiouracil (PTU) as described in Chapter 1 par. 1.1.2. The INDIGO study 
allowed the recruitment of patients within 6 weeks of ATD. Differences in the microbiota 
composition between untreated vs. treated GD (24 vs. 41, 8 not assessed) or GO (9 vs. 
33, 19 not assessed) patients were observed. Only samples from patients whose 
treatment was clearly stated in the database have been included in the analysis. 
Alpha diversity indices did not show differences in the composition of the gut microbiota 
between treated and untreated patients, either GD or GO (Figure 4.13A). Differences in 
the equitability index amongst treatments in GO patients were obtained from the mixed-
effect linear model with nation of recruitment as a random effects (P=0.046, Figure 
4.13B), with a decreased equitability in the untreated group. No clear separation between 
untreated and treated groups was showed in the NMDS based on the Bray-Curtis 
dissimilarity matrix (Figure 4.13C and D).  
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Within GD patients (Table 4.10), genera such as the Eubacterium (nodatum group), 
Adlercreutzia, Akkermansia, and Candidatus soleaferrea were enriched in the untreated 
group compared to both CBZ and MTZ. Other genera were differentially abundant either 
between untreated and CBZ or untreated and MTZ. Only Gordonibacter spp. was 
differentially abundant between CBZ and MTZ, being enriched in the CBZ-treated group. 
Within GO patients, 12 genera were differentially abundant amongst treatments 
(including the PTU) and without ATD (Table 4.11).  
Differences in the taxonomic composition of clearly untreated patients (n=24 GD, n=11 
GO) compared to healthy controls may give insights in the role of the gut microbiota in 
the onset of the disease. Although the number of patients was reduced from the 
observational cohort, especially the GO cases, five genera differentially abundant 
between GD/GO and healthy controls were identified (Table 4.12). Of those, 
Akkermansia and Anaerotruncus spp. were increased in the GD group compared to GO 
also after correction.  
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Figure 4.13. Diversity indices in untreated and ATD-treated patients.  
Alpha diversity indices: equit, equitability; obOTUS, observed OTUs and sh, Shannon 
index in (A) treated vs. untreated GD or GO patients and (B) according to the type of 
treatment. Beta-diversity NMDS based on the Bray-Curtis dissimilarity matrix in (C) 
treated vs. untreated GD or GO patients and (D) according to the type of treatment. 
Levothyroxine treatment was excluded from the analysis, since accounting only 2 GO 
patients.  
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Table 4.10 Genera differentially abundant between untreated and ATD-treated GD 
patients. 
 
1Mean values of each group. Standard deviations are included in Appendix 22. 2P values from 
regression model, only P<0.05 are included. §Post-hoc Bonferroni-corrected P values. ns, not 
significant. A: no ATD vs. CBZ; B: no ATD vs. MTZ; C: CBZ vs. MTZ.  
 
 
Table 4.11. Genera differentially abundant between untreated and ATD-treated GO 
patients. 
Genera differentially abundant CBZ
1 
(n=8) 
Levothyroxine1 
(n=2) 
MTZ1 
(n=17) 
no 
ATD1 
(n=11) 
P value2 
Actinomyces 0.0004 0.0010 0.0005 0.0030 0.009 
Capnocytophaga 0.0000 0.0007 0.0001 0.0000 0.003 
Clostridium_sensu_stricto_1 0.0073 0.0073 0.0045 0.0136 0.020 
Erysipelotrichaceae_UCG-003 0.0022 0.0043 0.0041 0.0099 0.012 
Erysipelotrichaceae_UCG-007 0.0000 0.0004 0.0000 0.0004 0.004 
Granulicatella 0.0004 0.0012 0.0004 0.0017 0.046 
Lachnospiraceae_NC2004_group 0.0097 0.0185 0.0129 0.0095 0.036 
Peptococcus 0.0001 0.0030 0.0000 0.0001 0.000 
Prevotella_7 0.0001 0.0023 0.0000 0.0000 0.000 
Ruminococcaceae_V9D2013_group 0.0000 0.0000 0.0000 0.0002 0.039 
Rummeliibacillus 0.0000 0.0004 0.0000 0.0000 0.000 
Shuttleworthia 0.0000 0.0000 0.0002 0.0006 0.025 
1Mean values of each group. Standard deviations are included in Appendix 23. 2P values from 
regression model, only P<0.05 are included.  
 
 
Genera differentially abundant Carbimazole
1 
(n=23) 
Metimazole1 
(n=16) 
no ATD1 
(n=24) P value
2 PW§ 
[Eubacterium]_nodatum_group 0.00015 0.00027 0.00097 0.003 A,B 
Acetanaerobacterium 0.00000 0.00000 0.00009 0.050 ns 
Adlercreutzia 0.00054 0.00056 0.00112 0.012 A,B 
Akkermansia 0.00062 0.00078 0.00159 0.002 A,B 
Candidatus_Soleaferrea 0.00006 0.00010 0.00059 0.000 A,B 
Christensenellaceae_R-7_group 0.02190 0.01433 0.02601 0.037 B 
Coprobacillus 0.00035 0.00011 0.00075 0.043 B 
Eggerthella 0.00037 0.00042 0.00098 0.046 ns 
Enterococcus 0.00000 0.00068 0.00174 0.022 A 
Faecalibacterium 0.08566 0.10393 0.06710 0.017 B 
Family_XIII_AD3011_group 0.00253 0.00172 0.00382 0.031 ns 
Gordonibacter 0.00063 0.00011 0.00097 0.010 B,C 
Lachnospiraceae_NC2004_group 0.01072 0.01157 0.00826 0.038 ns 
Lachnospiraceae_UCG-005 0.00619 0.00768 0.00470 0.029 B 
Lysinibacillus 0.00000 0.00000 0.00035 0.023 ns 
Paraprevotella 0.00000 0.00037 0.00000 0.005 ns 
Quinella 0.00015 0.00000 0.00004 0.045 ns 
Rhizobium 0.00000 0.00005 0.00031 0.016 ns 
Romboutsia 0.00048 0.00006 0.00031 0.038 ns 
Roseburia 0.03205 0.03909 0.02567 0.006 B 
Shuttleworthia 0.00009 0.00006 0.00042 0.008 ns 
  
 
 
175  
 
Table 4.12. Genera differentially abundant in untreated patients (n=24 GD, n=11 GO) 
compared to healthy controls (n=41). 
 
Genera control (mean) 
control 
(std) 
GD 
(mean) 
GD 
(std) 
GO 
(mean) 
GO 
(std) 
P 
value1 PW
2 
Akkermansia 0.0003 0.0004 0.0016 0.0009 0.0003 0.0004 0.001 GD-GO 
Anaerosporobacter 0.0005 0.0007 0.0000 0.0000 0.0000 0.0000 0.001 ns 
Anaerotruncus 0.0007 0.0010 0.0022 0.0016 0.0006 0.0009 0.046 GD-GO 
Lachnospiraceae 
AC2044_group 0.0012 0.0003 0.0003 0.0004 0.0001 0.0002 0.002 ns 
Mitsuokella 0.0005 0.0007 0.0000 0.0000 0.0002 0.0006 0.039 ns 
 
1P values generated from the regression model, only genera with P<0.05 are shown. 2Post-
hoc Bonferroni correction. ns, not significant after correction. 
  
4.4.12. Imputed metagenomic functions  
Metagenomic functions were predicted from the filtered and normalized OTU table using 
the Tax4Fun R script using the KEGG database accounting for 6,480 KEGG orthologs 
(KOs) and 274 pathways. Amongst GD/GO and healthy controls, 51 pathways showed 
a differential abundance (Figure 4.14A). The majority of those pathways were enriched 
in the control group, while six pathways were particularly enriched in the GD group (i.e. 
‘Drug metabolism-cytochrome P450’, ‘chemical carcinogenesis, prion disease’, 
‘complement and coagulation cascades’, ‘indole alkaloid biosynthesis’ and ‘clavulanic 
acid biosynthesis’), only one in the GO (‘photosynthesis’) and seven pathways were 
shared GD and GO compared to controls. After correction, ‘ABC transporters’ pathway 
was increased between GD and controls (P=0.01, Data not showed), as well as the 
‘bacterial invasion of epithelial cells’ (P=0.025), the ‘phosphotransferase system (PTS)’ 
(P=0.18).  
Dissecting for the ocular disease, 39 pathways showed a differential abundance (Figure 
4.14B). According to the Euclidean distances, moderate-severe GO patients predicted 
pathways clustered more closely to that of healthy controls, respective to GD patient’s 
microbiome and mild GO patients. Also from this analysis, the majority of the pathways 
differentially abundant were enriched in the control group. In contrast, mild GO group did 
shared some of the pathways increased in the GD group (no sign of ocular disease). 
Moderate-severe GO patients, instead, showed enrichment of some pathways, including 
the ‘N-glycan biosynthesis’ pathway, the ‘glycosaminoglycan biosynthesis-chondroitin 
sulphate’ pathway, although not retaining the significant threshold after correction (Data 
not showed).  
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Figure 4.14. Imputed KEGG metagenomic pathways.  
(A) Differentially abundant imputed metagenomic pathways amongst GD/GO and 
healthy controls or (B) amongst GO status. Only pathways with P value <0.05 from the 
regression model are shown. Averaged abundances of each pathway in each group were 
scaled according to the row Z-score, according to the R function ‘heatmap”. 
Dendrograms are based on Euclidean distances.  
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Out of the around 6,500 KEGG’s orthologs or molecular functions imputed, 1,154 were 
differentially abundant between GD, GO and healthy controls (Data not showed). The 
principal component analysis (PCA) did not show a clear separation of the groups based 
on the KOs, with 31.3% and 18.4% variances explained by the first two components, 
respectively (Figure 4.15A). Top-10 variables were identified in the biplot and amongst 
them, only three KOs showed significant changes between GD and control: chorismate 
mutase (P=0.049), hypothetical protein (P=0.029) and osmotically inducible protein 
OsmC (P=0.036).  
 
Figure 4.15. Principal component analysis and biplot of the KEGG orthologs.  
(A) PCA plot showing the coordinates of individuals based on the GD/GO and control 
groups. Ellipses represents the concentration of the points with 0.95 confidence. (B) 
Biplot showing the top-10 variables with highest Cos2 or those with the highest quality 
of representation of individuals on the PCA.  
 
4.4.13. GD to GO transition  
Until the completion of the study, two patients enrolled as GD patients later developed 
GO at Cardiff University Hospital (UK), referred here to as “GD to GO transition”. In 
particular, patient 1004, included in the study at her first visit in 03/10/2014 as untreated 
and first diagnosis of GD, developed mild GO (CAS2) as euthyroid after 2 months 
(12/12/2014). Patient 1013 has been enrolled as a relapsed GD in 31/10/2014 and 
developed GO (CAS3) as euthyroid after about 3 months (30/01/2015).  
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As observed in the paragraphs before, the Bacteroides spp. counts dramatically 
decreased during the GD to GO transition (Figure 4.16 A and B, left) and slightly 
increased in a third timepoint, although not reaching the same count number as in the 
GD status (Figure 4.16, right graph). Also, some other genera previously associated to 
GO status (see Table and Figure 4.7) were observed in the within-patient GD-to-GO 
transition, e.g. increased Bifidobacterium spp, Lachnospiraceae spp. and Clostridiaceae 
counts. Increased Roseburia spp., previously associated to a moderate-severe GO, was 
significantly increased in patients 1013, whose GO was considered to as more severe. 
 
 
Figure 4.16. Analysis of the gut microbiota of patients undergoing “GD to GO 
transition”.  
Extended bar-plots generated with STAMP testing differences at the genus level 
between GD and GO, individually. (A) Differences at genus level between 1004-BL (GD) 
and 1004-EU (GO). (B) Bar-plots representing difference at genus level of patient 1013-
BL (GD) to 1013-EU (GO) (left) and from the 1013-EU (GO) to 1013-EFU (stable GO). 
Two samples-test was performed in STAMP using the G-test with Yates’ correction and 
Fisher’s with 95% confidence interval. Only genera with P value<0.05 were shown. 
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4.5. DISCUSSION 
The present chapter aimed at comparing the gut microbiome of mostly European GD 
and GO patients with that of healthy controls in a cross-sectional study, with specific 
regards to differences in the thyroid status (i.e. hyperthyroid vs. euthyroid) and in the 
eye-disease severity (i.e. mild and moderate-severe, as assessed through EUGOGO 
guidelines [54]). In the framework of the EU-funded INDIGO project, patients and 
matched healthy controls were enrolled from four European countries (Italy, Germany, 
UK and Belgium) between 2014 and 2016. Faecal DNAs were sequenced in two different 
runs (one in late 2014 and the second one in August 2017), with some samples from the 
first sequencing batch being replicated in the second one. We are confident that through 
the same sequencing processing and a closed OTU-picking approach we did eliminated 
possible sequencing-batch effects, as there were no differences between inter and intra-
batch replicates. We are also fully aware that the gut microbiota varies across countries. 
I did not observe differences in the composition of the gut microbiota in terms of alpha 
and beta-diversity indices across countries, while some differences were observed at the 
taxonomic level. The prevalence of the Firmicutes-prevalent and the Bacteroides-
prevalent enterotypes, also, suggested a microbiota composition typical of the 
Americans and Western European countries, consuming a Western diet [442]. 
4.5.1. Reduction of Bacteroides spp. as a bacterial biomarker for GD/GO 
Similarly to what was observed in the animal model described in the previous chapters, 
GD and GO patients showed a decrease of the Bacteroidetes phylum and of the 
Bacteroides genus compared to that of the healthy controls population (HC). 
Interestingly, no geographical differences were observed in Bacteroidetes phylum and 
Bacteroides genus counts. Moreover, when looking at the thyroid status (i.e. 
hyperthyroid, euthyroid GD/GO patients and euthyroid HC), the decrease of Bacteroides 
spp. occurred in hyperthyroid patients compared to HC (which were euthyroid by 
definition of inclusion). Euthyroid patients showed a still decreased Bacteroides spp. 
counts compared to that of euthyroid-HC, while an increased Bacteroides counts were 
observed in few hypothyroid patients (possibly due to the anti-thyroid medication intake 
and thyroid hormones fluctuations). Bacteroides spp. was the only genus showing 
significant correlations with biochemical features such as thyroid-stimulating hormone 
(TSH) and the thyroxine hormone levels (fT4). In particular, the higher the TSH levels, 
the higher was the Bacteroides counts; and the higher the fT4, the lower was the 
Bacteroides counts, significantly occurring in hyperthyroid patients.  
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Along with the reduction in Bacteroides spp., a consequently increase of the 
Firmicutes:Bacteroidetes (F:B) ratio was also reported in GD/GO compared to HC. As 
the F:B ratio was previously associated with weight-gain and obesity [223], one may 
argue that the increase of F:B ratio in GD/GO patients was due to the weight loss, often 
occurring in the active form of GD/GO. To our knowledge, at the present, only one study 
specifically investigated the differences in the gut microbiota in hyperthyroid patients, 
although it was not clear if the hyperthyroidism had an autoimmune basis [443]. No 
significant associations with F:B ratio and weight-loss were reported. 
In line with our findings, Bacteroides spp. seemed reduced in a Chinese cohort of GD 
patients compared to HC; although not reaching the significant threshold [439]. The 
study, however, did not discriminate between GD and GO patients, or between 
hyperthyroid and euthyroid patients. In Hashimoto’s thyroiditis (HT) patients, a reduction 
in the phylum Bacteroidetes was reported in both hypothyroid [444] and euthyroid HT 
patients compared to euthyroid HC [438], while genus Bacteroides increased in 
hypothyroid patients only [444]. Interestingly, a recent meta-analysis of 2,700 individuals 
from the TwinsUK cohort suggested a correlation between the gut microbiota of 
hyperthyroid and hypothyroid patients (not necessarily with the autoimmune form) [445]. 
Bacteroides spp. was also associated to other autoimmune conditions, such as the type 
1 diabetes (T1D). Bacteroides vulgatus and, in particular, Bacteroides dorei were found 
increased in a Finnish cohort of children at high risk of T1D, few months before the 
seroconversion [446]. 
For which the severity of the eye disease is concerned (i.e. no sign, mild and moderate-
severe compared to HC), Bacteroides spp. showed a reduction between the GD with no 
sign of eye disease and the mild form of GO compared to HC. A very recent work showed 
instead an increased Bacteroidetes phylum in a GO Chinese cohort but a decreased 
Bacteroides massiliensis [447]. 
4.5.2. Other disease-associated gut microbiota taxonomies 
Other differential abundant taxonomies were identified between GD, GO (both mild or 
moderate-severe forms) and HC. Opposite to the decrease of Bacteroides spp., an 
increase of Fusicatenibacter genus was reported in GD and GO compared to HC an in 
hyperthyroid patients compared to the euthyroid controls. Zhao and collaborators 
reported an increased Fusicatenibacter spp. in euthyroid HT patients [438]. The 
Fusicatenibacter saccharivorans, a single species of the Clostridium XIVa, was found 
decreased in the faecal samples of ulcerative colitis (UC-IBD) patients [448].  
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In their recent work, Ishaq and collaborators found a significant increase of Prevotella 9 
and Haemophilus and a decrease of Alistipes and Faecalibacterium genera in GD 
patients compared to HC. Despite we used a different study design, sequencing primers 
and we enrolled a cohort on a prevalent western diet, we confirmed the decreased 
Alistipes spp. in GD and mild GO compared to HC and a decreased Prevotella 9, 
although occurring only in female GO patients compared to male GO patients. Similarly 
to Bacteroides spp., also Alistipes spp. are a butyrate-producing genus [439].  
While Bacteroides spp. and Fusicatenibacter spp. were differentially abundant in GD (no 
sign of eye disease) and in mild GO, they did not show associations with the moderate-
severe form of GO. In fact, the gut microbiota of moderate-severe patients showed fewer 
alterations, which included the reduction of Ruminococcaceae, Peptoclostridium and 
Clostridium sensu stricto genera and the increase of the Roseburia genus compared to 
both HC and GD. Interestingly, the increase of such a bacterial genus is often associated 
to a more healthy gut microbiota. A decrease of the butyrate-producing Roseburia spp. 
(in particular Roseburia hominis) was, in fact, previously associated to other autoimmune 
conditions, such as the ulcerative colitis [449], and also the acute uveitis, a rare and 
severe inflammation of the middle layer of the eye, potentially leading to blindness [450]. 
In our moderate-severe GO cohort, the increase of the butyrate-producing Roseburia 
spp. was also accompanied by an increased amount of butyrate, propionate and acetate 
SCFAs measured in their faecal water through NMR (Marchesi JR, personal 
communication). At this stage of the disease, patients may have experienced disease 
relapses, thyroid hormone fluctuations and may have undergone several anti-thyroid 
drug (ATD) treatments. Interestingly, Roseburia spp. increased in GD/GO patients under 
treatment with methimazole (within 6 weeks of commencing the medication intake) 
compared to untreated patients. Also, treatments with glucocorticosteroids and steroid 
bolus (one of the possible lines of treatment for GO, as described in Chapter 1 par. 1.1.3) 
may have increased the Treg milieu [451, 452]. PMBCs from the majority of moderate-
severe GO patients showed increased Tregs moiety when challenged in vitro with a 
Tregs-inducer molecule (i.e. rabbit anti-T lymphocyte globulin) [453].  Whether such an 
increase was due to or favoured by the increase of butyrate production in the gut has to 
be still proven.   
Bifidobacterium counts dropped in moderate-severe compared to mild GO and to GD 
patients, as it showed a significant increase in mild GO compared to HC. Benvenga and 
colleagues demonstrated in silico possible sequence homologies between 
Bifidobacterium strains epitopes and thyroid auto-antigens, in particular TPO and Tg 
[454]. This work supported also previous findings by Kiseleva and collaborators [455]. At 
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the present, however, there is no suggestion of a possible molecular mimicry between 
Bifidobacterium spp. antigens and the TSHR.  
I reported an overlap of some differentially abundant taxonomies between disease 
diagnosis (GD, GO and HC) and the thyroid status (hypothyroid and euthyroid). 
Interestingly, not all of them were present in both analysis, suggesting that other factors 
may have contributed to such differences, including the (auto)immune response, as also 
observed in the miRNA and proteins profiles [440]. In support to this findings, Turicibacter 
and Ruminococcaceae genera that were significantly correlated with anti-TSHR 
antibodies were not significantly associated to the thyroid status. On the contrary, they 
showed a different pattern of correlation associated to the disease diagnosis: negative 
correlation with TRAK, TRAB and cAMP levels in GD patients, while positive correlations 
with TRAK and cAMP in GO patients. Such a different correlation might be due to a 
higher anti-TSHR antibodies titres often occurring in GO patients, as we previously 
observed [440]. 
4.5.3. Effects of gender, ATD medications and smoking habits on GD/GO 
gut microbiota 
Many autoimmune diseases, including GD, present a gender prevalence. Gender-
related hormones, especially after pregnancy, in fact, constitute a risk factor for the 
development of such diseases. Moreover, it became clear that gender-related and sex 
hormones-related differences are also recapitulated in the gut microbiota [432]. 
According to Fransen et al. [456], microbiota-independent but gender-related differences 
in the immune response (i.e. interferon gamma signalling higher in the gut of female 
germ-free mice) may favour a specific gender-related gut microbiota composition, which 
in turns, may predispose gender-differences in the immune response, including the 
susceptibility for certain autoimmune conditions. A most striking example of this concept 
was described in the work of Markle and collaborators on the NOD mice [121]]. Despite 
a gender-related gut microbiota composition, a two-signal model, in which both the 
microbiota and the hormones act together in an additive manner, seemed the preferred 
mechanism for conferring protection from T1D development, compared to a linear model 
(i.e. microbiota directly regulated the hormones and vice versa) [434].  
Although our differential abundance analysis corrected for gender-biases as a covariate, 
I also focussed on differences in the gut microbiota between females and males in either 
GD or GO groups. None of these differentially abundant genera was previously 
associated to either the disease diagnosis or the eye-disease severity. Both GD and GO 
male patients showed an increase of Prevotellae genera, similarly to what observed by 
Mueller and collaborators in four different European countries [457]. It would be 
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interesting to study the interplay between immune response, sex-hormones and gut 
microbiota in the previously described GO mouse model.   
Smoking habits (i.e. current, ex and never smokers) was also considered to as a 
covariate, since it affects the composition of the gut microbiota. In a large cohort of 
Korean females and males, an increased Bacteroidetes phylum and a reduced 
Proteobacteria and Firmicutes, along with the Firmicutes:Bacteroidetes ratio were 
reported between current and never smokers [458]. Interestingly, no differences in the 
taxonomic composition were observed between ex and never smokers. The cessation 
of the smoking habits led to a decrease in Bacteroidetes and to an increase of Firmicutes 
and Actinobacteria phyla in individuals sampled before and at four and eight weeks after 
the smoking cessation  [459].  
Therefore, smoking habits can be considered as an environmental factor modulating the 
gut microbiota and possibly the immune response of an individual, even after the 
cessation. Cigarette smoking was also strongly correlated to the risk of developing GO 
[156]. In our ‘omics paper, in fact, we reported a prevalence of current smokers in GD/GO 
vs. controls (15:1) and in GO vs. GD (9:6) [440]. However, no smoking-associated 
biomarkers were detected. Differently from the ‘omics study, however, we included a 
higher number of never smokers patients. I specifically looked at smoking habits 
differences in the gut microbiota of either controls, GD and GO patients, individually. 
Interestingly, Bacteroides spp. counts, whose decrease was associated to GD/GO, 
decreased in current GO-smokers and further decreased in ex-GO smokers, similarly to 
what observed in [459]. 
Medications such as antibiotics have a profound effect on the gut microbiota 
composition. It has recently been showed that also common prescriptions such as 
proton-pump inhibitors (PPI) and antithyroid (ATD) medications may influence such a 
composition. In the recent TwinsUK meta-analysis [445], hyperthyroidism was 
associated with thyroxine/levothyroxine usage but also to PPI and anticholinergic. While 
positive and negative associations with the gut microbiota and thyroxine/levothyroxine 
were also described. More specifically, the effects of ATD carbimazole (CBZ), 
methimazole (MTZ), propylthiouracil (PTU) and levothyroxine were tested on the gut 
microbiota in vitro [264]. Interestingly, Maier et al [264] reported none or very few anti-
commensal activity upon CBZ or MTZ incubation, while I observed prevalently a 
decreased abundances of genera in the CBZ/MTZ groups compared to untreated GD or 
GO patients.  
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4.5.4. Prediction of GD/GO diagnosis based on the gut microbiota 
composition 
One of the most attractive goals when performing ‘omics approaches is to obtain a panel 
of biomarkers robust enough to be used for diagnosis purposes and/or prediction of the 
disease progression, towards the so called “individualized” or “precision medicine”. For 
a similar reason, we described a panel of combined circulating miRNAs and proteins 
discriminating between GD, GO and HC [440]. However, differences exist in modelling 
the outcome vs. modelling the progression of the disease, with the insurgence of possible 
selection bias afflicting the results of the analysis, as proposed in [460]. 
I employed the Random Forests [461] classification algorithm to either predict the 
diagnosis (i.e. GD vs. GO vs. HC) or the eye-disease status (i.e. no sign vs. mild vs. 
moderate-severe) using the genus-level taxonomy, although I’m fully aware that different 
approaches are also available [462-464] Random Forest allows to run dedicated models 
including also important covariates such as age and gender, amongst others. Loomba 
and collaborators obtained a panel of 37 bacterial species, plus some covariates (e.g. 
age, BMI and Shannon diversity) capable of discriminating mild/moderate non-alcoholic 
fatty liver disease (NAFLD) patients from patients with a more advanced fibrosis, with a 
nearly 94% accuracy of the RF classification model [465].  
When predicting the diagnosis the overall accuracy of the model was nearly 60%. The 
highest prediction rate occurred in the healthy control group (97.3% per-class accuracy) 
and in the GD patients (71.2% per-class accuracy). Prediction of the GO samples was 
less accurate, accounting only the 16% per-class accuracy. When stratifying for the 
severity of the eye-disease the overall accuracy of the model increased to nearly 62%; 
however, the majority of the mild GO samples and all the moderate-severe GO were 
predicted to as GD, showing a per-class accuracy of 8.4% and 0%, respectively. It 
appears that those classifications were driven preferably by the thyroid status (which was 
also the first important variable identified), rather than the composition of the gut 
microbiota by itself. A higher classification accuracy can be potentially obtained in cases 
vs. controls analysis.  
Shi et al. reported a nearly 75% accuracy of the prediction model for which HC and GO 
samples were concerned, although not stratifying for the severity of the eye-disease 
[447].  
Also, a different scenario for the classification of the GO samples was obtained using the 
circulating miRNA and proteins. The Lasso-penalized logistic regression on the 
combined miRNA and proteins dataset revealed an accuracy of 93% for the GO samples, 
compared to a 78% for GD and 86% for HC, respectively [440]. 
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4.5.5. Insights from the predicted metagenomic functions 
Prediction of the metagenomic pathways from the 16S rRNA gene sequencing may 
provide some insights about the functional role of the microbiome, despite the limitations 
of this technique addressed later in Chapter 6. 
Top-10 most abundant predicted pathways (Appendix 24) amongst disease diagnosis 
(HC, GD and GO) and eye-disease status (no sign, mild and moderate-severe GO) 
included the: “Arrhythmogenic right ventricular cardiomyopathy (ARVC)”, “Dilated 
cardiomyopathy (DCM)” and the “Regulation of actin cytoskeleton”. Interestingly, those 
three pathways were also identified in the pathway analysis using combined miRNA and 
proteins differentially abundant in GD, GO and HC [440]. Cardio-circulatory pathways 
can be imputed to the strain imposed by the hyperthyroidism and the thyroid hormones; 
but also, due to the expression of TSHR in the heart tissue, a similar autoimmune 
response may lead to both GD/GO and cardiomyopathy [466]. A link between the gut 
microbiota and cardiovascular diseases, including heart failure, was also proposed [467]. 
Also the “Complement and coagulation cascade” and the “ECM-receptor interaction” 
pathways which were increased in GD and GD/mild GO patients, respectively, were also 
identified in circulating proteins only in [440]. Interestingly, the NF-kB signalling pathway 
identified from the metagenomic function prediction was previously associated the 
hyperthyroidism and thyroid-eye disease [468]. 
The majority of differentially abundant pathways were enriched in the healthy control 
group, including “PPAR signalling cascade” and the “Antigen processing and 
presentation” pathways. The “Bacterial invasion of epithelial cells” was enriched in the 
GD group. The same pathway was also identified in [440], which presumably was due to 
the overexpression of Zonulin, responsible for the regulation of the intestinal-tight 
junctions [469]. Impairment of the gut permeability can favour bacterial translocation and 
activation of the immune system via GALT. Coeliac disease is also characterized by 
bacterial translocation due to an impaired gut permeability [469] and the cross-reaction 
between thyroid autoimmunity and coeliac disease in this cohort of patients is under 
investigation (Covelli D., personal communication).  
The “glycosaminoglycan biosynthesis- chondroitin sulphate” and the “N-glycan 
biosynthesis” pathways were increased in moderate-severe GO patients. As described 
in Chapter 1 par. 1.1.3, chondroitin sulphate (CS) is a major component of the 
glycosaminoglycans (GAGs) deposition occurring in the orbital tissues. Interestingly, 
some bacterial strains including E.coli O5:K4:H4 and Pasturella multocida are capable 
of chondroitin sulphate synthesis which have been used for biotechnological purposes 
as reviewed in [470]. A link between the gut and the CS supplementation in osteoarthritis 
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was proposed. In particular, the concomitant presence of Akkermansia muciniphila upon 
CS supplementation seems to ameliorate the osteoarthritis via the induction of anti-
inflammatory markers, while its absence seems to aggravates the symptoms [471]. It is 
interesting to note that Akkermansia spp. was increased in untreated GD patients with 
no sign of eye-disease vs. untreated GD patients and it was increased in the antibiotic-
treated GO mouse model, which did not show any signs of eye-disease (Chapter 3 par. 
3.4.1), although the specific role of the Akkermansia muciniphila in protecting from CS-
deposition in the orbits has still to be proved. Regarding the N-glycosylation, both anti-
TSHR autoantibodies (both IgG and IgG3) and the TSHR auto-antigen are heavily N-
glycosylated. Also, bacterial antigens of both commensals and pathogenic bacteria (i.e. 
flagellin) can be N-glycosylated [472]. For the theory of the molecular mimicry, the 
glycosylation moieties can play a role in the outcome of an autoimmune response. A 
glycosylation-mediated molecular mimicry between bacterial antigens and host 
sialyloglycans may secure the evasion from the immune surveillance [473]. Also, the 
Guillaume-Barrè syndrome, an acute form of paralysis usually occurring after infection 
with the foodborne Campylobacter jejuni, is caused by a glycosylation mimicry between 
the C. jejuni lipooligosaccharide and the human GM1 ganglioside, which lead the 
production of anti-GM1 autoantibodies [474]. A recent theory suggested the existence of 
a specific glycosylation pattern in antibody classes and subclasses for each autoimmune 
condition (“The altered glycan theory of Autoimmunity” [475]).   
4.6.  CHAPTER CONCLUSIONS 
In summary, Bacteroides spp. was consistently reduced in GD and mild GO patients and 
showed association with hyperthyroid status and risk factors such as the smoking habits. 
Similarly, a panel of bacterial biomarkers was identified and may serve as a supporting 
tool for clinicians, although not indicative of the eye-disease severity. Predicted 
metagenomic functions are in line with GD/GO disease hallmarks (e.g. CS-
glycosaminoglycan and N-glycans biosynthesis) and the immune response (e.g. 
complement cascade, NF-kB signalling), and suggested a broad role of the gut 
microbiota in sustaining the thyroid autoimmunity, although further studies are needed 
to deepen such interaction.  
The present chapter showed the GD/GO-associated microbiome perturbations at the 
enrolment phase in the cross-sectional study. The thyroid hormones fluctuations under 
ATD therapy may have a further impact on the gut microbiota composition, which may 
have, in turn, long-term effects protecting for example from disease relapses. We 
hypothesized whether the supplementation with beneficial bacteria (probiotics) could 
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have prevented such fluctuations and could have attenuated possible changes in the gut 
microbiota. The next chapter, in fact, describes the gut microbiota of GD/GO patients 
being treated with anti-thyroid medication (i.e. carbimazole or methimazole) in presence 
of either probiotics or placebo in a single centre, double-blind, placebo-controlled 
longitudinal trial.   
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5. Chapter 5 
 
 
Gut microbiota of GD/GO patients receiving a 
probiotic consortium: a pilot interventional trial 
 
Acknowledgments: 
 
Dr. Mario Salvi (MS), Dr. Giuseppe Colucci (GC) and Dr. Danila Covelli (DC) at the 
University of Milan for trial design, patients recruitment, clinical evaluation and sample 
collection. 
 
Dr. Sue Plummer (SP), Dr. Iveta Garaiova (IG), Dr. Daryn Michael (DM) and Cultech Ltd. 
for Lab4® production and randomisation.  
 
  
  
 
 
190  
5.1. INTRODUCTION 
The gut microbiota composition is generally stable during the lifespan of an adult, unless 
perturbed by diet (e.g. high-fat diet), surgery and/or medications (e.g. antibiotics). As 
shown in Chapter 3, however, there are approaches that may modulate the gut 
microbiota composition, even if in a transient manner, to confer beneficial effects to the 
host. 
An increasingly common and safe approach to microbiota manipulation in humans is 
constituted by the use of probiotics, which are defined as “live microorganisms that, when 
administered in adequate amounts, confer a health benefit on the host” [345]. The 
definition itself includes fundamental requirements for a probiotics claim, such as: i) 
viable bacteria surviving the stomach acidic environment and bile digestion and capable 
of reaching alive the target site, ii) administered in an adequate dose (i.e. at a minimum 
of 1x109 CFU/day according to the Italian legislation6), to iii) exert beneficial effects for 
the host health, such as the improvement of gut health and of the immune system [345].  
Bacterial species within the Lactobacillus (i.e. L. acidophilus, L. plantarum, L. reuteri, L. 
gasseri, L. rhamnosus, L. murinus) and Bifidobacterium (i.e. B. breve, B. bifidum, B. 
animalis) genera are the most used probiotics, administered either alone or in consortia 
(multi-strain probiotics). However, other bacterial species and strains such as 
Streptococcus salivarius, non-pathogenic Escherichia coli Nissle 1917, Pediococcus and 
Lactococcus spp. [476] or the yeast Saccharomyces boulardii [477] have been identified 
and used.  
Mechanisms and exerted beneficial effects can be either commonly shared through 
different probiotics species (“core benefits” as defined by [345]) or be more strain-
specific. Adhesion to the intestinal mucosa is one key feature showed by many 
probiotics. In particular, mucus adhesion of lactic-acid producing bacteria (LAB), is 
promoted by a series of surface proteins (e.g. adhesins or the L. reuteri mucus-binding 
protein [478]), as well as the lipoteichoic acid (LTA). By adhering to the mucus layer, 
probiotic bacteria may modulate  mucin production [479, 480] , although it may not 
directly happen in vivo. HT29 colorectal adenocarcinoma cell line showed increased 
expression of mucin genes (i.e. MUC2, MUC3 and MUC5AC, but not MUC1) when 
exposed in vitro to VSL#3 probiotic consortium (a commercially-available poly-biotic 
including 6 Lactobacillus strains, 3 Bifidobacterium strains and the Streptococcus 
                                               
6 Ministero della Salute, 2013. Direzione generale per l’igiene e la sicurezza degli alimenti e la 
nutrizione – Ufficio 4. “Linee guida su probiotici e prebiotici”. Revisione Marzo 2018. Access from: 
http://www.salute.gov.it  
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salivarius subsp. Thermophilus) [481]. When administered in vivo, VSL#3 significantly 
increased the mucin production via the over-expression of MUC2 in wild-type rats [482], 
but failed to increase the mucus layer or its thickness in control dextran-sodium sulphate 
(DSS) treated mice, as an animal model of ulcerative colitis [483]. 
Probiotics have also shown improvement of the intestinal epithelial barrier through the 
modulation of tight junction proteins, as reviewed in [294]. VSL#3 probiotic consortium 
improved the gut epithelial barrier condition and increased tightunction proteins via the 
p38 and ERK signalling pathways, as shown both in HT29 cells and in an in vivo model 
of induced colitis [484]. Increased mucus layer and improved tight-junctions may prevent 
pathogen adhesion and translocation through the intestinal epithelial barrier, also of food 
antigens causing possible sensitization.  
Such a prevention is also exerted via the modification of the environment. Secretion of 
lactic and acetic acids secretion by LABs, in fact, tends to lower the intracellular pH when 
internalized, inhibiting the growth of Gram-negative bacteria. The secretion of hydrogen 
peroxide (H2O2) by LAB species (including different strains of L. johnsonii and one strain 
of L. gasseri) was also proposed to selectively kill pathogens, at least in vitro [485]. 
Moreover, LAB strains, including bacteria and Archaea, are able to secrete antimicrobial 
peptides, called bacteriocins, that selectively cause the death of a narrow spectrum of 
bacterial strains, including pathogens (e.g. Listeria monocytogenes [486]). In contrast to 
antibiotics, in fact, targets of bacteriocins are usually restricted to closely related strains 
(e.g. Gram-positive strains against Gram-positive bacterial strains), as reviewed in [487], 
while mechanisms of actions generally involve inhibition of the synthesis of the bacterial 
cell wall and pores formation. The most important LAB-produced bacteriocins includes 
nisin from Lactococcus lactis, lactacin B from L. acidophilus, Lactacin F from L. johnsonii 
and different plantaricins from L. plantarum spp., as reviewed in [487]. Bifidobacteria-
produced bacteriocins includes, amongst others, bifidocin B, secreted by B. bifidum 
NCFB 1454 [488]. 
Besides organic acids and antimicrobial peptides, probiotics also secrete short-chain 
fatty-acids (SCFAs, Appendix 25), conferring a range of beneficial effects to the intestinal 
epithelium. Lactobacillus spp. only produce lactate, which can be converted to butyrate 
by butyrate-producing colonic-residing bacteria such as Roseburia intestinalis, 
Eubacterium rectale and Faecalibacterium prausnitzii [489]. Bifidobacteria instead 
produce SCFA from fermentation, whose end-products depend on carbohydrate 
availability: acetate and lactate are, in fact, produced in excess of carbohydrate moieties, 
while acetate and formate occur upon carbohydrate-restriction [490]. Supplementations 
with carbohydrates not digestible by the host (e.g. inulin or fructo-oligosaccharide, FOS), 
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or so called “prebiotics”, can favour the growth of certain bacteria and push towards the 
production of certain SCFA, especially when administered with probiotics (“synbiotics”).  
Probiotic bacteria themselves and their bio-products closely interact with immune system 
cells residing on the gut epithelium (e.g. dendritic cells). Such interactions reduce the 
pro-inflammatory response. Levels of TGF-β and anti-inflammatory IL-10 were increased 
in PBMCs isolated from a cohort of healthy adult volunteers after 12-week intake of Lab4 
(two strains L. acidophilus, B. lactis and B. bifidum), plus FOS [491]. On the contrary, 
decreased levels of IL-6 and IL-1β were shown when those PBMCs were challenged 
with LPS ex-vivo. As explained in Chapter 1 par. 1.2.2, TGF-β is the key regulator of 
Foxp3 expression leading to differentiation intoregulatory T-cells (Tregs). Probiotics have 
proved to trigger a Tregs response, at the expenses of a more pro-inflammatory Th1. As 
extensively reviewed in [108], a numbers of probiotics bacteria, either as a single species 
(i.e. L. casei, L. rhamnosus, B. longum etc) or in consortium (e.g. VSL#3) were shown to 
increase Foxp3+ Tregs, TGF-β, along with the reduction of pro-inflammatory cytokines. 
Also a role of prebiotics in inducing a Treg response has been proposed.  
Immunomodulatory effects of a probiotic administration, and possibly related beneficial 
effects, were also investigated in a range of inflammatory diseases both organ-related or 
more systemic, both using animal models and  in randomized controlled trials  in humans. 
Probiotics supplementation in irritable bowel syndrome (IBS), which is characterized by 
chronic abdominal pain, altered bowel motility (diarrhoea or constipation) and by an 
altered gut microbiota, induced differing responses [492, 493], ranging from no or weak 
improvement of some disease symptoms (i.e. bloating or flatulence scoring) to a 
significant improvement of the global severity score (GSS). Lab4® consortium 
administered for 8 weeks to active IBS volunteers provided an increase in GSS, quality 
of life along with reduction of pain compared to the placebo group [494]. From a recent 
meta-analysis focussing on the use of probiotics supplementation in IBD (including 
ulcerative colitis and Crohn's disease) emerged a general improvement of some related 
symptoms, occurring either in CD or UC or both, depending on the type of probiotics 
used. Amongst others, VSL#3 was also proved to be safe when used in combination of 
corticosteroids therapy [495] and was proposed to be efficient in reducing post-surgery 
CD recurrence [496]. Probiotics and synbiotics supplementations were also assessed at 
various stages of colorectal cancer management (i.e. when initiating anti-cancer therapy, 
undergoing surgery or post-surgery etc.), as reviewed in [497] Although evidence was 
heterogeneous, reduction of post-surgery or therapy-based complications (i.e. 
diarrhoea) were reported, also suggesting a favourable role in cancer prevention. 
Prevention of the necrotising enterocolitis (NEC, caused by severe inflammation upon 
feeding in premature babies, often requiring bowel resection and short-bowel syndrome 
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amongst other complications) was more successful following probiotics administration 
[498-500]. 
Probiotics effects in ameliorating autoimmune diseases (either systemic or not gut 
related) were also evaluated. A reduced incidence and severity of the multiple sclerosis 
induced animal model (EAE) were observed upon probiotics administration, as described 
in Chapter 3 par.. 3.1. Reduced type-1 diabetes (T1D) incidence was also observed in 
NOD mice upon probiotics administration. A clinical trial aimed at investigating the 
protective role of a probiotics intake in the 24 months of life in babies with a genetic high 
risk of developing T1D [501]. However, due to a high dropout rate by the parents, only 
the safety and the feasibility of the protocol could be assessed. Fermented milk with L. 
acidophilus and B. animalis administration in Type 2 diabetes (T2D) patients, 
characterized by a later onset, high glucose levels and insulin resistance, instead, 
showed an improvement of the glycaemic control, along with decrease in anti-
inflammatory cytokines and an increase in the SCFAs production [502].  
The role of probiotics  in treating autoimmune thyroid diseases were, so far, investigated 
less. The animal model of autoimmune thyroiditis (i.e. Hashimoto’s thyroiditis) showed a 
milder phenotype when induced in presence of L. rhamnosus and B. lactis strains [385]. 
At the present, only one randomized, placebo-controlled trial investigated the 
concomitant use of the VSL#3 consortium along with levothyroxine in hypothyroid 
patients [503]. The probiotics supplementation seemed to stabilize more the hormonal 
fluctuations, although no significant protective effects were observed in the probiotic 
group compared to the placebo.  
5.2. AIMS OF THE CHAPTER 
The role of the gut microbiota in GD and GO has been described in the previous chapter 
and, most recently, in Chinese patients [439, 447]. However, no studies have directly 
investigated the modification of the gut microbiota in GD/GO patients and related 
changes in the disease features. Therefore, by providing a probiotics consortium along 
with the anti-thyroid therapy for 6 months, we aimed at modifying the gut microbiome of 
GD/GO patients and decreasing the anti-TSHR antibody titres (i.e. TRAB) and the 
concentration of immunoglobulins, such as IgA and IgG, predictive of disease relapse 
and disease severity.  
As described in the intervention protocol (“Sinossi” submitted to the Comitato Etico 
Milano Area B, approval obtained on 11/11/2014), the primary endpoint of the probiotic 
trial involved the reduction of the Firmicutes:Bacteroidetes ratio of at least 5%. 
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Secondary endpoint was the reduction of anti-TSHR antibody titres and total IgG and 
IgA concentrations of at least 30% at the end of the probiotic treatment. 
The present chapter includes the analysis of the primary and secondary endpoint of the 
trial. Moreover it includes also the description of the microbiota changes upon probiotic 
intake compared to the placebo in other aspects of the gut microbiota (i.e. alpha and 
beta diversity and differential abundance of genera).  
5.3. MATERIALS AND METHODS 
5.3.1. Patients and samples collection 
A single-centre, double-blind, placebo-controlled pilot interventional trial was conducted 
at the Policlinico Cà Granda, University Hospital of Milan (Comitato Etico Milano Area B, 
approval obtained on 11/11/2014; ClinicalTrials.gov Identifier: NCT02373995) between 
2015 and 2016. Inclusion criteria for GD/GO patients were the same as those for the 
observational study (see chapter 4, par. 4.3.1.). Further exclusions criteria included: i) 
previous or planned treatment with 131I or thyroidectomy, ii) sight-threatening GO 
requiring orbital decompression, iii) antibiotics/antivirals intake, iv) IBD/acute diarrheal 
episodes within 4 weeks from recruitment, v) drug/alcohol abuse, vi) no informed 
consent, vii) age less than 18 or more than 65 years old and viii) ongoing pregnancy.  
Enrolled GD/GO patients were randomized to receive either the probiotic consortia 
Lab4® or placebo, along with the anti-thyroid drug (ATD) treatment, for 6 months. 
Production of the probiotic consortia and randomisation were performed in double-blind 
at Cultech Ltd. (Port Talbot, Wales, UK). As previously described (Chapter 3, par. 3.3.3), 
Lab4® is a consortium of lactic-acid producing bacteria comprising two bifidobacteria 
strains (Bifidobacterium bifidum and Bifidobacterium animalis var. lactis) and two 
lactobacilli strains (Lactobacillus acidophilus strain 1 and strain 2), which was 
administered at a final concentration of 25 billion colony-forming unit (cfu)/capsule, twice 
a day. Placebo capsules contained 200mg of maltodextrin carrier. 
Clinical evaluation and samples collection (i.e. blood for plasma and serum isolation and 
faecal samples) were performed by MS, GC and DC at the enrolment phase (baseline), 
when patients reached euthyroid status (EU timepoint, for definition see Chapter 4 par.. 
4.3.1) and at the end of the treatment (EFU timepoint), approximately 6 months after the 
beginning of probiotic/placebo intake. A summary of the trial rational is described in figure 
5.1.  
Thyroid function tests (TSH, fT4 and fT3) and TRAB values were measured in blood 
using local biochemical assays. Reference ranges were described in Chapter 4, Table 
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4.1. Anti-TSHR antibodies measurement was further repeated by UB-P using the 
Immulite XPI (Siemens) for TSI (IU/L; positive result cut-off >0.1IU/L) and the Cobas 
Roche for TRAK quantification (IU/L; cut-off >0.3IU/L).  
5.3.2. DNA extraction and 16S rRNA gene sequencing 
Faecal samples were collected following the procedure described in Chapter 4 par. 4.3.1, 
stored at -20°C soon after their collection at the University of Milan and shipped in dry 
ice to Cardiff University (UK), within approx. two months from collection. DNA extraction 
has followed the same procedure described in Chapter 4, par. 4.3.2. The resulting 
genomic DNA samples were included in the second sequencing batch, together with the 
human DNA samples for the observational study described in Chapter 4. Paired-end 
metataxonomics reads were generated at R&T Ltd. (Texas, USA), using 28-combo 
primers detecting the V1-V2 of the 16S rRNA gene plus bifidobacteria regions, as 
described in Table 2.2 (Chapter 2).  
Good-quality reads were processed as described in Chapter 4 par. 4.4.3 and Appendix 
8. Briefly, QIIME 1.9 was used to remove reads not matching the quality thresholds, align 
them against the closed reference 16S rRNA gene database and obtain the OTU-table 
along with the taxonomic description. Alpha diversity indices were calculated from the 
filtered OTU table (less than 10 counts in at least 2 samples), while beta diversity indices 
were calculated from the filtered and CSS-normalized [354] OTU table.  
5.3.3. Data analysis 
Statistical analysis was conducted within the R environment, v3.4.1. (R development 
2017), unless otherwise stated. Statistical analysis was conducted according to the 
intention-to-treat (ITT) basis, which includes all the participants who had been 
randomised in the study, despite noncompliance or withdrawal [504].   
5.3.3.1. Trial objectives 
Descriptive statistics included mean, standard deviation, median, Q1 (25%) and Q3 
(75%) for interquartile ranges (IQR).  
Comparison between probiotic and placebo at baseline (time of enrolment) was 
performed with a Chi-square test or Fisher’s exact-test for categorical/frequency data, 
while the non-parametric Wilcox-Mann test plus Benjamini-Hochberg (BH) correction 
was used with continuous data.  
At further timepoints (either euthyroid or end of follow-up), pairwise comparison between 
placebo and probiotic groups was performed with a non-parametric Wilcox-Mann test 
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plus Benjamini-Hochberg (BH) correction. Within each randomised group (either placebo 
or probiotic), a longitudinal analysis (amongst timepoint) was performed using the 
following linear model (Equation 7): 𝑦"#$ = 𝜇 + 𝑇𝑖𝑚𝑒" +	𝐺𝑂	𝑠𝑡𝑎𝑡𝑢𝑠# + 𝑒"#$ 
Where 𝑦"#$ is either Firmicutes:Bacteroidetes (F:B) ratio or thyroid function tests (fT4, 
fT3 and TSH), immunoglobulins (total IgAs and IgGs) and anti-TSHR antibodies titres 
(TSI and TRAK). 𝜇 is the overall mean; 𝑇𝑖𝑚𝑒" included the sampling timepoints as 
categories, (BL, EU and EFU), 𝐺𝑂	𝑠𝑡𝑎𝑡𝑢𝑠# included the categories “no signs”, “mild” or 
“moderate-severe”. And 𝑒"#$ is the vector of the residual effects. 
Baseline-corrected F:B counts and biochemical features were obtained subtracting the 
baseline values from the euthyroid and the end of follow-up observations in each sample 
individually. The non-parametric Wilcox-Mann test plus Benjamini-Hochberg (BH) 
correction was used for testing differences between timepoints and between groups.  
5.3.3.2. Microbiota analysis  
Alpha diversity indices (Chao1 and Shannon diversity) and the Bray Curtis dissimilarity 
matrix, as a beta-diversity measure, were calculated in QIIME1.9. Differences in alpha 
diversity amongst timepoint within each randomisation group were assessed using a 
linear regression model, correcting for GO status, thyroid status, smoking habits and 
age. Pairwise comparison between placebo and probiotic group in each timepoint was 
instead performed with a Welch’s t-test plus BH correction. Beta diversity was 
represented in a NMDS plot using ggpubr R package and statistical differences between 
randomisation groups and amongst timepoints were assessed with PERMANOVA from 
the R Vegan package.  
Differential abundance analyses amongst timepoints and within each randomisation 
group were conducted with the same linear regression model previously used for alpha 
diversity indices. Pairwise comparison between timepoints was performed using the 
Wilcox-Mann non-parametric test with Bonferroni correction. Taxonomic comparison 
between placebo and probiotic groups at each timepoint was performed using the linear  
discriminant analysis (LDA) effect-size (LEfSe) [464], in which the non-parametric 
Kruskall Wallis, followed by an unpaired Wilcoxon-Mann test were performed to  obtain 
differentially abundant taxonomies. A linear discriminant analysis (LDA) is then used for 
an effect-size estimation on the differentially abundant features previously identified. 
LEfSe was performed on Galaxy (http://huttenhower.sph.harvard.edu/galaxy/) with an 
alpha value (P values) of 0.05 and a logarithmic LDA threshold of |2|.   
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Baseline-corrected counts were obtained subtracting the baseline values from the 
euthyroid and the end of follow-up of each taxon in each sample individually. Differences 
using baseline-corrected counts amongst timepoints were assessed with the previous 
linear regression model, followed by the Welch’s t-test test and Bonferroni adjustment 
for pairwise comparisons.  
Differential abundance of genera across timepoints within the same patient (individual 
variability across timepoint) was assessed using the G-test with Yates’ correction as 
implemented in STAMP [319]. Only the top-20 most abundant genera were considered 
for the analysis.  
Correlation between bacterial biomarkers identified through the LEfSe analysis, plus 
Bifidobacterium and Lactobacillus spp., and the biochemical/clinical features was 
performed with the Pearson’s’ correlation coefficient in the Corrplot R package.  
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5.4. RESULTS  
5.4.1. Patients enrolment  
A total of 34 patients were potentially suitable for enrolment in the trial. One patient was 
excluded from the trial because of history of allergic reactions and two patients for 
previous foodborne infections (i.e. borreliosis and hepatitis). Out of the remaining 
patients, 28 patients provided faecal samples in at least one timepoint, whose 
characteristics at the enrolment phase (baseline) are described in Table 5.1. No 
significant differences in terms of age and thyroid function tests were observed at the 
baseline timepoint between placebo and probiotic groups (Table 5.1).  
Twenty-four out of 28 patients provided samples at the baseline timepoint. In line with 
the enrolment criteria and the purposes of the trial, all patients were treated with ATD 
(whose description is in Chapter 1 par. 1.1.2), in particular 2 patients were on a “block 
and replace” regimen, whereas the remaining patients were on a titration regimen 
(methimazole). The rational of the trial and the number of faecal samples per 
randomisation group in each timepoint is represented in Figure 5.1 and Table 5.2. 
 
Figure 5.1. Rationale of the probiotic trial and number of samples obtained.  
A total of 31 GD/GO patients complied with the inclusion criteria for the trial and were 
randomised to receive either probiotic (Lab4) or placebo (maltodextrin) capsules for 6 
months. Twenty-eight patients provided faecal samples in at least one timepoint. Only 
24 patients provided faecal samples at baseline. Eight probiotic-receiving patients and 7 
placebo-receiving patients provided faecal samples at the euthyroid timepoint, while 6 
and 7 patients in probiotic and placebo groups, respectively, provided samples at the 
end of follow-up in 6 months’ time from the beginning of the trial.  
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Table 5.1. Characteristics of the patients enrolled for the interventional trial 
 
  Placebo (n=15) Probiotic (n=13) Total (n=28) P value 
Age* 41.6 (12.67) 42.23 (12.47) 41.89 (12.35) 0.69 
Gender (F/M) 12/3 10/3 22/6 1 
Ethnicity° 2/13 0/13 2/26 0.48 
Smoking habits# 2/13 3/10 5/23 0.63 
GO status§ 6/6/3 4/6/3 10/12/6 0.87 
Thyroid statusa 11/4 7/6 18/10 0.43 
Thyroid function 
tests*    
 
fT4 (pmol/L) 13.70 (17.03) 23.92 (24.76) 18.62 (21.33) 0.17 
fT3 (pmol/L) 7.42 (7.67) 9.52 (12.53) 8.43 (10.12) 0.89 
TSH (mU/L) 3.25 (3.39) 4.76 (7.31) 3.95 (5.50) 0.85 
Anti-TSHR 
antibodies*    
 
TRAB (IU/L) 20.28 (17.93) 13.17 (20.61) 16.86 (19.24) 0.10 
TSI (IU/L) 100.05 (251.25) 97.92 (208.80) 99.08 (227.80) 0.93 
TRAK (IU/L) 16.65 (15.30) 13.27 (13.67) 15.10 (14.36) 0.72 
Immunoglobulins*     
IgA (mg/L) 175.41 (61.05) 177.81 (54.87) 176.56 (56.86) 0.88 
IgG (mg/L) 1058.75 (229.23) 1053.45 (266.52) 1047.60 (242.28) 0.44 
*represented as mean(standard deviation). °african/caucasian. #current/never smokers. §no 
sign/mild/moderate-severe GO status. ahyper/euthyroid. 
 
 
Table 5.2. Number of faecal samples for microbiome analysis provided per timepoint  
 
Timepoint Placebo Probiotic Total (per timepoint) 
Baseline (BL) 13 11 24 
Euthyroid (EU) 7 8 15 
End-of follow-up (EFU) 7 6 13 
Total (unique patient) 15 13 28 
 
5.4.2.  Primary endpoint 
The primary endpoint of the probiotic trial was the 5% reduction of the 
Firmicutes:Bacteroidetes (F:B) ratio following treatment with probiotics for 6 months. 
Firmicutes and Bacteroidetes were the most abundant of 15 phyla identified, followed by 
the phylum Actinobacteria (Figure 5.2). There was a significantly higher prevalence of 
Firmicutes than Bacteroidetes counts, which occurred in both groups in all the timepoints 
sampled (P=0.00).  
When looking at the F:B ratio, no significant differences between probiotic and placebo 
were observed at baseline. Between the euthyroid timepoint (EU) and the baseline (BL), 
the mean F:B ratio reduced by 14% in the probiotic group, compared to a 48% reduction 
in the placebo group. Between the end of follow-up (EFU) and the baseline, the mean 
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F:B ratio reduced by 32% in the placebo group but increased by 285% in the probiotic 
group. An average 22% reduction in the F:B ratio was reported between EU and EFU 
upon probiotic intake (Table 5.3). The F:B ratio however, showed some outliers, which 
may influence the mean value (Figure 5.3). Analysis using the median values, in fact, 
reported a 42% decrease of the F:B ratio at EU but a 18% increase at EFU compared to 
the baseline specifically in the probiotic group (Table 5.3). However, no significant 
differences were reported between probiotic and placebo in each timepoint, neither when 
using baseline-corrected F:B values.  
 
 
Figure 5.2. Phylum distribution in each randomisation group and per timepoint.  
Stacked bar chart graph representing the CSS-normalized phylum counts in either 
placebo or probiotic groups in each timepoint: BL, baseline; EU, euthyroid and EFU, end 
of follow-up.  
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Figure 5.3. Distribution of the Firmicutes:Bacteroidetes (F:B) ratio between 
randomisation groups in each timepoint.  
Box and whiskers plot of the F:B ratio in either placebo or probiotic groups in each 
timepoint: BL, baseline; EU, euthyroid and EFU, end of follow-up. 
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Placebo
Probiotic
group
mean
stdev
median
Q1
Q3
mean
stdev
median
Q1
Q3
P value°
Baseline (BL)
3.79
6.49
1.58
0.88
2.50
7.57
11.32
3.06
1.68
8.66
0.24
Euthyroid (EU)
1.93
0.84
1.53
1.36
2.79
6.52
10.10
1.76
1.33
6.91
0.69
End of follow-up (EFU)
14.59
33.69
1.22
0.63
4.15
5.11
4.72
3.61
2.13
6.12
0.37
EU-BL (%)
-48.92
-87.11
-3.01
54.82
11.59
-13.82
-10.75
-42.48
-21.01
-20.18
0.63
EFU-BL (%)
285.20
418.86
-22.61
-28.34
65.69
-32.47
-58.28
18.20
26.28
-29.33
0.69
EFU-EU (%)
654.10
3925.23
-20.21
-53.71
48.48
-21.64
-53.26
105.51
59.86
-11.47
0.34
dEU
(BL-corrected)
0.11
1.77
0.29
-0.05
0.38
2.20
13.73
-0.51
-1.69
4.49
1.00
dEFU
(BL-corrected)
18.87
39.34
2.41
0.48
2.49
0.06
3.88
1.44
-2.85
3.06
0.68
 
Q
1 (25%
) and Q
3 (75%
), interquartile range. (%
) percentage changes calculated as [(Tf – Ti)/Ti]x100, w
here Tf is either EU
 
or EFU
 and Ti is BL. dEU
 (EU
- BL) and dEFU
 (EFU
-BL). °P value from
 the non - param
etric com
parison betw
een placebo and 
probiotic in each  section.  
 Table 5.3 Prim
ary endpoint: percentage differences in Firm
icutes:B
acteroidetes ratio. 
 
  
 
 
203  
5.4.3. Secondary endpoint 
The secondary objective of the trial was the decrease of the anti-TSHR antibodies titres 
of at least 30% at the end of treatment (EFU) upon probiotic intake. A median reduction 
of more than 30% in the TRAK and TSI titres has been reported in both placebo and 
probiotic group in both EFU to baseline and EFU to EU timepoints (Table 5.4). Such a 
reduction was less evident in the probiotic group compared to the placebo. The TSI levels 
showed a progressive reduction across timepoints in the probiotic group (Figure 5.4), 
however just missing the significant threshold (P=0.063). However, no significant 
differences in the anti-TSHR antibodies titres between placebo and probiotic has been 
observed (Table 5.5).  
Other collateral objectives of the trials involved the improvement of the thyroid function 
and the immune response. The probiotic group showed significant variations of the fT4 
levels amongst timepoints (P=0.01), whose median values were reduced in the probiotic 
group compared to the placebo group at EU (5.01 vs. 12.7, P=0.055, Table 5.4). 
Circulating IgA and IgG showed a transient reduction at EU, which was more pronounced 
in the probiotic group, although not significant (Figure 5.4). Probiotic group also showed 
a reduced IgG titres compared to the placebo group at EU timepoint, although missing 
the significant threshold (P=0.07, Table 5.5).  
Although the significant threshold (P value) has been used widely in the scientific 
community, it is still worth commenting about the trends and the results which are not 
showing a significant value at P<0.05. A recent proposal7 in fact stated the reason why 
the significance threshold might be overcome, and other tests such as the Bayesian 
inference might result more appropriate.  
 
  
                                               
7 Wasserstein RL, Schirm AL and Lazar NA. 2019. “Moving to a world beyond “P<0.05”” 
available at https://www.tandfonline.com/doi/full/10.1080/00031305.2019.1583913  
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Baseline
Euthyroid
End of follow-up
EFU-BL(%
)
EFU-EU(%
)
features
group
mean
sd
median
Q1
Q3
mean
sd
median
Q1
Q3
mean
sd
median
Q1
Q3
P value #
mean 
median
mean
median
TSH
placebo
0.888
3.040
0.005
0.005
0.030
1.563
1.835
0.850
0.074
3.770
1.187
1.502
0.690
0.044
1.780
0.388
33.723
13700.000
-24.068
-18.824
TSH
probiotic
1.342
2.026
0.050
0.005
3.160
4.324
6.255
2.390
0.300
3.990
1.213
1.201
1.470
0.025
1.770
0.001
-9.583
2840.000
-71.936
-38.494
fT3
placebo
8.077
8.224
5.100
2.460
12.120
4.176
2.774
3.400
2.700
5.500
4.596
2.524
3.650
3.030
4.700
0.418
-43.100
-28.431
10.065
7.353
fT3
probiotic
6.434
4.930
3.660
3.300
9.100
3.059
1.044
2.440
2.370
3.360
4.516
4.074
2.800
2.690
3.000
0.113
-29.810
-23.497
47.651
14.754
fT4
placebo
14.974
18.045
7.400
0.750
21.700
11.386
4.910
12.700
9.700
13.200
15.915
10.137
14.500
11.200
26.900
0.805
6.283
95.946
39.780
14.173
fT4
probiotic
20.100
15.435
15.700
12.200
30.800
6.274
6.341
5.010
0.610
9.440
12.998
15.639
11.700
1.260
11.800
0.014
-35.333
-25.478
107.181
133.533
TSI
placebo
15.578
18.054
3.820
2.140
24.000
11.436
11.628
7.095
3.290
20.000
2.447
4.451
0.569
0.488
0.676
0.335
-84.290
-85.105
-78.599
-91.980
TSI
probiotic
5.035
6.407
3.660
0.651
6.300
10.129
11.883
2.490
0.503
19.700
1.454
1.967
0.849
0.503
0.975
0.063
-71.117
-76.803
-85.644
-65.904
TRAK
placebo
18.952
15.566
22.900
3.300
31.820
15.783
14.050
13.810
5.060
22.960
4.932
8.166
0.680
0.300
4.140
0.233
-73.976
-97.031
-68.752
-95.076
TRAK
probiotic
8.236
8.514
4.480
1.460
14.720
10.471
13.821
3.000
0.850
26.830
4.917
6.978
1.355
1.220
6.980
0.215
-40.300
-69.754
-53.047
-54.833
IgA
placebo
187.000
55.825
197.000
135.000
219.000
154.250
53.879
176.500
74.000
177.000
176.286
75.793
178.000
119.000
221.000
0.745
-5.730
-9.645
14.286
0.850
IgA
probiotic
165.111
36.347
182.000
157.000
188.000
147.600
35.949
155.000
151.000
170.000
201.833
52.457
187.000
173.000
198.000
0.250
22.241
2.747
36.743
20.645
IgG
placebo
1076.300
244.846
1096.500
1002.000
1203.000
1004.000
134.815
939.000
914.000
1159.000
1113.571
320.099
1097.000
905.000
1301.000
0.805
3.463
0.046
10.913
16.826
IgG
probiotic
980.556
225.905
929.000
918.000
995.000
810.600
128.025
850.000
763.000
902.000
959.000
263.030
912.500
774.000
960.000
0.186
-2.198
-1.776
18.307
7.353
Q
1 (25%
) and Q
3 (75%
), interquartile range. #P values generated from
 the linear regression m
odel ( equation 7), correcting for 
G
O
 status and thyroid status; (%
) m
edian percentage changes calculated as [(Tf –  Ti)/Ti] x 100 , w
here Tf is either EU
 or EFU
 
and Ti is BL.  
 Table 5.4 Secondary outcom
e: percentage difference in thyroid function tests, anti-TSH
R
 antibodies titres and total 
im
m
unoglobulin contents. 
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Table 5.5. Statistical summary of the differences in thyroid function tests, anti-TSHR 
antibodies titres and total immunoglobulin contents between probiotic and placebo. 
 
Features Timepoint 
Placebo  Probiotic  
P value# 
median IQR° median IQR° 
TSH 
BL 0.005 0.005-0.03 0.05 0.005-3.16 0.165 
EU 0.85 0.074-3.77 2.39 0.3-3.99 0.336 
EFU 0.69 0.044-1.78 1.47 0.025-1.77 0.876 
dEFU-BL 0.685  -0.003   
fT3 
BL 5.1 2.46-12.12 3.66 3.3-9.1 0.972 
EU 3.4 2.7-5.5 2.44 2.37-3.36 0.259 
EFU 3.65 3.03-4.7 2.8 2.69-3 0.310 
dEFU-BL -1.87  -0.4   
fT4 
BL 7.4 0.75-21.7 15.7 12.2-30.8 0.235 
EU 12.7 9.7-13.2 5.01 0.61-9.44 0.056* 
EFU 14.5 11.2-26.9 11.7 1.26-11.8 0.662 
dEFU-BL 2.4  -3.4   
TSI 
BL 3.82 2.14-24 3.66 0.651-6.3 0.270 
EU 7.095 3.29-20 2.49 0.503-19.7 0.445 
EFU 0.569 0.488-0.676 0.849 0.503-0.975 0.537 
dEFU-BL -1.082  -3.43   
TRAK 
BL 22.9 3.3-31.82 4.48 1.46-14.72 0.224 
EU 13.81 5.06-22.96 3 0.85-26.83 0.366 
EFU 0.68 0.3-4.14 1.355 1.22-6.98 0.583 
dEFU-BL -3.805  -2.48   
IgA 
BL 197 135-219 182 157-188 0.278 
EU 176.5 74-177 155 151-170 0.325 
EFU 178 119-221 187 173-198 0.668 
dEFU-BL -6  9   
IgG 
BL 1096.5 1002-1203 929 918-995 0.182 
EU 939 914-1159 850 763-902 0.071* 
EFU 1097 905-1301 912.5 774-960 0.295 
dEFU-BL -36  -40   
 
°IQR=Q1 (25%) -Q3 (75%). #P values generated from a pairwise comparison using 
Wilcoxon-Mann and BH correction, * P<0.1.   
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Figure 5.4. Changes in the F:B ratio and in biochemical features upon probiotic or 
placebo compared to the baseline.  
The median percentage of each feature (either F:B ratio or biochemical features) of either 
placebo or probiotic group was plotted in function of the time, expressed to as change 
from baseline. dBL is considered to as 0 and dEUBL: EU-BL and dEFUBL, EFU-BL.  
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5.4.4. Modification of the gut microbiota upon probiotic/placebo intake 
The within-sample or alpha diversity indices did not show any significant changes upon 
placebo/probiotic intake (Figure 5.5A), nor across timepoints. The between-samples or 
beta-diversity indices calculated trough the Bray-Curtis matrix did not show differences 
between randomisation groups in each timepoints (Figure 5.5B), or across timepoints.   
 
 
Figure 5.5. Alpha and beta diversity indices upon probiotic or placebo intake.  
(A) Box-and-whiskers plot representing the indices of richness (Chao1) and diversity 
(Shannon), P>0.05 between randomisation groups and amongst timepoints. (B) Non-
metric dimensional scaling (NMSDS) plot. Stress R2=0.95 non-metric fit; P>0.05 
PERMANOVA, using 999 permutations.  
 
The differential abundance analysis initially focussed on differences in either probiotic or 
placebo gut microbiota groups amongst timepoints, using the Equation 7 which corrected 
for GO status. Five genera were differentially abundant in the probiotic-receiving group 
(Figure 5.6). Amongst them,  taxa previously associated to a probiotics intake such as 
Coprococcus 3 and Eubacterium hallii spp. increased over time. In particular, 
Coprococcus 3, Eubacterium hallii spp., Ruminiclostrium 9 and Turicibacter show a 
significant increase between the baseline and the end of the follow-up (EFU), although 
not reaching the significant threshold after Bonferroni correction. Five taxa were 
differentially abundant in the placebo group (Figure 5.7), of those the phylum 
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Lentisphaerae and 4 genera. In pairwise comparisons, phylum Lentisphaerae and the 
Lentisphaerae single-genus Victivallis increased between baseline and EFU (P=0.018) 
and between EU and EFU (P=0.026), although not reaching significant threshold after 
Bonferroni correction.  
 
 
Figure 5.6. Differential abundant genera amongst timepoint in the probiotic group.  
Box-and-whiskers plot representing the CSS-normalized genera counts in each 
timepoint. Only genera with P<0.05 from the Equation 7 were included.  
  
Ruminiclostridium9 Turicibacter
CandidatusSoleaferrea Coprococcus3 [Eubacterium]halliigroup
BL EU EFU BL EU EFU
BL EU EFU
0.00
0.01
0.02
0.03
0.04
0.05
0.00
0.01
0.02
0.000
0.005
0.010
0.015
0.00000
0.00005
0.00010
0.00015
0.000
0.001
0.002
0.003
0.004
0.005
timepoint
CS
S 
no
rm
ali
ze
d 
co
un
ts
timepoint BL EU EFU
  
 
 
209  
 
Figure 5.7. Differential abundant genera amongst timepoint in the placebo group.  
Box-and-whiskers plot representing the CSS-normalized genera counts in each 
timepoint. Only genera with P<0.05 from the Equation 7 were included. 
 
 
The LDA effect-size (LEfSe) [464], provides robust biomarkers, by combining non-
parametric test statistics to the linear discriminant analysis to estimate the effect size of 
the significant features identified. LEfSe has been applied to compare placebo and 
probiotic groups gut microbiota in each timepoint. At baseline, placebo group showed an 
enrichment of the Salmonella spp., while 5 genera were enriched in the soon-to-receive 
probiotic group (Figure 5.8A). At the euthyroid timepoint (Figure 5.8B), four genera 
increased in each group, including two Clostridiales (Marvinbyrantia), one Bacteroidetes 
and one Proteobacteria in the probiotic group. Placebo group instead showed the 
increase of three Firmicutes (Lachnospiraceae, Coprobacillus and 
Erysipelatoclostridium) and one Bacteroidetes (Parabacteroides) genera. At the end of 
the follow-up (EFU), four genera were enriched in the probiotic group including the 
Eubacterium Hallii group and Coprococcus 3, confirming also previous analysis (Figure 
5.8C).  
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Figure 5.8. Bacterial biomarkers between probiotic and placebo in each timepoint 
identified through the LDA effect size (LEfSe).  
Bar-chart plots representing the enriched bacteria biomarkers in either probiotic or 
placebo group at each timepoint according the linear discriminant analysis (LDA) effect 
size (LEfSe), [464]. Bacterial biomarkers were P<0.05 in both Kruskall Wallis and Wilcox-
test and the minimum LDA threshold of 2 (as log10).  
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Baseline-corrected bacterial counts were obtained to account for differences in the gut 
microbiota of placebo and probiotic group at baseline. Twelve genera were differentially 
abundant across timepoints in the probiotic group (Table 5.6), confirming some of the 
linear regression results. Of those, 5 genera were differentially abundant both between 
baseline and the EFU and EU-EFU. Placebo groups showed 26 differentially abundant 
genera (Table 5.7). Some of previously identified differentially abundant genera were 
confirmed by this analysis, with some exception. Genus Bifidobacterium decreased in 
the placebo group between baseline and euthyroid (P=0.03). A higher number of genera 
were differentially abundant between BL and EU and EU and EFU compared to the 
probiotic group, potentially as the result of the ATD therapy on the gut microbiota 
composition. Only Intestinibacter spp. still showed a significant decrease between EU 
and BL after Bonferroni correction in the placebo group (P=0.017).  
At the euthyroid timepoint, Ruminococcus 2 (P=0.037) and Faecalitalea (P=0.016) were 
differentially abundant between placebo and probiotic groups after baseline correction, 
while Coprococcus 3 was differentially abundant between placebo and probiotic groups 
at EFU (P=0.044), as represented in Figure 5.9.  
 
Table 5.6. Differences between timepoints in the probiotics using BL-corrected genera. 
 
Differentially abundant genera 
dEU° dEFU° 
Pvalue1 PW2 
mean st dev mean st dev 
Prevotella1 0.00014727 0.0001983 9.20E-07 2.34E-05 0.0258 A,C 
Coprococcus3 0.0006403 0.0043078 0.009074 0.008659 0.0038 B,C 
Lachnospira 0.0011026 0.0016176 -0.000125 0.0007814 0.0487 ns 
LachnospiraceaeNC2004group -0.008904 0.0118492 -0.004959 0.0059762 0.0486 A 
[Eubacterium] hallii group 0.0001678 0.0119254 0.0276037 0.0212737 0.0006 B,C 
uncultured -0.0006915 0.0035229 0.0033214 0.002241 0.0121 B,C 
Ruminiclostridium9 0.0002429 0.0006058 0.0015281 0.0018231 0.0137 B,C 
Subdoligranulum -0.0199163 0.0219667 -0.001122 0.0205589 0.0328 A 
Dielma -0.0001232 0.0001243 -0.000181 0.0002122 0.0178 B 
Erysipelatoclostridium -0.0001079 0.0002672 0.0009839 0.0016308 0.0409 ns 
Turicibacter 0.0007152 0.0013257 0.0055762 0.0065813 0.0086 B,C 
Klebsiella 1.74E-05 2.18E-05 0 0 0.0156 A,C 
 
°BL-corrected EU and EFU (as EU-BL and EFU-BL) mean and standard deviation values. 1P 
value derived from Equation 7, including the dBL as of 0. Only significant genera are shown. 
2 Pairwise comparisons using the Welch’s t-test without correction for multiple testing. A: 
dEU-dBL; B: dEFU-dBL and C: dEFU-dEU comparisons. Ns, not significant after pairwise 
comparison.  
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Table 5.7. Differences between timepoints in placebo using BL-corrected genera.  
 
Differentially abundant 
genera 
dEU° dEFU° Pvalue
1 PW
2 
mean st dev mean st dev 
Bifidobacterium -0.051330879 0.033549 -0.02174718 0.068920 0.0401 A 
Gardnerella 2.07E-05 2.05E-05 -1.64E-05 3.72E-05 0.0242 C 
Atopobium 0 0 1.35E-05 2.03E-05 0.0347 B 
Collinsella -0.001377382 0.007396 0.019308936 0.024335 0.0127 B,C 
Eggerthella 0.00039064 0.000411 -2.20E-05 0.000151 0.0039 A,C 
Senegalimassilia 0.000777938 0.00095 0.0001435 0.000479 0.0246 A 
Capnocytophaga 0 0 -1.42E-05 1.95E-05 0.0196 B,C 
uncultured -2.96E-05 2.72E-05 -9.18E-06 2.05E-05 0.0077 A 
FamilyXIIIAD3011group 0.000720484 0.001081 0.000757159 0.000650 0.0261 ns 
[Eubacterium] nodatum 
group -3.04E-05 6.10E-05 7.49E-05 0.000127 0.0463 ns 
Coprococcus3 -0.002295046 0.001964 -0.00192313 0.003403 0.0414 ns 
Lachnospiraceae 
FCS020 group -0.000384774 0.000421 0.000478409 0.00061 0.0030 A,B,C 
Marvinbryantia -0.000129786 0.000177 0.00092266 0.001476 0.0382 ns 
Pseudobutyrivibrio -0.028084968 0.034214 -1.90E-05 0.028363 0.0451 ns 
unculturedbacterium -0.000175361 0.000168 -7.02E-06 7.94E-05 0.0031 A,C 
Intestinibacter -0.001669128 0.000694 0.000371362 0.002251 0.0136 A,C# 
Flavonifractor 0.000965976 0.001382 -0.00048027 0.000613 0.0111 A,C 
Subdoligranulum 0.013032176 0.030920 0.025564805 0.017653 0.0244 B 
[Eubacterium] 
Coprostanoligenes group 
0.011018647 0.015270 -0.00168526 0.004778 0.0199 A,C 
Coprobacillus 0.000166469 0.000281 -5.51E-05 9.13E-05 0.0413 ns 
Holdemania 0.00017116 0.00025 -1.68E-05 2.32E-05 0.0256 A,C 
Selenomonas3 1.56E-05 2.13E-05 0 0 0.0194 A,C 
Veillonella 5.48E-05 0.000102 -0.00031632 0.000430 0.0148 B,C 
Victivallis 0 0 2.49E-05 3.82E-05 0.0379 B 
uncultured 2.34E-05 3.45E-05 7.40E-05 5.71E-05 0.0009 B,C 
Hafnia -9.18E-06 2.05E-05 2.19E-05 3.51E-05 0.0411 C 
 
°BL-corrected EU and EFU (as EU-BL and EFU-BL) mean and standard deviation values. 1P 
value derived from the equation 7, including the dBL as of 0. Only significant genera are 
shown. 2 Pairwise comparisons using the Welch’s t-test without correction for multiple testing. 
A: dEU-dBL; B: dEFU-dBL and C: dEFU-dEU comparisons, ns, not significant in pairwise 
comparison. # P<0.05 after Bonferroni correction.   
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Figure 5.9. Differences between probiotics and placebo-treated group, using 
baseline-corrected genus counts.  
The median percentage of each genus in either placebo or probiotic group was plotted 
in function of the time, expressed to as change from baseline. dBL is considered to as 0 
and dEUBL: EU-BL and dEFUBL, EFU-BL. Differences between probiotics and placebo 
assessed using the pairwise t-test with Bonferroni correction: * P<0.05.  
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5.4.5. Correlations with clinical features and co-occurrence analysis 
Pairwise correlations between biochemical features (e.g. anti-TSHR antibodies, thyroid 
function tests and total immunoglobulins levels) and the bacterial biomarkers 
enriched  between placebo and probiotic in each timepoint were assessed using the 
Pearson’s correlation coefficient (r). Moreover, although not significantly different 
between the two groups, Lactobacillus and Bifidobacterium spp. counts were included in 
the correlation analysis to observe any possible direct correlation with the biochemical 
features or any co-occurrences (i.e. relationship between bacterial pairs, such as the 
coexistence or the mutual exclusion) with the previously identified bacterial biomarkers.  
At baseline (Figure 5.10), Bifidobacterium spp. weak positively correlated with the fT3 
levels (r=0.2 , P=0.002), which was significant in the placebo group (data not showed). 
Tyzzerella 4 (enriched in the probiotic group) positively correlated with fT4 levels 
(r=0.54  , P=0.049). On a biochemical point-of-view, as expected per diagnosis, TRAK 
positively correlated with TSI levels (r=0.78  , P<0.001), as well as fT3 and fT4 levels 
(r=0.93, P<0.001).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.10. Correlations and co-occurrences heatmap between bacterial 
biomarkers and clinical features at baseline.  
PCC, Pearson’s correlation coefficient. Only correlations with P<0.05 are shown. 
Correlation strength ranges from negative (blue colours) to positive (red colours), as 
described in the legend. (Lab4), bacteria enriched in probiotic group. (P), bacterial 
enriched in placebo group. Lactobacillus and Bifidobacterium spp. were also included 
although not enriched in any group.  
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At the euthyroid timepoint (Figure 5.11), TSH levels negatively correlated with fT3 (r=-1 , 
P=0.0089), as per euthyroid diagnosis. Lactobacillus counts positively correlated with 
TSH levels (r=0.89 , P=0.0084). Probiotic-enriched genera such as Intestinibacter (r=-
0.81, P=0.011) and an uncultured Enterobacteriaceae genus (r=-0.66 , P=0.0068) 
negatively correlated with fT4 levels; moreover, the two genera showed strong co-
occurrence between each other (r=0.65 , P=0.011). Also, genus Odoribacter showed 
negative correlation with total IgA titres (r=-0.46, P=0.033). Placebo-enriched 
Coprobacillus spp. positively correlated with total IgG titres (r=0.85 , P=0.027). 
Erysipelatoclostridium spp. and Lachnospiraceae UCG-004 showed negative correlation 
with TSH levels (r=-0.83, P<0.01), while Lachnospiraceae UCG-004 also positively 
correlated with fT3 levels (r=0.083 , P=0.019). Correlations involving the 
Lachnospiraceae UCG-004 occurred significantly in the placebo group (Figure 5.13). 
Several probiotic-enriched taxa and the genus Lactobacillus showed a mutual-exclusion 
relationship with the placebo enriched Lachnospiraceae UCG-004.  
Figure 5.11. Correlations and co-occurrences heatmap between bacterial 
biomarkers and clinical features at euthyroid.  
PCC, Pearson’s correlation coefficient. Only correlations with P<0.05 are shown. 
Correlation strength ranges from negative (blue colours) to positive (red colours), as 
described in the legend. (Lab4), bacteria enriched in probiotic group. (P), bacterial 
enriched in placebo group. Lactobacillus and Bifidobacterium spp. were also included 
although not enriched in any group. 
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After six months of probiotic or placebo intake (EFU, Figure 5.12), Bifidobacterium  (r=-
0.78 , P=0.016) and Lactobacillus  spp. (r=-0.55, P=0.032) counts strong negatively 
correlated with fT3 levels. However, a similar trend was observed in both placebo and 
probiotics (Data not showed), possibly due to the few samples observed in each group 
at this timepoint. The TSH levels strong negatively correlated to fT4 levels (r=-0.72 , 
P=0.007), as a result of a more euthyroid status. As a co-occurrence pattern identified, 
Bifidobacterium co-occurred with Coprococcus 3 spp. (enriched in probiotic group; 
r=0.75, P=0.02) and Coprococcus 3 co-occurred with Eubacterium hallii  (r=0.77, 
P=0.0026), which were both enriched in the probiotic-receiving group. Lactobacillus 
counts weak co-occurred with Scardovia spp., which was enriched in placebo group. 
Mutual exclusion was identified between probiotic-enriched and placebo-enriched 
genera, such as Anaerostipes and Scardovia spp. (r=-0.27, P=0.012) or Bifidobacterium 
and Megamonas spp. (r=-0.82, P=0.013).   
BL-corrected Ruminococcus 2 showed significant negative correlation with TSI (r=-0.46, 
P=0.013) and TRAK (r=-0.52, P=0.013) and weak positive correlation with TSH (r= 0.16, 
P<0.001) (Figure 5.14).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.12. Correlations and co-occurrences heatmap between bacterial 
biomarkers and clinical features at the end of follow-up.  
PCC, Pearson’s correlation coefficient. Only correlations with P<0.05 are shown. 
Correlation strength ranges from negative (blue colours) to positive (red colours), as 
described in the legend. (Lab4), bacteria enriched in probiotic group. (P), bacterial 
enriched in placebo group. Lactobacillus and Bifidobacterium spp. were also included 
although not enriched in any group.  
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Figure 5.13. Correlation between placebo-enriched Lachnospiraceae UCG-004 and 
clinical features (fT3 and TSH) at the euthyroid timepoint in randomised group.  
Previously identified significant correlations between the placebo-enriched 
Lachnospiraceae UCG-004 and TSH or fT3 in either placebo or probiotic. Pearson’s 
correlation coefficient (R) represents the strength of the correlation in either placebo or 
probiotic group.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.14. Correlations and co-occurrences heatmap between BL-corrected 
differential abundant genera and clinical features at baseline.  
PCC, Pearson’s correlation coefficient. Only correlations with P<0.05 are shown. 
Correlation strength ranges from negative (blue colours) to positive (red colours), as 
described in the legend.  
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5.4.6. Individual variability in response to probiotics intake 
The Lab4® probiotic is composed of bifidobacteria and lactobacilli strains; therefore, the 
change of those two genera across time was specifically observed to determine the rate 
of response to the probiotic intake. Overall, there was an increased amount of 
Bifidobacterium counts over time in the probiotic group compared to the placebo group, 
although not reaching the significant threshold (P=0.1). On the other hand, Lactobacillus 
spp. was generally of a low abundance, with the exception of few outliers (Figure 5.15). 
Individual variability plays an enormous contribution in the response to a probiotic intake.  
Figure 5.16 shows the fluctuation of both Bifidobacterium spp. and Lactobacillus spp. 
over time in each participant on an ITT basis.  
I defined as a “responder” a participant whose Bifidobacterium or Lactobacillus counts 
increased after the recruitment (e.g. at EU or at the EFU or both compared to the 
baseline, Table 5.9). Around 37% and 50% of participants in the probiotic group showed 
an increased Bifidobacterium counts at either EU or EFU, respectively, compared to 
baseline; while 14% and 28% of the placebo group participants in EU and EFU, 
respectively. Lactobacillus spp. increased in 37.5% and 42% of participants in probiotic 
and placebo groups, respectively, at the EU timepoint. At EFU, only 16% of probiotic 
participants showed an increased Lactobacillus counts compared to 28% of placebo 
participants. Moreover, 28% probiotic and 14% placebo participants showed an increase 
in Lactobacillus counts in both EU and EFU compared to the baseline.  
The individual variability was investigated in the 6 patients (4 in probiotic and 2 in placebo 
groups) who provided faecal samples in all timepoints. An heterogenous response to the 
probiotic or placebo intake was showed for which the Bifidobacterium and Lactobacillus 
spp. were concerned (Figure 5.17). As expected, patients showed an individual 
composition of the gut microbiota at baseline, which was slightly modulated either at EU 
or at the EFU (Figure 5.18), as the result of either the Lab4 and ATD or placebo and ATD 
intake. Also the thyroid status may have influenced such a composition. Differential 
abundance of the top-20 most abundant genera across time and within each patient are 
represented in Appendix 26. 
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Figure 5.15. Differences in the Bifidobacterium and Lactobacillus spp. between 
probiotic and placebo in each timepoint.  
Box-and-whiskers plot representing the CSS-normalized genera counts in each 
timepoint per each group. Only genera with P<0.05 from the equation 7 were included. 
 
 
Table 5.8. Rate of responders in placebo or probiotic groups 
 
Target Comparison Placebo  Probiotic  
 EU>BL 1/7 (0.14) 3/8 (0.37) 
Bifidobacterium EFU>BL 2/7 (0.28) 3/6 (0.50) 
 Both° 0/14 0/14 
 EU>BL 3/7 (0.42) 3/8 (0.37) 
Lactobacillus EFU>BL 2/7 (0.28) 1/6 (0.16) 
 Both° 1/7 (0.14) 2/7 (0.28) 
 
°for both EU>BL and EFU>BL.  
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Figure 5.16. Individual variability in Bifidobacterium and Lactobacillus spp counts 
over time.  
(Previous page) Each spot represents the amount of CSS normalized genus in each 
timepoint per each participant on a ITT basis. BL, baseline; EU, euthyroid and EFU, end 
of follow-up.  
 
 
 
Figure 5.17. Individual variability in response to probiotic or placebo intake in the 
per-protocol cohort.  
Bifidobacterium and Lactobacillus spp. CSS-normalized counts plotted in function of time 
in each of the 6 patients, who donated samples in all timepoints.  
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Figure 5.18. Individual variability in the most abundant genera in response to 
probiotic or placebo intake.  
Stacked bar-chart of the top-20 most abundant genera, whose CSS-normalized counts 
were plotted in function of time in each of the 6 patients who donated samples in all 
timepoints.  
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5.5. DISCUSSION  
Supplementation with probiotic bacteria, including lactobacilli and bifidobacteria strains, 
is considered safe [505] also during pregnancy [506]. Such intake, in fact, was previously 
evaluated in pregnant woman both healthy or carrying a foetus at risk of allergies or 
atopic eczema as reviewed in [507]. Probiotics supplementation in preterm babies 
showed a reduced risk of developing necrotizing enterocolitis (NEC) [498-500], while it 
is still debated whether the probiotics supplementation in the early months of life reduce 
the risk of developing allergic reactions, asthma and atopic dermatitis during childhood 
[508, 509]. In adults, effects from a probiotics intake were evaluated not only in patients 
(e.g. IBD) but also in healthy individuals, for immunomodulating purposes or prevention 
of obesity. 
One of the most studied mechanisms of action of probiotics is the stimulation of an anti-
inflammatory immune response, especially through the increase of Tregs [510]. In 
Chapter 3 we reported an increased Tregs moiety in βgal but not in the TSHR-immunised 
mice upon Lab4® early-life administration, possibly suggesting the reduction of Tregs in 
GD/GO pathogenesis. Restoration of Tregs under probiotics supplementation 
constitutes a great interest especially for those conditions characterized by an imbalance 
of Th1/Th2 or Th17/Tregs immune response.  
In this study, we aimed at modifying the gut microbiota of GD/GO patients through the 
concomitant administration of probiotics bacteria and the standard ATD (i.e. 
methimazole) and possibly improve symptoms, prevent hormonal unbalances and/or 
disease relapse.  
5.5.1. Primary and secondary outcomes of the trial 
We hypothesised that the composition of the gut microbiota could have been modulated 
by a probiotic intake and we selected the Firmicutes:Bacteroidetes (F:B) ratio as an index 
for such modulation. The primary endpoint aimed, in fact, at the reduction of the F:B ratio 
of at least 5% in probiotic-treated group compared to placebo group. At the euthyroid 
timepoint, a mean F:B reduction of 14% was observed in the probiotic-treated group, 
while the placebo-treated group showed a reduction of 48%. Using the median values, 
i.e. not influenced by outliers, the F:B ratio showed a 42% reduction in the probiotic-
treated group, while placebo group showed a 3% F:B reduction. At this stage, patients 
would have been treated with antithyroid medications (antithyroid drugs, ATD) to return 
into euthyroid status (see Chapter 1 par. 1.1.1 for definition of euthyroidism). The primary 
endpoint at the EU timepoint was centred (especially for which the median values are 
concerned), although the F:B reduction observed in both probiotics and placebo groups 
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can be due to the strain imposed by thyroid hormones/ATD intake on the gut microbiota 
(as I previously showed in Chapter 4). It might be speculated that the probiotics intake 
could have prevented fluctuations in the gut microbiota composition and potentially in the 
thyroid hormone levels. To this extent, in fact, the probiotics group showed a significantly 
reduced free-thyroxine (fT4) levels compared to the placebo group at the EU timepoint.  
At the euthyroid status, patients may stay euthyroid for a while, also after the cessation 
of the ATD, or may experience a disease relapse. F:B ratio results showed quite 
discordant trend between randomised groups at the end of the trial (end of follow-up, 
EFU) compared to the baseline. The primary endpoint was centred for which the mean 
F:B reduction is concerned (-32% in probiotic and +285% in placebo compared to 
baseline), but it was not centred when looking at the median values (+18% in probiotics 
and -23% in placebo group). An increased Firmicutes phylum can be imputed to the 
effect of probiotics in increasing Firmicutes-prevalent bacteria [511], as I will discuss 
later.  
By looking at the secondary endpoint, we can therefore speculate that the probiotics 
supplementation did mitigate the fluctuations in endocrine and immunological 
parameters, with significant effects on fT4 levels, but also in thyroid-stimulating 
immunoglobulins (TSI) and circulating IgGs and IgAs. Conversely, Spaggiari and 
collaborators did not show any significant improvement of thyroid functions in 
hypothyroid patients being treated with levothyroxine and the VSL#3 consortium [503], 
although they suggested a prevention of the hormonal fluctuations. It has to be noted 
also that the study focussed on primary hypothyroid patients, the opposite of 
hyperthyroidism.  
Overall, the individual variability to a probiotic/ATD intake still played a major role, as 
observed by the presence of outliers. Moreover, as it will be later discussed in Chapter 
6, the number of patients in EU and EFU timepoints was small, both at randomisation 
and at subsequent timepoints due to non-compliance in returning faecal samples. 
therefore the trial may better be considered as a “pilot study”. Moreover, due to the small 
cohort providing samples at all timepoints (4 probiotic-treated and 2 placebo), it was not 
possible to draw conclusions on the prevention of the eye disease or the disease relapse, 
contrary to what we aimed.  
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5.5.2. Modulation of the gut microbiota by ATD/probiotics  
In line with other findings, the administration of Lab4 in presence of ATD did not modify 
the diversity of the gut microbiota [512]. Differences in the gut microbiota were instead 
observed. Probiotic-treated GD/GO patients showed an increase of Eubacterium hallii 
and a range of Firmicutes genera (i.e. Coprococcus 3 and Ruminiclostrium 9) over 
timepoints.  It was interesting to note that the Eubacterium hallii can be itself considered 
to as a probiotic bacterium capable of SCFA (propionate) production [513]. When orally 
administered, it ameliorated the metabolic conditions of the obese and diabetes (db/db) 
mouse model of metabolic syndrome and Type 2 diabetes (T2D), by increasing the 
butyrate production and by modifying the bile acid profiles [514]. Also, species belonging 
to the genus Coprococcus are SCFAs-producers [515]. Both Eubacterium hallii and 
Coprococcus 3 were significantly increased in the probiotic-treated group compared to 
placebo at EFU. At euthyroid, other Clostridiales-related genera showed an enrichment 
upon probiotic intake. 
When correcting for the baseline gut microbiota composition, both Eubacterium hallii and 
Coprococcus 3 still showed a significant enrichment in EFU compared to baseline. 
Interestingly, Eubacterium hallii showed a strong co-occurrence with Coprococcus 3 at 
EFU, which in turn showed strong co-occurrence with Bifidobacterium spp. Although 
Bifidobacterium spp. was not significantly enriched in the gut microbiota compared to 
placebo, it might have favoured the growth of other SCFAs-producing bacteria.  
As far as the modification of bile acid profiles by probiotics is concerned, Lab4® proved 
to reduce the cholesterol levels in vitro and to modulate the bile salts excreted in the 
faeces in vivo [516]. In fact, C57BL/6 mice fed high-fat diet (HFD) plus Lab4+L.plantarum 
for 14 days showed a reduced cholesterol levels in the plasma accompanied by an 
increase of total and unconjugated bile salts in the faeces compared to HDF-alone mice. 
Amongst modulated bile salts, cholic acid (3a,7a,12a-trihydroxy-5b-cholan-24-oic acid) 
was increased upon Lab4+L.plantarum supplementation. The influence of the thyroid 
hormones on the cholesterol levels has been described. Hyperthyroid patients often 
show a reduced plasma low-density lipoprotein (LDL)/cholesterol levels. The reduction 
in the cholic acid synthesis, along with reduction in primary bile synthesis was observed 
in [517]. In a more recent study, however, Bonde and collaborators reported an increase 
in bile acids synthesis in hyperthyroid patients [518]. Interestingly, bile acids 
sequestrants (BAS), normally used for lowering the cholesterol levels in 
hypercholesterolemic patients, in combination with standard ATD showed a faster return 
to the euthyroid status [519] through the binding and the sequestration of thyroid 
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hormone T4 in the gut and their clearance through the faeces8. In the present study we 
did not measured the plasma cholesterol levels nor the bile acid profiles and the T4 levels 
excreted in the faeces; therefore, further studies are needed to explore in the details the 
possible effect of Lab4® on the bile acids levels in hyperthyroid patients. Of interest, our 
recent study on the miRNA and proteins profiles in GD/GO patients identified few 
biomarkers (e.g. Fibronectin, Alpha-2 macroglobulin, Haptoglobin, Fibrinogen amongst 
others) which were also related to the liver fibrosis [440].  
I reported no increase in either Bifidobacterium spp. or Lactobacillus spp. following 
probiotics intake. In a recent study, Zmora and collaborators [520] could not find any of 
the administered probiotic species in the faecal samples via 16S rRNA sequencing, 
implying that the faecal samples and/or the metataxonomic approach were not adequate 
enough for such analysis. On the contrary, they could have identified single probiotic 
bacterial species by performing a high sensitivity qPCR to specifically detect each 
probiotic species on the participant mucosa samples. Based on that, they identified 
participants with a high probiotics colonisation (i.e. “permissive”) and participants with a 
low colonisation rate (i.e. “resistant”). I considered the increase of bifidobacteria as a 
positive response to the probiotic intake (i.e. “responder”) and a slightly higher response 
rate in the probiotic group compared to that of the placebo was observed, although the 
number of samples was not adequate to reach any significant threshold.  
It would be of interest to understand the initial gut microbiota composition which would 
maximise the probiotic effects. Despite our small cohort, I compared the gut microbiota 
at the baseline of those patients considered “responder” to that of the “non-responder” 
and eight genera were enriched in the responder group (Appendix 27), which may favour 
the probiotic colonization. Interestingly, Bifidobacterium spp. was enriched in the non-
responder group, possibly meaning that no further increase in Bifidobacterium spp. 
would occur in presence of an already Bifidobacterium-enriched microbiota.  
5.5.3. Longitudinal modulation of the gut microbiota by antithyroid 
medications  
The gut microbiota of the placebo-treated GD/GO patients can be useful to dissect 
differences due to the ATD intake in a longitudinal manner. The ATD alone, in fact, could 
have had an impact on the gut microbiota composition. In their recent study, Maier and 
collaborators reported a reduced Bacteroides caccae in presence of methimazole (MTZ) 
                                               
8 Salazar, 2016. “Adjunctive bile acid sequestrant therapy for hyperthyroidism in adults” 
Cochrane Database of Systematic Review” accessible from 
https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012260/full  
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in vitro [264]. In the present study, Bacteroides spp. did not show any differences in either 
probiotic or placebo group, or when analysed longitudinally in each individual. One may 
suggests that the amount of active compound reaching the gut in vivo differs from the 
amount tested in vitro (i.e. 20µM). At present, no studies evaluated the amount and the 
role of MTZ on the gut microbiota in hyperthyroid patients.  
Taxonomies that were enriched following probiotic treatment, such as Coprococcus 3 
and Marvinbyrantia, were instead decreased in the placebo group, possibly suggesting 
their role in lowering the thyroid hormone levels. Moreover, none of the previous GD/GO 
associated genera (i.e. reduced Bacteroides spp. or increased Fusicatenibacter spp.) 
identified in Chapter 4 were here observed.  
5.6. CHAPTER CONCLUSIONS 
To conclude, the present chapter showed results of the pilot probiotics intervention on 
GD/GO patients under antithyroid medications treatment. Even if the number of samples 
available was small, modulation of the gut microbiota following LAB supplementation 
may have strengthened the action of the ATD in lowering the thyroid hormone levels 
(fT4) and in stabilizing hormone fluctuations.  
In order to confirm our results, it would therefore of interest to perform a bigger probiotic 
trial, exploring also mechanisms such as the interaction between probiotics, SCFAs, bile 
acids profiles and thyroid hormones.  
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6. Chapter 6  
 
 
 
 
 
 
 
 
 
 
General Discussion  
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6.1. GENERAL DISCUSSION 
The aetiology of autoimmune diseases is currently not completely understood, due to the 
complex interaction between genetic predisposition and the environmental stimulus, 
which may be by sex hormones (especially after pregnancy), stress, smoking habits, 
and/or microbial and viral infections.  
The role of bacterial antigens in triggering autoimmune thyroid diseases, including GD, 
it has been previously proposed [148, 454]. In particular, the molecular mimicry between 
Yersinia enterocolitica antigens and the TSHR epitopes was previously proposed for the 
breakdown of the immune tolerance to thyroid antigens, as reviewed in [454], although 
it has been long debated. To investigate the involvement of bacterial antigens in our GD 
cohort, I initially tested the immune response to whole-cells bacterial antigens from three 
foodborne environmental bacteria (E.coli, Yersinia enterocolitica, Salmonella 
typhimurium) in the serum of a small cohort of female GD patients and of female and 
male healthy controls (unpublished data, Figure 6.1A). Both patients and controls 
responded to all bacterial antigens (Figure 6.1B), which reflected the wide diffusion of 
these bacteria in the environment. Only Y. enterocolitica cultured at 37°C out of the other 
bacterial antigens, showed a significant response in both GD patients whole-serum and 
IgG fractions (Figure 6.1C and 6.1D). Although our results confirmed previous results 
from current literature, such a cross-reaction is unlikely to be responsible for the onset 
of all GD/GO cases. Moreover, I did not detect any Y. enterocolitica in the gut microbiota 
of either mouse models or patients from the 16S rRNA gene sequencing.  
The concept of the gut microbiome as a possible trigger for an autoimmune response 
has gained more attention in the past years, with evidence describing perturbed 
composition of the gut microbiota not only in gut-related autoimmune conditions (i.e. IBD, 
Crohn’s disease and ulcerative colitis), but also in non-gut related autoimmune diseases 
(i.e. diabetes, multiple sclerosis…), as previously introduced in Chapter 4.  
 
 
 
 
 
  
 
 
231  
 
Figure 6.1. Immune response to foodborne bacterial antigens in a GD patients.  
(A) The immune response to whole-cells bacterial antigens was tested in a cohort of 
female GD patients (n=10, enrolled in University Hospital Milano Cà Granda, Milan) and 
compared to that of healthy controls (HC, n=10 females and a pool of healthy young 
males, enrolled in University Hospital of Wales, Cardiff) through an indirect Enzyme-
Linked Immunosorbent Assay (ELISA). Bacterial whole-cells antigens derived from  
E.coli (EC), Salmonella typhimurium (ST) and Yersinia enterocolitica (YE), which were 
purchased from ATCC and cultured in Luria Bertani broth (Appendix 1) at 37°C. YE was 
also cultured at 30°C. Optimisation of the ELISA condition was performed using positive 
reference serum provided by University Clinic Duisburg-Essen. Each well contained 106 
cfu/mL bacterial antigens. (B) GD and HC responded according to the level of exposure 
to each bacterial antigens. Box and whiskers plot of the immune response of GD and HC 
using total serum to 4 different bacterial whole-cells antigens. According to the Mann-
Whitney-Wilcoxon test, only YE cultured at 37oC gave differential immune response 
between GD and HC (*** P=0.001). Statistics was performed with R package. (C) The 
specificity of the serum response to YE antigens was confirmed using purified IgGs. Total 
IgGs were purified from total serum using protein-A SpinTrap (GE, Healthcare), following 
manufacturer procedures. GD2, GD3 and GD8, GD9, individual GD patients tested for 
YE IgG-mediated response. STD, positive reference serum against YE. (D) Boxplots of 
the immune response (total serum and IgGs) to YE antigens cultures either at 30oC or 
37oC. According to the Mann-Whitney-Wilcoxon test, only YE cultured at 37oC gave 
differential immune response between GD and controls (*** P<0.01). 
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6.1.1. Main conclusions of the present work 
In order to unravel the role of the gut microbiome in GD/GO, my work was composed of 
two observational studies and of two interventional trials, involving both the GO animal 
model and GD/GO patients, respectively.  
I characterized the gut microbiota of the GO animal model described in [187], both during 
and at the end the immunisation process (Chapter 2). The gut microbiota composition 
differed between TSHR-A subunit immunised mice and controls, with a shift of the 
bacterial communities accompanied by a significantly increased Firmicutes and reduced 
Bacteroidetes phyla in the TSHR-immunised mice, compared to the others. Such 
changes occurred specifically along with the immunization procedure. Furthermore, I 
described a positive correlation between the phylum Firmicutes and the orbital-
adipogenesis in TSHR-immunised, but not in the control group. In the hypothesis that 
the gut microbiota can be considered to be an environmental factor, I found a different 
gut microbiota composition in TSHR-immunised mice established in two independent 
laboratories, possibly explaining the differences in the replication of the animal model.  
The second observational study involved GD/GO patients, whose microbiome was 
compared to that of healthy controls, as presented in Chapter 4. I described GD and GO-
associated taxonomies, such as reduced Bacteroides. and increased Fusicatenibacter 
genera. The gut microbiota composition and the predicted metagenomic functions of the 
moderate-severe GO were more similar to that of healthy controls, but it was 
accompanied by an increased Roseburia spp. Although there was the involvement of the 
immune system components (as also observed in the predicted metagenomic functions), 
our results on the patients’ microbiome suggested that thyroid hormones played a major 
role in shaping the gut microbiota composition. 
The two interventional studies here performed aimed at manipulating the gut microbiota 
composition of both GO mouse model and GD/GO patients, and were set to answer 
essentially two different questions: i) whether the gut microbiome is necessary for 
developing autoimmune thyroid disease and ii) whether supplementation with probiotic 
bacteria might have improved the symptoms and prevented hormonal fluctuations or 
disease relapses.  
In the first case, the GO mouse model was treated from the early days of life with either 
antibiotics, probiotics or faecal material transplant from sight-threatening GO patients 
(hFMT). The reduced and resilient bacterial community (including high counts of 
Bacteroides spp. and Akkermansia spp.) derived from the long-term vancomycin 
treatment protected from the disease outcome. The highest hFMT engraftment was 
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observed after three repeated gavages, but seemed to have long-term effect on the gut 
microbiota composition (i.e. lowest Bacteroides spp. in the TSHR group compared to the 
respective controls). Surprisingly, it induced signs of eye disease in fewer mice than 
expected. Lab4 probiotics administration increased the Actinobacteria and the 
Firmicutes phyla, amongst others. Despite increasing the Tregs population, exacerbated 
autoimmune hyperthyroidism, potentially through an independent mechanism compared 
to the pathogenic one.  
The same probiotic consortium was administered for six months along with the 
antithyroid treatment in GD/GO patients in a single-centre, placebo controlled trial. The 
gut microbiota of probiotic-treated GD/GO patients showed a more reduced 
Firmicutes:Bacteroidetes ratio when reaching the euthyroid timepoint compared to the 
placebo. Also, an increase of SCFA-producing bacteria (e.g. Bifidobacterium spp., 
Eubacterium hallii and Coprococcus spp.) occurred in probiotic-treated patients, which 
may have possibly prevented thyroid hormones fluctuations (i.e. fT4), instead observed 
in the placebo-receiving group.  
Until recently, only few studies have investigated the contribution of the gut microbiota in 
thyroid autoimmune diseases [521]. While this study is the first presenting the role of the 
gut microbiome in GO mouse models, in the last year, however, two published studies 
addressed the gut microbiota in Hashimoto’s thyroiditis (HT) patients [438, 444] and two 
studies addressed the gut microbiota in GD [439] and GO patients [447], respectively. I 
noted only few similarities between their results and those produced by the present work 
due to differences in the methodology but also in the cohort characteristics. In fact, they 
used primers against the V3-V4 regions of the 16S rRNA gene, which could lead to a 
different taxonomic identification [522]. Moreover, differences in the gut microbiota 
composition between Chinese and European populations (e.g. Danish) have been 
previously described [523]. 
 
6.1.2. Considerations on the 16S rRNA gene sequencing processing and data 
analysis  
16S rRNA gene sequencing data can be a statistical challenge due to reasons 
summarized by Weiss and collaborators [524]. i) different numbers of sequences might 
be attributed to the efficiency of sequencing itself rather than to a true variation in the 
microbial composition, since biological samples are complex. Moreover, the increase of 
the sequencing depth can result in the discovery of more bacterial species; ii) The OTU 
table often contains a high proportion of zero values being defined as “sparse” or “zero-
inflated” [354], resulting often in the uncertainty in the definition of rare OTU counts; and 
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iii) the resulting data is a small percentage of the original environment being sampled, 
thus we can refer to the amount of OTU as relative abundance, constraining the total 
number of rRNA gene sequences to a constant sum [524]. For such reasons, library 
normalization and pruning – or removal of low quantity OTUs - of the OTU table are most 
often conducted before statistical analysis.  
Reads obtained in this work were of a good quality and, after alignment to the reference 
database, the mean Good’s coverage was appreciable (i.e. calculated in Chapter 2). I’m 
confident that the depth of sequencing of the microbiota was sufficient to describe all the 
possible OTUs (sequenced-based rarefaction), and that the addition of any other 
samples would not increase the number of OTUs detected (sample-based rarefaction). 
In order to reduce differences in the library size, in Chapter 2, I opted for a subsampling 
or rarefying method in which each sample library size is reduced to the smallest one. It 
might be argued that subsampling can cause the loss of statistical power (type II-error) 
and, in turn, a possible increase of the number of false-positive differentially abundant 
taxa [525] However, it has been widely accepted in a large number of studies reported 
in the literature, supported by the majority of metataxonomics pipelines, e.g. [207, 208], 
and still retained as a good choice for normalization in a recent study [524].  
However, results from Chapter 3 are not directly comparable with those obtained in the 
Chapter 2 since the bioinformatic pipeline used is different (Mothur [207] vs. QIIME [208]) 
and it employs a different taxonomic assignment (open reference OTU picking vs. 
closed-reference OTU picking, respectively). Such a change in the bioinformatic 
methodology was dictated by highly heterogeneous library sizes obtained from the 
manipulation study in Chapter 3, for which the cumulative sum-scaling (CSS) 
normalization [354] was preferred to the sub-sampling. The small size of some 
sequencing libraries obtained in Chapter 3 might be due to the chronic antibiotic 
treatment, which might have depleted also the amount of 16S rRNA gene template 
available for PCR; although the bacterial load cannot be directly estimated from the 
library size [526]. I also interestingly observed a doubled amount of processed reads in 
the antibiotic-treated samples (Table 3.3), possibly derived from either a low abundant 
16S rRNA genetic template, or from a few but resistant bacterial species. However, only 
the quantification of the total bacterial load or the 16S rRNA gene sequencing using 
propidium monoazide (PMA) for death/alive bacterial discrimination [527] can resolve 
this observation. 
The QIIME pipeline employed in Chapter 3 was performed also in the subsequent 
Chapter 4 and 5. This decision was dictated by an easier implementation of downstream 
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analyses such as the prediction of the metagenomic functions (Tax4Fun) and the 
SourceTracker using QIIME-derived OTU table instead of Mothur.  
Prediction of the metagenomic functions from the 16S rRNA gene sequencing survey 
has been receiving an increasing interest, also due to its cost-effectiveness. Different 
pipelines are now available (PICRUSt [528], Tax4Fun [360] and Piphillin [529]), although 
no differences in terms of predicted functions/orthologs were observed between 
PICRUSt and Tax4Fun [352, 529], while some differences were observed using Piphillin, 
at least when using disease metadata [529]. Such a consistency in predicting 
metagenomic functions amongst bioinformatic tools may be due to: i) KEGG pathways 
and orthologs only imputed against known OTUs/functions, which constitutes also a 
limitation of the technique at the present, and ii) existing functional redundancy across 
bacterial species (i.e. different species encoding for the same functions), especially in 
stressed conditions [530]. 
With regard to the statistical approaches performed in Chapter 5, I’m fully aware that 
other methods are available for baseline-correction of a dataset. Another option, for 
example, could have been the use of mixed-effects models (MEMs). MEMs, by definition, 
would allow the introduction of random effects (e.g. each patient variability of the gut 
microbiota in response to a probiotics intake) to be modelled through random intercepts 
and/or through random slopes. The resulting standard error and P values will be adjusted 
and will represent the fixed effects taking into account the random variables. However, 
MEMs were not the focus of the analysis, also because of the small sample size.  
 
6.1.3. Strengths and weaknesses of the present work 
The present study benefited from the use of up-to-date tools and approaches, including 
microbiota manipulation using faecal material transplant (hFMT) and probiotics, as well 
as machine-learning algorithms, statistical analysis which evolved through the chapters 
and prediction of metagenomic functions. Moreover the following strengths are worth 
mentioning: 
i) The first two results chapters involved the expertise in producing, replicating and 
manipulating a GO animal model. Therefore, we were the first in describing the possible 
role of the microbiota in the establishment but also in the replication of the animal model 
in different laboratories [322]. 
ii) Chapter 4 is based on a large European cohort of GD/GO patients, benefiting also 
from the collaborations with members of the EUGOGO team. In fact, 211 patients and 
46 controls were initially enrolled in the study, of those 171 and 42 provided at least one 
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faecal samples. After removal of not-eligible patients, 105 patients and 41 controls were 
included in the analysis of the baseline samples. 
iii) It was interesting to note that the GO mouse model and GD/GO patients showed 
some consistent patterns of the gut microbiome, despite anatomical differences, gut 
microbiota compositions and also the immune system between murine and humans 
[531]. In fact, the reduction of Bacteroidetes and genus Bacteroides was reported in both 
TSHR-mice and GD/GO patients compared to controls, which was furthermore observed 
in hFMT-immunised mice. In a more speculative manner also, Akkermansia spp. was 
enriched in Lab4-treated TSHR-immunised mice, showing hyperthyroidism but not 
developing signs of eye disease and in untreated GD patients with no signs of 
concomitant eye disease compared to healthy controls. However, GO mouse model and 
GD/GO patients differed in their response to the probiotics consortium, since it increased 
hyperthyroidism in mice but mitigated thyroid hormones fluctuations (i.e. fT4) in humans.  
iv) Moreover, this study benefitted by another multi-omics study being performed within 
the INDIGO project. In [440], we combined circulating miRNAs and proteins to obtain a 
predictive panel of biomarkers for disease diagnosis and eye-disease prognosis. It was 
interesting to note similarities in some of the predicted metagenomic pathways with those 
obtained by miRNA and proteins, possibly supporting a common pathogenic 
mechanisms.  
Besides strengths, I also identified some weaknesses: 
i) In the comparison of the GO animal models in independent facilities presented in 
Chapter 1, I’m fully aware that the analysis lacks control samples from Centre 1 (βgal 
samples), and for that reason I focused on differences in the gut microbiota specifically 
in mice which underwent a protocol of immunization with the TSHR-plasmid, which have 
shown differences in the disease outcome, as described in the previous work [187]. 
Moreover, there was no faecal material left to perform a faecal material transfer between 
Centre 1 to Centre 2 mice, in order to confirm any protection/susceptibility conferred by 
the microbiota itself.  
ii) The chronic vancomycin treatment prevented the production of the stimulating 
antibodies (TSAb), the hallmark of GD/GO, along with hyperthyroidism and signs of eye 
disease. However, whether this could help GD patients would require assessment of the 
effects of vancomycin administration at different stages of the immunisation procedure 
in mice. Also, the use of more targeted antibiotics would better dissect which bacterial 
species have a major protective role in GO. In contrast, although hFMT induced TSAb it 
prevented the hyperthyroidism and the eye disease. This surprising result may be due 
to our using the faecal samples from sight-threatening GO patients to produce the freeze-
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dried material, as they are the most severe form of GO. However, in such a condition, 
patients have been treated with anti-thyroid drugs and/or cortisones for years and 
underwent ocular decompression surgery, and they do not present an active form of the 
eye disease. Moreover, the majority of donor patients currently smoked at the time of 
sample collection and smoking is known to alter the gut microbiota (reviewed in [441]). 
Also, I demonstrated that the microbiota composition changes based on thyroid activity 
(hyperthyroid vs. euthyroid patients) or a more active eye disease; thus, hFMT using 
material from different stages of disease might be also informative. Moreover, pre-
treatment with antibiotics or use of GF animals may help reducing heterogeneity in the 
engraftment.  
iii) The study presented in Chapter 4 lacks an adequate number of first-diagnosis 
untreated patients. Moreover, to fully understand the role of thyroid hormones in shaping 
the gut microbiota, it would have been of interest having other forms of hyperthyroidism 
included in the study, such as the multinodular goitre. The present cross-sectional study 
enrolled patients and matched healthy controls from four European centres. Although 
the diet consumed in those nations is prevalently a Western diet, differences in the gut 
microbiota can be also due to different intake of dietary proteins, carbohydrates and 
fibres. A diet and lifestyle questionnaire was provided to each patient at the moment of 
the enrolment. Not all of questionnaire were returned. Moreover, it was based on the 
patient’ self-assessment and not submitted with the help of a dietician. Therefore, those 
data were not considered in the analyses, although we value the importance. At present, 
an ongoing study is focussing on the role of food antigens in breaking down the immune 
tolerance in GD/GO patients (Covelli D, personal communication). 
iv) The probiotic trial presented in Chapter 5 was under-powered. The initial power 
calculation, in fact, required the presence of at least 31 patients in each arm, “to be able 
to detect a result present in 40% of cases and only 5% of controls” (“Sinossi” for Comitato 
Etico Milano). Moreover, there was a low-compliance in returning the faecal samples at 
further timepoints after baseline. Although not commonly used, there are some 
approaches available to calculate the power calculation for microbiome-based studies 
[532, 533]. Interestingly, the work of Spaggiari et al. [503] providing VSL#3 to hypothyroid 
patients during levothyroxine treatment included 39 and 41 patients in each arm. One 
may argue that the lack of highly significant effects on thyroid hormone levels may be 
due to the underpowered study. It would be therefore of interest to perform a bigger trial, 
potentially multi-centre, in order to include more patients in each arm and to potentially 
obtain more faecal samples in further timepoints for the microbiome analysis.  
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6.1.2. Future perspectives 
As often occur in cross-sectional case-control studies, patients enrolled already present 
some signs of disease and therefore, the composition of their gut microbiota is already 
to be considered to as a “disease-associated gut microbiota”. Moreover, as far as 
autoimmune diseases are concerned, it is of interest assessing the composition of the 
gut microbiota before the breakdown of the immune tolerance, in order to obtain a panel 
of bacteria able to predict the risk of developing and/or the prognosis of that disease. 
Studies on the animal models, as the one presented in Chapter 3, are therefore 
necessary. As being performed in other diseases such as IBD [534] or in Parkinson’s 
disease (ClinicalTrials.gov Identifier: NCT03645226), high-risk first-degree relatives 
could be followed over time to look for specific patterns determining the disease 
insurgence, or its protection. In the case of GD, however, it could be of a great interest 
analysing the gut microbiota of multiple sclerosis (MS) patients undergoing the Campath-
1H (Alemtuzumab) treatment in a longitudinal manner. As described in Chapter 1 par. 
1.4.2, MS-Alemtuzumab treated patients are at a high risk of developing GD in the three 
years after treatment, during the immune reconstitution phase.  
In the present study we considered the gut microbiota as an environmental factor, 
possibly conferring susceptibility in the breakdown of the immune tolerance. Patients 
enrolled in the study were genetically heterogeneous. We are aware that the genetic 
background is also conferring protection or susceptibility for developing such 
autoimmune conditions, as described in Chapter 1 par. 1.3.1. The link between the 
genetic background and the gut microbiota composition in the GO mouse model was 
described in our recent work [366]. C57BL/6J mouse strain, characterized by a different 
MHC/HLA genotype compared to that of the BALB/c (used in both Chapter 2 and 3), 
showed a more resistant phenotype after TSHR-immunisation. Also the gut microbiota 
between C57BL/6J and BALB/c mice being immunised with TSHR was different. It would 
be therefore of interest performing the HLA genotyping on the enrolled patients and 
perform a microbiome analysis in genetic susceptible and genetic non-susceptible 
patients. The effect of gender moreover can be extended to a further characterization of 
sex hormones (progesterone, oestrogen, oxytocin and testosterone). The interaction 
between these hormones and the gut microbiota in GD/GO patients can be investigated 
through their quantification in the blood and by obtaining a more accurate description of 
the menstrual/menopausal phase of the female patients.  
As expected, the differential abundant taxonomies identified in both GO mouse model 
and GO patients interacted to some extent with both endocrine (i.e. TSH, fT3 and fT4) 
and immunological parameters (i.e. anti-TSHR antibodies, IgG and IgA). Although GD is 
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an antibody-based autoimmunity, also T cells play an important role in the disease 
pathogenesis (see Chapter 1 par. 1.1.4). Apart from the proportion of Tregs at the 
draining lymph nodes observed in the mouse model, the Tregs/Th17 T cell populations 
were not quantified in the murine gut mucosa or in GD/GO patients. It would be of 
interest, in fact, performing a similar immunophenotyping to that described in multiple 
sclerosis patients [420]. 
This work was based on the 16S rRNA gene sequencing. This high throughput and cost-
effective approach allowed the sequencing of hundreds of samples and from their 
analysis I obtained the identity of the bacterial taxa present in the samples and from their 
relative abundance I obtained estimation on the diversity of the bacterial communities 
and their differential abundance between groups. Recent tools enabled us to predict the 
metagenomic pathways in which those bacterial taxonomies may be involved. Despite 
providing a broad information, such a prediction of the metagenomic pathways may not 
be accurate enough to understand the precise molecular mechanisms. Thus, a 
metagenomic approach, or the whole-genome sequencing would be necessary, in at 
least in a target number of samples, to confirm observed data. We tested a small cohort 
of patients for bacterial-derived metabolites through NMR, and we observed differences 
in the metabolite profiles of moderate-severe/sight-threatening GO patients compared to 
controls. It would be of interest extending such analysis to a larger cohort, including the 
quantification of SCFAs to draw more mechanistic conclusions on our first set of data. 
6.2. CONCLUSIONS 
Our data illustrate substantial perturbation of the gut microbiota microbiome associated 
to GD and GO in both mouse model and patients, with some similarities. Future studies 
are needed to dissect the mechanistic role of the gut microbiome in activating the 
immune system, determining the onset of GD/GO. Collectively, the present work 
provides new insights in understanding a multifactorial disease proposing a new “gut-
thyroid-eye” axis (Figure 6.2), and, even if preliminary, they would be of a potential help 
for the early diagnosis and prognosis of the eye-disease severity.  
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Figure 6.2. Summary of the thyroid, the eye and the gut relationship in Graves’ disease 
and Graves’ orbitopathy. 
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8. Appendix 
 
Appendix 1: Composition of the microbiology media used in the study 
 
1. Nutrient Agar (Sigma Aldrich, Germany): 
Composition Amount 
Agar 15 g/L 
Meat extract 1 g/L 
Peptone 5 g/L 
Sodium chloride 5 g/L 
Yeast extract 2 g/L 
Final pH 7.1 ± 0.2 (25 °C) 
 
2. Nutrient Broth (Sigma Aldrich, Germany): 
Composition Amount 
Glucose-D(+) 1 g/L 
Peptone 15 g/L 
Sodium chloride 6 g/L 
Yeast extract 3 g/L 
Final pH 7.5 ± 0.2 (25 °C) 
 
3. Luria Bertani (LB) Broth (Sigma Aldrich, Germany): 
Composition Amount 
Tryptone 10 g/L 
Sodium chloride 0.5 g/L 
Yeast extract 5 g/L 
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Appendix 2: Mothur Pipeline via Command-line according to [207]  
 
#tmux session command line 
tmux new -s INDIGO -n  #new session 
tmux kill-session -t INDIGO #stop session 
tmux ls #explore how many tmux you entered and the name of each one 
tmux a -t INDIGO #enter existing session 
Ctrl-B and then D #leave/detach session 
 
#Mothur command-line 
#reach the folder with all the unzipped fastq files via command line  
#if used on a multi-processor server, n. processors can be selected via e.g. ‘processor=30’ 
#Type ‘Mothur’ to enter the command-line: 
 
### Make contigs and count the number of reads obtained ### 
make.contigs(file=INDIGO.txt) 
 
summary.seqs(fasta=INDIGO.trim.contigs.fasta) 
 
screen.seqs(fasta=INDIGO.trim.contigs.fasta, group=INDIGO.contigs.groups, 
summary=INDIGO.trim.contigs.summary, maxn=0, maxambig=0, maxhomop=6, minlength=344, 
maxlength=377) 
 
#### Processing improved sequences ### 
summary.seqs(fasta=INDIGO.trim.contigs.good.fasta) 
 
unique.seqs(fasta=INDIGO.trim.contigs.good.fasta) 
 
count.seqs(name=INDIGO.trim.contigs.good.names, group=INDIGO.contigs.good.groups) 
 
count.groups(count=INDIGO.trim.contigs.good.count_table) 
 
align.seqs(fasta=INDIGO.trim.contigs.good.unique.fasta, reference=./16S_refDB/silva.bacteria.fasta) 
 
#### Processing aligned sequences ### 
summary.seqs(fasta=INDIGO.trim.contigs.good.unique.align, 
count=INDIGO.trim.contigs.good.count_table) 
 
screen.seqs(fasta=INDIGO.trim.contigs.good.unique.align, count=INDIGO.trim.contigs.good.count_table, 
summary=INDIGO.trim.contigs.good.unique.summary, start=1044, end=6424, maxhomop=5) 
  
summary.seqs(fasta=INDIGO.trim.contigs.good.unique.good.align, 
count=INDIGO.trim.contigs.good.good.count_table) 
 
count.groups(count=INDIGO.trim.contigs.good.good.count_table) 
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filter.seqs(fasta=INDIGO.trim.contigs.good.unique.good.align, vertical=T, trump=.) 
 
unique.seqs(fasta=INDIGO.trim.contigs.good.unique.good.filter.fasta, 
count=INDIGO.trim.contigs.good.good.count_table) 
 
pre.cluster(fasta=INDIGO.trim.contigs.good.unique.good.filter.unique.fasta, 
count=INDIGO.trim.contigs.good.unique.good.filter.count_table, diffs=2) 
 
chimera.uchime(fasta=INDIGO.trim.contigs.good.unique.good.filter.unique.precluster.fasta, 
count=INDIGO.trim.contigs.good.unique.good.filter.unique.precluster.count_table, dereplicate=t) 
 
remove.seqs(fasta=INDIGO.trim.contigs.good.unique.good.filter.unique.precluster.fasta, 
accnos=INDIGO.trim.contigs.good.unique.good.filter.unique.precluster.uchime.accnos) 
 
split.abund(fasta=INDIGO.trim.contigs.good.unique.good.filter.unique.precluster.pick.fasta, 
count=INDIGO.trim.contigs.good.unique.good.filter.unique.precluster.uchime.pick.count_table, cutoff=2) 
 
######### Remove singletons and non-bacterial sequences ######## 
classify.seqs(fasta=INDIGO.trim.contigs.good.unique.good.filter.unique.precluster.pick.abund.fasta, 
count=INDIGO.trim.contigs.good.unique.good.filter.unique.precluster.uchime.pick.abund.count_table,refer
ence=./16S_refDB/trainsettrainset14_032015.rdp/trainset14_032015.rdp.fasta, 
taxonomy=./16S_refDB/trainset14_032015.rdp/trainset14_032015.rdp.tax, cutoff=80) 
 
classify.seqs(fasta=INDIGO.final.fasta, 
count=INDIGO.trim.contigs.good.unique.good.filter.unique.precluster.uchime.pick.abund.count_table,refer
ence=./16S_refDB/trainset14_032015.rdp/trainset14_032015.rdp.fasta, 
taxonomy=./16S_refDB/trainset14_032015.rdp/trainset14_032015.rdp.tax, cutoff=80, output=simple)   
 
remove.lineage(fasta=INDIGO.trim.contigs.good.unique.good.filter.unique.precluster.pick.abund.fasta, 
count=INDIGO.trim.contigs.good.unique.good.filter.unique.precluster.denovo.uchime.pick.abund.count_tab
le, 
taxonomy=INDIGO.trim.contigs.good.unique.good.filter.unique.precluster.pick.abund.rdp.wang.taxonomy,t
axon=Chloroplast-Mitochondria-unknown-Archaea-Eukaryota) 
 
cluster.split(fasta=INDIGO.trim.contigs.good.unique.good.filter.unique.precluster.pick.abund.fasta,count=I
NDIGO.trim.contigs.good.unique.good.filter.unique.precluster.uchime.pick.abund.count_table,taxonomy=I
NDIGO.trim.contigs.good.unique.good.filter.unique.precluster.pick.abund.rdp.wang.taxonomy,splitmethod=
classify, taxlevel=4, cutoff=0.15) 
 
######### Obtain OTU table, taxonomy and perform a subsample based on smallest library size 
######## 
summary.tax(taxonomy=current, count=current) 
 
count.groups(count=current) 
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make.shared(list=INDIGO.trim.contigs.good.unique.good.filter.unique.precluster.pick.abund.an.unique_list.
list, count=INDIGO.trim.contigs.good.unique.good.filter.unique.precluster.uchime.pick.abund.count_table, 
label=0.03) 
 
classify.otu(list=INDIGO.trim.contigs.good.unique.good.filter.unique.precluster.pick.abund.an.unique_list.lis
t, count=INDIGO.trim.contigs.good.unique.good.filter.unique.precluster.uchime.pick.abund.count_table, 
taxonomy=INDIGO.trim.contigs.good.unique.good.filter.unique.precluster.pick.abund.rdp.wang.taxonomy, 
label=0.03) 
 
count.groups(count=INDIGO.trim.contigs.good.unique.good.filter.unique.precluster.uchime.pick.abund.cou
nt_table) 
 
sub.sample(shared=INDIGO.trim.contigs.good.unique.good.filter.unique.precluster.pick.abund.an.unique_li
st.shared) 
 
######### phylotypes analysis ################# 
phylotype(taxonomy=current) 
make.shared(list=INDIGO.trim.contigs.good.unique.good.filter.unique.precluster.pick.abund.rdp.wang.tx.lis
t, count=current, label=1-5) 
 
######### rename latest files to be used in subsequent analysis################# 
#on a linux bash (switch Tmux terminals): cp would copy and rename retaining the original #version of the 
file 
cp ./INDIGO.trim.contigs.good.unique.good.filter.unique.precluster.pick.abund.fasta ./INDIGO.final.fasta 
 
cp 
./INDIGO.trim.contigs.good.unique.good.filter.unique.precluster.pick.abund.an.unique_list.0.03.subsample.
shared  ./INDIGO.final.subsampled.shared 
 
cp ./INDIGO.trim.contigs.good.unique.good.filter.unique.precluster.pick.abund.an.unique_list.shared  
./INDIGO.final.shared    
 
cp INDIGO.trim.contigs.good.unique.good.filter.unique.precluster.pick.abund.an.unique_list.list 
INDIGO.final.list 
cp ./INDIGO.trim.contigs.good.names  ./INDIGO.final.names 
 
cp ./INDIGO.contigs.good.groups ./INDIGO.final.groups 
 
######### phylogenetic analysis ################# 
#on the Mothur command-line 
dist.seqs(fasta=INDIGO.final.fasta, output=phylip) 
 
#on a linux bash (switch Tmux terminals without having to close Mothur): lauching fasttree 
fastTree -nt INDIGO.final.fasta > INDIGO.final.tre 
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######### calculate ALPHA diversity ################# 
#using rarefied but not-subsampled dataset 
collect.single(shared=INDIGO.final.shared, calc=sobs-chao-ace-shannon-shannoneven-simpson, freq=1) 
summary.single(calc=nseqs-coverage-sobs-chao-ace-shannon-shannoneven-simpson) 
rarefaction.single(shared=INDIGO.final.subsampled.shared, calc=sobs, freq=5) 
 
#filtered-rarefied subsampled dataset 
collect.single(shared=INDIGO.final.subsampled.0.03.filter.shared, calc=sobs-chao-ace-shannon-
shannoneven-simpson, freq=1) 
summary.single(calc=nseqs-coverage-sobs-chao-ace-shannon-shannoneven-simpson) 
rarefaction.single(shared=INDIGO.final.subsampled.0.03.filter.shared, calc=sobs, freq=5) 
 
#filtered-rarefied non-subsampled dataset 
collect.single(shared=INDIGO.final.0.03.filter.shared, calc=sobs-chao-ace-shannon-shannoneven-
simpson, freq=1) 
summary.single(calc=nseqs-coverage-sobs-chao-ace-shannon-shannoneven-simpson) 
 
######### calculate BETA diversity ################# 
#when using Unifrac = weighted is natively normalized (subsample = N), while unweighted is 
presence/abscence #therefore use the non-subsampled shared 
unifrac.unweighted(tree=INDIGO.final.tre, name=INDIGO.final.names, group=INDIGO.final.groups, 
distance=square, random=F) 
unifrac.weighted(tree=INDIGO.final.tre, name=INDIGO.final.names, group=INDIGO.final.groups, 
distance=square, random=F, subsample=1046) 
 
######### modify the fasta file and process the taxonomic classification with RDP ######### 
#on the Mothur command-line: 
get.oturep(phylip=INDIGO.final.phylip.dist, 
list=INDIGO.trim.contigs.good.unique.good.filter.unique.precluster.pick.abund.an.unique_list.0.03.subsam
ple.list,fasta=INDIGO.final.fasta, label=0.03) #use large=true for very large distance files otherwise omit 
 
#get the otu.rep from the subsampled share and subsampled list 
sub.sample(list=INDIGO.trim.contigs.good.unique.good.filter.unique.precluster.pick.abund.an.unique_list.li
st) 
get.oturep(phylip=INDIGO.final.tre1.weighted.phylip.dist, 
list=INDIGO.trim.contigs.good.unique.good.filter.unique.precluster.pick.abund.an.unique_list.0.03.subsam
ple.list,fasta=INDIGO.final.fasta, label=0.03) 
 
get.otulist(list=INDIGO.trim.contigs.good.unique.good.filter.unique.precluster.pick.abund.an.unique_list.0.0
3.subsample.shared, 
 
#on a linux bash (switch Tmux terminals), without having to close Mothur: 
cp ./INDIGO.final.fasta ./INDIGO.final.format.fasta   
sed -i 's/-//g' INDIGO.final.format.fasta 
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vsearch --usearch_global INDIGO.final.format.fasta --db 
/home/technical/Documents/16S_refDB/rdp_download_9752seqs.fa --uc INDIGO_usearch97_RDP.txt --id 
0.98 --iddef 1 --maxaccepts 3 --maxrejects 0 --strand plus #to obtain species information 
 
rdp_classifier  -o INDIGO_classified.txt --format=fixrank ./INDIGO.final.format.fasta 
 
java -Xmx1g -jar /usr/bin/rdp_classifier classify -c 0.5 -o INDIGO_classified.txt -h INDIGO_hier.txt --
format=fixrank ./INDIGO.final.format.fasta 
 
#change the header of the FASTA 
sed -i 's/-//g' INDIGO.final.format.fasta 
cut -d '|' -f1 INDIGO.final.0.03.rep.fasta > INDIGO.oturep.fasta    
awk -F ' ' '/^>/ {print ">" $2; next } 1' INDIGO.oturep.fasta  > INDIGO1.oturep.fasta   
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Appendix 3: Alpha and Beta-diversity equations according to [352] 
 
Alpha diversity indices are mathematical estimators of within-sample richness and 
diversity of bacterial communities.  
Richness indexes: The Chao1 and Abundance-based Coverage Estimator (ACE) 
richness indexes were calculated as described by Chao and colleagues [Chao, 1984; 
Chao and Ming, 1992; Chao et al. 1993]: 
 
       (1) 
 
where  is the observed number of species, and F1 and F2 are the numbers of 
singletons (only one count) and doubletons (exactly two counts), respectively, in each 
sample. 
 
And for the ACE: 
     (2) 
 
where:  and  are the numbers of abundant and rare OTUs, with respect to 
a threshold of individuals in which OTUs are observed (3 in this study);  is the 
sample abundance coverage estimator obtained by , with F1 the frequency 
of singletons and , for j=3 the threshold for rare OTUs;  is the 
coefficient of variation for of OTU relative abundances 
. 
 
Diversity indexes: The Shannon index was obtained from [Shannon, 1948]: 
         (3) 
 
where pi is the relative abundance of each OTU. 
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Similarly, the Simpson index was also based on OTUs relative abundances [Simpson, 
1949]:  
         (4) 
 
Evenness indexes: Simpson’s evenness measure E was calculated as: 
          (6) 
where D is the Simpsons’s diversity from equation (4) and Sobs is the observed number 
of species [Smith & Wilson, 1996].  
 
Pielou’s J’ index (a.k.a. Shannon’s evenness) was obtained from the Shannon index 
(equation(3)) divided by the natural logarithm of the number of species [Smith & Wilson, 
1996; Pielou, 1975]: 
          (7) 
 
Beta-diversity compares bacterial communities among samples. UniFrac [320]  
computes a distance metrics which incorporates phylogenetic distances: 𝑊 =	∑ s"	tuRuvY	wRwvtxRyz∑ {|}|yz          (8) 
where: N is the number of nodes in the phylogenetic tree, S is the number of sequences 
represented by the tree. li is the branch length between node i and its parent node, Lj is 
the total branch length from the root to the tip of the tree for sequence j, Ai and Bi are the 
number of sequences from communities A and B that descend from the node, and AT 
and BT are the total number of sequences from communities A and B. The weighted 
UniFrac measure is natively normalized to ensure that each sequence contributes 
equally to the distance calculated.  
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Bray Curtis instead is a dissimilarity metrics [356]: 
 
      (9)
    
Where  and  are the number of species in samples i and j, and  is the number 
of species in common between the two samples (if there are no species in common, the 
numerator is equal to the denominator and the dissimilarity is one -maximum; if all 
species are in common, the dissimilarity is zero -minimum). 
 
References for Appendix 3 (not already included in the main text): 
- Chao A, Ma MC and Yang MCK 1993. Stopping rule and estimation for recapture 
debugging with unequal detection rates. Biometrika 80, 193–201. 
- Chao A 1984. Nonparametric Estimation of the Number of Classes in a 
Population Author. Scanadinavian Journal of Statistics 11, 265–270. 
- Chao A and Lee S-M 1992. Estimating the Number of Classes via Sample 
Coverage. Journal of the American Statistical Association 87, 210. 
- Pielou E. 1975. Ecological diversity. Wiley, New York. 
- Shannon C 1948. A Mathematical Theory of Communication, The Bell System 
Technical Journal. The Bell System Technical Journal, 379–427. 
- Simpson EH 1949. Measurement of diversity. Nature 163, 688. 
- Smith B and Wilson JB 1996. A Consumer’s Guide to Evenness Indices. Oikos 
76, 70. 
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Appendix 4: Bifidobacterium counts derived from the 28F-combo primers. 
 
Primers as described in Table 2.2. Comparison between the TSHR immunised mice in 
Center 1 (n=5) and Center 2 (n=10). ANOVA with Tukey’s HSD post-hoc analysis (95% 
confidence interval), P value=0.003 generated with STAMP. 
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Appendix 5: Generalized linear model (GLM) of genera counts differentially present in 
TSHR immunised mice over timepoints, in reference to the baseline (T0) using EdgeR. 
LogFC, Log2 fold change between each timepoint and the baseline (T0); LR, likelihood 
ratio. 
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Appendix 6: Generalized linear model (GLM) of genera counts in βgal control mice over 
timepoints using EdgeR. LogFC, Log2 fold change between each timepoint and the 
baseline (T0); LR, likelihood ratio. 
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Appendix 7: Comparison of the faecal and the gut microbiota of BALB/c mice in Centre 
2 collected at T4.  
 
 
(A) Alpha diversity indices of richness (Chao) and diversity (Shannon). (B) Beta-diversity 
measurement calculated from the weighted Unifrac. (C) Correlation coefficient matrix 
between each sample’s microbiota from faeces (x-axis) and from the gut scraping (y-
axis). Values in the diagonal represent the Spearman correlation coefficient within 
sample between faecal and gut microbiota, which vary from weak (0.50) to strong 
(>0.80). 
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Appendix 8: QIIME 1.9 Pipeline 
 
To process 16S rRNA gene sequencing data, the QIIME pipeline was used [208]. The specific steps and 
parameters used are detailed below. 
 
####  Core analysis #### 
1. Joining paired-end reads 
Paired-end reads were joined into single FASTQ files per sample: 
multiple_join_paired_ends.py --input_dir=<sample_path> --output_dir=./ --include_input_dir_path 
--parameter_fp=$PWD/qiime_parameters --read1_indicator _R1 --read2_indicator _R2 
 
The method “SeqPrep” for the joining of paired-end reads (https://github.com/jstjohn/SeqPrep) was 
selected via the parameter file (qiime_parameters): 
join_paired_ends:pe_join_method      SeqPrep 
 
2. Quality filtering 
Joined reads were then filtered for quality and saved into a unique FASTA file for all samples: 
multiple_split_libraries_fastq.py --demultiplexing_method sampleid_by_file --
input_dir=<multiple_join_paired_ends/> --output_dir=./ 
--include_input_dir_path --remove_filepath_in_name 
--parameter_fp=$PWD/qiime_parameters 
 
Quality filter parameter were specified via the parameter file (qiime_parameters): 
split_libraries_fastq:max_bad_run_length  3 >> ./qiime_parameters 
split_libraries_fastq:min_per_read_length_fraction 0.75 >> ./qiime_parameters 
split_libraries_fastq:sequence_max_n 0 >> ./qiime_parameters 
split_libraries_fastq:phred_quality_threshold 19 >> ./qiime_parameters 
 
3. OTU picking 
OTUs were determined by aligning quality-filtered reads against the QIIME-compatible SILVA reference 
FASTA file, release 123, with minimum 97% clustering (https://www.arb-silva.de/download/archive/qiime/): 
pick_closed_reference_otus.py  
--reference_fp SILVA123_QIIME/rep_set/rep_set_all/97/97_otus.fasta --taxonomy_fp 
SILVA123_QIIME/taxonomy/taxonomy_all/97/raw_taxonomy.txt 
--parallel --jobs_to_start=32 --force 
--input_fp=<multiple_split_library/>seqs.fna --output_dir=./ 
 
Convert .biom file into a .tsv file: 
biom convert -i ./otu_table.biom -o otu_table.txt --to-tsv --header-key taxonomy 
 
4. Filter OTUs 
OTUs were filtered by total count across samples greater than 15 of the number of OTUs in at least 2 
samples: 
filter_otus_from_otu_table.py -i <closed_otupicking/>otu_table.biom -n 15 -s 2 -o ./otu_table_filtered.biom 
 
5. Normalization of OTU counts 
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To account for uneven sequencing, OTU counts were normalized by cumulative sum scaling (CSS, [354]): 
normalize_table.py -i <filter_otus/>otu_table_filtered.biom -a CSS -o CSS_normalized_otu_table.biom 
 
Convert .biom file into a .tsv file: 
biom convert -i ./CSS_normalized_otu_table.biom -o normalized_otu_table.txt --to-tsv --header-key 
taxonomy 
 
6. Alpha diversity 
Alpha diversity indexes were estimated from the filtered OTU table: 
alpha_diversity.py -i <filter_otus/>otu_table_filtered.biom -m 
chao1,ace,fisher_alpha,observed_otus,observed_species,shannon,simpson 
-o ./alpha.txt -t SILVA123_QIIME/trees/97/97_otus.tre 
 
7. Beta diversity 
Beta diversity was estimated from the filtered and normalized OTU table: 
beta_diversity.py -i <normalize_otu/>CSS_normalized_otu_table.biom -m bray_curtis -o ./ -t 
SILVA123_QIIME/trees/97/97_otus.tre 
 
8. Sequence-based rarefaction 
To check whether sequencing depth was adequate, sequence-based rarefaction curves were generated 
from the unfiltered OTU table: 
alpha_rarefaction.py -i <closed_otupicking/>otu_table.biom -m metadatamapping.csv 
-o ./ --force --parameter=$PWD/qiime_parameters --parallel 
--jobs_to_start=32 --max_rare_depth 218850 --min_rare_depth 100 
 
Where metadatamapping.csv is the metadata file (feed supplementation treatments), and max_rare_depth 
is the median sequence counts per sample. 
Additional parameters were specified via the parameter file (qiime_parameters): 
Alpha_diversity:metrics observed_otus,chao1,observed_species,shannon,simpson, 
goods_coverage,ace,fisher_alpha >> ./qiime_parameters 
make_rarefaction_plots:resolution 
800 >> ./qiime_parameters 
 
#### Post-analysis #### 
9. Tax4Fun [360] 
 desc: functional profiling using tax4fun (+SILVA) 
 run:     
 # conda environment set up 
   - export PATH=<conda_path>:$PATH 
   - source activate <qiime_version>  
#!! Careful: the R in this environment has the Tax4Fun package installed !! 
# convert otu_table to csv file with taxonomy as header key (!! IMPORTANT !!) 
   - biom convert -i <normalize_otu/>CSS_normalized_otu_table.biom -o otu_table.csv --to-tsv --
header-key taxonomy 
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 # run R script for functional profiling (now using personal R libraries --> update/create conda R 
env) 
 # important: sample names in the otu table must not begin with a number! 
 # creates TWO FILES: one for ORTHOLOGS (proteins/enzymes), one for METABOLIC 
PATHWAYS 
 # - /storage/biscarinif/R-3.1.1/bin/Rscript --vanilla <tax4fun> otu_table.csv 
/storage/biscarinif/tax4fun/SILVA123/ 
   - Rscript --vanilla <tax4fun> otu_table.csv /storage/biscarinif/tax4fun/SILVA123/ 
    
   - source deactivate 
 
10. SourceTracker [363] 
 
- export SOURCETRACKER_PATH= yourPath/sourcetracker/ 
 
- Rscript sourcetracker_for_qiime.r -i out_table.txt -m metadata.txt -o outputFolder  
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Appendix 9: Summary of the statistics obtained from the linear regression model for 
treatment differences in colon + entire sources of the βgal immunisation control group. 
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Appendix 10: Summary of the statistics obtained from the linear regression model for 
treatment differences in small intestines of the βgal immunisation control group. 
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Appendix 11: Summary of the statistics obtained from the linear regression model for 
treatment differences in colon + entire sources of the TSHR immunisation control group. 
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Appendix 12: Summary of the statistics obtained from the linear regression model for 
treatment differences in small intestines of the TSHR immunisation control group. 
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Appendix 13: Alpha diversity indices differences between timepoints in each treatment.  
hFMT, humanized faecal material transplant from Graves’ orbitopathy (GO) patients. 
Lab4, probiotics consortium. Vanco, vancomycin antibiotics.  
 
Indices treatment 
Baseline 
(mean) 
Mid (mean) Pvalue 
chao1 control 842.2963 1072.6784 0.0038 
chao1 hFMT 816.3464 954.0984 0.0353 
chao1 lab4 897.3411 904.4632 0.9308 
chao1 vanco 181.2537 196.4155 0.3941 
observed_otus control 601.8750 825.9500 0.0014 
observed_otus hFMT 599.3333 707.0000 0.0611 
observed_otus lab4 657.5714 643.3636 0.8389 
observed_otus vanco 113.1500 118.4286 0.6004 
shannon control 6.3526 6.7244 0.0752 
shannon hFMT 6.0841 6.0410 0.8794 
shannon lab4 6.3872 6.2976 0.6243 
shannon vanco 2.9951 2.7525 0.0016 
equitability control 0.6907 0.6997 0.6294 
equitability hFMT 0.6684 0.6405 0.3501 
equitability lab4 0.6903 0.6812 0.6225 
equitability vanco 0.4457 0.4046 0.0052 
 
 
 
Appendix 14: Bacteroides spp. differences between timepoints in Lab4 (probiotics 
consortium) treatment and in each immunisation. 
 
Genus Treatment Immunisation 
Baseline 
(mean) 
Mid  
(mean) 
P value 
Bacteroides Lab4 βgal 46.58462 71.8608545 0.01071752 
Bacteroides Lab4 TSHR 21.1752333 56.2193555 0.023308 
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Appendix 15: Taxonomic differences at baseline amongst treatments from linear 
regression model.  
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Appendix 16: bacterial invaders as a result of the humanized faecal material transplant 
(hFMT) engraftment in the three timepoints. 
 
At baseline, mid and endpoint, between GO patients, hFMT mice and control mice. See 
Chapter 3 par. 3.3.6.7 for formula explanation. Sd, Standard deviation. 
Baseline – stool samples 
family 
GO 
(mean) 
GO 
(sd) 
hFMT 
(mean) 
hFMT 
(sd) 
control 
(mean) 
control 
(sd) 
dFMT 
ddFMT 
(%) 
Alcaligenaceae 3.2 3.2 4.4 4.3 6.2 2.5 -1.8 -155.6 
Bacteroidaceae 167.5 53.5 33.7 29.0 53.3 19.4 -19.6 -111.7 
Coriobacteriaceae 26.7 11.5 27.7 9.7 26.1 8.7 1.5 -94.3 
Enterobacteriaceae 33.2 32.5 4.9 5.9 2.3 1.8 2.6 -92.2 
Erysipelotrichaceae 33.3 8.8 16.7 8.0 13.5 3.9 3.1 -90.6 
Lachnospiraceae 957.0 162.2 768.0 309.1 672.7 236.1 95.3 -90.0 
Lactobacillaceae 29.8 52.6 98.1 48.4 133.9 55.8 -35.8 -219.9 
Peptococcaceae 0.2 0.4 9.0 5.8 7.5 3.9 1.5 622.4 
Porphyromonadaceae 64.0 16.4 25.1 13.4 29.5 9.1 -4.5 -107.0 
Prevotellaceae 7.6 5.9 19.2 10.3 24.1 7.1 -4.8 -163.6 
Rikenellaceae 39.5 21.2 36.6 27.9 63.5 21.3 -27.0 -168.3 
Ruminococcaceae 363.2 101.4 293.6 127.3 212.4 89.4 81.2 -77.6 
Streptococcaceae 16.0 11.2 2.8 2.5 2.6 1.4 0.2 -98.7 
Verrucomicrobiaceae 1.7 3.3 7.6 2.3 7.0 1.5 0.6 -65.4 
 
Mid – stool samples  
family 
GO 
(mean) 
GO 
(sd) 
hFMT 
(mean) 
hFMT 
(sd) 
control 
(mean) 
control 
(sd) 
dFMT 
ddFMT 
(%) 
Alcaligenaceae 3.2 3.2 4.6 4.6 7.1 3.8 -2.5 -178.0 
Bacteroidaceae 167.5 53.5 40.4 31.0 60.2 30.8 -19.7 -111.8 
Coriobacteriaceae 26.7 11.5 31.9 8.3 31.0 11.1 0.9 -96.7 
Enterobacteriaceae 33.2 32.5 5.7 2.2 5.1 3.5 0.6 -98.1 
Erysipelotrichaceae 33.3 8.8 16.7 7.0 16.3 6.0 0.4 -98.7 
Lachnospiraceae 957.0 162.2 974.8 252.3 1109.4 325.4 -134.6 -114.1 
Lactobacillaceae 29.8 52.6 95.4 55.2 63.0 33.8 32.4 8.9 
Peptococcaceae 0.2 0.4 11.7 4.7 13.9 2.9 -2.2 -1224.9 
Porphyromonadaceae 64.0 16.4 26.0 12.2 31.9 11.7 -5.9 -109.3 
Prevotellaceae 7.6 5.9 18.0 8.3 23.0 7.0 -5.1 -166.5 
Rikenellaceae 39.5 21.2 40.9 30.4 57.4 22.7 -16.5 -141.9 
Ruminococcaceae 363.2 101.4 386.8 111.4 439.2 134.2 -52.4 -114.4 
Streptococcaceae 16.0 11.2 3.8 1.6 3.3 1.9 0.5 -97.2 
Verrucomicrobiaceae 1.7 3.3 8.5 1.9 8.6 2.0 -0.1 -105.5 
 
Final – colon samples 
family 
GO 
(mean) 
GO 
(sd) 
hFMT 
(mean) 
hFMT 
(sd) 
control 
(mean) 
control 
(sd) 
dFMT 
ddFMT 
(%) 
Alcaligenaceae 3.2 3.2 6.3 3.5 5.5 3.5 0.8 -74.5 
Bacteroidaceae 167.5 53.5 45.8 34.4 41.4 27.4 4.4 -97.4 
Coriobacteriaceae 26.7 11.5 28.1 8.6 26.8 14.9 1.3 -95.1 
Enterobacteriaceae 33.2 32.5 4.9 2.8 5.1 3.2 -0.2 -100.6 
Erysipelotrichaceae 33.3 8.8 17.7 5.2 19.5 8.5 -1.9 -105.7 
Lachnospiraceae 957.0 162.2 859.0 289.7 918.2 345.9 -59.2 -106.2 
Lactobacillaceae 29.8 52.6 119.2 125.1 144.7 220.8 -25.6 -185.8 
Peptococcaceae 0.2 0.4 10.7 4.8 10.5 3.9 0.3 30.5 
Porphyromonadaceae 64.0 16.4 25.2 13.2 26.0 11.2 -0.8 -101.2 
Prevotellaceae 7.6 5.9 21.1 7.6 19.1 6.3 1.9 -74.8 
Rikenellaceae 39.5 21.2 54.1 25.4 52.8 23.4 1.2 -96.9 
Ruminococcaceae 363.2 101.4 322.0 135.1 294.8 126.8 27.2 -92.5 
Streptococcaceae 16.0 11.2 4.4 5.0 7.9 8.2 -3.5 -122.1 
Verrucomicrobiaceae 1.7 3.3 8.5 2.7 7.4 1.9 1.1 -36.1 
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Appendix 17: Correlation analysis between disease features and bacterial biomarkers 
in the small intestine of (top) TSHR-immune and (bottom) βgal-immune control mice.  
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Appendix 18: Statistical summary (mean and standard deviation) of genera differentially 
abundant across nations of recruitment (Table 4.5).  
Only genera with P<0.05 are shown. 
 
 Belgium Germany Italy UK 
Genera differentially abundant mean st. dev  mean st. dev  mean st. dev  mean st. dev  
Acidaminococcus 0.0000 0.0000 0.0002 0.0006 0.0006 0.0011 0.0002 0.0006 
Christensenellaceae_R-7_group 0.0167 0.0081 0.0167 0.0099 0.0151 0.0084 0.0214 0.0125 
Clostridium_sensu_stricto_1 0.0088 0.0055 0.0047 0.0035 0.0057 0.0053 0.0099 0.0088 
Coprococcus_2 0.0055 0.0042 0.0027 0.0032 0.0033 0.0035 0.0046 0.0044 
Corynebacterium_1 0.0002 0.0004 0.0000 0.0001 0.0000 0.0000 0.0000 0.0001 
Cronobacter 0.0000 0.0001 0.0000 0.0000 0.0001 0.0003 0.0000 0.0001 
Enterobacter 0.0016 0.0018 0.0013 0.0021 0.0034 0.0048 0.0051 0.0079 
Faecalibacterium 0.0913 0.0421 0.1044 0.0381 0.1049 0.0322 0.0795 0.0388 
Family_XIII_AD3011_group 0.0030 0.0019 0.0022 0.0018 0.0015 0.0018 0.0026 0.0022 
Hafnia 0.0001 0.0004 0.0000 0.0000 0.0000 0.0001 0.0000 0.0001 
Intestinibacter 0.0065 0.0032 0.0030 0.0024 0.0042 0.0021 0.0053 0.0036 
Klebsiella 0.0000 0.0000 0.0000 0.0000 0.0003 0.0007 0.0001 0.0004 
Lachnospiraceae_NC2004_group 0.0115 0.0038 0.0117 0.0040 0.0121 0.0039 0.0096 0.0040 
Lachnospiraceae_NK4A136_group 0.0075 0.0035 0.0114 0.0057 0.0071 0.0030 0.0074 0.0039 
Lactococcus 0.0011 0.0014 0.0011 0.0014 0.0004 0.0009 0.0005 0.0009 
Leuconostoc 0.0006 0.0011 0.0000 0.0001 0.0001 0.0002 0.0000 0.0001 
Pantoea 0.0007 0.0008 0.0005 0.0009 0.0011 0.0013 0.0015 0.0021 
Paraprevotella 0.0000 0.0000 0.0001 0.0002 0.0003 0.0006 0.0000 0.0003 
Peptoclostridium 0.0195 0.0121 0.0096 0.0104 0.0111 0.0088 0.0206 0.0181 
Peptococcus 0.0000 0.0002 0.0003 0.0007 0.0004 0.0011 0.0000 0.0002 
Romboutsia 0.0003 0.0007 0.0001 0.0003 0.0000 0.0001 0.0003 0.0005 
Roseburia 0.0353 0.0065 0.0343 0.0124 0.0360 0.0119 0.0301 0.0091 
Ruminiclostridium 0.0050 0.0013 0.0046 0.0029 0.0054 0.0030 0.0040 0.0022 
Ruminiclostridium_5 0.0093 0.0032 0.0131 0.0048 0.0104 0.0039 0.0102 0.0037 
Ruminococcaceae_V9D2013_group 0.0000 0.0001 0.0001 0.0002 0.0000 0.0001 0.0000 0.0001 
Saccharofermentans 0.0009 0.0010 0.0002 0.0005 0.0001 0.0003 0.0003 0.0006 
Sedimentibacter 0.0007 0.0008 0.0002 0.0005 0.0003 0.0005 0.0007 0.0011 
Succiniclasticum 0.0006 0.0014 0.0000 0.0000 0.0002 0.0007 0.0000 0.0000 
Syntrophomonas 0.0004 0.0005 0.0001 0.0003 0.0001 0.0003 0.0004 0.0007 
[Eubacterium]_nodatum_group 0.0003 0.0004 0.0008 0.0010 0.0007 0.0011 0.0004 0.0007 
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Appendix 19. Beta-diversity organisation amongst disease types and eye-disease in 
each recruiting centre.  
NMDS based on Bray-Curtis dissimilarity matrix amongst disease types (A) and GO 
groups (B). No significant associations were observed in either alpha or beta-diversity in 
both analysis (PERMANOVA, P>0.05).. 
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Appendix 20: Statistical summary (mean and standard deviation) of genera differentially 
abundant amongst eye-disease status (no sign, GO mild and GO moderate-severe) 
compared to healthy controls (Table 4.7).  
Only genera with P>0.05 are shown. 
 
 control GD no sign GO mild GO moderate-severe 
Genera differentially abundant mean st. dev  mean st. dev  mean st. dev  mean st. dev  
Alistipes 0.0158 0.0090 0.0115 0.0078 0.0104 0.0067 0.0130 0.0075 
Anaeroplasma 0.0002 0.0005 0.0001 0.0003 0.0000 0.0001 0.0005 0.0009 
Bacteroides 0.0781 0.0393 0.0562 0.0394 0.0529 0.0310 0.0626 0.0358 
Bifidobacterium 0.0088 0.0050 0.0117 0.0079 0.0135 0.0055 0.0088 0.0042 
Clostridium_sensu_stricto_1 0.0062 0.0050 0.0092 0.0085 0.0080 0.0071 0.0030 0.0019 
Collinsella 0.0079 0.0051 0.0127 0.0089 0.0122 0.0063 0.0100 0.0051 
Fusicatenibacter 0.0168 0.0061 0.0214 0.0099 0.0234 0.0103 0.0213 0.0096 
Intestinibacter 0.0036 0.0027 0.0050 0.0034 0.0056 0.0030 0.0030 0.0018 
Lachnospiraceae_FCS020 
group 0.0021 0.0015 0.0030 0.0021 0.0035 0.0022 0.0025 0.0024 
Lactococcus 0.0011 0.0014 0.0005 0.0010 0.0004 0.0009 0.0004 0.0007 
Luteimonas 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0003 0.0010 
Oscillospira 0.0008 0.0009 0.0003 0.0006 0.0004 0.0006 0.0004 0.0005 
Peptoclostridium 0.0130 0.0111 0.0177 0.0174 0.0182 0.0154 0.0062 0.0058 
Rikenellaceae_RC9_gut_group 0.0005 0.0021 0.0005 0.0022 0.0022 0.0041 0.0001 0.0002 
Roseburia 0.0310 0.0085 0.0320 0.0126 0.0339 0.0093 0.0418 0.0091 
Ruminococcaceae_NK4A214_ 
group 0.0061 0.0049 0.0048 0.0038 0.0042 0.0035 0.0022 0.0019 
Ruminococcaceae_UCG-011 0.0009 0.0009 0.0008 0.0010 0.0005 0.0007 0.0000 0.0001 
[Eubacterium]_nodatum_group 0.0009 0.0011 0.0004 0.0009 0.0004 0.0006 0.0003 0.0006 
[Eubacterium]_oxidoreducens 
group 0.0072 0.0035 0.0055 0.0030 0.0055 0.0034 0.0046 0.0033 
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Appendix 21: Statistical summary (mean and standard deviation) of genera differentially 
abundant amongst thyroid status (hyperthyroid, euthyroid, hypothyroid) compared to 
euthyroid-healthy controls, regardless of the type of disease. 
 
Only genera with P<0.05 are shown. Hyper, hyperthyroidism. Hypo, hypothyroidism (no 
standard deviation showed, just one sample). 
 
 Euthyroid Euthyroid-controls Hyper Hypo 
Genera differentially abundant mean st. dev  mean st. dev  mean st. dev  mean 
Alistipes 0.0116 0.0063 0.0158 0.0090 0.0111 0.0075 0.0231 
Allisonella 0.0001 0.0004 0.0001 0.0003 0.0000 0.0001 0.0000 
Ambiguous_taxa 0.0004 0.0009 0.0003 0.0007 0.0002 0.0006 0.0009 
Anaerostipes 0.0189 0.0084 0.0257 0.0139 0.0285 0.0136 0.0091 
Bacteroides 0.0624 0.0332 0.0781 0.0393 0.0538 0.0357 0.1382 
Bilophila 0.0006 0.0007 0.0010 0.0008 0.0006 0.0007 0.0015 
Blautia 0.0895 0.0213 0.0846 0.0337 0.0998 0.0334 0.0358 
Collinsella 0.0098 0.0048 0.0079 0.0051 0.0127 0.0080 0.0026 
Comamonas 0.0003 0.0011 0.0000 0.0000 0.0000 0.0000 0.0000 
Filifactor 0.0000 0.0000 0.0000 0.0001 0.0000 0.0001 0.0006 
Fusicatenibacter 0.0196 0.0103 0.0168 0.0061 0.0225 0.0099 0.0136 
Gordonibacter 0.0001 0.0002 0.0003 0.0005 0.0005 0.0008 0.0006 
Lachnospira 0.0017 0.0020 0.0019 0.0019 0.0016 0.0018 0.0069 
Lachnospiraceae_UCG-004 0.0195 0.0101 0.0236 0.0131 0.0169 0.0111 0.0400 
Lachnospiraceae_UCG-006 0.0007 0.0007 0.0004 0.0005 0.0003 0.0004 0.0000 
Lactococcus 0.0005 0.0007 0.0011 0.0014 0.0005 0.0010 0.0000 
Luteimonas 0.0002 0.0009 0.0000 0.0000 0.0000 0.0000 0.0000 
Oscillospira 0.0006 0.0006 0.0008 0.0009 0.0003 0.0006 0.0000 
Prevotella_6 0.0000 0.0000 0.0000 0.0002 0.0000 0.0000 0.0006 
Ruminiclostridium_5 0.0101 0.0033 0.0123 0.0050 0.0103 0.0037 0.0056 
Ruminococcaceae_UCG-003 0.0037 0.0023 0.0032 0.0025 0.0023 0.0022 0.0076 
Sutterella 0.0031 0.0019 0.0029 0.0030 0.0021 0.0027 0.0165 
Thalassospira 0.0002 0.0004 0.0005 0.0009 0.0002 0.0004 0.0029 
[Eubacterium]_hallii_group 0.0224 0.0093 0.0336 0.0153 0.0346 0.0158 0.0183 
[Eubacterium]_nodatum_group 0.0002 0.0002 0.0009 0.0011 0.0004 0.0008 0.0000 
[Eubacterium]_oxidoreducens 
group 0.0042 0.0029 0.0072 0.0035 0.0056 0.0032 0.0032 
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Appendix 22: Genera differentially abundant between untreated and antithyroid (ATD)-
treated GD patients. 
Genera differentially abundant ATD treatment mean Standard deviation 
[Eubacterium]_nodatum_group carbimazole 0.00015082 0.00043761 
[Eubacterium]_nodatum_group metimazole 0.00026903 0.00041533 
[Eubacterium]_nodatum_group none 0.00096583 0.001328 
Acetanaerobacterium carbimazole 0 0 
Acetanaerobacterium metimazole 0 0 
Acetanaerobacterium none 8.78E-05 0.00021191 
Adlercreutzia carbimazole 0.00054379 0.00051116 
Adlercreutzia metimazole 0.00055707 0.00070921 
Adlercreutzia none 0.00112342 0.00071739 
Akkermansia carbimazole 0.00061859 0.00073071 
Akkermansia metimazole 0.00078231 0.00074117 
Akkermansia none 0.00158647 0.00091255 
Candidatus_Soleaferrea carbimazole 6.00E-05 0.00018041 
Candidatus_Soleaferrea metimazole 0.00010336 0.00022714 
Candidatus_Soleaferrea none 0.00058506 0.0006483 
Christensenellaceae_R-7_group carbimazole 0.02190192 0.01621893 
Christensenellaceae_R-7_group metimazole 0.01433106 0.00745277 
Christensenellaceae_R-7_group none 0.02601032 0.01157746 
Coprobacillus carbimazole 0.00034904 0.00061262 
Coprobacillus metimazole 0.00011157 0.00034603 
Coprobacillus none 0.00074917 0.00104215 
Eggerthella carbimazole 0.00036846 0.00058089 
Eggerthella metimazole 0.00041637 0.00070189 
Eggerthella none 0.00097746 0.00117817 
Enterococcus carbimazole 0 0 
Enterococcus metimazole 0.00068399 0.00095725 
Enterococcus none 0.00174029 0.00337116 
Faecalibacterium carbimazole 0.08565961 0.0406152 
Faecalibacterium metimazole 0.10392557 0.03600793 
Faecalibacterium none 0.06710324 0.0259003 
Family_XIII_AD3011_group carbimazole 0.00253132 0.00212837 
Family_XIII_AD3011_group metimazole 0.00172043 0.00132831 
Family_XIII_AD3011_group none 0.00382234 0.00279306 
Gordonibacter carbimazole 0.00062717 0.00068493 
Gordonibacter metimazole 0.00011455 0.00029155 
Gordonibacter none 0.00096656 0.00111586 
Lachnospiraceae_NC2004_group carbimazole 0.0107168 0.00374984 
Lachnospiraceae_NC2004_group metimazole 0.01157183 0.00375921 
Lachnospiraceae_NC2004_group none 0.00826287 0.0031439 
Lachnospiraceae_UCG-005 carbimazole 0.00619365 0.00308454 
Lachnospiraceae_UCG-005 metimazole 0.00767672 0.00343655 
Lachnospiraceae_UCG-005 none 0.00470472 0.00232774 
Lysinibacillus carbimazole 0 0 
Lysinibacillus metimazole 0 0 
Lysinibacillus none 0.00034612 0.00086513 
Paraprevotella carbimazole 0 0 
Paraprevotella metimazole 0.0003742 0.00069466 
Paraprevotella none 0 0 
Quinella carbimazole 0.00015292 0.0002772 
Quinella metimazole 0 0 
Quinella none 3.87E-05 0.00015962 
Rhizobium carbimazole 0 0 
Rhizobium metimazole 4.94E-05 0.00013684 
Rhizobium none 0.00030618 0.00059448 
Romboutsia carbimazole 0.00048014 0.00071161 
Romboutsia metimazole 5.53E-05 0.00015663 
Romboutsia none 0.00030657 0.00042171 
Roseburia carbimazole 0.03205132 0.00999732 
Roseburia metimazole 0.03908794 0.01435251 
Roseburia none 0.02567453 0.00702159 
Shuttleworthia carbimazole 9.07E-05 0.00024209 
Shuttleworthia metimazole 5.88E-05 0.00023539 
Shuttleworthia none 0.00041942 0.00052241 
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Appendix 23: Genera differentially abundant between untreated and antithyroid (ATD)-
treated GO patients. 
 
Genera differentially abundant ATD treatment mean Standard deviation 
Actinomyces carbimazole 0.00039736 0.00057136 
Actinomyces metimazole 0.00050126 0.00052747 
Actinomyces none 0.00302249 0.00478227 
Capnocytophaga carbimazole 0 0 
Capnocytophaga metimazole 6.77E-05 0.00019855 
Capnocytophaga none 0 0 
Clostridium_sensu_stricto_1 carbimazole 0.00732152 0.00747452 
Clostridium_sensu_stricto_1 metimazole 0.00454353 0.00319704 
Clostridium_sensu_stricto_1 none 0.01363415 0.00897023 
Erysipelotrichaceae_UCG-003 carbimazole 0.00222359 0.00187543 
Erysipelotrichaceae_UCG-003 metimazole 0.00413711 0.00436951 
Erysipelotrichaceae_UCG-003 none 0.00991096 0.00931953 
Erysipelotrichaceae_UCG-007 carbimazole 0 0 
Erysipelotrichaceae_UCG-007 metimazole 0 0 
Erysipelotrichaceae_UCG-007 none 0.00035324 0.00056354 
Granulicatella carbimazole 0.00040958 0.00064298 
Granulicatella metimazole 0.00041845 0.00055356 
Granulicatella none 0.00167508 0.00306345 
Lachnospiraceae_NC2004_group carbimazole 0.00973729 0.00455773 
Lachnospiraceae_NC2004_group metimazole 0.01292562 0.00358218 
Lachnospiraceae_NC2004_group none 0.00952499 0.00424716 
Peptococcus carbimazole 0.00011535 0.0003052 
Peptococcus metimazole 2.35E-05 9.68E-05 
Peptococcus none 0.00010459 0.00029583 
Prevotella_7 carbimazole 0.00012022 0.00031807 
Prevotella_7 metimazole 0 0 
Prevotella_7 none 0 0 
Ruminococcaceae_V9D2013_group carbimazole 0 0 
Ruminococcaceae_V9D2013_group metimazole 0 0 
Ruminococcaceae_V9D2013_group none 0.00016404 0.00030637 
Rummeliibacillus carbimazole 0 0 
Rummeliibacillus metimazole 0 0 
Rummeliibacillus none 0 0 
Shuttleworthia carbimazole 0 0 
Shuttleworthia metimazole 0.00015507 0.0003917 
Shuttleworthia none 0.00056945 0.0006895 
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Appendix 24: Top and least 10 most variant predicted pathways (Tax4Fun) in (A) 
disease diagnosis and (B) in GO status.  
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Appendix 25: Schematic representation of Short-Chain Fatty Acid (SCFA) production 
via fermentative pathways. Figure adapted from [238] and [535].   
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Appendix 26: Within-individual top-20 most abundant genera differential abundance 
amongst the three timepoints.  
 
% Relative frequency of each genera in each timepoint. P value generated using the 
G-test with Yates’ correction as implemented in STAMP. 
Patient 5001 - Probiotic 
Genus 5002_BL 5002_EU 5002_EFU BL-EU P value 
BL-EFU 
P value 
EU-EFU 
P value 
[Eubacterium]coprostanoligenesgroup 0.0078 0.0067 0.0096 0.0280 0.0309 0.0300 
[Eubacterium]halliigroup 0.0221 0.0257 0.0174 0.0526 0.0480 0.0508 
Alistipes 0.0153 0.0095 0.0355 0.0379 0.0572 0.0549 
Anaerostipes 0.1158 0.0234 0.0351 0.1086 0.1086 0.0597 
Bacteroides 0.1153 0.0480 0.3310 0.1080 0.1972 0.2218 
Barnesiella 0.0022 0.0017 0.0046 0.0135 0.0186 0.0179 
Bifidobacterium 0.0389 0.2014 0.0380 0.1540 0.0658 0.1541 
Blautia 0.0734 0.0429 0.0237 0.0859 0.0839 0.0649 
ChristensenellaceaeR-7group 0.0183 0.0129 0.0067 0.0426 0.0388 0.0335 
Collinsella 0.0261 0.0289 0.0076 0.0564 0.0463 0.0487 
Coprococcus2 0.0258 0.0045 0.0095 0.0442 0.0471 0.0278 
Dialister 0.0001 0.0001 0.0002 0.0026 0.0031 0.0030 
Dorea 0.0135 0.0271 0.0106 0.0501 0.0369 0.0487 
Faecalibacterium 0.1511 0.2715 0.2033 0.1588 0.1314 0.1436 
Fusicatenibacter 0.0289 0.0264 0.0074 0.0564 0.0486 0.0465 
genus_low 0.1432 0.0959 0.1189 0.1169 0.1137 0.1064 
Lachnoclostridium 0.0243 0.0212 0.0106 0.0513 0.0464 0.0438 
LachnospiraceaeNC2004group 0.0100 0.0120 0.0065 0.0351 0.0302 0.0323 
LachnospiraceaeUCG-004 0.0050 0.0008 0.0145 0.0173 0.0339 0.0302 
LachnospiraceaeUCG-008 0.0201 0.0091 0.0042 0.0421 0.0389 0.0272 
Parabacteroides 0.0078 0.0047 0.0132 0.0260 0.0347 0.0321 
Pseudobutyrivibrio 0.0067 0.0182 0.0072 0.0387 0.0272 0.0390 
Roseburia 0.0259 0.0265 0.0126 0.0546 0.0487 0.0492 
Ruminiclostridium5 0.0142 0.0045 0.0057 0.0331 0.0340 0.0231 
RuminococcaceaeUCG-002 0.0029 0.0018 0.0061 0.0151 0.0217 0.0202 
RuminococcaceaeUCG-014 0.0043 0.0138 0.0006 0.0324 0.0156 0.0291 
Ruminococcus1 0.0114 0.0157 0.0192 0.0395 0.0426 0.0450 
Ruminococcus2 0.0012 0.0019 0.0008 0.0121 0.0094 0.0112 
Subdoligranulum 0.0534 0.0231 0.0181 0.0715 0.0703 0.0491 
uncultured 0.0151 0.0201 0.0216 0.0454 0.0465 0.0489 
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% Relative frequency of each genera in each timepoint. P value generated using the 
G-test with Yates’ correction as implemented in STAMP. 
Patient 5011 – Probiotic 
 
Genus 5011_BL 5011_EU 5011_EFU BL-EU P value 
BL-EFU 
P value 
EU-EFU 
P value 
[Eubacterium]coprostanoligenesgroup 0.0002 0.0000 0.0011 0.0031 0.0073 0.0067 
[Eubacterium]halliigroup 0.0022 0.0021 0.0197 0.0143 0.0369 0.0368 
Alistipes 0.0056 0.0517 0.0058 0.0655 0.0245 0.0656 
Anaerostipes 0.0032 0.0021 0.0283 0.0162 0.0457 0.0451 
Bacteroides 0.5593 0.6995 0.2139 0.1707 0.3121 0.4539 
Barnesiella 0.0061 0.0843 0.0041 0.0881 0.0231 0.0877 
Bifidobacterium 0.0201 0.0003 0.2677 0.0359 0.1951 0.2006 
Blautia 0.0082 0.0095 0.0224 0.0312 0.0435 0.0443 
ChristensenellaceaeR-7group 0.0035 0.0006 0.0030 0.0140 0.0179 0.0130 
Collinsella 0.0009 0.0030 0.0086 0.0137 0.0228 0.0252 
Coprococcus2 0.0001 0.0001 0.0002 0.0027 0.0035 0.0030 
Dialister 0.0162 0.0126 0.0357 0.0407 0.0576 0.0563 
Dorea 0.0142 0.0054 0.0056 0.0338 0.0340 0.0240 
Faecalibacterium 0.0767 0.0231 0.0995 0.0858 0.0992 0.0992 
Fusicatenibacter 0.0021 0.0020 0.0154 0.0140 0.0323 0.0323 
genus_low 0.0231 0.0271 0.0486 0.0541 0.0684 0.0694 
Lachnoclostridium 0.0109 0.0080 0.0159 0.0325 0.0394 0.0375 
LachnospiraceaeNC2004group 0.0029 0.0003 0.0032 0.0123 0.0173 0.0128 
LachnospiraceaeUCG-004 0.0480 0.0309 0.0187 0.0698 0.0669 0.0551 
LachnospiraceaeUCG-008 0.0050 0.0019 0.0101 0.0189 0.0291 0.0260 
Parabacteroides 0.0014 0.0008 0.0016 0.0100 0.0118 0.0105 
Pseudobutyrivibrio 0.1375 0.0074 0.1097 0.1213 0.1126 0.1044 
Roseburia 0.0373 0.0033 0.0257 0.0535 0.0618 0.0435 
Ruminiclostridium5 0.0008 0.0005 0.0005 0.0075 0.0073 0.0064 
RuminococcaceaeUCG-002 0.0027 0.0059 0.0012 0.0211 0.0136 0.0193 
RuminococcaceaeUCG-014 0.0001 0.0000 0.0000 0.0017 0.0017 0.4695 
Ruminococcus1 0.0007 0.0003 0.0087 0.0065 0.0227 0.0222 
Ruminococcus2 0.0026 0.0002 0.0075 0.0115 0.0234 0.0204 
Subdoligranulum 0.0024 0.0059 0.0101 0.0209 0.0265 0.0299 
uncultured 0.0061 0.0106 0.0074 0.0306 0.0270 0.0317 
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% Relative frequency of each genera in each timepoint. P value generated using the 
G-test with Yates’ correction as implemented in STAMP. 
Patient 5015 - Probiotic 
Genus 5015_BL 5015_EU 5015_EFU BL-EU P value 
BL-EFU 
P value 
EU-EFU 
P value 
[Eubacterium]coprostanoligenesgroup 0.0082 0.0076 0.0039 0.0292 0.0256 0.0249 
[Eubacterium]halliigroup 0.0030 0.0099 0.0513 0.0268 0.0643 0.0666 
Alistipes 0.0110 0.0705 0.0060 0.0799 0.0309 0.0788 
Anaerostipes 0.0135 0.0242 0.0189 0.0478 0.0435 0.0503 
Bacteroides 0.0242 0.2032 0.0332 0.1576 0.0586 0.1560 
Barnesiella 0.0000 0.0000 0.0093 0.0010 0.0227 0.0227 
Bifidobacterium 0.1225 0.0285 0.1070 0.1124 0.1067 0.1037 
Blautia 0.0651 0.1490 0.1181 0.1234 0.1085 0.1161 
ChristensenellaceaeR-7group 0.0444 0.0247 0.0415 0.0662 0.0697 0.0643 
Collinsella 0.0106 0.0155 0.0157 0.0387 0.0390 0.0419 
Coprococcus2 0.0000 0.0001 0.0028 0.0014 0.0114 0.0115 
Dialister 0.2730 0.0100 0.0058 0.2010 0.2022 0.0297 
Dorea 0.0337 0.0268 0.0077 0.0598 0.0527 0.0470 
Faecalibacterium 0.0263 0.0468 0.1370 0.0681 0.1205 0.1192 
Fusicatenibacter 0.0016 0.0023 0.0100 0.0136 0.0255 0.0262 
genus_low 0.1427 0.1395 0.1353 0.1104 0.1110 0.1098 
Lachnoclostridium 0.0264 0.0129 0.0190 0.0493 0.0520 0.0433 
LachnospiraceaeNC2004group 0.0214 0.0018 0.0076 0.0383 0.0422 0.0225 
LachnospiraceaeUCG-004 0.0010 0.0052 0.0052 0.0179 0.0178 0.0232 
LachnospiraceaeUCG-008 0.0098 0.0083 0.0282 0.0316 0.0492 0.0485 
Parabacteroides 0.0000 0.0012 0.0009 0.0070 0.0062 0.0096 
Pseudobutyrivibrio 0.0027 0.0154 0.0367 0.0329 0.0527 0.0581 
Roseburia 0.0072 0.0146 0.0225 0.0355 0.0430 0.0470 
Ruminiclostridium5 0.0070 0.0057 0.0057 0.0260 0.0260 0.0244 
RuminococcaceaeUCG-002 0.0067 0.0081 0.0020 0.0283 0.0215 0.0235 
RuminococcaceaeUCG-014 0.0026 0.0077 0.0031 0.0236 0.0168 0.0242 
Ruminococcus1 0.0042 0.0059 0.0122 0.0231 0.0307 0.0321 
Ruminococcus2 0.0013 0.0024 0.0135 0.0132 0.0295 0.0306 
Subdoligranulum 0.1088 0.0506 0.1260 0.1046 0.1080 0.1133 
uncultured 0.0212 0.1015 0.0139 0.1003 0.0456 0.0998 
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% Relative frequency of each genera in each timepoint. P value generated using the 
G-test with Yates’ correction as implemented in STAMP. 
Patient 5030 - Placebo 
Genus 5030_BL 5030_EU 5030_EFU BL-EU P 
value 
BL-EFU 
P value 
EU-EFU 
P value 
[Eubacterium]coprostanoligenesgroup 0.0119 0.0264 0.0036 0.0488 0.0298 0.0443 
[Eubacterium]halliigroup 0.0141 0.0329 0.0053 0.0547 0.0335 0.0508 
Alistipes 0.0302 0.0126 0.0324 0.0521 0.0599 0.0538 
Anaerostipes 0.0097 0.0114 0.0025 0.0343 0.0261 0.0281 
Bacteroides 0.4080 0.1888 0.4934 0.2041 0.1414 0.2445 
Barnesiella 0.0046 0.0019 0.0178 0.0182 0.0369 0.0348 
Bifidobacterium 0.1248 0.0347 0.0409 0.1135 0.1133 0.0663 
Blautia 0.0374 0.0833 0.0100 0.0909 0.0565 0.0881 
ChristensenellaceaeR-7group 0.0051 0.0058 0.0015 0.0240 0.0184 0.0195 
Collinsella 0.0073 0.0161 0.0016 0.0371 0.0218 0.0326 
Coprococcus2 0.0047 0.0019 0.0101 0.0183 0.0287 0.0258 
Dialister 0.0000 0.0001 0.0000 0.0020 0.0012 0.0016 
Dorea 0.0051 0.0125 0.0093 0.0317 0.0281 0.0350 
Faecalibacterium 0.0521 0.1858 0.1128 0.1435 0.1066 0.1324 
Fusicatenibacter 0.0064 0.0086 0.0031 0.0286 0.0225 0.0253 
genus_low 0.0453 0.0859 0.0343 0.0927 0.0688 0.0922 
Lachnoclostridium 0.0183 0.0567 0.0067 0.0725 0.0388 0.0695 
LachnospiraceaeNC2004group 0.0054 0.0041 0.0108 0.0223 0.0301 0.0289 
LachnospiraceaeUCG-004 0.0398 0.0198 0.0810 0.0617 0.0898 0.0880 
LachnospiraceaeUCG-008 0.0047 0.0153 0.0022 0.0344 0.0188 0.0324 
Parabacteroides 0.0012 0.0017 0.0294 0.0115 0.0455 0.0458 
Pseudobutyrivibrio 0.0349 0.0133 0.0121 0.0559 0.0555 0.0377 
Roseburia 0.0141 0.0125 0.0032 0.0388 0.0319 0.0301 
Ruminiclostridium5 0.0064 0.0070 0.0037 0.0268 0.0232 0.0240 
RuminococcaceaeUCG-002 0.0020 0.0008 0.0014 0.0113 0.0126 0.0100 
RuminococcaceaeUCG-014 0.0040 0.0071 0.0024 0.0244 0.0180 0.0225 
Ruminococcus1 0.0036 0.0075 0.0050 0.0245 0.0211 0.0260 
Ruminococcus2 0.0652 0.0486 0.0002 0.0820 0.0737 0.0612 
Subdoligranulum 0.0177 0.0829 0.0514 0.0889 0.0689 0.0914 
uncultured 0.0156 0.0139 0.0120 0.0409 0.0398 0.0382 
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% Relative frequency of each genera in each timepoint. P value generated using the 
G-test with Yates’ correction as implemented in STAMP. 
Patient 5033 - Probiotic 
Genus 5033_BL 5033_EU 5033_EFU BL-EU P 
value 
BL-EFU 
P value 
EU-EFU 
P value 
[Eubacterium]coprostanoligenesgroup 0.0056 0.0063 0.0058 0.0251 0.0245 0.0252 
[Eubacterium]halliigroup 0.0082 0.0071 0.0480 0.0287 0.0637 0.0633 
Alistipes 0.0129 0.0382 0.0122 0.0583 0.0375 0.0580 
Anaerostipes 0.0108 0.0059 0.0733 0.0306 0.0817 0.0807 
Bacteroides 0.1825 0.3194 0.0667 0.1687 0.1394 0.2088 
Barnesiella 0.0034 0.0210 0.0098 0.0391 0.0271 0.0432 
Bifidobacterium 0.0304 0.0169 0.1014 0.0540 0.1006 0.1000 
Blautia 0.0217 0.0203 0.0825 0.0490 0.0891 0.0889 
ChristensenellaceaeR-7group 0.1711 0.0626 0.0136 0.1345 0.1408 0.0753 
Collinsella 0.0037 0.0036 0.1111 0.0191 0.1050 0.1050 
Coprococcus2 0.0134 0.0213 0.0010 0.0454 0.0290 0.0377 
Dialister 0.0000 0.0064 0.0151 0.0183 0.0301 0.0355 
Dorea 0.0043 0.0046 0.0297 0.0213 0.0476 0.0477 
Faecalibacterium 0.1548 0.1658 0.0605 0.1164 0.1268 0.1322 
Fusicatenibacter 0.0171 0.0122 0.0122 0.0413 0.0413 0.0369 
genus_low 0.1354 0.1308 0.1420 0.1089 0.1107 0.1114 
Lachnoclostridium 0.0101 0.0064 0.0243 0.0303 0.0462 0.0441 
LachnospiraceaeNC2004group 0.0110 0.0039 0.0030 0.0290 0.0281 0.0187 
LachnospiraceaeUCG-004 0.0126 0.0236 0.0062 0.0469 0.0328 0.0433 
LachnospiraceaeUCG-008 0.0126 0.0041 0.0083 0.0310 0.0344 0.0259 
Parabacteroides 0.0070 0.0015 0.0003 0.0212 0.0197 0.0088 
Pseudobutyrivibrio 0.0637 0.0228 0.0065 0.0778 0.0743 0.0428 
Roseburia 0.0091 0.0039 0.0058 0.0268 0.0286 0.0226 
Ruminiclostridium5 0.0044 0.0182 0.0140 0.0371 0.0328 0.0432 
RuminococcaceaeUCG-002 0.0048 0.0130 0.0027 0.0320 0.0195 0.0302 
RuminococcaceaeUCG-014 0.0016 0.0054 0.0147 0.0190 0.0311 0.0343 
Ruminococcus1 0.0249 0.0083 0.0108 0.0457 0.0471 0.0326 
Ruminococcus2 0.0053 0.0005 0.0080 0.0172 0.0269 0.0214 
Subdoligranulum 0.0350 0.0325 0.0309 0.0622 0.0618 0.0602 
uncultured 0.0228 0.0136 0.0796 0.0467 0.0875 0.0863 
 
  
  
 
 
310  
% Relative frequency of each genera in each timepoint. P value generated using the 
G-test with Yates’ correction as implemented in STAMP. 
Patient 5036 - Placebo 
Genus 5036_BL 5036_EU 5036_EFU BL-EU P 
value 
BL-EFU 
P value 
EU-EFU 
P value 
[Eubacterium]coprostanoligenesgroup 0.0019 0.0382 0.0015 0.0535 0.0125 0.0533 
[Eubacterium]halliigroup 0.0080 0.0663 0.0150 0.0765 0.0366 0.0780 
Alistipes 0.0128 0.0416 0.0077 0.0607 0.0342 0.0588 
Anaerostipes 0.0056 0.0116 0.0113 0.0313 0.0310 0.0357 
Bacteroides 0.3922 0.2173 0.1699 0.1857 0.2048 0.1324 
Barnesiella 0.0054 0.0014 0.0040 0.0187 0.0221 0.0165 
Bifidobacterium 0.0485 0.0068 0.0703 0.0636 0.0847 0.0789 
Blautia 0.0296 0.0197 0.0526 0.0546 0.0724 0.0702 
ChristensenellaceaeR-7group 0.0029 0.0160 0.0029 0.0337 0.0169 0.0337 
Collinsella 0.0118 0.0006 0.0267 0.0267 0.0490 0.0427 
Coprococcus2 0.0007 0.0000 0.0007 0.0056 0.0079 0.0055 
Dialister 0.0000 0.0004 0.0004 0.0042 0.0040 0.0057 
Dorea 0.0071 0.0008 0.0183 0.0204 0.0390 0.0343 
Faecalibacterium 0.1200 0.0174 0.1903 0.1110 0.1329 0.1514 
Fusicatenibacter 0.0096 0.0005 0.0172 0.0238 0.0398 0.0330 
genus_low 0.1062 0.1770 0.1146 0.1299 0.1035 0.1283 
Lachnoclostridium 0.0229 0.0050 0.0212 0.0420 0.0503 0.0404 
LachnospiraceaeNC2004group 0.0035 0.0002 0.0058 0.0133 0.0221 0.0176 
LachnospiraceaeUCG-004 0.0095 0.0089 0.0098 0.0318 0.0325 0.0320 
LachnospiraceaeUCG-008 0.0039 0.0011 0.0094 0.0158 0.0272 0.0241 
Parabacteroides 0.0142 0.0019 0.0089 0.0309 0.0365 0.0244 
Pseudobutyrivibrio 0.0181 0.0013 0.0467 0.0346 0.0659 0.0601 
Roseburia 0.0266 0.0005 0.0245 0.0425 0.0542 0.0405 
Ruminiclostridium5 0.0048 0.0005 0.0076 0.0162 0.0258 0.0207 
RuminococcaceaeUCG-002 0.0026 0.0597 0.0034 0.0704 0.0173 0.0706 
RuminococcaceaeUCG-014 0.0002 0.1685 0.0010 0.1405 0.0072 0.1404 
Ruminococcus1 0.0853 0.0280 0.0327 0.0914 0.0917 0.0595 
Ruminococcus2 0.0246 0.0059 0.0753 0.0440 0.0852 0.0821 
Subdoligranulum 0.0109 0.0026 0.0423 0.0277 0.0605 0.0572 
uncultured 0.0103 0.1002 0.0078 0.0987 0.0317 0.0985 
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Appendix 27. Baseline gut microbiota composition in individual being “responder” or 
“non-responder” to the probiotic intake. 
Bar-chart plots representing the enriched bacteria biomarkers in either responder or non-
responder group at baseline, according the linear discriminant analysis (LDA) effect size 
(LEfSe). Bacterial biomarkers were P<0.05 in both Kruskal-Wallis and Wilcox-test and 
the minimum LDA threshold of 2 (as log10).  
 
 
 
